Starpharma und Dendritic Nanotech: Nanodrugs und der Erfinder der Dendrimere - 500 Beiträge pro Seite
eröffnet am 11.06.03 12:54:14 von
neuester Beitrag 14.07.05 19:20:57 von
neuester Beitrag 14.07.05 19:20:57 von
Beiträge: 242
ID: 741.698
ID: 741.698
Aufrufe heute: 0
Gesamt: 13.857
Gesamt: 13.857
Aktive User: 0
Top-Diskussionen
Titel | letzter Beitrag | Aufrufe |
---|---|---|
vor 30 Minuten | 1781 | |
vor 1 Stunde | 1419 | |
heute 07:03 | 931 | |
vor 3 Minuten | 910 | |
heute 07:40 | 906 | |
vor 1 Stunde | 709 | |
vor 4 Minuten | 582 | |
28.05.24, 23:11 | 577 |
Meistdiskutierte Wertpapiere
Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
---|---|---|---|---|---|---|---|
1. | 1. | 18.520,21 | +0,31 | 229 | |||
2. | 2. | 7,1380 | +2,06 | 75 | |||
3. | 3. | 161,44 | +0,52 | 67 | |||
4. | 4. | 24,795 | +1,83 | 54 | |||
5. | 5. | 10,680 | -0,37 | 52 | |||
6. | 8. | 2.331,92 | +0,22 | 44 | |||
7. | 6. | 29,46 | -0,07 | 43 | |||
8. | 7. | 0,1895 | +1,07 | 42 |
Ich verfolge das Nanoboard schon einige Zeit und muß sagen, daß mir die Haare zu Berge stehen, wenn ich sehe welche Aktien hier teilweise beweihräuchert werden. Meist sind sie völliger Schrott oder zumindest heillos überbewertet.
Ich habe die Vorstellung des "heissesten Unternehmens unter der australischen Sonne" bereits lange angekündigt und dieser Thread soll nun pünktlich zu einem entscheidenden Ereignis für STARPHARMA eröffnet werden, aber erst mal von vorne:
STARPHARMA besteht aus drei Subunternehmen, die sich mit der Herstellung von revolutionären Nanomedikamenten unter Anwendung von Dendrimeren beschäftigen.
Die Anwendungsgebiete reichen von Krebs, Malaria über Hepatitis B zu Genitalherpes und schließlich (und hier wird es besonders interessant) zu HIV/Aids.
Das HIV-Medikament würde ich normalerweise nicht besonders hervorheben, denn jedes Biotech-Unternehmen, das etwas auf sich hält, hat irgendetwas zur HIV-Bekämpfung in der Pipeline. Die Sache ist nur die, dass sich der Aidsvirus sehr schnell weiterentwickelt und verändert, was eine Heilung oder Impfung vielleicht für lange Zeit unmöglich macht. Hier kommt STARPHARMA ins Spiel, die ein Gel entwickelt haben, daß in Tierversuchen mit Makkaken-Affen einen 100%-igen Schutz !!!!!!! vor einer Infektion gewährleistete. Das übliche Problem der Aussagekraft von Tierversuchen ist hier zu vernachlässigen, da es sich hier schliesslich um keinen Wirkstoff handelt.
Noch diesen Monat soll die IND an die FDA gehen und damit wird STARPHARMA Geschichte schreiben als das erste Unternehmen, dass ein Nanomedikament in die klinische Erprobung unter FDA-Aufsicht gibt.
Bisher hat STARPHARMA die gesamten präklinischen Tests von diversen Organisationen bezahlt bekommen (u.a. NIH) und nach ihren Aussagen ist weitere Unterstützung im großen Stil zu erwarten.
Weitere Highlights kurz zusammengefasst:
- aus USA wurden Komponenten angefordert, die auf Wirksamkeit gegen SARS überprüft werden
- Zusammenarbeit mit IRL aus Neuseeland (ein staatseigenes Unternehmen) zur Entwicklung von Dendrimeren, die gezielt an bestimmte Stellen des Körpers manövriert werden können
Wem das nicht reicht, keine Sorge, der absolute Kracher kommt noch:
Ende letzten Jahres wurde ein Joint Venture gegründet, Dendritic Nanotechnologies (Beteiligung 49.99%). Einer der Mitbegründer und jetziger CTO von Dendritic N. ist Dr. Donald Tomalia, DER ERFINDER DER DENDRIMERE. Dendritic ist bereits finanziell selbständig, was wohl in der Liga der Nanotechs mehr als selten ist.
Alle Forschungsergebnisse die sich pharmazeutisch verwenden lassen sind exklusiv an STARPHARMA lizenziert.
Dendritic hat schon einige Millionen an Forschungsgeldern der Regierung eingesackt kaum das sie ihre Türen in the US of A. geöffnet hatten. Unter anderem eine Kooperation zum Schutz gegen Bioterrorismus.
Außerdem besteht ein Abkommen zum Vertrieb von Dendrimeren zu Forschungszwecken mit Sigma Aldrich.
Man könnte hier noch einiges erzählen und beizeiten werde ich diese Einführung auch noch detaillieren. Wer sich jetzt für STARPHARMA bzw. DENDRITIC etwas interessiert, sollte sich
starpharma.com
und
dnanotech.com
zu Gemüte führen und als kleiner Tip: Man schaue sich ins Besondere die Leute an die in bzw. im Umfeld dieser Firmen arbeiten. Hier wird was großes ausgebrütet. Starpharma behauptet nicht umsonst, daß sie mit Dendritic zusammen wohl das absolut bedeutenste Patentportfolio im Bereich der Dendrimere besitzen.
Marketcap.:
ca. 20 Millionen Euro
Gelistet:
ASX (Australien)
WKN:
deutsche WKN vorhanden und damit direkt in Australien orderbar. Kostenpunkt Ordergebühren: desaströse 110 Euro.Dafür ein Invest fürs Leben. Private Rentenvorsorge, usw...
Wer sich nun immer noch für die völlig unentdeckte Aktie interessiert, kann bei mir die WKN erfragen.
Ich habe die Vorstellung des "heissesten Unternehmens unter der australischen Sonne" bereits lange angekündigt und dieser Thread soll nun pünktlich zu einem entscheidenden Ereignis für STARPHARMA eröffnet werden, aber erst mal von vorne:
STARPHARMA besteht aus drei Subunternehmen, die sich mit der Herstellung von revolutionären Nanomedikamenten unter Anwendung von Dendrimeren beschäftigen.
Die Anwendungsgebiete reichen von Krebs, Malaria über Hepatitis B zu Genitalherpes und schließlich (und hier wird es besonders interessant) zu HIV/Aids.
Das HIV-Medikament würde ich normalerweise nicht besonders hervorheben, denn jedes Biotech-Unternehmen, das etwas auf sich hält, hat irgendetwas zur HIV-Bekämpfung in der Pipeline. Die Sache ist nur die, dass sich der Aidsvirus sehr schnell weiterentwickelt und verändert, was eine Heilung oder Impfung vielleicht für lange Zeit unmöglich macht. Hier kommt STARPHARMA ins Spiel, die ein Gel entwickelt haben, daß in Tierversuchen mit Makkaken-Affen einen 100%-igen Schutz !!!!!!! vor einer Infektion gewährleistete. Das übliche Problem der Aussagekraft von Tierversuchen ist hier zu vernachlässigen, da es sich hier schliesslich um keinen Wirkstoff handelt.
Noch diesen Monat soll die IND an die FDA gehen und damit wird STARPHARMA Geschichte schreiben als das erste Unternehmen, dass ein Nanomedikament in die klinische Erprobung unter FDA-Aufsicht gibt.
Bisher hat STARPHARMA die gesamten präklinischen Tests von diversen Organisationen bezahlt bekommen (u.a. NIH) und nach ihren Aussagen ist weitere Unterstützung im großen Stil zu erwarten.
Weitere Highlights kurz zusammengefasst:
- aus USA wurden Komponenten angefordert, die auf Wirksamkeit gegen SARS überprüft werden
- Zusammenarbeit mit IRL aus Neuseeland (ein staatseigenes Unternehmen) zur Entwicklung von Dendrimeren, die gezielt an bestimmte Stellen des Körpers manövriert werden können
Wem das nicht reicht, keine Sorge, der absolute Kracher kommt noch:
Ende letzten Jahres wurde ein Joint Venture gegründet, Dendritic Nanotechnologies (Beteiligung 49.99%). Einer der Mitbegründer und jetziger CTO von Dendritic N. ist Dr. Donald Tomalia, DER ERFINDER DER DENDRIMERE. Dendritic ist bereits finanziell selbständig, was wohl in der Liga der Nanotechs mehr als selten ist.
Alle Forschungsergebnisse die sich pharmazeutisch verwenden lassen sind exklusiv an STARPHARMA lizenziert.
Dendritic hat schon einige Millionen an Forschungsgeldern der Regierung eingesackt kaum das sie ihre Türen in the US of A. geöffnet hatten. Unter anderem eine Kooperation zum Schutz gegen Bioterrorismus.
Außerdem besteht ein Abkommen zum Vertrieb von Dendrimeren zu Forschungszwecken mit Sigma Aldrich.
Man könnte hier noch einiges erzählen und beizeiten werde ich diese Einführung auch noch detaillieren. Wer sich jetzt für STARPHARMA bzw. DENDRITIC etwas interessiert, sollte sich
starpharma.com
und
dnanotech.com
zu Gemüte führen und als kleiner Tip: Man schaue sich ins Besondere die Leute an die in bzw. im Umfeld dieser Firmen arbeiten. Hier wird was großes ausgebrütet. Starpharma behauptet nicht umsonst, daß sie mit Dendritic zusammen wohl das absolut bedeutenste Patentportfolio im Bereich der Dendrimere besitzen.
Marketcap.:
ca. 20 Millionen Euro
Gelistet:
ASX (Australien)
WKN:
deutsche WKN vorhanden und damit direkt in Australien orderbar. Kostenpunkt Ordergebühren: desaströse 110 Euro.Dafür ein Invest fürs Leben. Private Rentenvorsorge, usw...
Wer sich nun immer noch für die völlig unentdeckte Aktie interessiert, kann bei mir die WKN erfragen.
Ich seh schon...ist halt ein bißchen viel zum Lesen.
Um eines Tages die Performance zu belegen:
Mein Einstieg lag bei 0,194 € oder 0,34 A$
Um eines Tages die Performance zu belegen:
Mein Einstieg lag bei 0,194 € oder 0,34 A$
@ Neoe
ich hätte Interesse an diesem Wert. Kannst du bitte mal die WKN reinstellen. Warum gibt es eine deutsche WKN und dieser Wert kann trotzdem nicht in Frankfurt oder anderen deutschen Börsenplätzen gehandelt werden?? Danke für Deine Antwort.
ein Tip für Dich:
schau Dir mal Commonwealth Biotech an, ist ein interessanter Biotech Wert. oder Cygnus
ich hätte Interesse an diesem Wert. Kannst du bitte mal die WKN reinstellen. Warum gibt es eine deutsche WKN und dieser Wert kann trotzdem nicht in Frankfurt oder anderen deutschen Börsenplätzen gehandelt werden?? Danke für Deine Antwort.
ein Tip für Dich:
schau Dir mal Commonwealth Biotech an, ist ein interessanter Biotech Wert. oder Cygnus
Hört sich sehr interessant an.
Das Problem ist aber wirklich, dass Starpharma nur in Australien geordert werden kann. Und die dann anfallenden Odergebühren sind für mich wirklich absolut zu hoch, da ich wenn dann nur eine kleine, spekulative Position eingehen würde.
AG19
Das Problem ist aber wirklich, dass Starpharma nur in Australien geordert werden kann. Und die dann anfallenden Odergebühren sind für mich wirklich absolut zu hoch, da ich wenn dann nur eine kleine, spekulative Position eingehen würde.
AG19
WKN 796461. Damit kann man ordern, aber nur in Australien.
Wie gesagt 110 Euro Ordergebühren.
Wie gesagt 110 Euro Ordergebühren.
Hier die letzten drei Pressemeldungen, danach ist man wirklich sehr gut informiert:
Die erste ist ein Newsletter, der alles sehr gut zusammenfasst inkl. letztem Quartalsergebnis.
...........................................................
Letter to Shareholders - company update
05-05 1409
Let me first thank you for your interest and support of Starpharma.
The last twelve months have been particularly challenging times for
the Australian and Global biotechnology industry, and within this
context we are pleased to attach a copy of our ASX release of 30th
April 2003.
This release outlines very positive developments in Starpharma`s:
* US entity Dendritic Nanotechnologies Inc (DNT); and
* drug development programs in priority disease areas including HIV
and SARS.
I consider Starpharma`s role in the establishment of and investment
in DNT to be an outstanding achievement that will progressively be
recognised.
Starpharma is a world leader in the area of drug development using
polyvalent dendrimer nanotechnology. Because we were one of the first
in the area, Starpharma has a very strong international patent
position.
The potential of a polyvalent strategy in drug development has, until
recently, not been well recognised by major pharmaceutical companies.
Put simply, polyvalent strategy involves multiple drug groups on the
surface of a scaffold. Starpharma uses dendrimers as the scaffold,
because they can be precisely manufactured. We have demonstrated that
we can produce very active compounds against a wide range of disease
areas using the polyvalent approach.
One of the largest recent licence deals in the international
pharmaceutical industry involved the licensing of polyvalent
technology. The deal included a US$50 million up-front payment, up to
US$495 million milestone payments and greater than 10% royalty on
final product sales.
The technology involved in this deal is similar to Starpharma`s
polyvalent approach. However we use a different scaffolding -
dendrimers - which we believe offer advantages for the building of
polyvalent drugs. Starpharma, together with DNT, is in a very strong
position in this area with excellent prospects for future licensing.
Starpharma`s core business is drug discovery for the international
marketplace. The cost and resources required for drug development
dictate that Starpharma forms partnerships and licenses its drug
candidates to international pharmaceutical companies during varying
stages of the development phases, but not later than Phase II
clinical trials. There is an established international biotechnology
industry based on these principles, with established licensing
precedents.
The disease target of our lead project is sexually transmitted
disease prevention in a multibillion dollar market and there are
currently no pharmaceutical products on the market that work
effectively.
In primate studies, our product VivaGel(TM) was 100% effective in the
control of HIV infection. It is also showing promise for the control
of genital herpes and Chlamydia. The high selectivity of the compound
is demonstrated by trials which have shown that the compound is not
harmful to the natural vaginal flora.
Our dendrimer compounds have also demonstrated high activity in a
range of respiratory viruses including flu, RSV, adeno-virus and
exotic potential germ warfare viruses. One group of our dendrimers
has been shown to have very broad activity against RNA virus. SARS is
an RNA virus and hence the strong international interest in testing
our compounds against the SARS virus.
I have never been more confident about Starpharma`s international
technology position and our ability to develop new nanotechnology
based drugs against major diseases.
Our enthusiasm over the considerable potential of the Starpharma
technology has to be tempered by financial realities of the current
investment environment. Pharmaceutical product development takes time
and money, and it also takes time to negotiate significant licensing
deals with major pharmaceutical companies.
In the current financial environment it would be very difficult to
raise the new capital necessary for drug development without a major
dilution of shareholder equity. Our financial strategy is therefore:
* To streamline our operations to a level where we have sufficient
current cash reserves for at least the period to June 2005 assuming
no future income, whilst maintaining core functions and capabilities.
* To focus our development programs on areas where we can attract
major international grant funding, in particular HIV prevention, and
anti-viral and anti-toxin bio-defence. This funding support adds
value to our lead projects without causing shareholder dilution.
Starpharma has been very successful in the past in attracting
Australian and overseas grant funding and has established a network
of international collaborators who are world leaders in our target
disease areas.
* To actively seek collaborations and licensing with major
pharmaceutical companies and there is now strong interest in our
polyvalent technology.
We consider this to be a prudent strategy and, as funds become
available, we will be able to expand our operations rapidly. We have
a number of potential commercial projects in Starpharma`s pipeline.
We also have state of the art chemistry facilities at our Melbourne
laboratories together with an extensive international biology
research and testing network.
The pharmaceutical industry is recognising the potential of
polyvalence in drug development. This is an area in which Starpharma
is a world leader. If the recent progress continues the rewards for
the Company and shareholders will be high.
Dr J W Raff
CHIEF EXECUTIVE OFFICER
UPDATE AND QUARTERLY CASH FLOW REPORT FOR PERIOD
ENDED 31 MARCH 2003
Starpharma Pooled Development Limited (ASX:SPL) is pleased to present
its update and quarterly cashflow report for the period ended 31
March 2003.
SUMMARY
* Starpharma dendrimer compounds being tested against SARS virus in
the US.
* Starpharma advances HIV prevention (VivaGel(TM)).
* Anti-viral and anti-toxin bio-defence grant opportunities in the
pipeline.
* Starpharma investee company DNT successful in securing second
significant US Defense Department grant.
* DNT incorporated in the US and financially independent.
* Starpharma cash reserves still provide over 2 years of current
level operations without any further income.
The cash balance for the Starpharma group as at the end of the period
was $8.7m. The most significant impact on cash outflow during the
quarter was payment of the final balance of our investment in
Dendritic Nanotechnologies Ltd (DNT). Conversion of DNT into a US
entity has taken place and Starpharma now holds 49.99% of Dendritic
Nanotechnologies Inc, incorporated in Delaware.
DNT has been successful in securing a second significant US Defense
Department grant, the details of which remain confidential at this
stage. DNT is also working with industry to introduce dendrimer
technology in a range of commercially significant applications.
Starpharma has no further funding obligations to DNT and from this
point DNT will be financially independent of Starpharma. We believe
Starpharma`s equity investment in DNT has significant current value
and that the value of this asset will continue to increase. The
commercialisation rights over pharmaceutical applications arising
from DNT`s intellectual property have been licensed to Starpharma and
we are confident that this will be extremely valuable in the future.
DNT is also important in raising Starpharma`s profile in the US at
both government and industry level.
Excluding the final equity payment to DNT, the cash outflow for the
quarter was $1.4m as previously projected. This amount included
overseas and local expenditure associated with the preparation of the
submission of an IND to the US Food and Drug Administration (FDA) for
approval to begin human clinical safety trials of our vaginal
microbicide product VivaGel(TM), of which the active ingredient is
SPL7013. Additional studies have been completed, results have been
reviewed and Starpharma has been advised by its toxicology and
regulatory consultants that it will be in a position to lodge its IND
submission to the FDA in June 2003. VivaGel(TM) is recognised
internationally as a major product opportunity for HIV prevention as
well as for the prevention of other significant diseases such as
Chlamydia. Additional primate studies have commenced to investigate
the range of applications for VivaGel(TM), and these are being
carried out at no cost to Starpharma.
Starpharma`s strategy is to maintain its current level of core
operations in Australia, and we have sufficient funds to continue at
this level until at least June 2005 without additional funding. We
have every expectation that we will continue to obtain significant
additional external funding support. We are focusing our development
programs on areas where we can attract major international grant
funding, in particular HIV prevention and anti-viral and antitoxin
bio-defence. We also have significant dendrimer based anti-cancer and
HBV programs. Starpharma`s compounds are currently being tested for
specific high priority applications in the US, and a number of large
grant opportunities that would allow accelerated development of our
projects, are in the pipeline.
For example, in relation to SARS virus, Starpharma`s collaborative
projects with US respiratory virus leaders have previously shown
several of our dendrimer compounds have broad spectrum activity
against a wide range of RNA viruses. The SARS virus belongs to this
group and we have therefore been requested to urgently provide these
compounds for testing at high security SARS testing facilities in the
US. Starpharma has already despatched these compounds for testing
against SARS.
John W Raff
CHIEF EXECUTIVE OFFICER
CONTACTS:
Dr John Raff Ben Rogers
CHIEF EXECUTIVE OFFICER COMPANY SECRETARY
+61 3 8532 2701 +61 3 8532 2702
www.starpharma.com
...........................................................
Nummer 2:
DNT - MIT initiative & new appointments
26-05 1043
STARPHARMA`S USA AFFILIATE DNT INC AT THE HEART OF RECENT US
NANOTECHNOLOGY DEVELOPMENTS
Starpharma Pooled Development Limited (ASX: SPL) ("Starpharma")
announces the following developments that demonstrate the
opportunities and leading position in the US nanotechnology industry
for investee company Dendritic Nanotechnologies Inc ("DNT"):
1. The selection of DNT as an industrial partner with MIT`s Institute
for Soldier Nanotechnologies. The MIT press release is attached.
Starpharma`s CEO, John Raff, said "The selection of DNT as one of the
industrial partners in a highly competitive process highlights DNT`s
standing in the US nanotechnology industry".
2. New high-profile appointments to DNT:
* Mr Richard Hazelton, former President and CEO of Dow Corning has
agreed to join the Board of DNT. This is the first technology company
directorship that Richard Hazelton has accepted since his recent
retirement from Dow Corning.
* Mr Gifford E Brown, who recently retired from the position of
Vice-President of Planning & Finance and CFO of Dow Corning, has
accepted a part-time position as CFO of DNT.
* Dr Sonke Svensen, who was a senior scientist at Dow Corning
specialising in drug delivery, has accepted a senior scientific
position in DNT`s research laboratories.
"The ability of DNT to attract people of this calibre is an
outstanding achievement for an Australian-US joint venture
initiative," Dr Raff said.
3. The significance of nanotechnology is illustrated by the US House
of Representatives` recent announcement of an additional US$2.36
billion over three years to fund research in nanotechnology.
Starpharma and DNT are both specialist, dendrimer-based companies,
and dendrimers are a basic building block of nanotechnology.
Starpharma is a 49.9% equity owner of DNT, Inc and has
collaborations and commercialisation rights with DNT in the area of
pharmaceuticals. DNT has an extensive intellectual property portfolio
and is currently marketing dendrimers through Sigma-Aldrich. DNT also
has development projects in the areas of new battery technology,
electronic displays, drug delivery and diagnostic nanosensors. These
development projects are already supported by major grants.
Dr Raff said "The partnership between Dr Donald Tomalia and
Starpharma, which began in Melbourne two years ago, has created a
company - DNT, Inc - which is at the leading edge of the
international nanotechnology industry."
...........................................................
Nummer 3:
SPL&Industrial Res Ltd est Carbohydrate Nanotechnology All
03-06 0948
Starpharma Pooled Development Limited (ASX:SPL) ("Starpharma") and
Industrial Research Limited (IRL) today announced the establishment
of a collaborative initiative into the development of carbohydrate
functionalised dendrimers for use in therapeutics, antigen
presentation and as biologically active compounds in their own right.
This leading edge effort aims to make nanometre-sized particles that
can be used to target drugs to specific sites resulting in better
performance and fewer side effects.
The establishment of this alliance has been substantially supported
by the New Zealand Government, through its Foundation for Research,
Science and Technology ("FRST"), which has awarded IRL a contract
totalling NZ$5.9 million over five years. This Carbohydrate
Nanotechnology contract involves the preparation of carbohydrate
functionalised dendrimers and immune stimulatory complexes (ISCOMs)
functionalised to achieve active targeting for potential therapeutic
and vaccine applications. New Zealand collaborators in the contract
also include the School of Pharmacy, University of Otago (ISCOM
preparation and immunology), and the Cawthron Institute (enzymes from
natural sources to prepare complex carbohydrates).
Starpharma and IRL have executed a scientific, technological and
business co-operation agreement under which Starpharma will be
supplying dendrimers, know-how and development expertise. IRL will
draw upon its significant expertise in the design, synthesis,
analysis and commercial scale manufacture of carbohydrates.
Under the terms of the agreement, the parties intend to build a
glycodendrimer technology platform for commercialisation in the many
potential fields of application. As carbohydrates play a central role
in many human diseases, and dendrimer nanotechnology is recognised as
a key enabling technology, successful outcomes of this alliance will
include targeted delivery of drugs to specific tissues and the
potential for more effective vaccines. Starpharma is the commercial
partner to the initiative and will guide development of products.
Manufacture of the high value carbohydrate products will occur at
IRL`s cGMP facility in New Zealand.
Dr John Raff, Chief Executive Officer of Starpharma, said: "The FRST
Contract and IRL`s world-competitive position in carbohydrate
science, together with Starpharma`s expertise in the pharmaceutical
development of dendrimers, is the foundation for a highly significant
trans-Tasman alliance. This agreement with IRL expands our existing
relationship with IRL and New Zealand science and enhances
significantly Starpharma`s strategy of partnering with developers of
world-leading technologies that are complementary to our dendrimer
technology platform. This powerful combination enhances the strategic
value of dendrimers as pharmaceuticals."
Dr Phillip Rendle, IRL`s Programme Leader of the Carbohydrate
Nanotechnology contract, said he is flattered to be working with
Starpharma due to their high quality science and personnel.
"Starpharma`s support has been a major factor in being awarded this
contract and will be crucial in achieving IRL`s mandate of adding
value to New Zealand. The combination of expertise at Starpharma and
IRL gives this collaboration a world-class competitive edge."
Starpharma Limited, a wholly owned subsidiary of Starpharma Pooled
Development Limited, is a biopharmaceutical company focussed on the
development and application of dendrimer nanotechnologies as drugs
against major diseases. Starpharma has an extensive intellectual
property portfolio relating to dendrimer nanotechnology. It also has
a joint venture company - Dendritic Nanotechnologies, Inc. -
established with the US pioneer of dendrimer nanotechnology, Dr
Donald Tomalia.
Industrial Research is a commercial company with the New Zealand
government as shareholder. They are an innovation-focussed business,
utilising world-class science platforms to create globally
competitive, market viable technologies. A driving factor is to
establish science and business connections throughout the world, with
a view towards commercialising technology that will establish high
value industries.
Die erste ist ein Newsletter, der alles sehr gut zusammenfasst inkl. letztem Quartalsergebnis.
...........................................................
Letter to Shareholders - company update
05-05 1409
Let me first thank you for your interest and support of Starpharma.
The last twelve months have been particularly challenging times for
the Australian and Global biotechnology industry, and within this
context we are pleased to attach a copy of our ASX release of 30th
April 2003.
This release outlines very positive developments in Starpharma`s:
* US entity Dendritic Nanotechnologies Inc (DNT); and
* drug development programs in priority disease areas including HIV
and SARS.
I consider Starpharma`s role in the establishment of and investment
in DNT to be an outstanding achievement that will progressively be
recognised.
Starpharma is a world leader in the area of drug development using
polyvalent dendrimer nanotechnology. Because we were one of the first
in the area, Starpharma has a very strong international patent
position.
The potential of a polyvalent strategy in drug development has, until
recently, not been well recognised by major pharmaceutical companies.
Put simply, polyvalent strategy involves multiple drug groups on the
surface of a scaffold. Starpharma uses dendrimers as the scaffold,
because they can be precisely manufactured. We have demonstrated that
we can produce very active compounds against a wide range of disease
areas using the polyvalent approach.
One of the largest recent licence deals in the international
pharmaceutical industry involved the licensing of polyvalent
technology. The deal included a US$50 million up-front payment, up to
US$495 million milestone payments and greater than 10% royalty on
final product sales.
The technology involved in this deal is similar to Starpharma`s
polyvalent approach. However we use a different scaffolding -
dendrimers - which we believe offer advantages for the building of
polyvalent drugs. Starpharma, together with DNT, is in a very strong
position in this area with excellent prospects for future licensing.
Starpharma`s core business is drug discovery for the international
marketplace. The cost and resources required for drug development
dictate that Starpharma forms partnerships and licenses its drug
candidates to international pharmaceutical companies during varying
stages of the development phases, but not later than Phase II
clinical trials. There is an established international biotechnology
industry based on these principles, with established licensing
precedents.
The disease target of our lead project is sexually transmitted
disease prevention in a multibillion dollar market and there are
currently no pharmaceutical products on the market that work
effectively.
In primate studies, our product VivaGel(TM) was 100% effective in the
control of HIV infection. It is also showing promise for the control
of genital herpes and Chlamydia. The high selectivity of the compound
is demonstrated by trials which have shown that the compound is not
harmful to the natural vaginal flora.
Our dendrimer compounds have also demonstrated high activity in a
range of respiratory viruses including flu, RSV, adeno-virus and
exotic potential germ warfare viruses. One group of our dendrimers
has been shown to have very broad activity against RNA virus. SARS is
an RNA virus and hence the strong international interest in testing
our compounds against the SARS virus.
I have never been more confident about Starpharma`s international
technology position and our ability to develop new nanotechnology
based drugs against major diseases.
Our enthusiasm over the considerable potential of the Starpharma
technology has to be tempered by financial realities of the current
investment environment. Pharmaceutical product development takes time
and money, and it also takes time to negotiate significant licensing
deals with major pharmaceutical companies.
In the current financial environment it would be very difficult to
raise the new capital necessary for drug development without a major
dilution of shareholder equity. Our financial strategy is therefore:
* To streamline our operations to a level where we have sufficient
current cash reserves for at least the period to June 2005 assuming
no future income, whilst maintaining core functions and capabilities.
* To focus our development programs on areas where we can attract
major international grant funding, in particular HIV prevention, and
anti-viral and anti-toxin bio-defence. This funding support adds
value to our lead projects without causing shareholder dilution.
Starpharma has been very successful in the past in attracting
Australian and overseas grant funding and has established a network
of international collaborators who are world leaders in our target
disease areas.
* To actively seek collaborations and licensing with major
pharmaceutical companies and there is now strong interest in our
polyvalent technology.
We consider this to be a prudent strategy and, as funds become
available, we will be able to expand our operations rapidly. We have
a number of potential commercial projects in Starpharma`s pipeline.
We also have state of the art chemistry facilities at our Melbourne
laboratories together with an extensive international biology
research and testing network.
The pharmaceutical industry is recognising the potential of
polyvalence in drug development. This is an area in which Starpharma
is a world leader. If the recent progress continues the rewards for
the Company and shareholders will be high.
Dr J W Raff
CHIEF EXECUTIVE OFFICER
UPDATE AND QUARTERLY CASH FLOW REPORT FOR PERIOD
ENDED 31 MARCH 2003
Starpharma Pooled Development Limited (ASX:SPL) is pleased to present
its update and quarterly cashflow report for the period ended 31
March 2003.
SUMMARY
* Starpharma dendrimer compounds being tested against SARS virus in
the US.
* Starpharma advances HIV prevention (VivaGel(TM)).
* Anti-viral and anti-toxin bio-defence grant opportunities in the
pipeline.
* Starpharma investee company DNT successful in securing second
significant US Defense Department grant.
* DNT incorporated in the US and financially independent.
* Starpharma cash reserves still provide over 2 years of current
level operations without any further income.
The cash balance for the Starpharma group as at the end of the period
was $8.7m. The most significant impact on cash outflow during the
quarter was payment of the final balance of our investment in
Dendritic Nanotechnologies Ltd (DNT). Conversion of DNT into a US
entity has taken place and Starpharma now holds 49.99% of Dendritic
Nanotechnologies Inc, incorporated in Delaware.
DNT has been successful in securing a second significant US Defense
Department grant, the details of which remain confidential at this
stage. DNT is also working with industry to introduce dendrimer
technology in a range of commercially significant applications.
Starpharma has no further funding obligations to DNT and from this
point DNT will be financially independent of Starpharma. We believe
Starpharma`s equity investment in DNT has significant current value
and that the value of this asset will continue to increase. The
commercialisation rights over pharmaceutical applications arising
from DNT`s intellectual property have been licensed to Starpharma and
we are confident that this will be extremely valuable in the future.
DNT is also important in raising Starpharma`s profile in the US at
both government and industry level.
Excluding the final equity payment to DNT, the cash outflow for the
quarter was $1.4m as previously projected. This amount included
overseas and local expenditure associated with the preparation of the
submission of an IND to the US Food and Drug Administration (FDA) for
approval to begin human clinical safety trials of our vaginal
microbicide product VivaGel(TM), of which the active ingredient is
SPL7013. Additional studies have been completed, results have been
reviewed and Starpharma has been advised by its toxicology and
regulatory consultants that it will be in a position to lodge its IND
submission to the FDA in June 2003. VivaGel(TM) is recognised
internationally as a major product opportunity for HIV prevention as
well as for the prevention of other significant diseases such as
Chlamydia. Additional primate studies have commenced to investigate
the range of applications for VivaGel(TM), and these are being
carried out at no cost to Starpharma.
Starpharma`s strategy is to maintain its current level of core
operations in Australia, and we have sufficient funds to continue at
this level until at least June 2005 without additional funding. We
have every expectation that we will continue to obtain significant
additional external funding support. We are focusing our development
programs on areas where we can attract major international grant
funding, in particular HIV prevention and anti-viral and antitoxin
bio-defence. We also have significant dendrimer based anti-cancer and
HBV programs. Starpharma`s compounds are currently being tested for
specific high priority applications in the US, and a number of large
grant opportunities that would allow accelerated development of our
projects, are in the pipeline.
For example, in relation to SARS virus, Starpharma`s collaborative
projects with US respiratory virus leaders have previously shown
several of our dendrimer compounds have broad spectrum activity
against a wide range of RNA viruses. The SARS virus belongs to this
group and we have therefore been requested to urgently provide these
compounds for testing at high security SARS testing facilities in the
US. Starpharma has already despatched these compounds for testing
against SARS.
John W Raff
CHIEF EXECUTIVE OFFICER
CONTACTS:
Dr John Raff Ben Rogers
CHIEF EXECUTIVE OFFICER COMPANY SECRETARY
+61 3 8532 2701 +61 3 8532 2702
www.starpharma.com
...........................................................
Nummer 2:
DNT - MIT initiative & new appointments
26-05 1043
STARPHARMA`S USA AFFILIATE DNT INC AT THE HEART OF RECENT US
NANOTECHNOLOGY DEVELOPMENTS
Starpharma Pooled Development Limited (ASX: SPL) ("Starpharma")
announces the following developments that demonstrate the
opportunities and leading position in the US nanotechnology industry
for investee company Dendritic Nanotechnologies Inc ("DNT"):
1. The selection of DNT as an industrial partner with MIT`s Institute
for Soldier Nanotechnologies. The MIT press release is attached.
Starpharma`s CEO, John Raff, said "The selection of DNT as one of the
industrial partners in a highly competitive process highlights DNT`s
standing in the US nanotechnology industry".
2. New high-profile appointments to DNT:
* Mr Richard Hazelton, former President and CEO of Dow Corning has
agreed to join the Board of DNT. This is the first technology company
directorship that Richard Hazelton has accepted since his recent
retirement from Dow Corning.
* Mr Gifford E Brown, who recently retired from the position of
Vice-President of Planning & Finance and CFO of Dow Corning, has
accepted a part-time position as CFO of DNT.
* Dr Sonke Svensen, who was a senior scientist at Dow Corning
specialising in drug delivery, has accepted a senior scientific
position in DNT`s research laboratories.
"The ability of DNT to attract people of this calibre is an
outstanding achievement for an Australian-US joint venture
initiative," Dr Raff said.
3. The significance of nanotechnology is illustrated by the US House
of Representatives` recent announcement of an additional US$2.36
billion over three years to fund research in nanotechnology.
Starpharma and DNT are both specialist, dendrimer-based companies,
and dendrimers are a basic building block of nanotechnology.
Starpharma is a 49.9% equity owner of DNT, Inc and has
collaborations and commercialisation rights with DNT in the area of
pharmaceuticals. DNT has an extensive intellectual property portfolio
and is currently marketing dendrimers through Sigma-Aldrich. DNT also
has development projects in the areas of new battery technology,
electronic displays, drug delivery and diagnostic nanosensors. These
development projects are already supported by major grants.
Dr Raff said "The partnership between Dr Donald Tomalia and
Starpharma, which began in Melbourne two years ago, has created a
company - DNT, Inc - which is at the leading edge of the
international nanotechnology industry."
...........................................................
Nummer 3:
SPL&Industrial Res Ltd est Carbohydrate Nanotechnology All
03-06 0948
Starpharma Pooled Development Limited (ASX:SPL) ("Starpharma") and
Industrial Research Limited (IRL) today announced the establishment
of a collaborative initiative into the development of carbohydrate
functionalised dendrimers for use in therapeutics, antigen
presentation and as biologically active compounds in their own right.
This leading edge effort aims to make nanometre-sized particles that
can be used to target drugs to specific sites resulting in better
performance and fewer side effects.
The establishment of this alliance has been substantially supported
by the New Zealand Government, through its Foundation for Research,
Science and Technology ("FRST"), which has awarded IRL a contract
totalling NZ$5.9 million over five years. This Carbohydrate
Nanotechnology contract involves the preparation of carbohydrate
functionalised dendrimers and immune stimulatory complexes (ISCOMs)
functionalised to achieve active targeting for potential therapeutic
and vaccine applications. New Zealand collaborators in the contract
also include the School of Pharmacy, University of Otago (ISCOM
preparation and immunology), and the Cawthron Institute (enzymes from
natural sources to prepare complex carbohydrates).
Starpharma and IRL have executed a scientific, technological and
business co-operation agreement under which Starpharma will be
supplying dendrimers, know-how and development expertise. IRL will
draw upon its significant expertise in the design, synthesis,
analysis and commercial scale manufacture of carbohydrates.
Under the terms of the agreement, the parties intend to build a
glycodendrimer technology platform for commercialisation in the many
potential fields of application. As carbohydrates play a central role
in many human diseases, and dendrimer nanotechnology is recognised as
a key enabling technology, successful outcomes of this alliance will
include targeted delivery of drugs to specific tissues and the
potential for more effective vaccines. Starpharma is the commercial
partner to the initiative and will guide development of products.
Manufacture of the high value carbohydrate products will occur at
IRL`s cGMP facility in New Zealand.
Dr John Raff, Chief Executive Officer of Starpharma, said: "The FRST
Contract and IRL`s world-competitive position in carbohydrate
science, together with Starpharma`s expertise in the pharmaceutical
development of dendrimers, is the foundation for a highly significant
trans-Tasman alliance. This agreement with IRL expands our existing
relationship with IRL and New Zealand science and enhances
significantly Starpharma`s strategy of partnering with developers of
world-leading technologies that are complementary to our dendrimer
technology platform. This powerful combination enhances the strategic
value of dendrimers as pharmaceuticals."
Dr Phillip Rendle, IRL`s Programme Leader of the Carbohydrate
Nanotechnology contract, said he is flattered to be working with
Starpharma due to their high quality science and personnel.
"Starpharma`s support has been a major factor in being awarded this
contract and will be crucial in achieving IRL`s mandate of adding
value to New Zealand. The combination of expertise at Starpharma and
IRL gives this collaboration a world-class competitive edge."
Starpharma Limited, a wholly owned subsidiary of Starpharma Pooled
Development Limited, is a biopharmaceutical company focussed on the
development and application of dendrimer nanotechnologies as drugs
against major diseases. Starpharma has an extensive intellectual
property portfolio relating to dendrimer nanotechnology. It also has
a joint venture company - Dendritic Nanotechnologies, Inc. -
established with the US pioneer of dendrimer nanotechnology, Dr
Donald Tomalia.
Industrial Research is a commercial company with the New Zealand
government as shareholder. They are an innovation-focussed business,
utilising world-class science platforms to create globally
competitive, market viable technologies. A driving factor is to
establish science and business connections throughout the world, with
a view towards commercialising technology that will establish high
value industries.
Ich bin einfach mal so frei und stell den Chart rein:
@ Neoe
hab mich heut bei meinem online broker erkundigt, nämlich consors. die sagten mir, das es nicht möglich ist, diese aktie unter dieser wkn zu kaufen, auch nicht in australien. wenn es eine dt. wkn gibt, kann man auch in deutschland ordern. das ist fakt. bei welchem online broker bist du? du kannst ja einen depot übertrag machen auf meins. war blos nen scherz. danke
hab mich heut bei meinem online broker erkundigt, nämlich consors. die sagten mir, das es nicht möglich ist, diese aktie unter dieser wkn zu kaufen, auch nicht in australien. wenn es eine dt. wkn gibt, kann man auch in deutschland ordern. das ist fakt. bei welchem online broker bist du? du kannst ja einen depot übertrag machen auf meins. war blos nen scherz. danke
bullebio:
Comdirect (hier habe ich geordert), Diraba und Deutsche Bank ? oder Citibank ?.
Bei Consors habe ich auch angefragt geht aber nicht, wie du ja auh sagtest.
Comdirect (hier habe ich geordert), Diraba und Deutsche Bank ? oder Citibank ?.
Bei Consors habe ich auch angefragt geht aber nicht, wie du ja auh sagtest.
bullebio, die Zweite:
Commonwealth ist interessant. Hab ich mir auch überlegt, aber das Ganze scheint mir noch ncht nachhaltig genug. Besonders weil sich der Forensic-Markt gerade verändert, hierzu Weise ich auf DNA Print Genomics hin, die diesen Bereich momentan revolutionieren.
Commonwealth ist interessant. Hab ich mir auch überlegt, aber das Ganze scheint mir noch ncht nachhaltig genug. Besonders weil sich der Forensic-Markt gerade verändert, hierzu Weise ich auf DNA Print Genomics hin, die diesen Bereich momentan revolutionieren.
@Neoe,
interessantes Posting. Bitte erlaube mir zwei Fragen dazu :
1) Warum ist die Aktie im Rahmen der Aufwärtsbewegung, insbesondere vieler Small-Cap Unternehmen, nicht mitgelaufen ?
2)Warum ist eine Aktie, die angeblich ein solches Potenzial aufweist, nur in Australien notiert und nicht etwa auch an der Nasdaq (OTC) oder im Freiverkehr in Deutschland ?
Ohne jeden Zweifel lesen sich die von dir geposteten Unternehmensinformationen sehr interessant. Jedoch bin ich immer skeptisch, wenn eine Aktie auf positive Nachrichten nicht reagiert. Warum sollte sie das später noch tun ? Ich glaube das Märkte effizient sind und denke nicht, dass es nur daran liegt, dass eine Aktie "unentdeckt" sein kann, auch wenn sie "nur" in Australien notiert ist.
Schöne Grüße
G_d_A
interessantes Posting. Bitte erlaube mir zwei Fragen dazu :
1) Warum ist die Aktie im Rahmen der Aufwärtsbewegung, insbesondere vieler Small-Cap Unternehmen, nicht mitgelaufen ?
2)Warum ist eine Aktie, die angeblich ein solches Potenzial aufweist, nur in Australien notiert und nicht etwa auch an der Nasdaq (OTC) oder im Freiverkehr in Deutschland ?
Ohne jeden Zweifel lesen sich die von dir geposteten Unternehmensinformationen sehr interessant. Jedoch bin ich immer skeptisch, wenn eine Aktie auf positive Nachrichten nicht reagiert. Warum sollte sie das später noch tun ? Ich glaube das Märkte effizient sind und denke nicht, dass es nur daran liegt, dass eine Aktie "unentdeckt" sein kann, auch wenn sie "nur" in Australien notiert ist.
Schöne Grüße
G_d_A
Gedanken_der_Anleger:
Du wirst sehen was demnächst passiert, wenn Starpharma mit Vivagel in Phase I eintritt.
Das Starpharma nicht an der OTC gelistet ist, sehe ich als Vorteil, da die OTC ein Betrügernest ist. Zudem solltest du vielleicht berücksichtigen, wieviele Unternehmen von hier, die sogar weit höhere Marktkapitalisierungen haben, nicht in Amerika gelistet sind.
Weiteren Diskussionsbedarf zur Qualität des Unternehmens gibt es meinerseits nicht. Oben ist alles nachzulesen, also hinterher kann keiner sagen, er hätte es nicht gewusst.
Du wirst sehen was demnächst passiert, wenn Starpharma mit Vivagel in Phase I eintritt.
Das Starpharma nicht an der OTC gelistet ist, sehe ich als Vorteil, da die OTC ein Betrügernest ist. Zudem solltest du vielleicht berücksichtigen, wieviele Unternehmen von hier, die sogar weit höhere Marktkapitalisierungen haben, nicht in Amerika gelistet sind.
Weiteren Diskussionsbedarf zur Qualität des Unternehmens gibt es meinerseits nicht. Oben ist alles nachzulesen, also hinterher kann keiner sagen, er hätte es nicht gewusst.
Human trials for AIDS barrier gel
By CNN`s Grant Holloway
Monday, June 16, 2003 Posted: 0524 GMT ( 1:24 PM HKT)
Women in poorer countries are more vulnerable to contracting HIV.
--------------------------------------------------------------------------------
Story Tools
-------------------------------------------------------------------------
RELATED
• HIV epidemic could triple by 2010
• Proteins key to replication of HIV
• Interactive: AIDS statistics
• Interactive: How HIV infects cells
• Gallery: AIDS in Asia
• Special report: 20 years of an epidemic
SYDNEY, Australia (CNN) -- An Australian company may soon begin human trials for an anti-AIDS gel which could dramatically reduce the spread of the virus in developing countries.
Melbourne-based Starpharma is seeking approval from the U.S. Food and Drug Administration (FDA) to trial the gel which has proved 100 percent effective in preventing HIV and other sexually-transmitted diseases in primate trials.
The gel -- if human trials prove successful -- would be particularly targeted at women in poorer nations, giving them cheaper, easier personal control over HIV prevention.
A report by the Rockefeller Foundation into HIV prevention, released earlier this year, estimates up to 2.5 million lives could be saved over three years if such a product was readily available.
In animals trials using macaque monkeys, a single application of the VivaGel product proved 100 percent effective against the monkey version of HIV as well as animal versions of genital herpes and chlamydia.
More than 5 million people are infected by HIV each year, 1.8 million of them women.
Starpharma chief executive officer Dr John Raff told CNN Monday that if FDA approval is granted smoothly then phase-one human trials of the product could begin in Australia by the end of this year.
This would then be followed by a second 12-month trial involving at least 8,000 women with a possible prescription-only product available in three years` time. It would be another two years after that before an over-the-counter type product could be distributed.
Raff said VivaGel was a "first of its type" product which could set a precedent for the development of other disease treatments in years to come.
AIDS has the potential to devastate the economies of struggling nations.
"A lot of people will be watching very carefully what the FDA will do," Raff said.
Starpharma had enough funding to continue its work for the next 30 months and was confident of gaining additional external finance from governments or AIDS foundations to fully realize the potential of its product, he said.
A lot more international money and effort was now being put into developing preventatives for HIV/AIDS than cures, including a $15 billion U.S. program to combat AIDS in Africa and the Caribbean which came into effect last month, he said.
And the development of a cream or a gel to help prevent HIV transmission was boosted in late March by a $60 million donation from the Bill and Melinda Gates Foundation.
The money was donated to the International Partnership for Microbicides (IPM), a non-profit organization set up to promote the development of low-cost HIV/AIDS preventions.
Microbicides are gels, films, sponges or other products applied directly to the skin to help prevent the spread of disease.
The IPM says the development of these types of treatments is downplayed by large pharmaceutical companies because they are not big money-spinners.
Looming crises
But microbicides are particularly useful for women in poorer countries as they give them more control in helping prevent disease, particularly in cultures where condoms are a male-dominated product.
Women are also more vulnerable to contracting HIV from a single sexual encounter.
Countries such as Myanmar and Papua New Guinea face looming AIDS crises of a scale similar to those seen in Africa because of a lack of preventative measures.
A recent Australian government aid report says the working population of PNG could be cut by 38 percent by 2020 if infection rates follow those seen in Zimbabwe. (PNG on the brink)
In Myanmar it is estimated that as many as 1 in 50 people has HIV with the disease spreading rapidly among the general population from high-risk groups such as prostitutes and intravenous drug users.
At the end of last year, 42 million people were infected with AIDS and by 2010 it is estimated a further 45 million people will be infected.
Die IND is also bei der FDA angekommen und sowie es aussieht kommt Starpharmas Geld für die anstehenden Studien direkt aus Bill Gates` Tasche.
By CNN`s Grant Holloway
Monday, June 16, 2003 Posted: 0524 GMT ( 1:24 PM HKT)
Women in poorer countries are more vulnerable to contracting HIV.
--------------------------------------------------------------------------------
Story Tools
-------------------------------------------------------------------------
RELATED
• HIV epidemic could triple by 2010
• Proteins key to replication of HIV
• Interactive: AIDS statistics
• Interactive: How HIV infects cells
• Gallery: AIDS in Asia
• Special report: 20 years of an epidemic
SYDNEY, Australia (CNN) -- An Australian company may soon begin human trials for an anti-AIDS gel which could dramatically reduce the spread of the virus in developing countries.
Melbourne-based Starpharma is seeking approval from the U.S. Food and Drug Administration (FDA) to trial the gel which has proved 100 percent effective in preventing HIV and other sexually-transmitted diseases in primate trials.
The gel -- if human trials prove successful -- would be particularly targeted at women in poorer nations, giving them cheaper, easier personal control over HIV prevention.
A report by the Rockefeller Foundation into HIV prevention, released earlier this year, estimates up to 2.5 million lives could be saved over three years if such a product was readily available.
In animals trials using macaque monkeys, a single application of the VivaGel product proved 100 percent effective against the monkey version of HIV as well as animal versions of genital herpes and chlamydia.
More than 5 million people are infected by HIV each year, 1.8 million of them women.
Starpharma chief executive officer Dr John Raff told CNN Monday that if FDA approval is granted smoothly then phase-one human trials of the product could begin in Australia by the end of this year.
This would then be followed by a second 12-month trial involving at least 8,000 women with a possible prescription-only product available in three years` time. It would be another two years after that before an over-the-counter type product could be distributed.
Raff said VivaGel was a "first of its type" product which could set a precedent for the development of other disease treatments in years to come.
AIDS has the potential to devastate the economies of struggling nations.
"A lot of people will be watching very carefully what the FDA will do," Raff said.
Starpharma had enough funding to continue its work for the next 30 months and was confident of gaining additional external finance from governments or AIDS foundations to fully realize the potential of its product, he said.
A lot more international money and effort was now being put into developing preventatives for HIV/AIDS than cures, including a $15 billion U.S. program to combat AIDS in Africa and the Caribbean which came into effect last month, he said.
And the development of a cream or a gel to help prevent HIV transmission was boosted in late March by a $60 million donation from the Bill and Melinda Gates Foundation.
The money was donated to the International Partnership for Microbicides (IPM), a non-profit organization set up to promote the development of low-cost HIV/AIDS preventions.
Microbicides are gels, films, sponges or other products applied directly to the skin to help prevent the spread of disease.
The IPM says the development of these types of treatments is downplayed by large pharmaceutical companies because they are not big money-spinners.
Looming crises
But microbicides are particularly useful for women in poorer countries as they give them more control in helping prevent disease, particularly in cultures where condoms are a male-dominated product.
Women are also more vulnerable to contracting HIV from a single sexual encounter.
Countries such as Myanmar and Papua New Guinea face looming AIDS crises of a scale similar to those seen in Africa because of a lack of preventative measures.
A recent Australian government aid report says the working population of PNG could be cut by 38 percent by 2020 if infection rates follow those seen in Zimbabwe. (PNG on the brink)
In Myanmar it is estimated that as many as 1 in 50 people has HIV with the disease spreading rapidly among the general population from high-risk groups such as prostitutes and intravenous drug users.
At the end of last year, 42 million people were infected with AIDS and by 2010 it is estimated a further 45 million people will be infected.
Die IND is also bei der FDA angekommen und sowie es aussieht kommt Starpharmas Geld für die anstehenden Studien direkt aus Bill Gates` Tasche.
Guten Abend!
Entschuldigung für die vielleicht etwas dumme Frage. Aber was muss ich, z.B. bei Comdirect eingeben, um wenigstens den Kurs verfolgen zu können? Wenn ich schon für teuer Geld kaufen müsste.
Danke!!!
Gruß, greenhorn
Entschuldigung für die vielleicht etwas dumme Frage. Aber was muss ich, z.B. bei Comdirect eingeben, um wenigstens den Kurs verfolgen zu können? Wenn ich schon für teuer Geld kaufen müsste.
Danke!!!
Gruß, greenhorn
Bei Comdirect geht nichts, außer wenn du sie im Depot hast.
Bei "yahoo finance" als Kürzel SPL.AX eingeben oder direkt unter der australischen Börsenseite www.asx.com.au SPL eingeben.
Ziemlich kompliziert, aber eigentlich lechzt doch immer jeder nach Geheimtips.
Ganz nebenbei:
Obwohl ich schon von Starpharma selbst sehr begeistert bin, alleine wegen der 50%-Beteiligung an Dendritic Nanotech ist man hier auf der sicheren Seite. SigmaAldrich,
Dr.Tomalia und die US-Administration haben dafür schon gesorgt.
Bei "yahoo finance" als Kürzel SPL.AX eingeben oder direkt unter der australischen Börsenseite www.asx.com.au SPL eingeben.
Ziemlich kompliziert, aber eigentlich lechzt doch immer jeder nach Geheimtips.
Ganz nebenbei:
Obwohl ich schon von Starpharma selbst sehr begeistert bin, alleine wegen der 50%-Beteiligung an Dendritic Nanotech ist man hier auf der sicheren Seite. SigmaAldrich,
Dr.Tomalia und die US-Administration haben dafür schon gesorgt.
Hallo!!!
Ganz herzlichen Dank für die prompte Antwort! Jetzt habe ich wenigstens die Möglichkeit, den Kurs zu verfolgen. Habe mit sehr viel Interesse deine Postings gelesen. Scheint sich wirklich noch um einen Geheimtipp zu handeln, was ich allerdings nicht ganz verstehe. Vielleicht daher noch eine dumme Frage:
Der Kurs dümpelt weiterhin in den Niederungen des Charts herum, auch die Meldung von Mitte Juni, die du gestern netterweise hereingestellt hast, hat sich nicht wirklich ausgewirkt. Warum? Wenn die Erfolgsaussichten so gut sind, das Unternehmen patenttechnisch abgesichert ist, quasi Alleinstellungsmerkmale hat, warum scheint sich keiner darum zu kümmern? Wie sieht denn die Aktionärsstruktur bei Starpharma aus? Sind Insider, Management oder Fonds investiert?
Ich bin sehr interessiert und dankbar für die bisherigen Info`s. Vielleicht kannst du dich ja noch einmal äußern.
Gruß, greenhorn
Ganz herzlichen Dank für die prompte Antwort! Jetzt habe ich wenigstens die Möglichkeit, den Kurs zu verfolgen. Habe mit sehr viel Interesse deine Postings gelesen. Scheint sich wirklich noch um einen Geheimtipp zu handeln, was ich allerdings nicht ganz verstehe. Vielleicht daher noch eine dumme Frage:
Der Kurs dümpelt weiterhin in den Niederungen des Charts herum, auch die Meldung von Mitte Juni, die du gestern netterweise hereingestellt hast, hat sich nicht wirklich ausgewirkt. Warum? Wenn die Erfolgsaussichten so gut sind, das Unternehmen patenttechnisch abgesichert ist, quasi Alleinstellungsmerkmale hat, warum scheint sich keiner darum zu kümmern? Wie sieht denn die Aktionärsstruktur bei Starpharma aus? Sind Insider, Management oder Fonds investiert?
Ich bin sehr interessiert und dankbar für die bisherigen Info`s. Vielleicht kannst du dich ja noch einmal äußern.
Gruß, greenhorn
greenhorn:
Hier weitere Infos, in Hülle und Fülle, für dich:
Starpharma Corporate Structure
The Starpharma Group ("Starpharma") is an Australian-owned Research and Development organisation consisting of three subsidiary companies operating under a parent funding entity established as a Pooled Development Fund (PDF).
Starpharma Pooled Development Limited (ACN 078 532 180) is a registered PDF and the primary funding entity for Starpharma. For more information on PDFs, click here (siehe unten: What is a PDF). Since inception, Starpharma has evolved its structure to reflect the activities it will concentrate on as it develops its intellectual property and licensing opportunities. There are currently 3 wholly owned subsidiary companies in the Starpharma Group being:
Starpharma Limited (ACN 075 081 908), which holds the Licence for the Technology and manages the Group`s intellectual property portfolio. Starpharma Limited also manages research programs, START grants and administrative functions for the Group.
Viralstar Limited (ACN 083 205 421), which has agreed to provide research funding for further development of the Technology in the field of antiviral therapeutics. Viralstar may become involved in the commercialisation process of this area of the Technology.
Angiostar Limited (ACN 080 492 404), which has agreed to provide research funding for further development of the Technology in the field of inhibition of angiogenesis. Angiostar may become involved in the commercialisation process of this area of the Technology.
Starpharma will assess other opportunities on an ongoing basis. Some preliminary work has been undertaken in testing the Compounds as anti-toxins and this may be furthered as the Group`s development work in the antiviral and anti-angiogenesis areas matures.
......................................................................................................................
What is a PDF?
A Pooled Development Fund (PDF) is an Australian company that is registered and regulated by the PDF Board in accordance with the PDF Act. The objective of the PDF Act is to encourage the provision of patient equity capital for growing small to medium sized enterprises by conferring certain tax benefits to investors in a PDF. Starpharma was registered as a PDF on 23 July 1997.
Investments under the PDF Act
The following restrictions apply to investments made by a PDF, subject to any exemptions granted by the PDF Board:
It must not invest in a company the primary activity of which is an “excluded activity". Excluded Activities include:
(a) retail sales operations; and
(b) the acquisition or disposal of an interest in, or development of, land except where this is wholly incidental to the conduct of an activity other than retail sale operations.
It must subscribe for new equity in a company and, after the investment, hold at least 10% of the issued capital of that investee company.
It must not invest in companies with total assets in excess of $50 million at the date of the initial investment;
It must not invest more than 30% of the PDFs shareholders` funds in one company; and
It must invest at least 65% of any capital raised within five years of that raising.
Taxation Benefits
To encourage investment in PDFs, privileged taxation status is conferred on both PDFs and their shareholders. The key benefits (and related consequences) are as follows:
A PDF is taxed at the following concessional rates:
15% on the "SME income component" of its taxable income (which includes dividends received from investee companies gains from the sale of shares in those companies); and
25% on the "unregulated investment income component" of its taxable income (which includes income derived from other investments, such as interest income from money market deposits).
Despite being taxed at concessional rates, a PDF is entitled to credit its franking account for tax paid based on the general company tax rate which is presently 34%. From 1 July 2001 the company tax rate will be reduced to 30%.
Shareholders in a PDF are not assessed on gains made from from the sale of PDF shares and are not entitled to deductions or capital losses for losses made from the sale of PDF shares.
Dividends paid by a PDF to non-resident shareholders are exempt from both income tax and withholding tax.
Unfranked dividends paid by a PDF to resident shareholders are exempt from tax.
Resident shareholders have the choice of also being exempt from tax on franked dividends paid by a PDF, or being taxed on such dividends. If they choose to be taxed on franked dividends, they are entitled to the benefit of imputation credits attached to such dividends.
A "venture capital franked dividend" paid by a PDF to an "eligible shareholder` is exempt from tax but nevertheless also eligible for a franking rebate. An eligible shareholder includes a complying superannuation fund, a complying approved deposit fund or a pooled superannuation trust. It also includes life assurance companies and registered organisation where they engage in superannuation business (although the amount of the rebate available is designed so as to effectively render capital gains made by a PDF tax free to the extent that the gains flow through to the eligible shareholders).
To the extent that dividends paid by a PDF are exempt from tax, no deduction is available for borrowing expenses (such as interest) incurred in making an investment in a PDF.
Unlike other companies, a PDF cannot transfer either its "revenue" losses or "capital" losses to wholly owned group (investee) companies. Investee companies are not prevented from transferring losses to a PDF, but the lower rates of tax in a PDF may not make this attractive. Also there are a range of provisions affecting a company`s ability to carry forward its losses (including now unrealised losses).
A PDF`s investee companies are not taxed concessionally.
This summary is general in nature, and is neither exhaustive, nor necessarily applicable to an investor`s individual circumstances.
Potential investors should obtain their own professional taxation advice or make their own inquiries if the taxation treatment of PDFs is material to their investment.
............................................................................................................................................................................................................................................
DIRECTORS´ INTEREST:
NOTICE OF DIRECTORS` INTERESTS
Section 205G of the Corporations Law
UPDATING NOTICE
The Company has been advised of the following changes in directors` interests:
Name of Director: John William Raff
Date of change: 13 October 2000
The director has a relevant interest in the following shares in the Company or related bodies corporate: 70,000 fully paid ordinary shares purchased on market.
Director`s total interests:
Fully paid ordinary shares: 4,333,581 (previously 4,263,581)
Options over ordinary shares: 600,000 (no change)
Name of Director: Richard John Donald Oliver
Date of change: 13 October 2000
The director has a relevant interest in the following shares in the Company or related bodies corporate: 100,000 fully paid ordinary shares purchased on market.
Director`s total interests:
Fully paid ordinary shares: 4,713,000 (previously 4,613,000)
Options over ordinary shares: 360,000 (no change)
Name of Director: Peter James Jenkins
Name of Company: Starpharma Pooled Development Ltd.
Date of last notification to ASX: N/A (first updating notice)
I have a relevant interest in the following securities of the Company or a related body corporate:
Type of security: Ordinary shares.
Number of securities: 1,874,000
Type of security: Options.
Number of securities: 280,000
Circumstances giving rise to change in relevant interests:
Purchase on market of 50,000 ordinary shares at 45 cents per share by a related party.
Interest in contracts to which I am a party or under which I am entitled to a benefit that confer a right to call for or deliver shares in, debentures of, or interests in a collective investment scheme made available by, the company or a related body corporate:
Nil.
(Hinweis: Dies entspricht knapp 10 Prozent der gesamten Aktienzahl)
......................................................................................................................
Infos zu Institutionellen und anderen Anlegern:
Das IPO brachte 22 Millionen AUD ein. Die Shareholderzahl stieg dadurch von 300 auf 1400 unter Anteilnahme zahlreicher Instituionen.
Genaue Zahlen habe ich lediglich zum Aufsichtsrat, die 20 Millionen Aktien besassen, die aber seit 2002 keiner Haltefrist mehr unterliegen.
Hier weitere Infos, in Hülle und Fülle, für dich:
Starpharma Corporate Structure
The Starpharma Group ("Starpharma") is an Australian-owned Research and Development organisation consisting of three subsidiary companies operating under a parent funding entity established as a Pooled Development Fund (PDF).
Starpharma Pooled Development Limited (ACN 078 532 180) is a registered PDF and the primary funding entity for Starpharma. For more information on PDFs, click here (siehe unten: What is a PDF). Since inception, Starpharma has evolved its structure to reflect the activities it will concentrate on as it develops its intellectual property and licensing opportunities. There are currently 3 wholly owned subsidiary companies in the Starpharma Group being:
Starpharma Limited (ACN 075 081 908), which holds the Licence for the Technology and manages the Group`s intellectual property portfolio. Starpharma Limited also manages research programs, START grants and administrative functions for the Group.
Viralstar Limited (ACN 083 205 421), which has agreed to provide research funding for further development of the Technology in the field of antiviral therapeutics. Viralstar may become involved in the commercialisation process of this area of the Technology.
Angiostar Limited (ACN 080 492 404), which has agreed to provide research funding for further development of the Technology in the field of inhibition of angiogenesis. Angiostar may become involved in the commercialisation process of this area of the Technology.
Starpharma will assess other opportunities on an ongoing basis. Some preliminary work has been undertaken in testing the Compounds as anti-toxins and this may be furthered as the Group`s development work in the antiviral and anti-angiogenesis areas matures.
......................................................................................................................
What is a PDF?
A Pooled Development Fund (PDF) is an Australian company that is registered and regulated by the PDF Board in accordance with the PDF Act. The objective of the PDF Act is to encourage the provision of patient equity capital for growing small to medium sized enterprises by conferring certain tax benefits to investors in a PDF. Starpharma was registered as a PDF on 23 July 1997.
Investments under the PDF Act
The following restrictions apply to investments made by a PDF, subject to any exemptions granted by the PDF Board:
It must not invest in a company the primary activity of which is an “excluded activity". Excluded Activities include:
(a) retail sales operations; and
(b) the acquisition or disposal of an interest in, or development of, land except where this is wholly incidental to the conduct of an activity other than retail sale operations.
It must subscribe for new equity in a company and, after the investment, hold at least 10% of the issued capital of that investee company.
It must not invest in companies with total assets in excess of $50 million at the date of the initial investment;
It must not invest more than 30% of the PDFs shareholders` funds in one company; and
It must invest at least 65% of any capital raised within five years of that raising.
Taxation Benefits
To encourage investment in PDFs, privileged taxation status is conferred on both PDFs and their shareholders. The key benefits (and related consequences) are as follows:
A PDF is taxed at the following concessional rates:
15% on the "SME income component" of its taxable income (which includes dividends received from investee companies gains from the sale of shares in those companies); and
25% on the "unregulated investment income component" of its taxable income (which includes income derived from other investments, such as interest income from money market deposits).
Despite being taxed at concessional rates, a PDF is entitled to credit its franking account for tax paid based on the general company tax rate which is presently 34%. From 1 July 2001 the company tax rate will be reduced to 30%.
Shareholders in a PDF are not assessed on gains made from from the sale of PDF shares and are not entitled to deductions or capital losses for losses made from the sale of PDF shares.
Dividends paid by a PDF to non-resident shareholders are exempt from both income tax and withholding tax.
Unfranked dividends paid by a PDF to resident shareholders are exempt from tax.
Resident shareholders have the choice of also being exempt from tax on franked dividends paid by a PDF, or being taxed on such dividends. If they choose to be taxed on franked dividends, they are entitled to the benefit of imputation credits attached to such dividends.
A "venture capital franked dividend" paid by a PDF to an "eligible shareholder` is exempt from tax but nevertheless also eligible for a franking rebate. An eligible shareholder includes a complying superannuation fund, a complying approved deposit fund or a pooled superannuation trust. It also includes life assurance companies and registered organisation where they engage in superannuation business (although the amount of the rebate available is designed so as to effectively render capital gains made by a PDF tax free to the extent that the gains flow through to the eligible shareholders).
To the extent that dividends paid by a PDF are exempt from tax, no deduction is available for borrowing expenses (such as interest) incurred in making an investment in a PDF.
Unlike other companies, a PDF cannot transfer either its "revenue" losses or "capital" losses to wholly owned group (investee) companies. Investee companies are not prevented from transferring losses to a PDF, but the lower rates of tax in a PDF may not make this attractive. Also there are a range of provisions affecting a company`s ability to carry forward its losses (including now unrealised losses).
A PDF`s investee companies are not taxed concessionally.
This summary is general in nature, and is neither exhaustive, nor necessarily applicable to an investor`s individual circumstances.
Potential investors should obtain their own professional taxation advice or make their own inquiries if the taxation treatment of PDFs is material to their investment.
............................................................................................................................................................................................................................................
DIRECTORS´ INTEREST:
NOTICE OF DIRECTORS` INTERESTS
Section 205G of the Corporations Law
UPDATING NOTICE
The Company has been advised of the following changes in directors` interests:
Name of Director: John William Raff
Date of change: 13 October 2000
The director has a relevant interest in the following shares in the Company or related bodies corporate: 70,000 fully paid ordinary shares purchased on market.
Director`s total interests:
Fully paid ordinary shares: 4,333,581 (previously 4,263,581)
Options over ordinary shares: 600,000 (no change)
Name of Director: Richard John Donald Oliver
Date of change: 13 October 2000
The director has a relevant interest in the following shares in the Company or related bodies corporate: 100,000 fully paid ordinary shares purchased on market.
Director`s total interests:
Fully paid ordinary shares: 4,713,000 (previously 4,613,000)
Options over ordinary shares: 360,000 (no change)
Name of Director: Peter James Jenkins
Name of Company: Starpharma Pooled Development Ltd.
Date of last notification to ASX: N/A (first updating notice)
I have a relevant interest in the following securities of the Company or a related body corporate:
Type of security: Ordinary shares.
Number of securities: 1,874,000
Type of security: Options.
Number of securities: 280,000
Circumstances giving rise to change in relevant interests:
Purchase on market of 50,000 ordinary shares at 45 cents per share by a related party.
Interest in contracts to which I am a party or under which I am entitled to a benefit that confer a right to call for or deliver shares in, debentures of, or interests in a collective investment scheme made available by, the company or a related body corporate:
Nil.
(Hinweis: Dies entspricht knapp 10 Prozent der gesamten Aktienzahl)
......................................................................................................................
Infos zu Institutionellen und anderen Anlegern:
Das IPO brachte 22 Millionen AUD ein. Die Shareholderzahl stieg dadurch von 300 auf 1400 unter Anteilnahme zahlreicher Instituionen.
Genaue Zahlen habe ich lediglich zum Aufsichtsrat, die 20 Millionen Aktien besassen, die aber seit 2002 keiner Haltefrist mehr unterliegen.
Hier noch der Link zur offiziellen Pressemeldung bezüglich des FDA-Filings (vom 30.06.03):
http://www.asx.com.au/asxpdf/20030630/pdf/00367902.pdf
Und zwei sehr interessante Artikel über Starpharma:
Starpharma: A Rising Nano Star
BY DARRYL NELSON (profile) | November 28, 2002
Starpharma Pooled Development Ltd has been granted its third US nanotechnology patent for biotech applications of dendrimer-based pharmaceuticals. It is just the latest piece of good news for the Government-backed Australian company in recent months, as it prepares to apply for its first clinical trials.
The new patent, for "Anionic or cationic dendrimer anti-microbial or anti-parasitic compositions", comes on top of patents already granted for dendrimer-based anti-viral and anti-cancer treatments. Dr John Raff, CEO, says the company expects a fourth to be passed in the next couple of months, for anti-toxin treatments. "It`s a 3-4 year challenge to get a broad-based patent through the US," he says.
Last month, Dendritic Nanotechnologies Ltd (DNT) - Starpharma`s joint venture in the US with leading dendrimer nanotech scientist Dr Donald Tomalia - won a huge vote of confidence from the US Government. DNT was granted US$3.5 million out of the defence budget, to establish a dendrimer research facility for the discovery and delivery of drugs and protection against biological warfare.
"The US military is very interested in protection against respiratory diseases," says Dr Raff. "But it`s also interested in diagnostics and anti-toxin treatments, like protective creams." The grant covers the first year`s set-up costs, enabling DNT to build the facility at its Central Michigan University Technology Park premises.
The dendrimer promise
Dr Raff describes dendrimer nanotechnology as "a hot area," claiming around 2000 scientists are now studying the rather unique form of polymer chemistry in the US alone, up from "just a few" 5 years ago.
He also says it`s one of the purest forms of nanotechnology, because of its bottom-up development process. "Nanotechnology produces only 3 defined structures - buckyballs, carbon nanotubes and dendrimers," he explains. "We`re putting 16-20,000 atoms in an array so each one is in exactly the same spot in each [dendrimer] structure."
The `defined structure` nature is what`s important about these nano-synthetics, because it provides the basis for predictable results in whatever application. According to Dr Raff, dendrimers are the only ones that are water soluble, and therefore suitable for biotech applications: "Dendrimers are basically a scaffolding for attaching things to." But pharmaceuticals are only one application area; they can be used for many others, including electronics and thin materials, he says.
The Starpharma promise
The company was spun out of the Biomolecular Research Institute of Melbourne in 1996, and is now listed on the Australian Stock Exchange. Dr Raff says it has total capital of A$40 million. The company intends deriving revenues from licensing its intellectual property to application developers, and is in negotiations with potential partners for commercialisation of its drug patents.
It`s also preparing to submit application for IND (Investigational New Drug) approval in the US for its first bio medical application. This will give it the right to move from animal testing to clinical trials with humans. The company hopes this will be granted in December and, if successful, Dr Raff says it will see dendrimers used in the human body for the first time.
Apart from rejection by the US Food and Drug Administration, one aspect of dendrimers that may at least slow Starpharma`s progress is their cost. Like virtually all nanotechnology, production processes are still expensive, and dendrimers currently cost around US$300 per gram. Indeed, Dr Raff adds that some of Starpharma`s new patents in the pipeline are for lower-cost synthesis procedures, which will reduce that figure "100-fold". He also argues they`re not relatively expensive for pharmaceutical applications, because of their increased efficacy.
Nevertheless, the current price dendrimers command in the marketplace is also good news for the company; Dr Raff says they`ve just begun to commercially supply dendrimers to R&D labs worldwide. While it`s not the only source, he adds they have the IP behind them to enable developers to eventually commercialise any successes. "We can give the freedom to operate," he says.
In part 2, Nanotech Planet will examine dendrimers in more detail, and look at Starpharma`s pending first application, which could forever change sexual health.
Starpharma; A Rising Nano Star, part 2
BY DARRYL NELSON (profile) | December 03, 2002
Starpharma Pooled Development Ltd, a Melbourne based company that heads up a research and development group for dendrimer nanotechnologies, is working to build an extensive intellectual property portfolio for licensing to a range of applications.
As its name suggests, the company is a Pooled Development Fund, whereby the investors enjoy tax incentives from the Commonwealth Government. It has also previously qualified for two R&D Start Grants.
To date, the group is focused on development of dendrimers as pharmaceutical agents, focusing on global health problem areas where current treatments are either non-existent or inadequate: cancers, toxins, exotic and tropical diseases, respiratory diseases and sexually transmitted diseases (STDs).
A sexual revolution
It`s in the latter that the company`s drug development is most advanced, on a topical vaginal microbicide for broad-spectrum prevention of STD infections - including HIV and HSV (herpes). An application is about to be lodged in the US to move to human (phase II) clinical trials. "STDs are the number one area of health priority in the US," says Dr John Raff, Starpharma`s CEO. According to the company, the US spends US$8.4 billion annually treating STDs.
Vaginal microbicides ideally act by stopping the STDs adhering to the body`s cells and/or kill them before they have a chance to enter the body and spread. "It`s a vaginal gel which blocks uptake of the viruses," says Dr Raff. As well as acting as a barrier, trials have also shown promising results as an ointment treatment for genital herpes.
If successful with the application, clinical trials will be held in Australia and could start as early as the beginning of next year.
But therapeutic treatments are only one possible application sector for dendrimers. Research by Starpharma`s joint venture company, Dendritic Nanotechnologies Ltd (DNT), is examining the potential for these polyvalent structures to be used in applications such as optical and electronic devices. Dendrimers reportedly could be applied in the development of high-powered lasers, and act as advanced nanoelectronic materials, or as templates for the precise manufacture of such components.
Dendrimer`s star quality
Dendrimers are a unique class of polymeric chemistry, based on large, single molecule compounds. They are formed by the orderly reaction of chemicals to form branch-like structures that, when symmetrical, form a 3D star shape.
The vital difference in dendrimers over other polymers is their predictable, controllable structure, in which all of the chemical bonds between the atoms can be accurately described. The most common polymers are plastics, including nylon, but these are mixtures of many different molecules, tangled together to give an average molecular structure. The distribution of the constituent molecules is probabilistic and, as such, they have very poorly defined chemical structures.
Dendrimers also provide perfect structures to attach other molecules to, and this is what makes them suitable for therapeutic applications. A variety of molecules, each with varying yet complementary functionality, can be attached to a core dendrimer. It is this combined efficacy that gives dendrimer-based drugs their potency, enabling highly-efficient cocktails to be delivered precisely where needed. As Dr Raff explains, Starpharma`s vaginal gel contains an active dendrimer-based ingredient that costs only 20 cents to produce, "because the amount required is so small."
As well as being synthesised as new drugs in their own right, dendrimers could be used in vivo as drug delivery systems, to deliver existing drugs more effectively.
The chemical consistency of dendrimers also makes them ideal for other nano-scale applications, and they may well become one of the most common building blocks of nanotechnology as a whole. Although typically in the order of 3-5 nanometres in size, which is about the same size as a small protein, they can be synthesised to varying sizes.
http://www.asx.com.au/asxpdf/20030630/pdf/00367902.pdf
Und zwei sehr interessante Artikel über Starpharma:
Starpharma: A Rising Nano Star
BY DARRYL NELSON (profile) | November 28, 2002
Starpharma Pooled Development Ltd has been granted its third US nanotechnology patent for biotech applications of dendrimer-based pharmaceuticals. It is just the latest piece of good news for the Government-backed Australian company in recent months, as it prepares to apply for its first clinical trials.
The new patent, for "Anionic or cationic dendrimer anti-microbial or anti-parasitic compositions", comes on top of patents already granted for dendrimer-based anti-viral and anti-cancer treatments. Dr John Raff, CEO, says the company expects a fourth to be passed in the next couple of months, for anti-toxin treatments. "It`s a 3-4 year challenge to get a broad-based patent through the US," he says.
Last month, Dendritic Nanotechnologies Ltd (DNT) - Starpharma`s joint venture in the US with leading dendrimer nanotech scientist Dr Donald Tomalia - won a huge vote of confidence from the US Government. DNT was granted US$3.5 million out of the defence budget, to establish a dendrimer research facility for the discovery and delivery of drugs and protection against biological warfare.
"The US military is very interested in protection against respiratory diseases," says Dr Raff. "But it`s also interested in diagnostics and anti-toxin treatments, like protective creams." The grant covers the first year`s set-up costs, enabling DNT to build the facility at its Central Michigan University Technology Park premises.
The dendrimer promise
Dr Raff describes dendrimer nanotechnology as "a hot area," claiming around 2000 scientists are now studying the rather unique form of polymer chemistry in the US alone, up from "just a few" 5 years ago.
He also says it`s one of the purest forms of nanotechnology, because of its bottom-up development process. "Nanotechnology produces only 3 defined structures - buckyballs, carbon nanotubes and dendrimers," he explains. "We`re putting 16-20,000 atoms in an array so each one is in exactly the same spot in each [dendrimer] structure."
The `defined structure` nature is what`s important about these nano-synthetics, because it provides the basis for predictable results in whatever application. According to Dr Raff, dendrimers are the only ones that are water soluble, and therefore suitable for biotech applications: "Dendrimers are basically a scaffolding for attaching things to." But pharmaceuticals are only one application area; they can be used for many others, including electronics and thin materials, he says.
The Starpharma promise
The company was spun out of the Biomolecular Research Institute of Melbourne in 1996, and is now listed on the Australian Stock Exchange. Dr Raff says it has total capital of A$40 million. The company intends deriving revenues from licensing its intellectual property to application developers, and is in negotiations with potential partners for commercialisation of its drug patents.
It`s also preparing to submit application for IND (Investigational New Drug) approval in the US for its first bio medical application. This will give it the right to move from animal testing to clinical trials with humans. The company hopes this will be granted in December and, if successful, Dr Raff says it will see dendrimers used in the human body for the first time.
Apart from rejection by the US Food and Drug Administration, one aspect of dendrimers that may at least slow Starpharma`s progress is their cost. Like virtually all nanotechnology, production processes are still expensive, and dendrimers currently cost around US$300 per gram. Indeed, Dr Raff adds that some of Starpharma`s new patents in the pipeline are for lower-cost synthesis procedures, which will reduce that figure "100-fold". He also argues they`re not relatively expensive for pharmaceutical applications, because of their increased efficacy.
Nevertheless, the current price dendrimers command in the marketplace is also good news for the company; Dr Raff says they`ve just begun to commercially supply dendrimers to R&D labs worldwide. While it`s not the only source, he adds they have the IP behind them to enable developers to eventually commercialise any successes. "We can give the freedom to operate," he says.
In part 2, Nanotech Planet will examine dendrimers in more detail, and look at Starpharma`s pending first application, which could forever change sexual health.
Starpharma; A Rising Nano Star, part 2
BY DARRYL NELSON (profile) | December 03, 2002
Starpharma Pooled Development Ltd, a Melbourne based company that heads up a research and development group for dendrimer nanotechnologies, is working to build an extensive intellectual property portfolio for licensing to a range of applications.
As its name suggests, the company is a Pooled Development Fund, whereby the investors enjoy tax incentives from the Commonwealth Government. It has also previously qualified for two R&D Start Grants.
To date, the group is focused on development of dendrimers as pharmaceutical agents, focusing on global health problem areas where current treatments are either non-existent or inadequate: cancers, toxins, exotic and tropical diseases, respiratory diseases and sexually transmitted diseases (STDs).
A sexual revolution
It`s in the latter that the company`s drug development is most advanced, on a topical vaginal microbicide for broad-spectrum prevention of STD infections - including HIV and HSV (herpes). An application is about to be lodged in the US to move to human (phase II) clinical trials. "STDs are the number one area of health priority in the US," says Dr John Raff, Starpharma`s CEO. According to the company, the US spends US$8.4 billion annually treating STDs.
Vaginal microbicides ideally act by stopping the STDs adhering to the body`s cells and/or kill them before they have a chance to enter the body and spread. "It`s a vaginal gel which blocks uptake of the viruses," says Dr Raff. As well as acting as a barrier, trials have also shown promising results as an ointment treatment for genital herpes.
If successful with the application, clinical trials will be held in Australia and could start as early as the beginning of next year.
But therapeutic treatments are only one possible application sector for dendrimers. Research by Starpharma`s joint venture company, Dendritic Nanotechnologies Ltd (DNT), is examining the potential for these polyvalent structures to be used in applications such as optical and electronic devices. Dendrimers reportedly could be applied in the development of high-powered lasers, and act as advanced nanoelectronic materials, or as templates for the precise manufacture of such components.
Dendrimer`s star quality
Dendrimers are a unique class of polymeric chemistry, based on large, single molecule compounds. They are formed by the orderly reaction of chemicals to form branch-like structures that, when symmetrical, form a 3D star shape.
The vital difference in dendrimers over other polymers is their predictable, controllable structure, in which all of the chemical bonds between the atoms can be accurately described. The most common polymers are plastics, including nylon, but these are mixtures of many different molecules, tangled together to give an average molecular structure. The distribution of the constituent molecules is probabilistic and, as such, they have very poorly defined chemical structures.
Dendrimers also provide perfect structures to attach other molecules to, and this is what makes them suitable for therapeutic applications. A variety of molecules, each with varying yet complementary functionality, can be attached to a core dendrimer. It is this combined efficacy that gives dendrimer-based drugs their potency, enabling highly-efficient cocktails to be delivered precisely where needed. As Dr Raff explains, Starpharma`s vaginal gel contains an active dendrimer-based ingredient that costs only 20 cents to produce, "because the amount required is so small."
As well as being synthesised as new drugs in their own right, dendrimers could be used in vivo as drug delivery systems, to deliver existing drugs more effectively.
The chemical consistency of dendrimers also makes them ideal for other nano-scale applications, and they may well become one of the most common building blocks of nanotechnology as a whole. Although typically in the order of 3-5 nanometres in size, which is about the same size as a small protein, they can be synthesised to varying sizes.
Greenhorn:
Und hier Posting Nummer 3 für dich; die Charts bleiben aktuell. Dann kannst du zukünftig hier nachschauen, wenn du willst.
Und hier Posting Nummer 3 für dich; die Charts bleiben aktuell. Dann kannst du zukünftig hier nachschauen, wenn du willst.
Hallo Neoe!
Was bleibt mir anderes übrig, als "Danke" zu sagen!!! Vielleicht kann ich mich ja mal irgendwann revanchieren, obwohl man dir - das ist zumindest mein Eindruck - in Sachen Starpharma nicht viel Neues erzählen kann.
Noch mal vielen Dank!
Gruß, greenhorn
Was bleibt mir anderes übrig, als "Danke" zu sagen!!! Vielleicht kann ich mich ja mal irgendwann revanchieren, obwohl man dir - das ist zumindest mein Eindruck - in Sachen Starpharma nicht viel Neues erzählen kann.
Noch mal vielen Dank!
Gruß, greenhorn
Tests on HIV cure
http://www.smh.com.au/articles/2003/07/02/1056825460870.html
Melbourne biotech Starpharma is one step closer to testing a potential cure for the AIDS precursor, HIV, on humans.
The company, which has developed a vaginal gel to stop the spread of HIV, genital herpes and chlamydia, has applied to the US Food and Drug Administration to begin phase I human trials of VivaGel.
If the FDA gives the green light, Starpharma will test its gel on 36 healthy women aged between 18 and 45 over seven days. The gel is designed to be used by women before sexual intercourse.
Earlier trials of VivaGel used on monkeys successfully stopped the spread of a virus equivalent to HIV in humans, while its use on guinea pigs protected against genital herpes and chlamydia.
Monday`s announcement aroused some excitement, with investors pushing the shares up 3c to 34.5c. The shares closed down 1.5c at 33c yesterday.
Credit Suisse First Boston, which has an "outperform" recommendation on Starpharma, said a partner would be the key to helping Starpharma get through phase II trials.
@greenhorn:
Starpharma ist ein Microcap-Unternehmen und in keinem Index gelistet und wird trotzdem von Credit Suisse First Boston gecovert. Sollte für dich ein weiteres Zeichen sein, daß im Hintergrund einiges arbeitet.
Credit Suisse war auch an der IPO beteiligt und dürfte selbst einen guten Batzen Papiere im heimischen Tresor lagern.
http://www.smh.com.au/articles/2003/07/02/1056825460870.html
Melbourne biotech Starpharma is one step closer to testing a potential cure for the AIDS precursor, HIV, on humans.
The company, which has developed a vaginal gel to stop the spread of HIV, genital herpes and chlamydia, has applied to the US Food and Drug Administration to begin phase I human trials of VivaGel.
If the FDA gives the green light, Starpharma will test its gel on 36 healthy women aged between 18 and 45 over seven days. The gel is designed to be used by women before sexual intercourse.
Earlier trials of VivaGel used on monkeys successfully stopped the spread of a virus equivalent to HIV in humans, while its use on guinea pigs protected against genital herpes and chlamydia.
Monday`s announcement aroused some excitement, with investors pushing the shares up 3c to 34.5c. The shares closed down 1.5c at 33c yesterday.
Credit Suisse First Boston, which has an "outperform" recommendation on Starpharma, said a partner would be the key to helping Starpharma get through phase II trials.
@greenhorn:
Starpharma ist ein Microcap-Unternehmen und in keinem Index gelistet und wird trotzdem von Credit Suisse First Boston gecovert. Sollte für dich ein weiteres Zeichen sein, daß im Hintergrund einiges arbeitet.
Credit Suisse war auch an der IPO beteiligt und dürfte selbst einen guten Batzen Papiere im heimischen Tresor lagern.
AIDS cure closer: expert
From AAP
http://www.dailytelegraph.news.com.au/common/story_page/0,59…
A CURE for HIV could be in sight within five years and Australia is at the forefront of revolutionary disease-fighting technology, an expert has revealed.
Professor Donald Tomalia is the world authority on nanotechnology (the manipulation of materials at the molecular level) and US government adviser on the relatively new science.
He is in Australia to help develop the use of cutting-edge "nanodrugs", called dendrimers, in conjunction with an Australian joint venture.
Australia would pioneer the application to humans of the synthetic molecular structures to prevent and cure diseases such as STDs, malaria and Hepatitis B, Prof Tomalia told reporters in Sydney.
Dendrimers would be adapted for a variety of treatment methods, including inhalation, oral or injected.
"They (dendrimers) can also be used to intercede, to shut down, external pathogens like a virus," said Prof Tomalia.
Dendrimers were being touted by the joint-venture Dendritic Nanotechnologies Ltd as having implications for anything from preventing tumour growth to detecting biological warfare.
Dendritic is made up of Melbourne-based pharmaceutical company Starpharma and Brisbane-based diagnostic firm Panbio.
One product already in development is a gel-like substance to be inserted into the vagina to prevent HIV and herpes infections, said Dr John Raff, CEO of Starpharma.
"It`s the first product we`ve got going through the system to be put inside a human. It blocks the uptake of HIV and stops it from infecting the cells. It has a lot of potential ... it will be our first product for testing on humans," said Dr Raff.
When asked if this could mean a cure for AIDS within five years, Dr Raff replied, "Absolutely".
"It stops the virus multiplying in the body as well as stopping the virus from getting into the body in the first place. We`re looking at having a product on the market in the next four to five years," said Dr Raff.
In terms of cancer, dendrimers could prevent tumour cells spreading to other parts of the body as well as preventing the growth of existing tumours, he said.
"We`re now getting responses to cancer that we`ve never seen because we can get such high local concentrations (of drugs) down there without collateral damage to tissue."
Dr Raff said the federal government had committed $6 million to the company`s research.
The Australian army was embracing nanotechnology, following in the footsteps of the US, which was equipping its army with detection devices against germ warfare, he said.
"The opportunities of broadscale protections against a range of respiratory viruses is enormous," he said.
"The US army has made a very serious commitment to the nano area. The army intends to give every foot soldier out there devices to detect biological threats. That is now a reality. Australia is just now coming into this very exciting area," he said.
From AAP
http://www.dailytelegraph.news.com.au/common/story_page/0,59…
A CURE for HIV could be in sight within five years and Australia is at the forefront of revolutionary disease-fighting technology, an expert has revealed.
Professor Donald Tomalia is the world authority on nanotechnology (the manipulation of materials at the molecular level) and US government adviser on the relatively new science.
He is in Australia to help develop the use of cutting-edge "nanodrugs", called dendrimers, in conjunction with an Australian joint venture.
Australia would pioneer the application to humans of the synthetic molecular structures to prevent and cure diseases such as STDs, malaria and Hepatitis B, Prof Tomalia told reporters in Sydney.
Dendrimers would be adapted for a variety of treatment methods, including inhalation, oral or injected.
"They (dendrimers) can also be used to intercede, to shut down, external pathogens like a virus," said Prof Tomalia.
Dendrimers were being touted by the joint-venture Dendritic Nanotechnologies Ltd as having implications for anything from preventing tumour growth to detecting biological warfare.
Dendritic is made up of Melbourne-based pharmaceutical company Starpharma and Brisbane-based diagnostic firm Panbio.
One product already in development is a gel-like substance to be inserted into the vagina to prevent HIV and herpes infections, said Dr John Raff, CEO of Starpharma.
"It`s the first product we`ve got going through the system to be put inside a human. It blocks the uptake of HIV and stops it from infecting the cells. It has a lot of potential ... it will be our first product for testing on humans," said Dr Raff.
When asked if this could mean a cure for AIDS within five years, Dr Raff replied, "Absolutely".
"It stops the virus multiplying in the body as well as stopping the virus from getting into the body in the first place. We`re looking at having a product on the market in the next four to five years," said Dr Raff.
In terms of cancer, dendrimers could prevent tumour cells spreading to other parts of the body as well as preventing the growth of existing tumours, he said.
"We`re now getting responses to cancer that we`ve never seen because we can get such high local concentrations (of drugs) down there without collateral damage to tissue."
Dr Raff said the federal government had committed $6 million to the company`s research.
The Australian army was embracing nanotechnology, following in the footsteps of the US, which was equipping its army with detection devices against germ warfare, he said.
"The opportunities of broadscale protections against a range of respiratory viruses is enormous," he said.
"The US army has made a very serious commitment to the nano area. The army intends to give every foot soldier out there devices to detect biological threats. That is now a reality. Australia is just now coming into this very exciting area," he said.
AIDS cure closer: expert
From AAP
http://www.dailytelegraph.news.com.au/common/story_page/0,59…
A CURE for HIV could be in sight within five years and Australia is at the forefront of revolutionary disease-fighting technology, an expert has revealed.
Professor Donald Tomalia is the world authority on nanotechnology (the manipulation of materials at the molecular level) and US government adviser on the relatively new science.
He is in Australia to help develop the use of cutting-edge "nanodrugs", called dendrimers, in conjunction with an Australian joint venture.
Australia would pioneer the application to humans of the synthetic molecular structures to prevent and cure diseases such as STDs, malaria and Hepatitis B, Prof Tomalia told reporters in Sydney.
Dendrimers would be adapted for a variety of treatment methods, including inhalation, oral or injected.
"They (dendrimers) can also be used to intercede, to shut down, external pathogens like a virus," said Prof Tomalia.
Dendrimers were being touted by the joint-venture Dendritic Nanotechnologies Ltd as having implications for anything from preventing tumour growth to detecting biological warfare.
Dendritic is made up of Melbourne-based pharmaceutical company Starpharma and Brisbane-based diagnostic firm Panbio.
One product already in development is a gel-like substance to be inserted into the vagina to prevent HIV and herpes infections, said Dr John Raff, CEO of Starpharma.
"It`s the first product we`ve got going through the system to be put inside a human. It blocks the uptake of HIV and stops it from infecting the cells. It has a lot of potential ... it will be our first product for testing on humans," said Dr Raff.
When asked if this could mean a cure for AIDS within five years, Dr Raff replied, "Absolutely".
"It stops the virus multiplying in the body as well as stopping the virus from getting into the body in the first place. We`re looking at having a product on the market in the next four to five years," said Dr Raff.
In terms of cancer, dendrimers could prevent tumour cells spreading to other parts of the body as well as preventing the growth of existing tumours, he said.
"We`re now getting responses to cancer that we`ve never seen because we can get such high local concentrations (of drugs) down there without collateral damage to tissue."
Dr Raff said the federal government had committed $6 million to the company`s research.
The Australian army was embracing nanotechnology, following in the footsteps of the US, which was equipping its army with detection devices against germ warfare, he said.
"The opportunities of broadscale protections against a range of respiratory viruses is enormous," he said.
"The US army has made a very serious commitment to the nano area. The army intends to give every foot soldier out there devices to detect biological threats. That is now a reality. Australia is just now coming into this very exciting area," he said.
From AAP
http://www.dailytelegraph.news.com.au/common/story_page/0,59…
A CURE for HIV could be in sight within five years and Australia is at the forefront of revolutionary disease-fighting technology, an expert has revealed.
Professor Donald Tomalia is the world authority on nanotechnology (the manipulation of materials at the molecular level) and US government adviser on the relatively new science.
He is in Australia to help develop the use of cutting-edge "nanodrugs", called dendrimers, in conjunction with an Australian joint venture.
Australia would pioneer the application to humans of the synthetic molecular structures to prevent and cure diseases such as STDs, malaria and Hepatitis B, Prof Tomalia told reporters in Sydney.
Dendrimers would be adapted for a variety of treatment methods, including inhalation, oral or injected.
"They (dendrimers) can also be used to intercede, to shut down, external pathogens like a virus," said Prof Tomalia.
Dendrimers were being touted by the joint-venture Dendritic Nanotechnologies Ltd as having implications for anything from preventing tumour growth to detecting biological warfare.
Dendritic is made up of Melbourne-based pharmaceutical company Starpharma and Brisbane-based diagnostic firm Panbio.
One product already in development is a gel-like substance to be inserted into the vagina to prevent HIV and herpes infections, said Dr John Raff, CEO of Starpharma.
"It`s the first product we`ve got going through the system to be put inside a human. It blocks the uptake of HIV and stops it from infecting the cells. It has a lot of potential ... it will be our first product for testing on humans," said Dr Raff.
When asked if this could mean a cure for AIDS within five years, Dr Raff replied, "Absolutely".
"It stops the virus multiplying in the body as well as stopping the virus from getting into the body in the first place. We`re looking at having a product on the market in the next four to five years," said Dr Raff.
In terms of cancer, dendrimers could prevent tumour cells spreading to other parts of the body as well as preventing the growth of existing tumours, he said.
"We`re now getting responses to cancer that we`ve never seen because we can get such high local concentrations (of drugs) down there without collateral damage to tissue."
Dr Raff said the federal government had committed $6 million to the company`s research.
The Australian army was embracing nanotechnology, following in the footsteps of the US, which was equipping its army with detection devices against germ warfare, he said.
"The opportunities of broadscale protections against a range of respiratory viruses is enormous," he said.
"The US army has made a very serious commitment to the nano area. The army intends to give every foot soldier out there devices to detect biological threats. That is now a reality. Australia is just now coming into this very exciting area," he said.
Hallo zusammen!
Nun, ich muss ehrlich zugeben, ich bin mächtig interessiert. Habe mein Depot bei der Deutschen Bank, bzw. bei maxblue. Wenn ich dort die WKN eingebe, steht auf der Order
796461
Name: STARPHARMA POOLED DEV.LTD.SHARES O.N.
Das dürfte doch richtig sein, oder? Das Limit müsste ich dann in AUD angeben, habe das gerade mal ausprobiert (nicht abgeschickt), das kommt betragsmäßig in Euro einigermaßen hin (inkl. dieser Gebühr
)
Gruß, greenhorn
Nun, ich muss ehrlich zugeben, ich bin mächtig interessiert. Habe mein Depot bei der Deutschen Bank, bzw. bei maxblue. Wenn ich dort die WKN eingebe, steht auf der Order
796461
Name: STARPHARMA POOLED DEV.LTD.SHARES O.N.
Das dürfte doch richtig sein, oder? Das Limit müsste ich dann in AUD angeben, habe das gerade mal ausprobiert (nicht abgeschickt), das kommt betragsmäßig in Euro einigermaßen hin (inkl. dieser Gebühr
)
Gruß, greenhorn
greenhorn:
Würde mich freuen einen zweiten Investor an meiner Seite begrüßen zu dürfen. Ich glaube kaum, dass du es bereuen wirst.
Würde mich freuen einen zweiten Investor an meiner Seite begrüßen zu dürfen. Ich glaube kaum, dass du es bereuen wirst.
Hallo!
Tja, der erste Versuch, Starpharma zu kaufen ist heute Nacht fehlgeschlagen. Verstehe ich nur nicht. Hatte ein Limit zu 0,34 AUD eingegeben, die Aktie ging im frühen Handel auf 0,32 AUD. Später wieder hoch, ohne dass ich berücksichtigt worden wäre. Naja, Pech.
Wie sollte ich mich verhalten? Ist es ratsam, das Limit zu erhöhen?
Gruß, greenhorn
Tja, der erste Versuch, Starpharma zu kaufen ist heute Nacht fehlgeschlagen. Verstehe ich nur nicht. Hatte ein Limit zu 0,34 AUD eingegeben, die Aktie ging im frühen Handel auf 0,32 AUD. Später wieder hoch, ohne dass ich berücksichtigt worden wäre. Naja, Pech.
Wie sollte ich mich verhalten? Ist es ratsam, das Limit zu erhöhen?
Gruß, greenhorn
greenhorn:
Vorausgesetzt es kommen keine Nachrichten, dürftest du mit 0,34 AUD gut liegen. Allerdings weisst du ja, was an der Börse alles möglich ist. Vielleicht stehen wir morgen unter 0,30 oder vielleicht auch über 0,40...also bitte alles ohne Gewähr.
Überprüfe ansonsten nochmal, ob die Order richtig aufgegeben wurde und ob es vielleicht Verzögerungen bei der Ausführungsbestätiging gab. Ich persönlich hatte überhaupt keine Probleme meine Stücke zu bekommen, aber wer weiss in welchen Dimensionen du orderst !?
Vorausgesetzt es kommen keine Nachrichten, dürftest du mit 0,34 AUD gut liegen. Allerdings weisst du ja, was an der Börse alles möglich ist. Vielleicht stehen wir morgen unter 0,30 oder vielleicht auch über 0,40...also bitte alles ohne Gewähr.
Überprüfe ansonsten nochmal, ob die Order richtig aufgegeben wurde und ob es vielleicht Verzögerungen bei der Ausführungsbestätiging gab. Ich persönlich hatte überhaupt keine Probleme meine Stücke zu bekommen, aber wer weiss in welchen Dimensionen du orderst !?
Hallo Neoe!
Nun, in der zwischenzeit musste ich weitere Niederlagen in Sachen Starpharma einstecken. Der Kurs steht bei 0,33 AUD, mein Limit weiterhin bei 0,34 AUD. Ausgeführt wurde meine Order noch immer nicht und eins kann ich mit Sicherheit sagen: Den ganzen Laden wollte ich nicht gleich kaufen, zu viele Stücke sind es also bestimmt nicht.
Vielleicht bin ich ja tatsächlich zu blöde, eine Order an einen ausländischen Böersenplatz aufzugeben. Deswegen will ich hier mal kurz meine Order reinstellen:
WKN.: 796461
BP: Melbourne
Stück: x
Limit: 0,34 AUD (Die Order gehen doch immer in
Landeswährung raus, oder? Zumindest passt das mit
der Umrechnung in Euro, was mir bei einer
Ausführung dann belastet wird. Also gehe ich mal
davon aus, dass das richtig ist.)
Orderzusatz: Keiner
Gültigkeit: Hatte ich drei Tage drin - halt bis zum
Wochenende.
Naja, und akzeptiert worden ist die Order auch, wenn irgendwas falsch läuft, schlägt Maxblue eigentlich immer sofort Alarm.
Nächste Woche ist auch noch eine Woche!!! Schönes Wochenende!!!
Gruß, greenhorn
Nun, in der zwischenzeit musste ich weitere Niederlagen in Sachen Starpharma einstecken. Der Kurs steht bei 0,33 AUD, mein Limit weiterhin bei 0,34 AUD. Ausgeführt wurde meine Order noch immer nicht und eins kann ich mit Sicherheit sagen: Den ganzen Laden wollte ich nicht gleich kaufen, zu viele Stücke sind es also bestimmt nicht.
Vielleicht bin ich ja tatsächlich zu blöde, eine Order an einen ausländischen Böersenplatz aufzugeben. Deswegen will ich hier mal kurz meine Order reinstellen:
WKN.: 796461
BP: Melbourne
Stück: x
Limit: 0,34 AUD (Die Order gehen doch immer in
Landeswährung raus, oder? Zumindest passt das mit
der Umrechnung in Euro, was mir bei einer
Ausführung dann belastet wird. Also gehe ich mal
davon aus, dass das richtig ist.)
Orderzusatz: Keiner
Gültigkeit: Hatte ich drei Tage drin - halt bis zum
Wochenende.
Naja, und akzeptiert worden ist die Order auch, wenn irgendwas falsch läuft, schlägt Maxblue eigentlich immer sofort Alarm.
Nächste Woche ist auch noch eine Woche!!! Schönes Wochenende!!!
Gruß, greenhorn
greenhorn:
Melbourne ist jedenfalls ein ungewöhnlicher Handelsplatz. Bei Comdirect zum Beispiel kann man nur per Telefon ordern und mit der Wkn war es auch nicht ganz einfach. Falls es weiter nicht klappen sollte, würde ich einfach mal den Tlefonservice in Anspruch nehmen.
Aus deiner Order kann ich keine Fehler entnehmen, bleibt nur das "x" als Unbekannte....
Melbourne ist jedenfalls ein ungewöhnlicher Handelsplatz. Bei Comdirect zum Beispiel kann man nur per Telefon ordern und mit der Wkn war es auch nicht ganz einfach. Falls es weiter nicht klappen sollte, würde ich einfach mal den Tlefonservice in Anspruch nehmen.
Aus deiner Order kann ich keine Fehler entnehmen, bleibt nur das "x" als Unbekannte....
Hallo Neoe!
Danke für den Hinweis. Ich werde es die nächsten Tagen noch einmal so versuchen und wenn es nicht klappen sollte, tatsächlich den Telefonservice nutzen.
Wann rechnest du bei Starpharma mit Neuigkeiten? Im Moment tut sich ja kursmäßig - zum Glück für mich - noch nicht ganz so viel. Anscheinend wird hier weiter das Potenzial nicht erkannt.
Was ich noch fragen wollte: Wo informierst du dich in der Regel über das Unternehmen, außer auf der Home-Page? Hast du Quellen (z.B. im Internet), die du regelmäßig nutzt?
Gruß und noch einen schönen Sonntag!!!
greenhorn
Danke für den Hinweis. Ich werde es die nächsten Tagen noch einmal so versuchen und wenn es nicht klappen sollte, tatsächlich den Telefonservice nutzen.
Wann rechnest du bei Starpharma mit Neuigkeiten? Im Moment tut sich ja kursmäßig - zum Glück für mich - noch nicht ganz so viel. Anscheinend wird hier weiter das Potenzial nicht erkannt.
Was ich noch fragen wollte: Wo informierst du dich in der Regel über das Unternehmen, außer auf der Home-Page? Hast du Quellen (z.B. im Internet), die du regelmäßig nutzt?
Gruß und noch einen schönen Sonntag!!!
greenhorn
Ich informiere mich über
www.ozestock.com.au
www.asx.com.au
und über die Suchmaschinen, aber von diesen Ergebnissen steht schon einiges im Thread.
Da Starpharma in vielen Bereichen tätig ist und bei Dendritic Nanotech auch jederzeit wichtiges passieren kann, ist hier jede Voraussage unmöglich. Ich denke aber, daß sehr gute Chancen bestehen, daß aus dem IPM-Fond, der von Bill Gates mit 60 Millionen ausgestattet wurde, einiges an Geld für Starpharma fliesst.
Aber wir befinden uns nach wie vor in einer allzubekannten Lage:
Es ist nichts in trockenen Tüchern, aber die Perspektiven sind grandios. Treten in die ersten positiven Entwicklungen ein ist es wie immer zu spät, da die Fans einer Aktie immer überproportional zum Kursgewinn wachsen.
www.ozestock.com.au
www.asx.com.au
und über die Suchmaschinen, aber von diesen Ergebnissen steht schon einiges im Thread.
Da Starpharma in vielen Bereichen tätig ist und bei Dendritic Nanotech auch jederzeit wichtiges passieren kann, ist hier jede Voraussage unmöglich. Ich denke aber, daß sehr gute Chancen bestehen, daß aus dem IPM-Fond, der von Bill Gates mit 60 Millionen ausgestattet wurde, einiges an Geld für Starpharma fliesst.
Aber wir befinden uns nach wie vor in einer allzubekannten Lage:
Es ist nichts in trockenen Tüchern, aber die Perspektiven sind grandios. Treten in die ersten positiven Entwicklungen ein ist es wie immer zu spät, da die Fans einer Aktie immer überproportional zum Kursgewinn wachsen.
Moin!
Um es kurz zu machen: Ich bin drin!!! Habe doch vor dem letzten Wochenende noch zu 0,34 AUD Stücke bekommen. Mal schauen, was draus wird. Werde eifrig beobachten, in der Hoffnung, dass es eine große Story wird.
Gruß und bis bald, greenhorn
Um es kurz zu machen: Ich bin drin!!! Habe doch vor dem letzten Wochenende noch zu 0,34 AUD Stücke bekommen. Mal schauen, was draus wird. Werde eifrig beobachten, in der Hoffnung, dass es eine große Story wird.
Gruß und bis bald, greenhorn
Guten Morgen!
Gibt es igendwelche Neuigkeiten, oder warum ist der Kurs kuz vor Schluss nach unten abgetaucht? Ich habe nichts gefunden.
Naja, wahscheinlich eh egal, die Umsätze sind ja eh noch verschwindend gering.
Noch einen schönen Tag!
Gruß, greenhorn
Gibt es igendwelche Neuigkeiten, oder warum ist der Kurs kuz vor Schluss nach unten abgetaucht? Ich habe nichts gefunden.
Naja, wahscheinlich eh egal, die Umsätze sind ja eh noch verschwindend gering.
Noch einen schönen Tag!
Gruß, greenhorn
greenhorn:
Viel Negatives kann nicht passieren, eher schon keine Neuigkeiten, was ja nach Börsen-Einmaleins auch schlecht sein soll.
Die Devise heisst Füße still halten, die Aufregung und der Nervenkitzel kommen hier noch. Dann umso mehr....
Viel Negatives kann nicht passieren, eher schon keine Neuigkeiten, was ja nach Börsen-Einmaleins auch schlecht sein soll.
Die Devise heisst Füße still halten, die Aufregung und der Nervenkitzel kommen hier noch. Dann umso mehr....
Guten Morgen!
Heute gab es sehr gute Neuigkeiten von Starpharma bezüglich der weiteren Entwicklung von Vivagel. Leider bin ich zu blöde, die PDF-Datei hier hineinzustellen. Da kenne ich mich nicht mit aus. Neoe, kriegst du das hin?
Der Kurs ist explodiert unter - im Vergleich zum durchschnitlichen Handelsvolumen - extrem hohen Umsätzen. Das ist doch mal ein guter Start in den Tag.
Gruß und einen schönen Tag!
greenhorn
Heute gab es sehr gute Neuigkeiten von Starpharma bezüglich der weiteren Entwicklung von Vivagel. Leider bin ich zu blöde, die PDF-Datei hier hineinzustellen. Da kenne ich mich nicht mit aus. Neoe, kriegst du das hin?
Der Kurs ist explodiert unter - im Vergleich zum durchschnitlichen Handelsvolumen - extrem hohen Umsätzen. Das ist doch mal ein guter Start in den Tag.
Gruß und einen schönen Tag!
greenhorn
SYDNEY, Australia (CNN) -- An Australian company has won regulatory approval to begin human trials for an anti-AIDS gel which could dramatically reduce the spread of the virus in developing countries.
Melbourne-based Starpharma announced Thursday that the U.S. Food and Drug Administration (FDA) has given clearance for phase one human trials of the trial the gel.
The drug has proved 100 percent effective in preventing HIV and other sexually-transmitted diseases in primate trials.
The gel -- if human trials prove successful -- would be particularly targeted at women in poorer nations, giving them cheaper, easier personal control over HIV prevention.
"This is a major achievement for Starpharma as there have been very few locally developed new chemical entity drugs that have undergone phase one trials in Australia under the rigorous requirements of the US regulatory system," Starpharma CEO Dr John Raff said in a statement.
A report by the Rockefeller Foundation into HIV prevention, released earlier this year, estimates up to 2.5 million lives could be saved over three years if such a product was readily available.
In animals trials using macaque monkeys, a single application of the VivaGel product proved 100 percent effective against the monkey version of HIV as well as animal versions of genital herpes and chlamydia.
The human trials of the product are now planned to begin in Australia by the end of this year.
These will then be followed by a second 12-month trial involving at least 8,000 women with a possible prescription-only product available in three years` time. It would be another two years after that before an over-the-counter type product could be distributed.
Raff told CNN VivaGel was a "first of its type" product which could set a precedent for the development of other disease treatments in years to come.
Microbicides are gels, films, sponges or other products applied directly to the skin to help prevent the spread of disease.
They are particularly useful for women in poorer countries as they give them more control in helping prevent disease, particularly in cultures where condoms are a male-dominated product.
Women are also more vulnerable to contracting HIV from a single sexual encounter.
Countries such as Myanmar and Papua New Guinea face looming AIDS crises of a scale similar to those seen in Africa because of a lack of preventative measures.
A recent Australian government aid report says the working population of PNG could be cut by 38 percent by 2020 if infection rates follow those seen in Zimbabwe.
In Myanmar it is estimated that as many as 1 in 50 people has HIV with the disease spreading rapidly among the general population from high-risk groups such as prostitutes and intravenous drug users.
At the end of last year, 42 million people worldwide were infected with AIDS and by 2010 it is estimated a further 45 million people will be infected.
Melbourne-based Starpharma announced Thursday that the U.S. Food and Drug Administration (FDA) has given clearance for phase one human trials of the trial the gel.
The drug has proved 100 percent effective in preventing HIV and other sexually-transmitted diseases in primate trials.
The gel -- if human trials prove successful -- would be particularly targeted at women in poorer nations, giving them cheaper, easier personal control over HIV prevention.
"This is a major achievement for Starpharma as there have been very few locally developed new chemical entity drugs that have undergone phase one trials in Australia under the rigorous requirements of the US regulatory system," Starpharma CEO Dr John Raff said in a statement.
A report by the Rockefeller Foundation into HIV prevention, released earlier this year, estimates up to 2.5 million lives could be saved over three years if such a product was readily available.
In animals trials using macaque monkeys, a single application of the VivaGel product proved 100 percent effective against the monkey version of HIV as well as animal versions of genital herpes and chlamydia.
The human trials of the product are now planned to begin in Australia by the end of this year.
These will then be followed by a second 12-month trial involving at least 8,000 women with a possible prescription-only product available in three years` time. It would be another two years after that before an over-the-counter type product could be distributed.
Raff told CNN VivaGel was a "first of its type" product which could set a precedent for the development of other disease treatments in years to come.
Microbicides are gels, films, sponges or other products applied directly to the skin to help prevent the spread of disease.
They are particularly useful for women in poorer countries as they give them more control in helping prevent disease, particularly in cultures where condoms are a male-dominated product.
Women are also more vulnerable to contracting HIV from a single sexual encounter.
Countries such as Myanmar and Papua New Guinea face looming AIDS crises of a scale similar to those seen in Africa because of a lack of preventative measures.
A recent Australian government aid report says the working population of PNG could be cut by 38 percent by 2020 if infection rates follow those seen in Zimbabwe.
In Myanmar it is estimated that as many as 1 in 50 people has HIV with the disease spreading rapidly among the general population from high-risk groups such as prostitutes and intravenous drug users.
At the end of last year, 42 million people worldwide were infected with AIDS and by 2010 it is estimated a further 45 million people will be infected.
Starpharmas Bekanntheitsgrad steigt weiter:
Posted: Fri, 1 Aug 2003 10:12 AEST
ABC NEWS http://www.abc.net.au/news/australia/vic/metvic-1aug2003-4.h…
HIV gel to undergo human trial
A Melbourne company has developed a new gel that could slash HIV infection rates in developing countries.
The company has just been given the go ahead to conduct human trials.
VivaGel was developed by Melbourne biotech company Starpharma.
The vaginal gel, which blocks healthy cells from infection, has already proven 100 per cent effective in monkeys.
Now the product will be tested on humans in developing countries where thousands are infected daily.
Development manager Dr Tom McCarthy says the gel works to block healthy cells from infection, and tests will be conducted on a population of women who are at risk of infection.
"There`s a protein, a glycic protein on the surface of HIV called GP120, which HIV uses to attach to healthy cells," he said.
"And this compound latches onto that protein, essentially binding to it so it`s not free to bind to healthy cells.
"The effect we`ll be looking for will be after application of the gel in a population of women who are at risk of infection - does this gel lead to an underlying lower rate of HIV infection?"
Director at Melbourne`s Burnet Institute Professor Steve Wesselingh says the secret to the gel`s success is that women apply it.
"Men put on condoms so they make the decision whether to put on condoms and that`s not a decision women have been able to have a big input into," he said.
The gel also protects against most sexually transmitted diseases
Posted: Fri, 1 Aug 2003 10:12 AEST
ABC NEWS http://www.abc.net.au/news/australia/vic/metvic-1aug2003-4.h…
HIV gel to undergo human trial
A Melbourne company has developed a new gel that could slash HIV infection rates in developing countries.
The company has just been given the go ahead to conduct human trials.
VivaGel was developed by Melbourne biotech company Starpharma.
The vaginal gel, which blocks healthy cells from infection, has already proven 100 per cent effective in monkeys.
Now the product will be tested on humans in developing countries where thousands are infected daily.
Development manager Dr Tom McCarthy says the gel works to block healthy cells from infection, and tests will be conducted on a population of women who are at risk of infection.
"There`s a protein, a glycic protein on the surface of HIV called GP120, which HIV uses to attach to healthy cells," he said.
"And this compound latches onto that protein, essentially binding to it so it`s not free to bind to healthy cells.
"The effect we`ll be looking for will be after application of the gel in a population of women who are at risk of infection - does this gel lead to an underlying lower rate of HIV infection?"
Director at Melbourne`s Burnet Institute Professor Steve Wesselingh says the secret to the gel`s success is that women apply it.
"Men put on condoms so they make the decision whether to put on condoms and that`s not a decision women have been able to have a big input into," he said.
The gel also protects against most sexually transmitted diseases
Und weiter geht`s:
Saturday, 02 August 2003 08:35
The Sun · www.the-sun.co.uk
AIDS GEL TO SAVE 2M LIVES
A cheap gel has been developed that can stop Aids spreading through sex.
Trials on monkeys have been 100 per cent effective and makers have now been given the go-ahead to start tests on humans.
If successful, the gel could be available on prescription in three years and in five years over the counter.
Experts say it could save 2.5million lives in three years.
The product, called VivaGel, is applied by a woman before sex.
It will be aimed at developing countries where men may be reluctant to wear condoms.
......................................................................................................................
Sydney Morning Herald, Australia -
http://www.smh.com.au/articles/2003/08/03/1059849275153.html
Australian women to trial vaginal gel to fight HIV
August 4 2003
Australian women will trial a new vaginal gel, which aims to stop HIV infection.
The trial will initially involve groups of 12 women, with eight using VivaGel and four using a placebo.
It is expected to begin before the end of the year.
Melbourne biotech company Starpharma has been working on the gel since 1996 and has successfully trialled the microbicide - which blocks healthy cells from infection - on monkeys.
Development manager Tom McCarthy said that, while condoms remained an excellent barrier to HIV, the gel would allow women to take control when men refused to co-operate.
advertisement
advertisement
"The goal of the product is to lower the risk of HIV infection in women ... for example, they don`t have to negotiate for the use of a condom with a male," Dr McCarthy told AAP.
"The long-term benefits are in offering women the ability to control the risk of infection with STDs, especially HIV but also diseases such as herpes and chlamydia."
If the gel - which is meant to be applied about half an hour before sex - passes the safety trial, it is expected to hit the market in about 2007.
Australia`s largest communicable diseases research institute, the Burnet Institute, will work with Starpharma to fund the trials.
Institute director, Professor Steve Wesselingh, said the gel could provide an important third arm - in addition to vaccines and drugs - in the fight against HIV.
Meanwhile, Dr McCarthy said HIV had started as a disease spread between gay males but in some regions around the world it now infected more than 50 per cent of women.
He said the gel had not been designed as a contraceptive and scientists did not yet know whether it would stop pregnancies.
Dr McCarthy said women would apply small amounts of the gel once a day for seven days during the initial trials, in the interests of establishing safety.
He said scientists would study the effect the gel had on vaginal and cervical tissue and examine whether the product affected natural organisms in the vagina that are essential for women`s health.
Volunteers will need to be healthy women with no sexually transmitted diseases and stable menstrual cycles.
Starpharma is also working on a rectal gel for gay men.
Saturday, 02 August 2003 08:35
The Sun · www.the-sun.co.uk
AIDS GEL TO SAVE 2M LIVES
A cheap gel has been developed that can stop Aids spreading through sex.
Trials on monkeys have been 100 per cent effective and makers have now been given the go-ahead to start tests on humans.
If successful, the gel could be available on prescription in three years and in five years over the counter.
Experts say it could save 2.5million lives in three years.
The product, called VivaGel, is applied by a woman before sex.
It will be aimed at developing countries where men may be reluctant to wear condoms.
......................................................................................................................
Sydney Morning Herald, Australia -
http://www.smh.com.au/articles/2003/08/03/1059849275153.html
Australian women to trial vaginal gel to fight HIV
August 4 2003
Australian women will trial a new vaginal gel, which aims to stop HIV infection.
The trial will initially involve groups of 12 women, with eight using VivaGel and four using a placebo.
It is expected to begin before the end of the year.
Melbourne biotech company Starpharma has been working on the gel since 1996 and has successfully trialled the microbicide - which blocks healthy cells from infection - on monkeys.
Development manager Tom McCarthy said that, while condoms remained an excellent barrier to HIV, the gel would allow women to take control when men refused to co-operate.
advertisement
advertisement
"The goal of the product is to lower the risk of HIV infection in women ... for example, they don`t have to negotiate for the use of a condom with a male," Dr McCarthy told AAP.
"The long-term benefits are in offering women the ability to control the risk of infection with STDs, especially HIV but also diseases such as herpes and chlamydia."
If the gel - which is meant to be applied about half an hour before sex - passes the safety trial, it is expected to hit the market in about 2007.
Australia`s largest communicable diseases research institute, the Burnet Institute, will work with Starpharma to fund the trials.
Institute director, Professor Steve Wesselingh, said the gel could provide an important third arm - in addition to vaccines and drugs - in the fight against HIV.
Meanwhile, Dr McCarthy said HIV had started as a disease spread between gay males but in some regions around the world it now infected more than 50 per cent of women.
He said the gel had not been designed as a contraceptive and scientists did not yet know whether it would stop pregnancies.
Dr McCarthy said women would apply small amounts of the gel once a day for seven days during the initial trials, in the interests of establishing safety.
He said scientists would study the effect the gel had on vaginal and cervical tissue and examine whether the product affected natural organisms in the vagina that are essential for women`s health.
Volunteers will need to be healthy women with no sexually transmitted diseases and stable menstrual cycles.
Starpharma is also working on a rectal gel for gay men.
Ex-Coles chief joins Starpharma
Wednesday 6 August 2003, 12:05 PM
http://www.theage.com.au/articles/2003/08/06/1060064231017.h…
Former chief executive of Coles Myer and Fosters Group Peter Bartels has accepted a position as chairman of biotech outfit Starpharma Pooled Development Ltd.
Mr Bartels is chairman of the Australian Sports Commission, the Australian Institute of Sport and a director of the Australian Grand Prix Corporation.
Mr Bartels said he consulted widely before accepting the Starpharma board appointment.
"The feedback I received indicated that Starpharma is an international leader in an exciting new area of science and has an understanding of the realities of commercialising biotechnology," Mr Bartels said.
He has had broad-based experience in the pharmaceutical industry in previous roles with DHA Pharmaceuticals and Abbott Laboratories.
Last Friday, shares in Starpharma surged 11.5 cents to 46.5 cents after the company gained FDA clearance to proceed with human clinical trials of a new dendrimer nano-drug that will be used as a preventative against the transmission of HIV during sexual intercourse.
Wednesday 6 August 2003, 12:05 PM
http://www.theage.com.au/articles/2003/08/06/1060064231017.h…
Former chief executive of Coles Myer and Fosters Group Peter Bartels has accepted a position as chairman of biotech outfit Starpharma Pooled Development Ltd.
Mr Bartels is chairman of the Australian Sports Commission, the Australian Institute of Sport and a director of the Australian Grand Prix Corporation.
Mr Bartels said he consulted widely before accepting the Starpharma board appointment.
"The feedback I received indicated that Starpharma is an international leader in an exciting new area of science and has an understanding of the realities of commercialising biotechnology," Mr Bartels said.
He has had broad-based experience in the pharmaceutical industry in previous roles with DHA Pharmaceuticals and Abbott Laboratories.
Last Friday, shares in Starpharma surged 11.5 cents to 46.5 cents after the company gained FDA clearance to proceed with human clinical trials of a new dendrimer nano-drug that will be used as a preventative against the transmission of HIV during sexual intercourse.
Hier wird es interessant, Starpharma setzt zum zweiten Run an, doch bereits von deutlich höherer Basis.
Greenhorn , bist du noch dabei oder hast du dich mit läppischen 50 Prozent zufrieden gegeben ?
Greenhorn , bist du noch dabei oder hast du dich mit läppischen 50 Prozent zufrieden gegeben ?
Hallo Neoe!
Um Gottes Willen, ich habe nicht verkauft. Bin weiter dabei und ich werde so schnell auch keine einzige Aktie verkaufen. Keine Ahnung, wann das überhaupt mal der Fall sein wird.
Ich komme gerade von einem einwöchigen Urlaub nach Hause und sehe mit Freude, dass wir über 0,50 AUD notieren. Habe leider sehr wenig Zeit, frage deshalb einfach mal ganz dreist, was du meinst, dass Starpharma zum nächsten Run ansetzt. Gibt es News? Danke dafür!
Werde mich erst in ein zwei Tagen wieder näher mit diesem Thema auseinandersetzen können.
Wünsche noch einen schönen Tag!!!
Gruß, greenhorn
Um Gottes Willen, ich habe nicht verkauft. Bin weiter dabei und ich werde so schnell auch keine einzige Aktie verkaufen. Keine Ahnung, wann das überhaupt mal der Fall sein wird.
Ich komme gerade von einem einwöchigen Urlaub nach Hause und sehe mit Freude, dass wir über 0,50 AUD notieren. Habe leider sehr wenig Zeit, frage deshalb einfach mal ganz dreist, was du meinst, dass Starpharma zum nächsten Run ansetzt. Gibt es News? Danke dafür!
Werde mich erst in ein zwei Tagen wieder näher mit diesem Thema auseinandersetzen können.
Wünsche noch einen schönen Tag!!!
Gruß, greenhorn
News gibt es (noch) keine, aber entweder es sind größere Fische auf Starpharma aufmerksam geworden oder wir erwarten wieder Neuigkeiten, denn nachdem das Volumen schon wieder abgeebbt war, steigt das Volumen (und der Kurs dazu) in erheblichem Ausmaß.
Also Daumen drücken.
......................................................................................................................
P.S.:
Demnächst werde ich übrigens noch einen Kandidaten für einen Höhenflug vorstellen. Vielleicht interessiert es dich ja. Meiner Meinung nach schlummert da was unentdeckt, was BESSER ALS FLAMEL(der derzeitige Nanotechüberflieger) ist.
Also Daumen drücken.
......................................................................................................................
P.S.:
Demnächst werde ich übrigens noch einen Kandidaten für einen Höhenflug vorstellen. Vielleicht interessiert es dich ja. Meiner Meinung nach schlummert da was unentdeckt, was BESSER ALS FLAMEL(der derzeitige Nanotechüberflieger) ist.
Hi Neoe!
Ich drücke ganz fest die Daumen!!! Bin gespannt was uns die Aktie vielleicht sogar kurzfristig weiter bringt, muss allerdings sagen, dass ich in Sachen Starpharma ziemlich viel Zeit habe.
Man bemüht ja immer gerne dieses geflügelte Wort, am Anfang einer großen Story zu stehen. Ich mag das eigentlich nicht so sehr, glaube aber, dass, wenn sich Starpharma tatsächlich zu einer Story entwickelt, wir in der Tat ziemlich am Anfang stehen. News- und kursmäßig
Das gestiegene Volumen ist mir ebenfalls aufgefallen, der gestiegene Kurs natürlich auch
Mal sehen, was da kommt. Wir bleiben am Ball!!!
Natürlich bin ich daran interessiert, welchen Wert du da genau im Auge hast!!! Freue mich schon auf dein Posting diesbezüglich und sage schon einmal Danke!
Gruß, greenhorn
Ich drücke ganz fest die Daumen!!! Bin gespannt was uns die Aktie vielleicht sogar kurzfristig weiter bringt, muss allerdings sagen, dass ich in Sachen Starpharma ziemlich viel Zeit habe.
Man bemüht ja immer gerne dieses geflügelte Wort, am Anfang einer großen Story zu stehen. Ich mag das eigentlich nicht so sehr, glaube aber, dass, wenn sich Starpharma tatsächlich zu einer Story entwickelt, wir in der Tat ziemlich am Anfang stehen. News- und kursmäßig
Das gestiegene Volumen ist mir ebenfalls aufgefallen, der gestiegene Kurs natürlich auch
Mal sehen, was da kommt. Wir bleiben am Ball!!!
Natürlich bin ich daran interessiert, welchen Wert du da genau im Auge hast!!! Freue mich schon auf dein Posting diesbezüglich und sage schon einmal Danke!
Gruß, greenhorn
Einen wunderschönen guten Abend!
Auf der Homepage von Starpharma gibt einen Präsentations-Update, in dem sich das Unternehmen noch einmal vorstellt, inklusive der neuesten Entwicklungen. Ist ganz interessant!
Wo ich gerade von "interessant" schreibe: Starpharma ist in meinen Augen ein höchstinteressantes Unternehmen mit gewaltigem Potenzial. Immer unter der Voraussetzung natürlich, alles geht mehr oder weniger glatt. Auch der Kurs hat sich in den letzten Wochen sehr freundlich entwickelt. Verstehe gar nicht, warum sich niemand für diesen Wert interessiert. Naja, macht ja nichts.
In diesem Sinne, freu mich von dir zu lesen, Neoe!
Gruß, greenhorn
Auf der Homepage von Starpharma gibt einen Präsentations-Update, in dem sich das Unternehmen noch einmal vorstellt, inklusive der neuesten Entwicklungen. Ist ganz interessant!
Wo ich gerade von "interessant" schreibe: Starpharma ist in meinen Augen ein höchstinteressantes Unternehmen mit gewaltigem Potenzial. Immer unter der Voraussetzung natürlich, alles geht mehr oder weniger glatt. Auch der Kurs hat sich in den letzten Wochen sehr freundlich entwickelt. Verstehe gar nicht, warum sich niemand für diesen Wert interessiert. Naja, macht ja nichts.
In diesem Sinne, freu mich von dir zu lesen, Neoe!
Gruß, greenhorn
greenhorn:
Hab gerade das Update entdeckt. Für mich der absolute Hammer.
1.Sie kündigen die Zusammenarbeit mit einer/mehreren Regierung/en im südostasiatischen bzw. afrikanischen Raum bei den VivaGel-Tests an.
2. Dendritic Nanotech denkt bereits an zwei Spin-offs, das heisst es müssen sich irgendwelche großen Partner aufgetan haben, die mit Dendritic N. auf den Gebieten (auf die sie als potientelle weitere Forschungsbereiche in dem Update hinweisen) zusammenarbeiten wollen (z.B. Batterien, etc.,etc.).
3.Die Krönung: Ich weiss nicht, ob ich es falsch übersetze. Aber schau mal im Abschnitt "Respiratory"
nach. Da steht zum Schluss ganz klar ...and established BIG PHARMA relationships.
Wenn ich mir in dem Zusammenhang dann noch das Beispiel mit Glaxo und Theravance anschaue wird zumindest heftigst Fantasie bei mir geweckt.
Bleibt die Frage: wer sind Starpharmas Partner ??? Ich vermute, wir hören bald was.
Der Link zum Update:
http://www.starpharma.com/docs/SPL_02_Sept-03.pdf
Hab gerade das Update entdeckt. Für mich der absolute Hammer.
1.Sie kündigen die Zusammenarbeit mit einer/mehreren Regierung/en im südostasiatischen bzw. afrikanischen Raum bei den VivaGel-Tests an.
2. Dendritic Nanotech denkt bereits an zwei Spin-offs, das heisst es müssen sich irgendwelche großen Partner aufgetan haben, die mit Dendritic N. auf den Gebieten (auf die sie als potientelle weitere Forschungsbereiche in dem Update hinweisen) zusammenarbeiten wollen (z.B. Batterien, etc.,etc.).
3.Die Krönung: Ich weiss nicht, ob ich es falsch übersetze. Aber schau mal im Abschnitt "Respiratory"
nach. Da steht zum Schluss ganz klar ...and established BIG PHARMA relationships.
Wenn ich mir in dem Zusammenhang dann noch das Beispiel mit Glaxo und Theravance anschaue wird zumindest heftigst Fantasie bei mir geweckt.
Bleibt die Frage: wer sind Starpharmas Partner ??? Ich vermute, wir hören bald was.
Der Link zum Update:
http://www.starpharma.com/docs/SPL_02_Sept-03.pdf
Guten Abend! (Oder besser gute Nacht!)
Für meinen Geschmack hast du das sehr richtig übersetzt und verstanden. Bin von weiteren positiven News in den kommenden Wochen überzeugt. Dementsprechend dürfte sich der Kurs weiter nach oben entwickeln.
Korrigiere mich bitte, wenn ich falsch liege: Du hast zu Beginn dieser Diskussion gesagt, Starpharma habe eine Marktkapitalisierung von ca. 20 Millionen Euro. Damals stand der Kurs bei rund 0,35 AUD. Dementsprechend dürfte Starpharma derzeit mit rund 35 Millionen Euro bewertet werden. Macht rund 100 Millionen Aktien, die im Umlauf sind. Richtig?
Noch immer recht billig, wie ich finde. Vor allen Dingen, wenn man sich die News so anschaut.
Gruß, greenhorn
Für meinen Geschmack hast du das sehr richtig übersetzt und verstanden. Bin von weiteren positiven News in den kommenden Wochen überzeugt. Dementsprechend dürfte sich der Kurs weiter nach oben entwickeln.
Korrigiere mich bitte, wenn ich falsch liege: Du hast zu Beginn dieser Diskussion gesagt, Starpharma habe eine Marktkapitalisierung von ca. 20 Millionen Euro. Damals stand der Kurs bei rund 0,35 AUD. Dementsprechend dürfte Starpharma derzeit mit rund 35 Millionen Euro bewertet werden. Macht rund 100 Millionen Aktien, die im Umlauf sind. Richtig?
Noch immer recht billig, wie ich finde. Vor allen Dingen, wenn man sich die News so anschaut.
Gruß, greenhorn
Hi!Bin von der Story auch überzeugt und hab etwas investiert.
greenhorn1998:
Shares Oustanding: 88,900,000
Market Cap: 56 Mill AUD$ = 32,9 Mill€
(bei Umrechnungskurs 1,7)
gr nanoplay
greenhorn1998:
Shares Oustanding: 88,900,000
Market Cap: 56 Mill AUD$ = 32,9 Mill€
(bei Umrechnungskurs 1,7)
gr nanoplay
Hallo zusammen!
@nanoplay
Dann sage ich doch mal herzlich willkommen und vielen Dank für die Information!
@all
Das war ja wieder eine sehr erfolgreiche Nacht für Starpharma. Weiß gar nicht, wo die Aktie kurzfristig noch so hin will
Die Umsätze sind weiterhin ganz gut, mal sehen, was uns da noch so erwartet an Neuigkeiten in nächster Zeit.
Gruß, greenhorn
@nanoplay
Dann sage ich doch mal herzlich willkommen und vielen Dank für die Information!
@all
Das war ja wieder eine sehr erfolgreiche Nacht für Starpharma. Weiß gar nicht, wo die Aktie kurzfristig noch so hin will
Die Umsätze sind weiterhin ganz gut, mal sehen, was uns da noch so erwartet an Neuigkeiten in nächster Zeit.
Gruß, greenhorn
Trading halt in Australien; ich vermute da kommen wichtige News auf uns zu. Unter Umständen sogar ein Riesenhammer. Mal abwarten.
greenhorn:
Bist du der Schweizer vom Ozestock-SPL-Board ?
greenhorn:
Bist du der Schweizer vom Ozestock-SPL-Board ?
Hallo Neoe!
Nein, die Grüße aus der Schweiz waren nicht von mir, I`m sorry. Wegen der 98?
Ich bin dort gar nicht registriert, verfolge aber die Diskussionen dort. Bist du dort aktiv?
Ich denke auch, dass wir uns auf kommende Nachrichten bezüglich der Handlsaussetzung freuen können. Was auch immer es ist. Im Ozestock-Board gehen einige Vermutungen herum. Weiß nicht, ob ich das überlesen habe, aber wie lange ist der Kurs denn ausgesetzt?
Gruß, greenhorn
Nein, die Grüße aus der Schweiz waren nicht von mir, I`m sorry. Wegen der 98?
Ich bin dort gar nicht registriert, verfolge aber die Diskussionen dort. Bist du dort aktiv?
Ich denke auch, dass wir uns auf kommende Nachrichten bezüglich der Handlsaussetzung freuen können. Was auch immer es ist. Im Ozestock-Board gehen einige Vermutungen herum. Weiß nicht, ob ich das überlesen habe, aber wie lange ist der Kurs denn ausgesetzt?
Gruß, greenhorn
Es wurden knapp 14 Millionen neue Aktien platziert zu 0,52 AUD, also rund 7 Millionen AUD.
Eigentlich regt mich diese Verwässerung auf, da eindeutig gesagt wurde, daß Starpharma kein Geld benötigt.
Aber immerhin liegt der Preis weit über unserem Einstiegskurs.
Outstanding shares:
nun über 100 Millionen, das dürfte dann wohl genug sein....
Eigentlich regt mich diese Verwässerung auf, da eindeutig gesagt wurde, daß Starpharma kein Geld benötigt.
Aber immerhin liegt der Preis weit über unserem Einstiegskurs.
Outstanding shares:
nun über 100 Millionen, das dürfte dann wohl genug sein....
Hallo zusammen!
Ich kann es auch nicht so ganz verstehen, dass hier Shares platziert wurden. Am knapp werdenden Geld kann es jedenfalls zu diesem Zeitpunkt nicht gelegen haben. Naja.
Der Kurs ist heute wieder deutlich nach oben gegangen.
Derzeit findet eine ganz interessante Diskussion über die Wirksamkeit des Wirkstoffes von Vivagel als Schutz vor Aids statt. Ein Wirkstoff, der - wie so oft schon hier erwähnt - bei Makkaken-Affen einhundertprozentig gewirkt hat.
Nun ist aber Aids und die "tierische Variante" nicht eins zu eins zu vergleichen, die Frage ist, ob diese Wirkung auch tatsächlich beim Menschen erreicht werden kann.
Das war natürlich von vorneherin klar, man sollte nur immer im Hinterkopf behalten, dass die Zulassung von Vivagel nicht schon jetzt beschlossene Sache ist. Starpharma ist und wird auch noch lange ein Risikoinvestment bleiben. Allerdings natürlich ein sehr (!) aussichtsreiches!!
Weiß auch nicht, warum ich das jetzt schreibe, muss mich halt ab und zu auch mal wieder auf den Boden der Tatsachen zurückholen, ich freue mich nämlich so über den Kursverlauf.
In diesem Sinne,
Gruß, greenhorn
Ich kann es auch nicht so ganz verstehen, dass hier Shares platziert wurden. Am knapp werdenden Geld kann es jedenfalls zu diesem Zeitpunkt nicht gelegen haben. Naja.
Der Kurs ist heute wieder deutlich nach oben gegangen.
Derzeit findet eine ganz interessante Diskussion über die Wirksamkeit des Wirkstoffes von Vivagel als Schutz vor Aids statt. Ein Wirkstoff, der - wie so oft schon hier erwähnt - bei Makkaken-Affen einhundertprozentig gewirkt hat.
Nun ist aber Aids und die "tierische Variante" nicht eins zu eins zu vergleichen, die Frage ist, ob diese Wirkung auch tatsächlich beim Menschen erreicht werden kann.
Das war natürlich von vorneherin klar, man sollte nur immer im Hinterkopf behalten, dass die Zulassung von Vivagel nicht schon jetzt beschlossene Sache ist. Starpharma ist und wird auch noch lange ein Risikoinvestment bleiben. Allerdings natürlich ein sehr (!) aussichtsreiches!!
Weiß auch nicht, warum ich das jetzt schreibe, muss mich halt ab und zu auch mal wieder auf den Boden der Tatsachen zurückholen, ich freue mich nämlich so über den Kursverlauf.
In diesem Sinne,
Gruß, greenhorn
greenhorn:
Ich darf deine angezogene Handbremse wieder etwas lösen:
Vivagel ist kein Wirkstoff sondern ein simpler Schutz gegen Aidsübertragung bei Geschlechtsverkehr.
Das heisst einerseits, das Vivagel nicht das Wundermedikament ist, auf das jeder wartet, andererseits lässt sich relativ gut abschätzen, dass die Funktionalität nur sehr, sehr begrenzt von der Form des Viruses abhängt.
Das lässt sich außerdem daran ablesen, das Vivagel vor einer ganzen Reihe von Infektionen, die bei Geschlechtsverkehr übertragen werden, schützt.
Also lieber greenhorn, bitte wieder richtig freuen.
Übrigens: Nächster Tip, auch Nanoforum, kommt gleich.
Ich darf deine angezogene Handbremse wieder etwas lösen:
Vivagel ist kein Wirkstoff sondern ein simpler Schutz gegen Aidsübertragung bei Geschlechtsverkehr.
Das heisst einerseits, das Vivagel nicht das Wundermedikament ist, auf das jeder wartet, andererseits lässt sich relativ gut abschätzen, dass die Funktionalität nur sehr, sehr begrenzt von der Form des Viruses abhängt.
Das lässt sich außerdem daran ablesen, das Vivagel vor einer ganzen Reihe von Infektionen, die bei Geschlechtsverkehr übertragen werden, schützt.
Also lieber greenhorn, bitte wieder richtig freuen.
Übrigens: Nächster Tip, auch Nanoforum, kommt gleich.
Der Jahresbericht. Nochmal eine schöne Zusammenfassung, die das ganze Potential zeigt, das Starpharma in den nächsten Jahren ausreizen wird:
http://www.starpharma.com/docs/4E_commentary.pdf
http://www.starpharma.com/docs/4E_commentary.pdf
Hi Neoe!
Okay, du hast mich überzeugt. Denke aber, dass es ganz wichtig ist, auch immer die Risiken im Auge zu behalten, auch wenn sie - wie im Fall von Starpharma - den Chancen deutlichst unterliegen. Wie sagtest du doch gleich in deinem ersten Posting hier? Ein Wert für die Rente, oder so ähnlich? Nun, mit etwas Glück und genügend Ausdauer - da könntest du Recht haben.
Mal ganz in Ruhe abwarten.
Wie du selbst sagtest: das ist eine Sache von Jahren.
Habe den Jahresbericht auch gefunden, aber bislang nur kurz überflogen. Fühle mich aber in einem kleinen Investment absolut bestätigt!
Gruß, greenhorn
Okay, du hast mich überzeugt. Denke aber, dass es ganz wichtig ist, auch immer die Risiken im Auge zu behalten, auch wenn sie - wie im Fall von Starpharma - den Chancen deutlichst unterliegen. Wie sagtest du doch gleich in deinem ersten Posting hier? Ein Wert für die Rente, oder so ähnlich? Nun, mit etwas Glück und genügend Ausdauer - da könntest du Recht haben.
Mal ganz in Ruhe abwarten.
Wie du selbst sagtest: das ist eine Sache von Jahren.
Habe den Jahresbericht auch gefunden, aber bislang nur kurz überflogen. Fühle mich aber in einem kleinen Investment absolut bestätigt!
Gruß, greenhorn
Und weiter geht`s:
Die Örtlichkeit für die PhaseI-Tests steht fest. Starpharma bleibt Australien treu:
http://www.asx.com.au/asxpdf/20030916/pdf/3j1v7cw1wqkb3.pdf
Die Örtlichkeit für die PhaseI-Tests steht fest. Starpharma bleibt Australien treu:
http://www.asx.com.au/asxpdf/20030916/pdf/3j1v7cw1wqkb3.pdf
Hi Neoe!
Weiter geht es auch mit dem Kurs. Schlusskurs 0,77 AUD, knapp 14 Prozent im Plus.
Nun ehrlich gesagt bin ich schon fast der Meinung, dass bald die Zeit für eine Konsolidierung gekommen sein könnte. Die Aktie ist rasant gelaufen und steuert auf alte Hochs zu, die wahrscheinlich nicht so leicht zu überwinden sind. Die Betonung liegt auf wahrscheinlich, schließlich ist diese Rally untermauert von fundamental sehr guten Nachrichten der letzten Zeit, auch die Umsätze haben sich vervielfacht und liegen auf konstant hohem Niveau. Vielleicht ist es auch einfach so, dass bei dieser Aktie schon jetzt eine kleine Neubewertung ansteht und wir diese gerade durchmachen. Vielleicht. Fakt ist: Starpharma ist und bleibt ein extrem aussichtsreiches Investment, auch wenn es tatsächlich bald oder irgendwann zu einer Konsolidierung kommen sollte.
In diesem Sinne noch viel Spaß!
Gruß, greenhorn
Weiter geht es auch mit dem Kurs. Schlusskurs 0,77 AUD, knapp 14 Prozent im Plus.
Nun ehrlich gesagt bin ich schon fast der Meinung, dass bald die Zeit für eine Konsolidierung gekommen sein könnte. Die Aktie ist rasant gelaufen und steuert auf alte Hochs zu, die wahrscheinlich nicht so leicht zu überwinden sind. Die Betonung liegt auf wahrscheinlich, schließlich ist diese Rally untermauert von fundamental sehr guten Nachrichten der letzten Zeit, auch die Umsätze haben sich vervielfacht und liegen auf konstant hohem Niveau. Vielleicht ist es auch einfach so, dass bei dieser Aktie schon jetzt eine kleine Neubewertung ansteht und wir diese gerade durchmachen. Vielleicht. Fakt ist: Starpharma ist und bleibt ein extrem aussichtsreiches Investment, auch wenn es tatsächlich bald oder irgendwann zu einer Konsolidierung kommen sollte.
In diesem Sinne noch viel Spaß!
Gruß, greenhorn
Hallo zusammen!
Es gibt mal wieder News von Starpharma und wahrlich keine schlechten!!!! Starpharma und AGT Biosciences arbeiten in Sachen Diabetis Typ II zusammen.
Gruß, greenhorn
http://www.starpharma.com/PDFs/030918_AGT_SPL_Collab.pdf
Es gibt mal wieder News von Starpharma und wahrlich keine schlechten!!!! Starpharma und AGT Biosciences arbeiten in Sachen Diabetis Typ II zusammen.
Gruß, greenhorn
http://www.starpharma.com/PDFs/030918_AGT_SPL_Collab.pdf
Hi!
Nun, die angesprochene Konsolidierung ist eingetreten. Wir haben uns deutlich vom Zwischenhoch entfernt. Nur eine kleine Atempause?
Gruß, greenhorn
Nun, die angesprochene Konsolidierung ist eingetreten. Wir haben uns deutlich vom Zwischenhoch entfernt. Nur eine kleine Atempause?
Gruß, greenhorn
Wie süß, Boerse-Go empfiehlt in eine australische Aktie, zu der ich bei niedrigen Kursen keinen überreden konnte. Bin gespannt, wer aufspringt. Für uns kann es nur gut sein, mein lieber greenhorn.
Starpharma – Mit Nanostrukturen gegen HIV
--------------------------------------------------------------------------------
(©BörseGo - http://www.boerse-go.de)
Firmensitz: Melbourne, Victoria, Australien
Mitarbeiter: k. A.
Spezialgebiet: Nanomedizin
Börse/Symbol: ASX/SPL
Webseite: http://www.starpharma.com
Der spekulative Tipp aus dem Bereich der BioNanotechnologie
Starpharma Pooled Development Ltd., nennt sich ein 1996 in Melbourne, Australien, gegründetes Unternehmen, dessen Spezialgebiet eine am Biomolecular Research Institute in Melbourne erforschte Technologie ist und für die das Unternehmen die weltweiten Exklusivrechte erworben hat. Die Technologie, die durch eine Anzahl wichtiger Patente geschützt ist, umfasst eine Klasse hochmolekularer stark verzweigter chemischer Verbindungen, sogenannte Dendrimere, die aktiv gegenüber einer großen Anzahl von Viren und anderen bisher nur inadäquat behandelbaren Erkrankungen sein sollen. Der Name Starpharma leitet sich übrigens von den sternförmigen Strukturen der Dendrimer-Moleküle ab, die die Basis für die in der Entwicklung befindlichen Wirkstoffe des Unternehmens sind.
Auf zwei Programme konzentriert sich Starpharma gegenwärtig, diese sollen bis in die Phase II, also bis zur Ermittlung einer Wirksamkeit im Menschen, geführt werden und im Anschluss daran an ein großes Pharmaunternehmen lizenziert werden. Das „Vaginal Microbicide Program“, zur Prävention von Erkrankungen die durch Geschlechtsverkehr übertragen werden, und das “Angiogenesis Inhibitor Program”, zur möglichen Therapie von Krebserkrankungen, befinden sich gegenwärtig noch in der präklinischen Entwicklung. Allerdings hat Starpharma für das zur HIV-Prävention entwickelte Gel, VivaGel, das auf Nanopartikeln basiert, erst im Juli die FDA-Genehmigung zur Durchführung eines Phase I Versuches erhalten. Damit ist VivaGel das erste auf Nanopartikeln basierende Gel, das demnächst am Menschen getestet werden soll.
Im Juli 2002 gründete Starpharma speziell zur Entwicklung von nanotechnologischen Anwendungen in den USA ein neues Tochterunternehmen. Dendritic Nanotechnologies wird von Donald Tomalia, einem Spezialisten auf dem Gebiet der Nanotechnologie geleitet und hat zur Entwicklung von VivaGel beigetragen. Das neuartige Vaginalgel auf Wasserbasis, das als aktive Komponente das Polylysin Dendrimer SPL7013 enthält, soll zuerst auf seine Wirksamkeit gegen HIV getestet werden. Allerdings konnten präklinische Studien auch eine Aktivität des Gels gegenüber Chlamydien und Genital-Herpes zeigen.
Die Wirkung von SPL7013 soll darauf beruhen, dass die Dendrimere die Bindung von HIV an Körperzellen verhindern, wodurch keine Infektion zustande kommen kann. Das Gel hat aber laut Starpharma gegenüber den üblichen physikalischen Barrieren den Vorteil, dass die Nanopartikel die Viren nicht nur am Eindringen in die Körperzellen hindern, sondern sie gleichzeitig auch zerstören.
Dendrimere sind synthetische Nanostrukturen, die so maßgeschneidert werden können, dass sie sich für pharmazeutische Anwendungen eignen. Spezialisierte chemische Prozesse erlauben es, die physikalischen und chemischen Eigenschaften der Dendrimere präzise zu kontrollieren. Die Dendrimere werden in einer Serie von einzelnen kontrollierten Reaktionen konstruiert, dabei ordnet sich eine Vielzahl von kleinen Molekülen um ein Zentralmolekül an. Vorstellen muss man sich so ein Dendrimer wie einen sehr stark verästelten Zweig. Im letzten Reaktionsschritt werden dann die verschiedenen aktiven Gruppen an das stark verzweigte Molekül angelagert. Das so entstehende Dendrimer verfügt dann auf seiner Oberfläche über eine Vielzahl möglicher Reaktionsstellen, die mit verschiedenen Rezeptoren auf der Oberfläche von Viren oder Bakterien in Wechselwirkung treten können.
In der Präklinik war die SPL7013 Nanostruktur nicht nur aktiv gegen HIV, sondern auch gegenüber Genitalherpes, Chlamydien, Hepatitis B, und Genitalwarzen, ausgelöst durch Papillomviren. In Primaten, die dem Affen-AIDS-Virus ausgesetzt wurden, konnte VivaGel die Infektion zu 100 Prozent verhindern. Eine HIV-Infektion erfolgt durch die Bindung des Proteins gp120 auf der Oberfläche des Virus an den CD4-Rezeptor auf der Zielzelle. Die aktiven Gruppen im Dendrimer SPL7013 binden ihrerseits an gp120 und verhindern dadurch eine Interaktion des Virus mit gesunden Körperzellen, die den CD4-Rezeptor tragen. Umfassende toxikologische Studien in verschiedenen Versuchstieren sprechen zudem für die Sicherheit des neuartigen Gels. Gegenwärtig untersucht Starpharma das Sicherheitsprofil bei wiederholter Verabreichung in der dem Menschen ähnlichsten Affenart, dem Makaken.
Sollten die Phase I Versuche die präklinischen Daten bestätigen, wäre das von Starpharma entwickelte Produkt, auf Basis von Nanostrukturen, eine echte Sensation. Denn mit VivaGel ließe sich die Ausbreitung von Geschlechtskrankheiten, die bereits wieder auf dem Vormarsch sind, effektiv und viel unkomplizierter als mit einem Kondom eindämmen. Vor allem die sich rasend verbreitende HPV-Infektion, die durch das humane Papillomvirus ausgelöst wird und sich durch Genitalwarzen bemerkbar macht, wird immer mehr zu einem Problem. Besonders problematisch ist die Tatsache, dass einige Typen von HPV das Risiko für Gebärmutterhalskrebs dramatisch ansteigen lassen. VivaGel wäre also die perfekte Prävention gegen Geschlechtskrankheiten aller Art. Sollte das Produkt bis zur Zulassung gelangen, würde es ein bisher kaum abschätzbares Marktvolumen erwarten
Starpharma – Mit Nanostrukturen gegen HIV
--------------------------------------------------------------------------------
(©BörseGo - http://www.boerse-go.de)
Firmensitz: Melbourne, Victoria, Australien
Mitarbeiter: k. A.
Spezialgebiet: Nanomedizin
Börse/Symbol: ASX/SPL
Webseite: http://www.starpharma.com
Der spekulative Tipp aus dem Bereich der BioNanotechnologie
Starpharma Pooled Development Ltd., nennt sich ein 1996 in Melbourne, Australien, gegründetes Unternehmen, dessen Spezialgebiet eine am Biomolecular Research Institute in Melbourne erforschte Technologie ist und für die das Unternehmen die weltweiten Exklusivrechte erworben hat. Die Technologie, die durch eine Anzahl wichtiger Patente geschützt ist, umfasst eine Klasse hochmolekularer stark verzweigter chemischer Verbindungen, sogenannte Dendrimere, die aktiv gegenüber einer großen Anzahl von Viren und anderen bisher nur inadäquat behandelbaren Erkrankungen sein sollen. Der Name Starpharma leitet sich übrigens von den sternförmigen Strukturen der Dendrimer-Moleküle ab, die die Basis für die in der Entwicklung befindlichen Wirkstoffe des Unternehmens sind.
Auf zwei Programme konzentriert sich Starpharma gegenwärtig, diese sollen bis in die Phase II, also bis zur Ermittlung einer Wirksamkeit im Menschen, geführt werden und im Anschluss daran an ein großes Pharmaunternehmen lizenziert werden. Das „Vaginal Microbicide Program“, zur Prävention von Erkrankungen die durch Geschlechtsverkehr übertragen werden, und das “Angiogenesis Inhibitor Program”, zur möglichen Therapie von Krebserkrankungen, befinden sich gegenwärtig noch in der präklinischen Entwicklung. Allerdings hat Starpharma für das zur HIV-Prävention entwickelte Gel, VivaGel, das auf Nanopartikeln basiert, erst im Juli die FDA-Genehmigung zur Durchführung eines Phase I Versuches erhalten. Damit ist VivaGel das erste auf Nanopartikeln basierende Gel, das demnächst am Menschen getestet werden soll.
Im Juli 2002 gründete Starpharma speziell zur Entwicklung von nanotechnologischen Anwendungen in den USA ein neues Tochterunternehmen. Dendritic Nanotechnologies wird von Donald Tomalia, einem Spezialisten auf dem Gebiet der Nanotechnologie geleitet und hat zur Entwicklung von VivaGel beigetragen. Das neuartige Vaginalgel auf Wasserbasis, das als aktive Komponente das Polylysin Dendrimer SPL7013 enthält, soll zuerst auf seine Wirksamkeit gegen HIV getestet werden. Allerdings konnten präklinische Studien auch eine Aktivität des Gels gegenüber Chlamydien und Genital-Herpes zeigen.
Die Wirkung von SPL7013 soll darauf beruhen, dass die Dendrimere die Bindung von HIV an Körperzellen verhindern, wodurch keine Infektion zustande kommen kann. Das Gel hat aber laut Starpharma gegenüber den üblichen physikalischen Barrieren den Vorteil, dass die Nanopartikel die Viren nicht nur am Eindringen in die Körperzellen hindern, sondern sie gleichzeitig auch zerstören.
Dendrimere sind synthetische Nanostrukturen, die so maßgeschneidert werden können, dass sie sich für pharmazeutische Anwendungen eignen. Spezialisierte chemische Prozesse erlauben es, die physikalischen und chemischen Eigenschaften der Dendrimere präzise zu kontrollieren. Die Dendrimere werden in einer Serie von einzelnen kontrollierten Reaktionen konstruiert, dabei ordnet sich eine Vielzahl von kleinen Molekülen um ein Zentralmolekül an. Vorstellen muss man sich so ein Dendrimer wie einen sehr stark verästelten Zweig. Im letzten Reaktionsschritt werden dann die verschiedenen aktiven Gruppen an das stark verzweigte Molekül angelagert. Das so entstehende Dendrimer verfügt dann auf seiner Oberfläche über eine Vielzahl möglicher Reaktionsstellen, die mit verschiedenen Rezeptoren auf der Oberfläche von Viren oder Bakterien in Wechselwirkung treten können.
In der Präklinik war die SPL7013 Nanostruktur nicht nur aktiv gegen HIV, sondern auch gegenüber Genitalherpes, Chlamydien, Hepatitis B, und Genitalwarzen, ausgelöst durch Papillomviren. In Primaten, die dem Affen-AIDS-Virus ausgesetzt wurden, konnte VivaGel die Infektion zu 100 Prozent verhindern. Eine HIV-Infektion erfolgt durch die Bindung des Proteins gp120 auf der Oberfläche des Virus an den CD4-Rezeptor auf der Zielzelle. Die aktiven Gruppen im Dendrimer SPL7013 binden ihrerseits an gp120 und verhindern dadurch eine Interaktion des Virus mit gesunden Körperzellen, die den CD4-Rezeptor tragen. Umfassende toxikologische Studien in verschiedenen Versuchstieren sprechen zudem für die Sicherheit des neuartigen Gels. Gegenwärtig untersucht Starpharma das Sicherheitsprofil bei wiederholter Verabreichung in der dem Menschen ähnlichsten Affenart, dem Makaken.
Sollten die Phase I Versuche die präklinischen Daten bestätigen, wäre das von Starpharma entwickelte Produkt, auf Basis von Nanostrukturen, eine echte Sensation. Denn mit VivaGel ließe sich die Ausbreitung von Geschlechtskrankheiten, die bereits wieder auf dem Vormarsch sind, effektiv und viel unkomplizierter als mit einem Kondom eindämmen. Vor allem die sich rasend verbreitende HPV-Infektion, die durch das humane Papillomvirus ausgelöst wird und sich durch Genitalwarzen bemerkbar macht, wird immer mehr zu einem Problem. Besonders problematisch ist die Tatsache, dass einige Typen von HPV das Risiko für Gebärmutterhalskrebs dramatisch ansteigen lassen. VivaGel wäre also die perfekte Prävention gegen Geschlechtskrankheiten aller Art. Sollte das Produkt bis zur Zulassung gelangen, würde es ein bisher kaum abschätzbares Marktvolumen erwarten
Hallo zusammen, hi neoe!
Ein bisschen was zu lesen, aber nicht wirklich etwas neues.
http://www.smalltimes.com/document_display.cfm?document_id=6…
Und die neuesten Neuigkeiten.
http://www.starpharma.com/PDFs/030929_Annual_Report.pdf
Neoe, was hälst du von der Kursentwicklung zur Zeit?
Gruß, greenhorn
Ein bisschen was zu lesen, aber nicht wirklich etwas neues.
http://www.smalltimes.com/document_display.cfm?document_id=6…
Und die neuesten Neuigkeiten.
http://www.starpharma.com/PDFs/030929_Annual_Report.pdf
Neoe, was hälst du von der Kursentwicklung zur Zeit?
Gruß, greenhorn
War klar das der Kurs nochmal etwas zurückkommt, er wird aber keinesfalls signifikant unter den Aktienpreis der letzten Finanzierungsrunde fallen und der war glaube ich bei 0,52(?)-0,55(?) AUD.
Wenn du deinen Artikel genau durchgelesen hast, weisst du ja schon fast das Datum, wenn es wieder mächtig bergauf gehen wird.
Und ich sag es nochmal: Wir sind dabei !!!
Wenn du deinen Artikel genau durchgelesen hast, weisst du ja schon fast das Datum, wenn es wieder mächtig bergauf gehen wird.
Und ich sag es nochmal: Wir sind dabei !!!
Bio`s star turn
By Beth Quinlivan
When Starpharma announced in July that it had approval from United States regulators to begin human trials of its HIV-preventive gel, it was a milestone for the Melbourne biotech fund. Three years after its public listing, receiving the go-ahead by the Food & Drug Administration (FDA) means Starpharma is one step closer to having a product on the market and a revenue stream. The phase-one clinical trials of VivaGel will start immediately.
Starpharma`s announcement initially created only minor interest among investors. But that is not surprising. Worldwide, there are thousands of phase-one trials running at any time, of which about 70% fail.
What made the Starpharma approval more interesting than the usual company announcement about an "exciting new clinical trial about to start" is that it is the first time the FDA has approved a dendrimer-based drug for human testing.
Starpharma`s share price was only 19¢ in March this year. By July, when the trial approval was announced, it was 35¢. A placement of 13.3 million shares was made to institutions on September 10 at 52¢ a share (raising $6.9 million); recent trades have been about 70¢.
Dendrimers are a form of nanotechnology. They are man-made, three-dimensional molecules, constructed in layers around a central hollow core with a number of sticky points on the outside that attach to viral or cell targets. Dendrimer drugs are polyvalent, which means each molecule is able to bind to the viral or other disease target on several sites. In theory, this means a dendrimer drug is likely to be stronger, it may extend the duration of the drug`s action, and may offer broader protection or coverage.
They are a form of nanotechnology because their structure comprises tiny molecular building blocks - each with dimensions between one and 100 nanometres (a nanometre is one millionth of a millimetre).
Starpharma is one of the leading groups internationally in the new field of dendrimer-based pharmaceuticals. The first dendrimers were constructed in the late 1970s, but early interest in them was for their chemical and industrial applications. Scientists at the Biomolecular Research Institute (BMI) in Melbourne were among the first in the world to look at pharmaceutical applications of dendrimers when they began their studies more than a decade ago. BMI licensed the intellectual property to Starpharma in 1996.
Starpharma has developed on that early research and now has many patents covering dendrimer-based antimicrobial, antiviral, anti-parasitic and anti-cancer compounds. In 2001, it co-founded the US company Dendritic Nanotechnologies (DNT) with Donald Tomalia, a former Dow Chemical scientist and nanotechnology/dendrimer expert. DNT is looking to develop pharmaceutical and other uses for dendrimers, including optical and electroactive applications, and as chemical catalysts.
Although no nano-structured drugs have previously been approved for human trials, Starpharma`s chief executive, John Raff, says there is growing interest in the use of dendrimers across all applications. "You can gauge the increased interest from the level of scientific publications. In 2002, across all fields, there were 2500 new dendrimer publications. The number has been growing at 32% a year over the past five years."
Aside from the publications, he says the lucrative alliance struck earlier this year between the San Francisco biotech company Theravance and GlaxoSmithKline is evidence of the money pharmaceutical companies are prepared to spend in securing a foothold in the area of polyvalent drugs.
The Theravance deal included a $US50 million upfront payment, with potential for large milestone and royalty payments at later dates. Raff says GlaxoSmithKline`s interest in Theravance was based on its polyvalent technology, which is similar to Starpharma`s dendrimers.
If Raff is right and dendrimers are one of the pharmaceutical industry`s new frontiers, that augurs well for the small biotech company.
Apart from its intellectual property portfolio covering dendrimer-based compounds, the fact that Starpharma was the first company to achieve FDA approval for a nano-structured molecule has lifted its profile in the pharmaceutical industry. That should be useful as it looks for alliances and deals in the next few months to develop new dendrimer-based drugs in specific areas.
These deals will be needed to help Starpharma recover lost ground after it floated in 2000, raising $22 million with shares issued at 85¢.
In the three years since, its share price performance has been unexceptional, and even after recent rises it is still trading below its listing price. However, all that could change as a result of Starpharma`s strong research portfolio.
By Beth Quinlivan
When Starpharma announced in July that it had approval from United States regulators to begin human trials of its HIV-preventive gel, it was a milestone for the Melbourne biotech fund. Three years after its public listing, receiving the go-ahead by the Food & Drug Administration (FDA) means Starpharma is one step closer to having a product on the market and a revenue stream. The phase-one clinical trials of VivaGel will start immediately.
Starpharma`s announcement initially created only minor interest among investors. But that is not surprising. Worldwide, there are thousands of phase-one trials running at any time, of which about 70% fail.
What made the Starpharma approval more interesting than the usual company announcement about an "exciting new clinical trial about to start" is that it is the first time the FDA has approved a dendrimer-based drug for human testing.
Starpharma`s share price was only 19¢ in March this year. By July, when the trial approval was announced, it was 35¢. A placement of 13.3 million shares was made to institutions on September 10 at 52¢ a share (raising $6.9 million); recent trades have been about 70¢.
Dendrimers are a form of nanotechnology. They are man-made, three-dimensional molecules, constructed in layers around a central hollow core with a number of sticky points on the outside that attach to viral or cell targets. Dendrimer drugs are polyvalent, which means each molecule is able to bind to the viral or other disease target on several sites. In theory, this means a dendrimer drug is likely to be stronger, it may extend the duration of the drug`s action, and may offer broader protection or coverage.
They are a form of nanotechnology because their structure comprises tiny molecular building blocks - each with dimensions between one and 100 nanometres (a nanometre is one millionth of a millimetre).
Starpharma is one of the leading groups internationally in the new field of dendrimer-based pharmaceuticals. The first dendrimers were constructed in the late 1970s, but early interest in them was for their chemical and industrial applications. Scientists at the Biomolecular Research Institute (BMI) in Melbourne were among the first in the world to look at pharmaceutical applications of dendrimers when they began their studies more than a decade ago. BMI licensed the intellectual property to Starpharma in 1996.
Starpharma has developed on that early research and now has many patents covering dendrimer-based antimicrobial, antiviral, anti-parasitic and anti-cancer compounds. In 2001, it co-founded the US company Dendritic Nanotechnologies (DNT) with Donald Tomalia, a former Dow Chemical scientist and nanotechnology/dendrimer expert. DNT is looking to develop pharmaceutical and other uses for dendrimers, including optical and electroactive applications, and as chemical catalysts.
Although no nano-structured drugs have previously been approved for human trials, Starpharma`s chief executive, John Raff, says there is growing interest in the use of dendrimers across all applications. "You can gauge the increased interest from the level of scientific publications. In 2002, across all fields, there were 2500 new dendrimer publications. The number has been growing at 32% a year over the past five years."
Aside from the publications, he says the lucrative alliance struck earlier this year between the San Francisco biotech company Theravance and GlaxoSmithKline is evidence of the money pharmaceutical companies are prepared to spend in securing a foothold in the area of polyvalent drugs.
The Theravance deal included a $US50 million upfront payment, with potential for large milestone and royalty payments at later dates. Raff says GlaxoSmithKline`s interest in Theravance was based on its polyvalent technology, which is similar to Starpharma`s dendrimers.
If Raff is right and dendrimers are one of the pharmaceutical industry`s new frontiers, that augurs well for the small biotech company.
Apart from its intellectual property portfolio covering dendrimer-based compounds, the fact that Starpharma was the first company to achieve FDA approval for a nano-structured molecule has lifted its profile in the pharmaceutical industry. That should be useful as it looks for alliances and deals in the next few months to develop new dendrimer-based drugs in specific areas.
These deals will be needed to help Starpharma recover lost ground after it floated in 2000, raising $22 million with shares issued at 85¢.
In the three years since, its share price performance has been unexceptional, and even after recent rises it is still trading below its listing price. However, all that could change as a result of Starpharma`s strong research portfolio.
Hallo zusammen!
Ganz kurz:
Latest News, 8 October 2003: DNT Receives Award
Mehr nachzulesen auf der Homepage von Starpharma.
Gruß, greenhorn
Ganz kurz:
Latest News, 8 October 2003: DNT Receives Award
Mehr nachzulesen auf der Homepage von Starpharma.
Gruß, greenhorn
Wenn es der Biotech-Experte sagt, muss es ja stimmen....:
Mit Nanostrukuren gegen HIV
Starpharma hat gute Chancen auf den ersten Nanowirkstoff
Starpharma Pooled Development Ltd., nennt sich ein 1996 in Melbourne, Australien, gegründetes Unternehmen, dessen Spezialgebiet eine am Biomolecular Research Institute in Melbourne erforschte Technologie ist und für die das Unternehmen die weltweiten Exklusivrechte erworben hat. Die Technologie, die durch eine Anzahl wichtiger Patente geschützt ist, umfasst eine Klasse hochmolekularer stark verzweigter chemischer Verbindungen, sogenannte Dendrimere, die aktiv gegenüber einer großen Anzahl von Viren sein sollen. Der Name Starpharma leitet sich übrigens von den sternförmigen Strukturen der Dendrimer-Moleküle ab, die die Basis für die in der Entwicklung befindlichen Wirkstoffe des Unternehmens sind.
Im Juli 2002 gründete Starpharma speziell zur Entwicklung von nanotechnologischen Anwendungen in den USA ein neues Tochterunternehmen. Dendritic Nanotechnologies wird von Donald Tomalia, einem Spezialisten auf dem Gebiet der Nanotechnologie geleitet und hat zur Entwicklung von VivaGel beigetragen. Das neuartige Vaginalgel auf Wasserbasis, das als aktive Komponente das Polylysin Dendrimer SPL7013 enthält, soll nun auf seine Wirksamkeit gegen HIV getestet werden.
Ebenfalls im Juli erst erhielt Starpharma für sein auf Nanopartikeln basierendes Gel zur HIV-Prävention die FDA-Genehmigung zur Durchführung eines Phase I Versuches. Damit ist das von Starpharma entwickelte VivaGel das erste auf Nanopartikeln basierende Gel, das demnächst am Menschen getestet werden soll.
Die Wirkung von SPL7013 soll darauf beruhen, dass die Dendrimere die Bindung von HIV an Körperzellen blockieren und dadurch eine Infektion verhindern. Das Gel hat aber laut Starpharma gegenüber den üblichen physikalischen Barrieren den Vorteil, dass die Nanopartikel die Viren nicht nur am Eindringen in die Körperzellen hindern, sondern sie gleichzeitig auch zerstören.
Dendrimere sind synthetische Nanostrukturen, die so maßgeschneidert werden können, dass sie sich für pharmazeutische Anwendungen eignen. Mit speziellen chemischen Prozessen wird eine präzise Kontrolle der physikalischen und chemischen Eigenschaften der Dendrimere möglich. Die Dendrimere werden in einer Serie von kontrollierten Reaktionsschritten konstruiert, dabei ordnen sich viele kleine Moleküle um ein Zentralmolekül an. Vorstellen muss man sich so ein Dendrimer wie einen sehr stark verästelten Zweig. Im letzten Reaktionsschritt werden dann die verschiedenen aktiven Gruppen an das stark verzweigte Molekül angelagert. Das so entstehende Dendrimer verfügt dann auf seiner Oberfläche über eine Vielzahl möglicher Reaktionsstellen, die mit verschiedenen Rezeptoren auf der Oberfläche von Viren oder Bakterien in Wechselwirkung treten können.
In der Präklinik war die SPL7013 Nanostruktur nicht nur aktiv gegen HIV, sondern auch gegenüber Genitalherpes, Chlamydien, Hepatitis B, und Genitalwarzen, ausgelöst durch Papillomviren. In Primaten, die dem Affen-AIDS-Virus ausgesetzt wurden, konnte VivaGel die Infektion zu 100 Prozent verhindern. Eine HIV-Infektion erfolgt durch die Bindung des Proteins gp120 auf der Oberfläche des Virus an den CD4-Rezeptor auf der Zielzelle.
Die aktiven Gruppen im Dendrimer SPL7013 binden ihrerseits an gp120 und verhindern dadurch eine Interaktion des Virus mit gesunden Körperzellen, die den CD4-Rezeptor tragen. Umfassende toxikologische Studien in verschiedenen Versuchstieren sprachen zudem für die Sicherheit des neuartigen Gels. Gegenwärtig untersucht Starpharma das Sicherheitsprofil bei wiederholter Verabreichung in der dem Menschen ähnlichsten Affenart, dem Makaken.
Sollten die Phase I Versuche die präklinischen Daten bestätigen, wäre das von Starpharma entwickelte Produkt, auf Basis von Nanostrukturen, eine echte Sensation. Denn mit VivaGel ließe sich die Ausbreitung von Geschlechtskrankheiten, die bereits wieder auf dem Vormarsch sind, effektiv und viel unkomplizierter als mit mechanischen Barrieren eindämmen.
Vor allem die sich rasend verbreitende HPV-Infektion, die durch das humane Papillomvirus ausgelöst wird und sich durch Genitalwarzen bemerkbar macht, wird immer mehr zu einem Problem. Besonders problematisch ist die Tatsache, dass einige Typen von HPV das Risiko für Gebärmutterhalskrebs dramatisch ansteigen lassen. VivaGel wäre also die perfekte Prävention gegen Geschlechtskrankheiten aller Art. Sollte das Produkt bis zur Zulassung gelangen, würde es ein wohl bisher kaum abschätzbares Marktvolumen erwarten.
Eine Studien zum Thema BioNanotechnologie, einschließlich der Vorstellung von interessanten Unternehmen, finden Sie auch auf unserer Webseite unter www.Biotech-Experte.de.
Mit Nanostrukuren gegen HIV
Starpharma hat gute Chancen auf den ersten Nanowirkstoff
Starpharma Pooled Development Ltd., nennt sich ein 1996 in Melbourne, Australien, gegründetes Unternehmen, dessen Spezialgebiet eine am Biomolecular Research Institute in Melbourne erforschte Technologie ist und für die das Unternehmen die weltweiten Exklusivrechte erworben hat. Die Technologie, die durch eine Anzahl wichtiger Patente geschützt ist, umfasst eine Klasse hochmolekularer stark verzweigter chemischer Verbindungen, sogenannte Dendrimere, die aktiv gegenüber einer großen Anzahl von Viren sein sollen. Der Name Starpharma leitet sich übrigens von den sternförmigen Strukturen der Dendrimer-Moleküle ab, die die Basis für die in der Entwicklung befindlichen Wirkstoffe des Unternehmens sind.
Im Juli 2002 gründete Starpharma speziell zur Entwicklung von nanotechnologischen Anwendungen in den USA ein neues Tochterunternehmen. Dendritic Nanotechnologies wird von Donald Tomalia, einem Spezialisten auf dem Gebiet der Nanotechnologie geleitet und hat zur Entwicklung von VivaGel beigetragen. Das neuartige Vaginalgel auf Wasserbasis, das als aktive Komponente das Polylysin Dendrimer SPL7013 enthält, soll nun auf seine Wirksamkeit gegen HIV getestet werden.
Ebenfalls im Juli erst erhielt Starpharma für sein auf Nanopartikeln basierendes Gel zur HIV-Prävention die FDA-Genehmigung zur Durchführung eines Phase I Versuches. Damit ist das von Starpharma entwickelte VivaGel das erste auf Nanopartikeln basierende Gel, das demnächst am Menschen getestet werden soll.
Die Wirkung von SPL7013 soll darauf beruhen, dass die Dendrimere die Bindung von HIV an Körperzellen blockieren und dadurch eine Infektion verhindern. Das Gel hat aber laut Starpharma gegenüber den üblichen physikalischen Barrieren den Vorteil, dass die Nanopartikel die Viren nicht nur am Eindringen in die Körperzellen hindern, sondern sie gleichzeitig auch zerstören.
Dendrimere sind synthetische Nanostrukturen, die so maßgeschneidert werden können, dass sie sich für pharmazeutische Anwendungen eignen. Mit speziellen chemischen Prozessen wird eine präzise Kontrolle der physikalischen und chemischen Eigenschaften der Dendrimere möglich. Die Dendrimere werden in einer Serie von kontrollierten Reaktionsschritten konstruiert, dabei ordnen sich viele kleine Moleküle um ein Zentralmolekül an. Vorstellen muss man sich so ein Dendrimer wie einen sehr stark verästelten Zweig. Im letzten Reaktionsschritt werden dann die verschiedenen aktiven Gruppen an das stark verzweigte Molekül angelagert. Das so entstehende Dendrimer verfügt dann auf seiner Oberfläche über eine Vielzahl möglicher Reaktionsstellen, die mit verschiedenen Rezeptoren auf der Oberfläche von Viren oder Bakterien in Wechselwirkung treten können.
In der Präklinik war die SPL7013 Nanostruktur nicht nur aktiv gegen HIV, sondern auch gegenüber Genitalherpes, Chlamydien, Hepatitis B, und Genitalwarzen, ausgelöst durch Papillomviren. In Primaten, die dem Affen-AIDS-Virus ausgesetzt wurden, konnte VivaGel die Infektion zu 100 Prozent verhindern. Eine HIV-Infektion erfolgt durch die Bindung des Proteins gp120 auf der Oberfläche des Virus an den CD4-Rezeptor auf der Zielzelle.
Die aktiven Gruppen im Dendrimer SPL7013 binden ihrerseits an gp120 und verhindern dadurch eine Interaktion des Virus mit gesunden Körperzellen, die den CD4-Rezeptor tragen. Umfassende toxikologische Studien in verschiedenen Versuchstieren sprachen zudem für die Sicherheit des neuartigen Gels. Gegenwärtig untersucht Starpharma das Sicherheitsprofil bei wiederholter Verabreichung in der dem Menschen ähnlichsten Affenart, dem Makaken.
Sollten die Phase I Versuche die präklinischen Daten bestätigen, wäre das von Starpharma entwickelte Produkt, auf Basis von Nanostrukturen, eine echte Sensation. Denn mit VivaGel ließe sich die Ausbreitung von Geschlechtskrankheiten, die bereits wieder auf dem Vormarsch sind, effektiv und viel unkomplizierter als mit mechanischen Barrieren eindämmen.
Vor allem die sich rasend verbreitende HPV-Infektion, die durch das humane Papillomvirus ausgelöst wird und sich durch Genitalwarzen bemerkbar macht, wird immer mehr zu einem Problem. Besonders problematisch ist die Tatsache, dass einige Typen von HPV das Risiko für Gebärmutterhalskrebs dramatisch ansteigen lassen. VivaGel wäre also die perfekte Prävention gegen Geschlechtskrankheiten aller Art. Sollte das Produkt bis zur Zulassung gelangen, würde es ein wohl bisher kaum abschätzbares Marktvolumen erwarten.
Eine Studien zum Thema BioNanotechnologie, einschließlich der Vorstellung von interessanten Unternehmen, finden Sie auch auf unserer Webseite unter www.Biotech-Experte.de.
Hi Neoe!
Schön von dir zu lesen! Scheinbar will an dieser (wahrscheinlich extrem) großen Erfolgsgeschichte so recht niemand teilhaben. Das Volumen ist ja derart abgeebt, alle Achtung. Da passiert ja im Moment gar nichts.
Naja, irgendwann wollen sie wieder alle gleichzeitig rein
Gruß, greenhorn
Schön von dir zu lesen! Scheinbar will an dieser (wahrscheinlich extrem) großen Erfolgsgeschichte so recht niemand teilhaben. Das Volumen ist ja derart abgeebt, alle Achtung. Da passiert ja im Moment gar nichts.
Naja, irgendwann wollen sie wieder alle gleichzeitig rein
Gruß, greenhorn
Hallo greenhorn,
nur keine Panik, gut Ding braucht bekanntlich etwas länger. Es sieht aber momentan so aus, als ob Starpharma bei den Investoren und Spekulanten ein wenig in Vergessenheit geraten ist. Trotz der miesen Umsätze werde ich meine Position in Starpharma weiter ausbauen. Wegen der Orderspesen, da habe ich in Österreich einen etwas billigeren Broker als ihr in Deutschland. Meine Ordergebühren betragen lediglich 68,50 €.
Bin überzeugt, dass Starpharma eine Investition für die Zukunft ist und mir in meiner wohlverdienten Pension so manch netten Abend bescheren wird.
Grüße Wurze
nur keine Panik, gut Ding braucht bekanntlich etwas länger. Es sieht aber momentan so aus, als ob Starpharma bei den Investoren und Spekulanten ein wenig in Vergessenheit geraten ist. Trotz der miesen Umsätze werde ich meine Position in Starpharma weiter ausbauen. Wegen der Orderspesen, da habe ich in Österreich einen etwas billigeren Broker als ihr in Deutschland. Meine Ordergebühren betragen lediglich 68,50 €.
Bin überzeugt, dass Starpharma eine Investition für die Zukunft ist und mir in meiner wohlverdienten Pension so manch netten Abend bescheren wird.
Grüße Wurze
greenhorn:
Noch diesen Monat, spätestens nächsten, wollen sie wieder alle rein.
Noch diesen Monat, spätestens nächsten, wollen sie wieder alle rein.
Hi Neoe!
Nun, der Oktober läuft aus, dann hoffen wir mal auf den November. Wollte mal fragen, ob wir tatsächlich von denselben Neuigkeiten ausgehen.
Ich sehe das folgendermaßen: Die erste klinische Testphase von Vivagel soll(te) Ende Oktober anfangen. Zudem geht es wohl auch darum, sich für die weitere Entwicklung einen Pharmakonzern mit ins Boot zu holen. Richtig?
Gruß, greenhorn
Nun, der Oktober läuft aus, dann hoffen wir mal auf den November. Wollte mal fragen, ob wir tatsächlich von denselben Neuigkeiten ausgehen.
Ich sehe das folgendermaßen: Die erste klinische Testphase von Vivagel soll(te) Ende Oktober anfangen. Zudem geht es wohl auch darum, sich für die weitere Entwicklung einen Pharmakonzern mit ins Boot zu holen. Richtig?
Gruß, greenhorn
Hallo zusammen!
Hier mal wieder eine Meldung von Starpharma, mit Vivagel geht es weietr voran.
http://www.starpharma.com/PDFs/031113_VivaGel_Volunteer_Enro…
Auch der Kurs hat wieder etwas reagiert, vor allen Dingen war das Volumen endlich mal wieder vorzeigbar.
Gruß, greenhorn
Hier mal wieder eine Meldung von Starpharma, mit Vivagel geht es weietr voran.
http://www.starpharma.com/PDFs/031113_VivaGel_Volunteer_Enro…
Auch der Kurs hat wieder etwas reagiert, vor allen Dingen war das Volumen endlich mal wieder vorzeigbar.
Gruß, greenhorn
Eigentlich sollte auch mal was Dendritic Nanotech zu hören sein. Könnte jederzeit was kommen, genauso wie von Starpharma selbst.
Sehr gute News, vergleichbar geringe Reaktion.
Starpharma gets US nod to work on HIV gel
By Eli Greenblat
November 20, 2003
http://www.theage.com.au/articles/2003/11/19/1069027186895.h…
Biotech play Starpharma is five years away from the full commercialisation of its topical HIV/AIDS protection product, chairman Peter Bartels told shareholders yesterday.
Speaking at the annual meeting, he said the company recently started human trials in Adelaide of its VivaGel product after approval from the US Federal Drug Administration.
He said Starpharma had chosen the more difficult path of seeking clearance for the gel in the US rather than Australia as success overseas would deliver greater kudos and earnings.
VivaGel is a vaginal gel. Since Starpharma was established in 1992, it has concentrated on using nanotechnology to develop pharmaceutical and non-pharmaceutical applications.
Mr Bartels said after the human trials of VivaGel now being conducted at the Royal Adelaide Hospital to test if the gel was harmful to humans, tests would start on people living in regions that were highly exposed to HIV/AIDS, such as sub-Saharan Africa or parts of South-East Asia.
Starpharma also announced yesterday that its US subsidiary, DNT, had been granted US patents relating to dendritic technologies as well as a $US6.5 million ($A9 million) grant from the US Defence Department.
Dendrimers are tiny core-shell structures that can be synthesised for applications in the medical, electronic and chemical industries.
Printer friendly version Print this article Email to a friend
Starpharma gets US nod to work on HIV gel
By Eli Greenblat
November 20, 2003
http://www.theage.com.au/articles/2003/11/19/1069027186895.h…
Biotech play Starpharma is five years away from the full commercialisation of its topical HIV/AIDS protection product, chairman Peter Bartels told shareholders yesterday.
Speaking at the annual meeting, he said the company recently started human trials in Adelaide of its VivaGel product after approval from the US Federal Drug Administration.
He said Starpharma had chosen the more difficult path of seeking clearance for the gel in the US rather than Australia as success overseas would deliver greater kudos and earnings.
VivaGel is a vaginal gel. Since Starpharma was established in 1992, it has concentrated on using nanotechnology to develop pharmaceutical and non-pharmaceutical applications.
Mr Bartels said after the human trials of VivaGel now being conducted at the Royal Adelaide Hospital to test if the gel was harmful to humans, tests would start on people living in regions that were highly exposed to HIV/AIDS, such as sub-Saharan Africa or parts of South-East Asia.
Starpharma also announced yesterday that its US subsidiary, DNT, had been granted US patents relating to dendritic technologies as well as a $US6.5 million ($A9 million) grant from the US Defence Department.
Dendrimers are tiny core-shell structures that can be synthesised for applications in the medical, electronic and chemical industries.
Printer friendly version Print this article Email to a friend
Grüß euch,
es ist ruhig um Starpharma geworden, trotzdem zieht der Kurs in den letzten 1 1/2 Wochen kontinuierlich an. Sind schon wieder über 0,60 AUD (Aktuell 0,62 AUD). Gibt es Neuigkeiten betreffend Viva Gel ??????
mfg Wurze
es ist ruhig um Starpharma geworden, trotzdem zieht der Kurs in den letzten 1 1/2 Wochen kontinuierlich an. Sind schon wieder über 0,60 AUD (Aktuell 0,62 AUD). Gibt es Neuigkeiten betreffend Viva Gel ??????
mfg Wurze
Hallo zusammen!
Ich weiß leider nichts dazu, nehme den sanften Kursanstieg aber frohlockend zur Kenntnis!
Ich halte es generell eigentlich für ein gutes Zeichen, wenn eine Aktie, wenn auch unter geringerem Volumen, ohne News steigt. Das Gegenteil ist nämlich eher der Fall, wenn ich das richtig beobachtet habe.
Gruß, greenhorn
Ich weiß leider nichts dazu, nehme den sanften Kursanstieg aber frohlockend zur Kenntnis!
Ich halte es generell eigentlich für ein gutes Zeichen, wenn eine Aktie, wenn auch unter geringerem Volumen, ohne News steigt. Das Gegenteil ist nämlich eher der Fall, wenn ich das richtig beobachtet habe.
Gruß, greenhorn
Das Who-is-Who der Branche versammelt sich weiter in und um Starpharma und Dendritic Nanotech herum:
http://www.asx.com.au/asxpdf/20031216/pdf/3k42qp8841blp.pdf
http://www.asx.com.au/asxpdf/20031216/pdf/3k42qp8841blp.pdf
Hallo!
Der Nano-Hype scheint ja an Starpharma, Psivida, und Ambri (WKN 938156 / ASX-Ticker abi) völlig vorüberzugehen.
Ich hoffe es kommen bald einige gute Nachrichten!
Hier einige interessante Links:
http://www.starpharma.com/PDFs/Developing%20Polyvalent%20Pha…
http://www.starpharma.com/PDFs/Product%20Focus%20-%20VivaGel…
http://www.starpharma.com/PDFs/Novel%
20Chemotherapeutic%20Agents.pdf" target="_blank" rel="nofollow ugc noopener">http://www.starpharma.com/PDFs/Novel%
20Chemotherapeutic%20Agents.pdf
http://www.starpharma.com/PDFs/031119_AGM_Chair_%20&_%20CEO_…
Der Nano-Hype scheint ja an Starpharma, Psivida, und Ambri (WKN 938156 / ASX-Ticker abi) völlig vorüberzugehen.
Ich hoffe es kommen bald einige gute Nachrichten!
Hier einige interessante Links:
http://www.starpharma.com/PDFs/Developing%20Polyvalent%20Pha…
http://www.starpharma.com/PDFs/Product%20Focus%20-%20VivaGel…
http://www.starpharma.com/PDFs/Novel%
20Chemotherapeutic%20Agents.pdf" target="_blank" rel="nofollow ugc noopener">http://www.starpharma.com/PDFs/Novel%
20Chemotherapeutic%20Agents.pdf
http://www.starpharma.com/PDFs/031119_AGM_Chair_%20&_%20CEO_…
Keine Angst das kommt schon noch! Bist du auch in allen 3
investiert? Was hälst du von Ambri?
Starpharma und psivida laufen ja nicht schlecht.
Besser gute news sind ausschlaggeber für den Kurs als ein
Hype ohne Fundamentaldaten. Da besteht nämlich langfristig weniger Risiko auf die Schnauze zu fallen!!!
Gruß Joe
investiert? Was hälst du von Ambri?
Starpharma und psivida laufen ja nicht schlecht.
Besser gute news sind ausschlaggeber für den Kurs als ein
Hype ohne Fundamentaldaten. Da besteht nämlich langfristig weniger Risiko auf die Schnauze zu fallen!!!
Gruß Joe
Ambri ist auch top, was das Produkt angeht, nur das Marktpotential kann ich nicht abschätzen.
#78/79
Hallo Joe und Neoe!
Ich bin zurzeit nur in Starpharma, GPC-Biotech und in Aeterna Labs (mein Favorit) drin.
Die Ordererteilung australischer Werte ist zumindest bei der DAB-bank ziemlich beschwerlich. Hatte Donnerstag letzter Woche zwei größere Order sowohl bei Ambri als auch bei Starpharma gestellt. Nachdem ich bis Montag abends trotz passenden Limits keine Bestätigung erhielt strich ich beide Order. Am Mittwoch kam jedoch trotzdem noch die Orderbestätigung von Starpharma. Ambri steht weiterhin auf meiner Watchlist ganz oben. Der Wert Abmris hat sich im letzen Jahr geviertelt. Spätestens im Mai sollen Kurstreibende News kommen.
http://www.wallstreetreporter.com/linked/AmbriLimited.html
Bei Starpharma macht mir etwas Sorgen die extrem hohen Kosten der Herstellung von Dentrimeren.
http://www.smalltimes.com/document_display.cfm?document_id=2…
Ich hoffe das dies nicht potentielle Pharmaunternehmen abhält Entwicklungspartnerschaften mit Starpharma einzugehen. Was meint Ihr dazu?
Gruß Christrader
Hallo Joe und Neoe!
Ich bin zurzeit nur in Starpharma, GPC-Biotech und in Aeterna Labs (mein Favorit) drin.
Die Ordererteilung australischer Werte ist zumindest bei der DAB-bank ziemlich beschwerlich. Hatte Donnerstag letzter Woche zwei größere Order sowohl bei Ambri als auch bei Starpharma gestellt. Nachdem ich bis Montag abends trotz passenden Limits keine Bestätigung erhielt strich ich beide Order. Am Mittwoch kam jedoch trotzdem noch die Orderbestätigung von Starpharma. Ambri steht weiterhin auf meiner Watchlist ganz oben. Der Wert Abmris hat sich im letzen Jahr geviertelt. Spätestens im Mai sollen Kurstreibende News kommen.
http://www.wallstreetreporter.com/linked/AmbriLimited.html
Bei Starpharma macht mir etwas Sorgen die extrem hohen Kosten der Herstellung von Dentrimeren.
http://www.smalltimes.com/document_display.cfm?document_id=2…
Ich hoffe das dies nicht potentielle Pharmaunternehmen abhält Entwicklungspartnerschaften mit Starpharma einzugehen. Was meint Ihr dazu?
Gruß Christrader
@neoe
Das Marktpotential ist auch schwer abzuschätzen. Hier einige Zahlen: Das Volumen des "Point of Care" Marktes beträgt weltweit ca. 7-8 Billionen $ und steigt jährlich um 10%. 50%-60% davon entfallen auf die U.S.
Hier hat Ambri schon vorgesort und eine Kooperation mit zwei amerikanischen Konzernen geschlossen. DOW CORNING und GENENCOR. Deren Kooperation nennt sich BIOSENSOR ENTERPRISES.
Dies ist aber nur ein Anwendungsbereich der durch die ICS-Technologie bedient werden kann. Weitere Gebiete die angestrebt werden sind u.a. Bioterrorismus und Food Detection.
Was die Aktie interessant macht ist der derzeitige Kurs von 0,28Aus$ nahe dem Tiefstpunkt.Also noch nicht vom NANO-HYPE erfasst. Bei News könnte einiges geh´n!
@cristrader
Bei Starpharma würd ich mir keine Sorgen machen. Zweifelsohne sind Dendrimere der Schlüssel einer bahnbrechenden Technologie.
Außerdem ist der H&A Nanofond auch groß investiert! Und Beckmanns Anforderungen an ein Unternehmen in das der Fond investiert beschreibt er so: "Um sich für den H&A Nanotechfond zu qualifizieren, müssen Unternehmen extrem hohen Anforderungen gerecht werden. Ein weit über dem Durchschnitt liegendes Wachstum, saubere Bilanzen und ein erfahrenes Management sind nur einige dieser Anforderungen.
Das Marktpotential ist auch schwer abzuschätzen. Hier einige Zahlen: Das Volumen des "Point of Care" Marktes beträgt weltweit ca. 7-8 Billionen $ und steigt jährlich um 10%. 50%-60% davon entfallen auf die U.S.
Hier hat Ambri schon vorgesort und eine Kooperation mit zwei amerikanischen Konzernen geschlossen. DOW CORNING und GENENCOR. Deren Kooperation nennt sich BIOSENSOR ENTERPRISES.
Dies ist aber nur ein Anwendungsbereich der durch die ICS-Technologie bedient werden kann. Weitere Gebiete die angestrebt werden sind u.a. Bioterrorismus und Food Detection.
Was die Aktie interessant macht ist der derzeitige Kurs von 0,28Aus$ nahe dem Tiefstpunkt.Also noch nicht vom NANO-HYPE erfasst. Bei News könnte einiges geh´n!
@cristrader
Bei Starpharma würd ich mir keine Sorgen machen. Zweifelsohne sind Dendrimere der Schlüssel einer bahnbrechenden Technologie.
Außerdem ist der H&A Nanofond auch groß investiert! Und Beckmanns Anforderungen an ein Unternehmen in das der Fond investiert beschreibt er so: "Um sich für den H&A Nanotechfond zu qualifizieren, müssen Unternehmen extrem hohen Anforderungen gerecht werden. Ein weit über dem Durchschnitt liegendes Wachstum, saubere Bilanzen und ein erfahrenes Management sind nur einige dieser Anforderungen.
In folgendem Dokument, dass erste Patent genauer betrachten. DNT hat ein Verfahren zur Herstellung von Dendrimeren zu niedrigen kosten entwickelt.Das dürfte eure Sorgen etwas verringern:
http://www.starpharma.com/PDFs/031118%20DNT_Patents_Fund_Rai…
http://www.starpharma.com/PDFs/031118%20DNT_Patents_Fund_Rai…
@neoe
Danke für die super Info! Jetzt fehlt nur noch die Meldung einer Kooperation mit einem Pharaunternehmen!
Ich denke nach dem Shareholder-Meeting am 19.01.04 und nach der evtl. Aufhebung des "Pooled Development Fund"-Status geht der Kurs weiter nach oben.
Danke cristrader
Danke für die super Info! Jetzt fehlt nur noch die Meldung einer Kooperation mit einem Pharaunternehmen!
Ich denke nach dem Shareholder-Meeting am 19.01.04 und nach der evtl. Aufhebung des "Pooled Development Fund"-Status geht der Kurs weiter nach oben.
Danke cristrader
Hallo zusammen!
Ich denke auch, dass 2004 ein sehr interessantes Jahr für Starpharma werden dürfte. Meiner Meinung nach kann man auch mit der Aktienentwicklung zufrieden sein, auch wenn der ganz große Hype bislang tatsächlich noch ausgeblieben ist. Dürfte vor allen Dingen daran liegen, dass Starpharma bislang ausschließlich in Australien handelbar ist. Aber was lange währt, wird irgendwann gut und ich habe Zeit.
Mal was anderes: Bei http://www.ozestock.com.au muss man sich jetzt registrieren lassen, selbst wenn man die Postings nur lesen will. Ts, ts, ts. Naja.
@Neoe
Danke für deine prompte Antwort!
Gruß, greenhorn
Ich denke auch, dass 2004 ein sehr interessantes Jahr für Starpharma werden dürfte. Meiner Meinung nach kann man auch mit der Aktienentwicklung zufrieden sein, auch wenn der ganz große Hype bislang tatsächlich noch ausgeblieben ist. Dürfte vor allen Dingen daran liegen, dass Starpharma bislang ausschließlich in Australien handelbar ist. Aber was lange währt, wird irgendwann gut und ich habe Zeit.
Mal was anderes: Bei http://www.ozestock.com.au muss man sich jetzt registrieren lassen, selbst wenn man die Postings nur lesen will. Ts, ts, ts. Naja.
@Neoe
Danke für deine prompte Antwort!
Gruß, greenhorn
Vieleicht von Interesse einige ältere Reasearch-Berichte:
http://www.bioshares.com.au/bioshares1.pdf
http://www.bioshares.com.au/bioshares8.pdf
http://www.bioshares.com.au/bioshares26F.pdf
http://www.bioshares.com.au/bioshares1.pdf
http://www.bioshares.com.au/bioshares8.pdf
http://www.bioshares.com.au/bioshares26F.pdf
Interessanter Bericht, der Dendritics und Starpharmas Position unterstreicht und nochmals den Wert des Dendriticpatents zur kostengünstigen Herstellung von Dendrimerstrukturen herausstellt, das den Autoren des folgenden Berichts noch nicht bekannt war:
http://www.foley.com/FILES/tbl_s31Publications/FileUpload137…
http://www.foley.com/FILES/tbl_s31Publications/FileUpload137…
http://www.aktienboard.com/vb/lesson.php?eventchat=inhalt
Empfehlungen von Beckmann im Chat:
Konservativ:
ACO
AFCO
AMRI
MDCC
HDWR
KEI
MTSC
NVEC
ZIGO
Spekulativ "für die Hartgesottenen"
MFIC
Obducat
Starpharma
cristrader
Empfehlungen von Beckmann im Chat:
Konservativ:
ACO
AFCO
AMRI
MDCC
HDWR
KEI
MTSC
NVEC
ZIGO
Spekulativ "für die Hartgesottenen"
MFIC
Obducat
Starpharma
cristrader
Hallo zusammen!
Was war denn da heute in Australien los? Deutlich erhöhtes Volumen, zigfach über dem Durchschnitt. Find ich gut!
Gruß, greenhorn
Was war denn da heute in Australien los? Deutlich erhöhtes Volumen, zigfach über dem Durchschnitt. Find ich gut!
Gruß, greenhorn
Hallo Greenhorn!
Erhöhtes Volumen durch einen einzigen Trade über 2,5 Mio Aktien!!!
Grüße Cristrader
Erhöhtes Volumen durch einen einzigen Trade über 2,5 Mio Aktien!!!
Grüße Cristrader
Ist da etwas im "Busch", ein großer Investor vielleicht ?????? Gibt es dazu irgendwelche Nachrichten ??? Man hört in der letzten Zeit sehr wenig von Starpharma. Weiß jemand mehr ????
Grüße wurze
Grüße wurze
Vielleicht war Beckmann auf Einkaufstour!?
Im Ernst- Dauert nicht lange, dann schiessen die Nanotechfonds wie Pilze aus dem Boden.
Wenn es in Deutschland 2 gibt und in USA noch keinen ist es nur eine Frage der Zeit bis die da drüben zwischen 5 und 10 Fonds die Auswahl haben. Und die müssen auch erst mal einkaufen.
Am meisten hasse ich diese Weltuntergangsverschwörungen von denen die die Nanotechnologie unterschätzt haben und jetzt darauf warten daß die Preise wieder in den Keller fallen. Denn die haben jetzt auch erkannt-NANOTECHNOLOGIE
IST ZUKUNFT.
Das man nicht quer durch den Garten alles kaufen darf wo NANO draufsteht ist klar. Das es manche nicht schaffen-trotz toller Ideen,auch. Aber mir persönlich reicht nur eine zweite Microsoft im Depot!
Und ich befasse mich täglich mit der Frage welche Firma hat das Zeug dazu.
An dieser Stelle noch ein großes Lob an diejenigen die schon länger hier im Nanosektor verweilen. Isonics,usw.
Sich ebenfalls täglich mit dem Thema auseinandersetzen und das langfristige der NANOTECHNOLOGIE erkannt haben.
Im Ernst- Dauert nicht lange, dann schiessen die Nanotechfonds wie Pilze aus dem Boden.
Wenn es in Deutschland 2 gibt und in USA noch keinen ist es nur eine Frage der Zeit bis die da drüben zwischen 5 und 10 Fonds die Auswahl haben. Und die müssen auch erst mal einkaufen.
Am meisten hasse ich diese Weltuntergangsverschwörungen von denen die die Nanotechnologie unterschätzt haben und jetzt darauf warten daß die Preise wieder in den Keller fallen. Denn die haben jetzt auch erkannt-NANOTECHNOLOGIE
IST ZUKUNFT.
Das man nicht quer durch den Garten alles kaufen darf wo NANO draufsteht ist klar. Das es manche nicht schaffen-trotz toller Ideen,auch. Aber mir persönlich reicht nur eine zweite Microsoft im Depot!
Und ich befasse mich täglich mit der Frage welche Firma hat das Zeug dazu.
An dieser Stelle noch ein großes Lob an diejenigen die schon länger hier im Nanosektor verweilen. Isonics,usw.
Sich ebenfalls täglich mit dem Thema auseinandersetzen und das langfristige der NANOTECHNOLOGIE erkannt haben.
Kann auch mit Umschichtungen zu haben, immerhin wird der PDF-Status zurückgenommen, dass kann zu größeren Umwälzungen führen, da durch die Änderung der rechtlichen Situation sich auch für die institutionellen Anleger einiges ändern wird. So schätze ich die Situation als Laie ein.
Am 22.01.04 wird über den PDF-Status abgestimmt!
http://www.starpharma.com/PDFs/031218%20Notice%20GM.pdf
"Rationale for Deregistration as a PDF
Despite the tax concessions afforded to the Company and its shareholders under the PDF regime, your
directors believe that the investment guidelines and compliance rules under the PDF Act limit the investment
options of the Company as well as its ability to participate in initiatives to grow and develop the Company.
The aspects of the PDF Act investment guidelines that your directors feel have this effect include the
following:
• The restrictions on investing in overseas companies or conducting follow-on investments in
Australian companies that have migrated offshore. The Company invested in Dendritic
Nanotechnologies (known as DNT) which has since relocated to the US. As a PDF, the Company
is restricted from increasing its investment in DNT or participating in any capital raisings or USbased
"spin offs".
• The restrictions on investing in companies whose total assets are greater than $50 million. This
severely limits the range of companies that the Company can invest in.
• The restrictions on making "secondary purchases" of securities in companies. This means that the
Company may only undertake investments where it is subscribing for new capital – it cannot
acquire shares from existing shareholders. This means the Company would be restricted from
acquiring secondary securities at potentially attractive prices."
http://www.starpharma.com/PDFs/031218%20Notice%20GM.pdf
"Rationale for Deregistration as a PDF
Despite the tax concessions afforded to the Company and its shareholders under the PDF regime, your
directors believe that the investment guidelines and compliance rules under the PDF Act limit the investment
options of the Company as well as its ability to participate in initiatives to grow and develop the Company.
The aspects of the PDF Act investment guidelines that your directors feel have this effect include the
following:
• The restrictions on investing in overseas companies or conducting follow-on investments in
Australian companies that have migrated offshore. The Company invested in Dendritic
Nanotechnologies (known as DNT) which has since relocated to the US. As a PDF, the Company
is restricted from increasing its investment in DNT or participating in any capital raisings or USbased
"spin offs".
• The restrictions on investing in companies whose total assets are greater than $50 million. This
severely limits the range of companies that the Company can invest in.
• The restrictions on making "secondary purchases" of securities in companies. This means that the
Company may only undertake investments where it is subscribing for new capital – it cannot
acquire shares from existing shareholders. This means the Company would be restricted from
acquiring secondary securities at potentially attractive prices."
===> Neuer Großaktionär!!!
http://www.asx.com.au/asxpdf/20040120/pdf/3kdf5tqz2v7f8.pdf
Morgen am 22.01.2004 ist ein wichtiger Termin für Starpharma. Die Abstimmung und Entscheidung über den PDF-Status steht an. Die Unternehmensführung möchte den PDF-Status abgeben um evtl. die Beteiligung an DNT zu erhöhen bzw. ein Spin-Off in den USA durchzuführen!!!
Vergleicht man die Kursentwicklung und Bewertung Starpharmas mit US-Nanotechs kann man sich vorstellen wie sich ein Spin-Off oder eine Börsenlistung in den USA auswirken wird.
http://www.asx.com.au/asxpdf/20040120/pdf/3kdf5tqz2v7f8.pdf
Morgen am 22.01.2004 ist ein wichtiger Termin für Starpharma. Die Abstimmung und Entscheidung über den PDF-Status steht an. Die Unternehmensführung möchte den PDF-Status abgeben um evtl. die Beteiligung an DNT zu erhöhen bzw. ein Spin-Off in den USA durchzuführen!!!
Vergleicht man die Kursentwicklung und Bewertung Starpharmas mit US-Nanotechs kann man sich vorstellen wie sich ein Spin-Off oder eine Börsenlistung in den USA auswirken wird.
Kannst du das Abstimmungsergebnis erläuern!
Vielen Dank
Vielen Dank
#97
Dem Antrag der Geschäftsleitung zur Änderung des PDF-Status und der Namensänderung in Starpharma Holdings Limited wurde mit einfacher Mehrheit stattgegeben. Die Geschäftsleitung kann nun jederzeit bis zur nächsten Hauptversammlung bei den australischen Behörden den Antrag auf Aufhebung des PDF-Status stellen.
Dem Antrag der Geschäftsleitung zur Änderung des PDF-Status und der Namensänderung in Starpharma Holdings Limited wurde mit einfacher Mehrheit stattgegeben. Die Geschäftsleitung kann nun jederzeit bis zur nächsten Hauptversammlung bei den australischen Behörden den Antrag auf Aufhebung des PDF-Status stellen.
Danke!Bin schon lange investiert und vom Potential Starpharma`s überzeugt!!!
Hallo zusammen!
Danke, cristrader, für die Auskünfte. Es geht doch nichts über gute Nachrichten! Wir werden noch viel Freude haben!
Gruß, greenhorn
Danke, cristrader, für die Auskünfte. Es geht doch nichts über gute Nachrichten! Wir werden noch viel Freude haben!
Gruß, greenhorn
Commitments Test Entity - Second Quarter Report
http://www.asx.com.au/asxpdf/20040129/pdf/3kgs6xb6csk21.pdf
http://www.asx.com.au/asxpdf/20040129/pdf/3kgs6xb6csk21.pdf
QUARTERLY CASHFLOW REPORT FOR PERIOD ENDED 31 DECEMBER 2003
Attached is the Appendix 4C – Quarterly Cashflow Report – for Starpharma Pooled
Development Limited for the period ended 31 December 2003.
The cashflow results are in line with projections and Starpharma remains in a strong
financial position.
Activities during the quarter included final preparations for the phase I clinical trials of the
HIV preventative VivaGel. These trials are now underway in Adelaide, and there is strong
international interest in the product.
Whilst the VivaGel project is currently the main development project, we are continuing to
obtain interesting results in other areas. Positive results were obtained in the biodefense
area particularly in the use of dendrimer based drugs against exotic viruses. All of the
biology testing for this work has been carried out in the US at no cost to the Company, and
the project will be significantly expanded if we are successful with current funding
applications.
During this period Starpharma has had a number of inquiries from international and local
companies regarding the potential for dendrimer technology in a diverse range of
applications such as vaccines, radiolabelled materials, and enhancing the bioavailability of
existing drugs. The VivaGel product has demonstrated Starpharma’s unique ability to
produce nano-sized molecules to precise quality standards suitable for submission to the US
FDA and this is of strong interest to companies developing products in a wide range of
applications. Our strategy is to work with these companies to establish collaborative
development programs.
John W Raff
Chief Executive Officer
Attached is the Appendix 4C – Quarterly Cashflow Report – for Starpharma Pooled
Development Limited for the period ended 31 December 2003.
The cashflow results are in line with projections and Starpharma remains in a strong
financial position.
Activities during the quarter included final preparations for the phase I clinical trials of the
HIV preventative VivaGel. These trials are now underway in Adelaide, and there is strong
international interest in the product.
Whilst the VivaGel project is currently the main development project, we are continuing to
obtain interesting results in other areas. Positive results were obtained in the biodefense
area particularly in the use of dendrimer based drugs against exotic viruses. All of the
biology testing for this work has been carried out in the US at no cost to the Company, and
the project will be significantly expanded if we are successful with current funding
applications.
During this period Starpharma has had a number of inquiries from international and local
companies regarding the potential for dendrimer technology in a diverse range of
applications such as vaccines, radiolabelled materials, and enhancing the bioavailability of
existing drugs. The VivaGel product has demonstrated Starpharma’s unique ability to
produce nano-sized molecules to precise quality standards suitable for submission to the US
FDA and this is of strong interest to companies developing products in a wide range of
applications. Our strategy is to work with these companies to establish collaborative
development programs.
John W Raff
Chief Executive Officer
http://www.berlin-boerse.de/bekanntmachungen/b9-starp.pdf?de…
Starpharma ab sofort an Berliner Börse handelbar!!!
WKN 796461
Starpharma ab sofort an Berliner Börse handelbar!!!
WKN 796461
Sorry erst ab 04.02.2004 !!!
Na, das ist ja noch lange hin!
Bin sehr gespannt auf die weitere Entwicklung! Durch diesen Schritt wird Starpharma auf breiterer Basis interessant.
Gruß, greenhorn
Bin sehr gespannt auf die weitere Entwicklung! Durch diesen Schritt wird Starpharma auf breiterer Basis interessant.
Gruß, greenhorn
hast völlig recht! Schaut Euch doch mal lieber was fundamental Gutes an:
Thema: ~~~~~~~~~ungezockte nanobude~~~~~~~~~~ [Thread-Nr.: 815845]
von tradecentre:
MASTERFLEX
Sehr geehrte Professional Abonnenten,
ich habe im aktuellen TradeCentre Börsenbrief die Nanotechnologie angesprochen. Diese Branche durchläuft gerade einen beeindruckenden Spekulationsprozess, der nicht unbedingt rational erscheint, sich dennoch für den Spekulanten als profitabel erweisen kann.
Es gibt am deutschen Aktienmarkt ein recht solides Unternehmen, das sich ebenfalls an der Grundlagenforschung zur Oberflächenbearbeitung mittels Nanotechnologie beteiligt. Vor 2 Jahren wurde das Unternehmen dieser Technologie-Sparte auch noch häufig zugeordnet. Warum die Aktie bislang noch kaum entdeckt wurde, ist mir ein Rästel. Machen wir kein Geheimnis daraus. Es handelt sich um Masterflex (WKN 549 293). Die Kennzahlen von Masterflex sind viel versprechend. Sehen Sie selbst. Die Zahlen beziehen sich auf die ersten 9 Monate:
Umsatz +17,3% auf 49,5 Millionen Euro
EBIT +27,1% auf 5,3 Millionen Euro
Börsenwert: 90 Millionen Euro
Die Marktteilnehmer suchen gerade verzweifelt nach Playern im Bereich Nanotechnologie. Charttechnisch und fundamental spricht nichts dagegen, eine Position in Masterflex einzugehen. Die Umsätze sind in den letzten Handelstagen bereits angezogen. Das könnte darauf hindeuten, dass auch Masterflex bald von der Spekulationswelle ergriffen wird!
Text-Zitat von www.masterflex.de
" In Deutschland wurden 1998 insgesamt 12,5 Mio. Tonnen Kunststoffe hergestellt. Der Anteil der Spezialkunststoffe, zu denen Polyurethan
(PU) gehört, lag lediglich bei 2,5% bzw. 312.500 Tonnen. Masterflex verarbeitet das PU im sogenannten Extrusionsverfahren. Experten schätzen, daß erst ca. 15% der Einsatzmöglichkeiten von Polyurethan genutzt werden. Polyurethan ist ein vielseitiger Kunststoff mit hohem Innovationspotential, denn er bietet eine interessante Eigenschaftskombination aus Elastizität, Widerstandsfähigkeit und Alterungsbeständigkeit in einem weiten Temperaturbereich.
Zudem kann PU durch Zugabe der unterschiedlichsten sogenannten Additive modifiziert werden. Die Nanotechnologie erweitert das Anwendungsspektrum von PU nochmals, weil eine Oberflächenbearbeitung möglich wird, die die Produktqualität nochmals enorm verbessern kann. Außerdem wird die Kombination mit anderen Werkstoffen ermöglicht. Damit ist Polyurethan vergleichbar mit einem Baukastensystem, aus dem man maßgeschneiderte Lösungen individuell zusammenstellen kann."
Thema: ~~~~~~~~~ungezockte nanobude~~~~~~~~~~ [Thread-Nr.: 815845]
von tradecentre:
MASTERFLEX
Sehr geehrte Professional Abonnenten,
ich habe im aktuellen TradeCentre Börsenbrief die Nanotechnologie angesprochen. Diese Branche durchläuft gerade einen beeindruckenden Spekulationsprozess, der nicht unbedingt rational erscheint, sich dennoch für den Spekulanten als profitabel erweisen kann.
Es gibt am deutschen Aktienmarkt ein recht solides Unternehmen, das sich ebenfalls an der Grundlagenforschung zur Oberflächenbearbeitung mittels Nanotechnologie beteiligt. Vor 2 Jahren wurde das Unternehmen dieser Technologie-Sparte auch noch häufig zugeordnet. Warum die Aktie bislang noch kaum entdeckt wurde, ist mir ein Rästel. Machen wir kein Geheimnis daraus. Es handelt sich um Masterflex (WKN 549 293). Die Kennzahlen von Masterflex sind viel versprechend. Sehen Sie selbst. Die Zahlen beziehen sich auf die ersten 9 Monate:
Umsatz +17,3% auf 49,5 Millionen Euro
EBIT +27,1% auf 5,3 Millionen Euro
Börsenwert: 90 Millionen Euro
Die Marktteilnehmer suchen gerade verzweifelt nach Playern im Bereich Nanotechnologie. Charttechnisch und fundamental spricht nichts dagegen, eine Position in Masterflex einzugehen. Die Umsätze sind in den letzten Handelstagen bereits angezogen. Das könnte darauf hindeuten, dass auch Masterflex bald von der Spekulationswelle ergriffen wird!
Text-Zitat von www.masterflex.de
" In Deutschland wurden 1998 insgesamt 12,5 Mio. Tonnen Kunststoffe hergestellt. Der Anteil der Spezialkunststoffe, zu denen Polyurethan
(PU) gehört, lag lediglich bei 2,5% bzw. 312.500 Tonnen. Masterflex verarbeitet das PU im sogenannten Extrusionsverfahren. Experten schätzen, daß erst ca. 15% der Einsatzmöglichkeiten von Polyurethan genutzt werden. Polyurethan ist ein vielseitiger Kunststoff mit hohem Innovationspotential, denn er bietet eine interessante Eigenschaftskombination aus Elastizität, Widerstandsfähigkeit und Alterungsbeständigkeit in einem weiten Temperaturbereich.
Zudem kann PU durch Zugabe der unterschiedlichsten sogenannten Additive modifiziert werden. Die Nanotechnologie erweitert das Anwendungsspektrum von PU nochmals, weil eine Oberflächenbearbeitung möglich wird, die die Produktqualität nochmals enorm verbessern kann. Außerdem wird die Kombination mit anderen Werkstoffen ermöglicht. Damit ist Polyurethan vergleichbar mit einem Baukastensystem, aus dem man maßgeschneiderte Lösungen individuell zusammenstellen kann."
Womit habe ich recht? Dass ich Starpharma für sehr interessant halte und deswegen investiert bin? Natürlich habe ich da recht!
Warum sollte ich mir "lieber mal Masterflex ansehen"?
Gruß, greenhorn
Warum sollte ich mir "lieber mal Masterflex ansehen"?
Gruß, greenhorn
Hallo,
starpharma ist schon seit dem 29.01.2004 in Frankfurt unter WKN 796 461 handelbar.
Viel Spass damit.
Gruss clem
starpharma ist schon seit dem 29.01.2004 in Frankfurt unter WKN 796 461 handelbar.
Viel Spass damit.
Gruss clem
Hallo!
http://www.forbes.com/2004/01/29/cz_jw_0129soapbox.html
Nanotechnology Takes On Cancer
Josh Wolfe, Forbes Wolf Nanotech Report, 01.29.04, 4:28 PM ET
NEW YORK - On Sept. 30, National Institutes of Health director Elias A. Zerhouni laid out a series of far-reaching initiatives known as the NIH Roadmap for Medical Research. Developed with input from more than 300 nationally recognized leaders from academia, industry, government and the public, the Roadmap`s goal is to speed the movement of research discoveries from the bench to the bedside. One of its top five priorities? Nanomedicine. And nowhere is the use of nanotech in medical advances more critical than at the National Cancer Institute (NCI), which sees the potential for nanoscience to dramatically enhance our ability to effectively detect cancer, deliver targeted therapeutics and monitor the effectiveness of cancer interventions.
Forbes Gurus just released a FREE special report: "13 Bold Buys for 2004." Click here to download 13 new stock and fund picks now.
Improved Diagnostics
While substantial progress has been made in drugs and other therapeutic approaches against cancer, advances in diagnostic tools continue to lag. Today`s blood tests and imaging technologies, such as X-ray and CT/MRI scans, provide only limited information and often correlate poorly with the disease`s progression and response to therapy. All are expensive and potentially harmful to patients. Meanwhile, companies such as Quantum Dot Corporation and Immunicon are developing new diagnostics for breast cancer based on semiconducting nanocrystals and magnetic nanoparticles.
One of the most exciting advancements, recently funded by the NCI, is Dr. Vadim Backman`s work in colon cancer diagnostics--inventing a new way to detect cancer even before it forms. Dubbed "Four-Dimensional Elastic Light Scattering Fingerprinting" (4D-ELF), this method uses a tool called a light spectrometer (typically used in the semiconductor industry to monitor wafer defects) to measure biological tissues. "Normal light microscopes can get down to only 300nm to 400nm resolution," says Backman. "Using our technology, we can see the structure of tissues all the way down to 30nm to 40nm. The important discovery we made is that the nanoscale structure of cells changes before cancer forms in your body." Backman`s technology could be an important breakthrough in colonoscopies, a very uncomfortable and expensive process. "We can see the changes in cells before they form into polyps (what colonoscopies search for) and might be able to detect cancerous lesions farther up the colon with a simple rectal test by your normal physician," continues Backman.
The Future Of Cancer Treatments
For patients, Backman`s technology could provide critical information that might prompt a physician to prescribe a cancer drug earlier. It could also provide major anti-cancer companies like Bristol-Myers Squibb (nyse: BMY - news - people ) or Genentech (nyse: DNA - news - people ) with new approaches to treatment. How? Consider Genentech, which last summer announced that its experimental anti-angiogenesis (preventing tumor blood vessel formation) drug Avastin allowed cancer patients to live 30% longer. The news doubled its stock price. The FDA gave Avastin fast track status, speeding up the approval process to bring the drug to market. Avastin`s focus? Colorectal cancer.
With Backman`s technology, biotechs like Genentech could not only generate significant early-stage cancer data helpful in developing new drugs, but also help pharmaceutical companies save millions. "Normally, when they test anti-cancer compounds, they expose a rat to a carcinogen and have to wait about 40 weeks to see a developing cancer," says Backman. "In 20 weeks you start to see polyps. Thanks to recent advances in cell biology, that threshold can be brought down to about eight weeks in the lab. We can discover precursors to cancer in as little as two weeks." Speeding up the research and development process means getting new treatments on the market sooner and saving lives.
Another entirely new platform for cancer therapy is being developed by James Baker, the director of the Center For Biologic Nanotechnology at the University of Michigan. His is based on dendrimers, molecules shaped like spheres and made up of nanoscale polymers in a very specific pattern, sometimes resembling a complex snowflake.
Baker has functionalized these dendrimers to create smart-therapeutic nanodevices that will be used to treat disease. One type seeks out and recognizes only cancer cells. Another type can diagnose what type of cancer it is, while a third type of dendrimer is able to deliver drugs to destroy it. A fourth type can report the location of the tumor to a doctor (a labeling molecule for X-ray or MRI), and yet another can confirm that a cancer cell has been killed. Typically each one of these processes is lengthy, expensive and indiscriminate towards healthy cells. Integrating them into one larger molecule creates a nanodevice able to perform them all at once while leaving healthy cells unscathed.
"We`ve shown 30-fold improvement in animal studies," says Baker. "We have totally detoxified the anti-cancer drug methotrexate (a chemotherapy that is given as a treatment for many types of cancer). Tumors stopped growing with no toxicity, whereas the same animals tested with generic methotrexate died." Baker`s breakthrough cuts to the heart of the problems with current chemotherapy, much of which still brings toxic side effects such as nausea and hair loss.
Opportunities For Investors
Baker and Backman`s technologies represent just two of the exciting advancements in cancer treatment and diagnosis. Companies such as Chelmsford, Mass.-based Triton Biosystems, Houston, Tex.-based Nanospectra Biosciences, St.Louis-based Kereos and Australia-based Starpharma (asx: SPL.AX)are all using nanotechnology to change the cancer landscape.
Starpharma recently won Food and Drug Administration approval to begin Phase I human trials for an anti-AIDS gel. The underlying technology? Dendrimers. It is also exploring its dendrimers-based platform for respiratory viruses, biodefense and oncology. Starpharma`s focus is drug delivery and the same area Genentech is interested in: angiogenesis inhibitors. Through its 49.9% stake in U.S.-based Dendritic Nanotechnologies, Starpharma has started selling dendritic research products through chemical giant Sigma-Aldrich (nasdaq: SIAL - news - people ). With nanotech showing marked improvements in cancer treatments and the FDA showing interest in dendrimer technology, I wouldn`t be surprised if a major pharma company signs a partnership and licensing agreement with Starpharma in the next year. Right now, the stock is only freely traded on the Australian Stock Exchange. Priced at a recent 74 cents per share, up from 19 cents last March.
Grüße cristrader
http://www.forbes.com/2004/01/29/cz_jw_0129soapbox.html
Nanotechnology Takes On Cancer
Josh Wolfe, Forbes Wolf Nanotech Report, 01.29.04, 4:28 PM ET
NEW YORK - On Sept. 30, National Institutes of Health director Elias A. Zerhouni laid out a series of far-reaching initiatives known as the NIH Roadmap for Medical Research. Developed with input from more than 300 nationally recognized leaders from academia, industry, government and the public, the Roadmap`s goal is to speed the movement of research discoveries from the bench to the bedside. One of its top five priorities? Nanomedicine. And nowhere is the use of nanotech in medical advances more critical than at the National Cancer Institute (NCI), which sees the potential for nanoscience to dramatically enhance our ability to effectively detect cancer, deliver targeted therapeutics and monitor the effectiveness of cancer interventions.
Forbes Gurus just released a FREE special report: "13 Bold Buys for 2004." Click here to download 13 new stock and fund picks now.
Improved Diagnostics
While substantial progress has been made in drugs and other therapeutic approaches against cancer, advances in diagnostic tools continue to lag. Today`s blood tests and imaging technologies, such as X-ray and CT/MRI scans, provide only limited information and often correlate poorly with the disease`s progression and response to therapy. All are expensive and potentially harmful to patients. Meanwhile, companies such as Quantum Dot Corporation and Immunicon are developing new diagnostics for breast cancer based on semiconducting nanocrystals and magnetic nanoparticles.
One of the most exciting advancements, recently funded by the NCI, is Dr. Vadim Backman`s work in colon cancer diagnostics--inventing a new way to detect cancer even before it forms. Dubbed "Four-Dimensional Elastic Light Scattering Fingerprinting" (4D-ELF), this method uses a tool called a light spectrometer (typically used in the semiconductor industry to monitor wafer defects) to measure biological tissues. "Normal light microscopes can get down to only 300nm to 400nm resolution," says Backman. "Using our technology, we can see the structure of tissues all the way down to 30nm to 40nm. The important discovery we made is that the nanoscale structure of cells changes before cancer forms in your body." Backman`s technology could be an important breakthrough in colonoscopies, a very uncomfortable and expensive process. "We can see the changes in cells before they form into polyps (what colonoscopies search for) and might be able to detect cancerous lesions farther up the colon with a simple rectal test by your normal physician," continues Backman.
The Future Of Cancer Treatments
For patients, Backman`s technology could provide critical information that might prompt a physician to prescribe a cancer drug earlier. It could also provide major anti-cancer companies like Bristol-Myers Squibb (nyse: BMY - news - people ) or Genentech (nyse: DNA - news - people ) with new approaches to treatment. How? Consider Genentech, which last summer announced that its experimental anti-angiogenesis (preventing tumor blood vessel formation) drug Avastin allowed cancer patients to live 30% longer. The news doubled its stock price. The FDA gave Avastin fast track status, speeding up the approval process to bring the drug to market. Avastin`s focus? Colorectal cancer.
With Backman`s technology, biotechs like Genentech could not only generate significant early-stage cancer data helpful in developing new drugs, but also help pharmaceutical companies save millions. "Normally, when they test anti-cancer compounds, they expose a rat to a carcinogen and have to wait about 40 weeks to see a developing cancer," says Backman. "In 20 weeks you start to see polyps. Thanks to recent advances in cell biology, that threshold can be brought down to about eight weeks in the lab. We can discover precursors to cancer in as little as two weeks." Speeding up the research and development process means getting new treatments on the market sooner and saving lives.
Another entirely new platform for cancer therapy is being developed by James Baker, the director of the Center For Biologic Nanotechnology at the University of Michigan. His is based on dendrimers, molecules shaped like spheres and made up of nanoscale polymers in a very specific pattern, sometimes resembling a complex snowflake.
Baker has functionalized these dendrimers to create smart-therapeutic nanodevices that will be used to treat disease. One type seeks out and recognizes only cancer cells. Another type can diagnose what type of cancer it is, while a third type of dendrimer is able to deliver drugs to destroy it. A fourth type can report the location of the tumor to a doctor (a labeling molecule for X-ray or MRI), and yet another can confirm that a cancer cell has been killed. Typically each one of these processes is lengthy, expensive and indiscriminate towards healthy cells. Integrating them into one larger molecule creates a nanodevice able to perform them all at once while leaving healthy cells unscathed.
"We`ve shown 30-fold improvement in animal studies," says Baker. "We have totally detoxified the anti-cancer drug methotrexate (a chemotherapy that is given as a treatment for many types of cancer). Tumors stopped growing with no toxicity, whereas the same animals tested with generic methotrexate died." Baker`s breakthrough cuts to the heart of the problems with current chemotherapy, much of which still brings toxic side effects such as nausea and hair loss.
Opportunities For Investors
Baker and Backman`s technologies represent just two of the exciting advancements in cancer treatment and diagnosis. Companies such as Chelmsford, Mass.-based Triton Biosystems, Houston, Tex.-based Nanospectra Biosciences, St.Louis-based Kereos and Australia-based Starpharma (asx: SPL.AX)are all using nanotechnology to change the cancer landscape.
Starpharma recently won Food and Drug Administration approval to begin Phase I human trials for an anti-AIDS gel. The underlying technology? Dendrimers. It is also exploring its dendrimers-based platform for respiratory viruses, biodefense and oncology. Starpharma`s focus is drug delivery and the same area Genentech is interested in: angiogenesis inhibitors. Through its 49.9% stake in U.S.-based Dendritic Nanotechnologies, Starpharma has started selling dendritic research products through chemical giant Sigma-Aldrich (nasdaq: SIAL - news - people ). With nanotech showing marked improvements in cancer treatments and the FDA showing interest in dendrimer technology, I wouldn`t be surprised if a major pharma company signs a partnership and licensing agreement with Starpharma in the next year. Right now, the stock is only freely traded on the Australian Stock Exchange. Priced at a recent 74 cents per share, up from 19 cents last March.
Grüße cristrader
Very small rocks?
Hallo zusammen!
Bin wirklich kein Charttechniker, aber wenn ich das richtig sehe, sind wir an einem sehr wichtigen Punkt angekommen - das Jahreshoch. Wäre schon schön, wenn wir in den nächsten Tagen durch die 80 AUD-Cent gingen, dann könnten wir kurzfristig bis an 1 AUD laufen. Korrigiert mich, wenn ich gerade Blödsinn rede.
Gruß, greenhorn
Bin wirklich kein Charttechniker, aber wenn ich das richtig sehe, sind wir an einem sehr wichtigen Punkt angekommen - das Jahreshoch. Wäre schon schön, wenn wir in den nächsten Tagen durch die 80 AUD-Cent gingen, dann könnten wir kurzfristig bis an 1 AUD laufen. Korrigiert mich, wenn ich gerade Blödsinn rede.
Gruß, greenhorn
Guten Morgen!
Sehr schade heute der Tag in Australien. Bei 0,84 AUD im Hoch und unverändert geschlossen.
Naja, morgen ist ja auch noch ein Tag
Gruß, greenhorn
Sehr schade heute der Tag in Australien. Bei 0,84 AUD im Hoch und unverändert geschlossen.
Naja, morgen ist ja auch noch ein Tag
Gruß, greenhorn
Starpharma ist seit dieser Woche in Deutsc´hland (berlin-Bremen) handelbar. also, los gehts!
mit VIVA-GEL sollte trotz der guten aussichten bei erfolg und dessen vermarktung nur daran gedacht werden das es erst bei guten verlauf der studie I und II im jahr 2007 soweit ist.bis dahin ist es noch ein steiniger weg mit vielen hindernissen.daher ist die jetzige bewertung vollkommen ausreichend.erst bei einer wirksamkeit bei den probanden ist eine deutlicher kursaufschlag gerechtfertigt.bin selbst aktionär, habe sie aber bis jetztan an der OTC gekauft.(etrade provisions kosten 14,95€).denn bis jetzt ist es nichts anderes als eine gute idee die bei affen funktioniert hat.der erfolg bei menschen ist der schlüssel zum erfolg.zur FDA ist zu sagen da es sich um ein medikament handelt muß eine FDA zulassung erfolgen...bei medizinprodukten z.b. HIV TEST verfahren sind diese zulassung nicht notwendig.(z.b VIROLOGIC)um eine zulassung zu erhalten bei der FDA ist viel geduld und forschungsgelder notwendig weshalb ich den verkauf neuer aktien nur begrüßen kann.FDA sieht sehr genau hin ,bis zur produktion wird allse durchleuchtet und daran sind schon einige baden gegangen. nur mal so 20 % scheitern selst in phase III noch.45 % gehen in phase I unter.
grüße t.1
grüße t.1
grüße t.1
grüße t.1
Guten Abend zusammen!
Das ist wirklich nicht gut, dass Starpharma von den Zockern entdeckt wird. Und ich dachte, als ich gerade nach Hause gekommen bin, dass es irgendwelche News gab. Gab es wohl nicht, außer dieser Empfehlung.
Glaube ich werde mir gar nicht erst angewöhnen, nach den deutschen Euro-Kursen zu schauen. Der Kurs wird - noch - in Australien gemacht, und da steht er bei 0,80 AUD. Mal sehen, wo er morgen früh steht, von einem 25%-Kurssprung gehe ich aber nicht aus. Morgen werden wir also tiefrote Zeichen in Deutschland sehen. Einmal rauf und wieder runter - und was ist passiert? NIchts!
Gruß, greenhorn
Das ist wirklich nicht gut, dass Starpharma von den Zockern entdeckt wird. Und ich dachte, als ich gerade nach Hause gekommen bin, dass es irgendwelche News gab. Gab es wohl nicht, außer dieser Empfehlung.
Glaube ich werde mir gar nicht erst angewöhnen, nach den deutschen Euro-Kursen zu schauen. Der Kurs wird - noch - in Australien gemacht, und da steht er bei 0,80 AUD. Mal sehen, wo er morgen früh steht, von einem 25%-Kurssprung gehe ich aber nicht aus. Morgen werden wir also tiefrote Zeichen in Deutschland sehen. Einmal rauf und wieder runter - und was ist passiert? NIchts!
Gruß, greenhorn
greenhorn:
Ich denke es werden demnächst News zu PhaseI kommen, das Volumen steigt in Australien. Außerdem stehen noch Kooperationen/Investitionen an, die für einen weiteren Kursschub sorgen könnten. Natürlich alles kurzfristig, was jetzt noch zur Bewertung dazukommt, ist reiner Hype. Außer Starpharma zieht einen Deal an Land, wie Theravance es damals schaffte. Dann muß alles neu bewertet werden.
Die Zocker übernehmen jetzt das Ruder, ich hoffe wir halten hier die Diskussion wie bisher aufrecht, es lief immer recht sachlich und informativ ab:An dieser Stelle dafür nochmals besonderen Dank an dich und cristrader
Ich denke es werden demnächst News zu PhaseI kommen, das Volumen steigt in Australien. Außerdem stehen noch Kooperationen/Investitionen an, die für einen weiteren Kursschub sorgen könnten. Natürlich alles kurzfristig, was jetzt noch zur Bewertung dazukommt, ist reiner Hype. Außer Starpharma zieht einen Deal an Land, wie Theravance es damals schaffte. Dann muß alles neu bewertet werden.
Die Zocker übernehmen jetzt das Ruder, ich hoffe wir halten hier die Diskussion wie bisher aufrecht, es lief immer recht sachlich und informativ ab:An dieser Stelle dafür nochmals besonderen Dank an dich und cristrader
Zur Erinnerung:
Aus dem Forbes-Artikel von 30.9.2003
Opportunities For Investors
Baker and Backman`s technologies represent just two of the exciting advancements in cancer treatment and diagnosis. Companies such as Chelmsford, Mass.-based Triton Biosystems, Houston, Tex.-based Nanospectra Biosciences, St.Louis-based Kereos and Australia-based Starpharma (asx: SPL.AX)are all using nanotechnology to change the cancer landscape.
Starpharma recently won Food and Drug Administration approval to begin Phase I human trials for an anti-AIDS gel. The underlying technology? Dendrimers. It is also exploring its dendrimers-based platform for respiratory viruses, biodefense and oncology. Starpharma`s focus is drug delivery and the same area Genentech is interested in: angiogenesis inhibitors. Through its 49.9% stake in U.S.-based Dendritic Nanotechnologies, Starpharma has started selling dendritic research products through chemical giant Sigma-Aldrich (nasdaq: SIAL - news - people ). With nanotech showing marked improvements in cancer treatments and the FDA showing interest in dendrimer technology, I wouldn`t be surprised if a major pharma company signs a partnership and licensing agreement with Starpharma in the next year. Right now, the stock is only freely traded on the Australian Stock Exchange. Priced at a recent 74 cents per share, up from 19 cents last March.
Aus dem Forbes-Artikel von 30.9.2003
Opportunities For Investors
Baker and Backman`s technologies represent just two of the exciting advancements in cancer treatment and diagnosis. Companies such as Chelmsford, Mass.-based Triton Biosystems, Houston, Tex.-based Nanospectra Biosciences, St.Louis-based Kereos and Australia-based Starpharma (asx: SPL.AX)are all using nanotechnology to change the cancer landscape.
Starpharma recently won Food and Drug Administration approval to begin Phase I human trials for an anti-AIDS gel. The underlying technology? Dendrimers. It is also exploring its dendrimers-based platform for respiratory viruses, biodefense and oncology. Starpharma`s focus is drug delivery and the same area Genentech is interested in: angiogenesis inhibitors. Through its 49.9% stake in U.S.-based Dendritic Nanotechnologies, Starpharma has started selling dendritic research products through chemical giant Sigma-Aldrich (nasdaq: SIAL - news - people ). With nanotech showing marked improvements in cancer treatments and the FDA showing interest in dendrimer technology, I wouldn`t be surprised if a major pharma company signs a partnership and licensing agreement with Starpharma in the next year. Right now, the stock is only freely traded on the Australian Stock Exchange. Priced at a recent 74 cents per share, up from 19 cents last March.
Hallo zusammen!
Ich hoffe auch das dieser Thread weiterhin als sachlicher Infothread dienen kann.
Die Aufnahme Starpharmas an den Börsen Frankfurt und Berlin sehe ich auf jeden Fall positiv. An den deutschen Börsen sind am Freitag insgesamt 2.386.490 Aktien gehandelt worden, d.h. die Makler müssen diese Aktien Anfang der Woche in Australien an der ASX wieder zurückkaufen. Bei dem hohen Volumen und Kaufinteresse wird der Kurs an der ASX auf jeden Fall steigen. Der Bewertungsunterschied wird nicht lange Bestand haben!
Im Vergleich zu US-Werten haben die australischen Nanotechs wie Starpharma und Ambri den Nanohype seit November`03 doch gar nicht mitgemacht. Wenn die ganzen Börsenbriefe, Hotlines usw. die Aktie Starpharma bekannt macht und so den Bewertungsunterschied abbauen hilft, kann das uns bereits Investierten doch nur Recht sein
Grüße cristrader!
Ich hoffe auch das dieser Thread weiterhin als sachlicher Infothread dienen kann.
Die Aufnahme Starpharmas an den Börsen Frankfurt und Berlin sehe ich auf jeden Fall positiv. An den deutschen Börsen sind am Freitag insgesamt 2.386.490 Aktien gehandelt worden, d.h. die Makler müssen diese Aktien Anfang der Woche in Australien an der ASX wieder zurückkaufen. Bei dem hohen Volumen und Kaufinteresse wird der Kurs an der ASX auf jeden Fall steigen. Der Bewertungsunterschied wird nicht lange Bestand haben!
Im Vergleich zu US-Werten haben die australischen Nanotechs wie Starpharma und Ambri den Nanohype seit November`03 doch gar nicht mitgemacht. Wenn die ganzen Börsenbriefe, Hotlines usw. die Aktie Starpharma bekannt macht und so den Bewertungsunterschied abbauen hilft, kann das uns bereits Investierten doch nur Recht sein
Grüße cristrader!
@cristrader
denke, das ein deutlicher teil schon in den USA abgeholt wurde.glaube aber auch das es noch deutlich nach oben gehen wird,da STARPHARMA nun erst bekannt wird und der zug erst ins rollen kommt.
grüße t.1
denke, das ein deutlicher teil schon in den USA abgeholt wurde.glaube aber auch das es noch deutlich nach oben gehen wird,da STARPHARMA nun erst bekannt wird und der zug erst ins rollen kommt.
grüße t.1
@t.1
Starpharma ist in USA auch nicht offiziell gelistet, nur Pink-Sheets-Handel. Einzige offizielle Listung an der ASX. Von dort müssen die Aktien besorgt werden oder sehe ich das falsch
Grüße cristrader
Starpharma ist in USA auch nicht offiziell gelistet, nur Pink-Sheets-Handel. Einzige offizielle Listung an der ASX. Von dort müssen die Aktien besorgt werden oder sehe ich das falsch
Grüße cristrader
@cristrader
OTC BB ,denke reicht für diesen handel aus.in den letzten 5 monaten wurden täglich um die 20000 aktien gehandelt.gestern ging es auf 722000 ungewöhnlich hoch-so hoch wie es noch nie war.das sind 30 % an einem tag-und woher kommen diese kauforder ???
http://www.stockhouse.com/comp_info.asp?symbol=SPHRF&table=L…
grüße t.1
OTC BB ,denke reicht für diesen handel aus.in den letzten 5 monaten wurden täglich um die 20000 aktien gehandelt.gestern ging es auf 722000 ungewöhnlich hoch-so hoch wie es noch nie war.das sind 30 % an einem tag-und woher kommen diese kauforder ???
http://www.stockhouse.com/comp_info.asp?symbol=SPHRF&table=L…
grüße t.1
Hallo Neoe!
Ein ganz großes Danke geht vor allen Dingen auch an dich! Wünsche uns allen eine erfolgreiche Woche mit Starpharma!
Gruß, greenhorn
Ein ganz großes Danke geht vor allen Dingen auch an dich! Wünsche uns allen eine erfolgreiche Woche mit Starpharma!
Gruß, greenhorn
Hallo zusammen!
Das sieht ja alles sehr schön aus, derzeit. Exorbitant gestiegenes Volumen mit steigenden Kursen. Bin gespannt, was uns da an Neuigkeiten ins Haus stehen. Neoe, du hattest ja noch einmal auf mögliche Themen hingewiesen, die Seitens Starpharma aktualisiert werden könnten.
Frage: Wie sieht das denn charttechnisch derzeit aus? Wir haben bei einem AUD geschlossen. Laut comdirect wäre das ein All Time High. Weitere Widerstände? Fehlanzeige.
Kann das sein, dass ganz am Schluss noch mal ein riesiger Batzen über die Theke gegangen ist?
Ich bin sehr gespannt.
Gruß, greenhorn
Das sieht ja alles sehr schön aus, derzeit. Exorbitant gestiegenes Volumen mit steigenden Kursen. Bin gespannt, was uns da an Neuigkeiten ins Haus stehen. Neoe, du hattest ja noch einmal auf mögliche Themen hingewiesen, die Seitens Starpharma aktualisiert werden könnten.
Frage: Wie sieht das denn charttechnisch derzeit aus? Wir haben bei einem AUD geschlossen. Laut comdirect wäre das ein All Time High. Weitere Widerstände? Fehlanzeige.
Kann das sein, dass ganz am Schluss noch mal ein riesiger Batzen über die Theke gegangen ist?
Ich bin sehr gespannt.
Gruß, greenhorn
Könnte nach kurzer Erholung weitergehen. Noch keine signifikanten News.
Frechet hat laut News von gestern einige Optionen für seine Arbeit im Dezember erhalten.
Frechet hat laut News von gestern einige Optionen für seine Arbeit im Dezember erhalten.
Hallo zusammen!
Hier noch ein kleiner Link dazu!
http://ist-socrates.berkeley.edu/~jfrechet/
Gruß, greenhorn
Hier noch ein kleiner Link dazu!
http://ist-socrates.berkeley.edu/~jfrechet/
Gruß, greenhorn
Hallo zusammen!
Gerade gefunden:
Nanotech and Biotech Convergence – 2004. The third annual BCC conference. Diagnostics, Drug delivery, and drug discovery.
Nanotechnology and biotechnology have been on a collision course for years and now, in the fourth year of the third millennium, BCC celebrates the inevitable convergence of these two technologies with the 3rd annual Nanotech and Biotech Convergence conference.
Where Does the Industry Stand Now? Where Is It Going?
Where the Technology Meets the Market: Directions, Opportunities
Blend of the Scientific and the Applied
Major Developments, Major Applications, Emerging Technologies
This conference has traditionally fielded a blend of academic and industry speakers, in the belief that cross-fertilization was the shortest path to a hybrid science of extraordinary vigor. This year will be no exception. However, we are now focusing on specific, high-value applications of nanobiotechnology: molecular diagnostics, biosensors, molecular imaging, MRI contrast agents, drug discovery, drug development and drug and vaccine delivery. Let it not be said that nanobiotech is the wave of the future. Nanotech-enabled drugs and drug delivery systems are in clinical trials NOW. Nanoscale devices, such as quantum dots, nanoparticles, single-molecule sensors and nanofluidic devices are being used in imaging and molecular diagnostics NOW.
This year there will be two workshops associated with the conference: Trends in Nanoscale Diagnostic Technologies, and Nanotech Patents and Licensing.
The following companies and institutions are among those represented at the conference by speakers, instructors, exhibitors or attendees:
Dendritic Nanotechnologies, C-Sixty, Starpharma Lmtd., MedActinium, Inc., Anosys, Inc., NanoSpectra Biosciences, BioTrove, Inc., Evident Technologies, Qiagen Sciences, NascaCell IP GmbH, Bionic Bros GmbH, Genencor, Nanosys, Harris & Harris, Min Hsieh and Hack, Kalow and Springut, Kereos, Business Communications Co., Phaelixe, Inc., Orion Recruiting Group, Biophan Technologies, Bawa Biotechnology Consulting, Nanodel Technologies GmbH, Foley and Lardner, Cooper Hill Partners, Mitsui Chemical America, Quantum Dot Corp., Eclipse Diagnostics, New York University, Central Michigan University, Penn State University, University of California at Los Angeles, University of California at San Diego, Massachusetts Institute of Technology, Massachusetts General Hospital, Harvard University, Rensselaer Polytechnic Institute, University of Magdeburg, Clarkson University, University of Florida, University of South Florida, Ohio State University, and Polytechnic University (Brooklyn, NY)...
March 29
Keynote Presentation 8:15-9:00 p.m.
THE ROLE OF DENDRIMERS IN NANOBIOLOGY: FROM BIOMIMICRY TO DRUG DELIVERY AND NANOMEDICAL APPLICATIONS
Donald A. Tomalia, Ph.D., President and CTO, Dendritic NanoTechnologies, Inc., Distinguished Research Scientist/Professor, Central Michigan University, Mt. Pleasant, MI
Dendrimers are the most significant and widely researched members of a new architectural class of macromolecules referred to as, dendritic polymers. Poly (amidoamine) (PAMAM) dendrimers are historically the first complete dendrimer family to be synthesized, characterized and commercialized. Based on this extensive activity, they are recognized as a unique new class of synthetic nanostructures that allows precise control of size, shape and placement of functional groups so desirable for many life science applications. Dendrimers have been referred to as "artificial proteins."
This lecture will overview the implications of dendrimers in nanobiology and discusses new nanoscale rules and relations that are evolving in this size regime. The role of "dendrimers" as fundamental synthetic building blocks for the creation of new nanodevices and nanopharmaceuticals will be introduced. As such, their precise nanoscale dimensions, shapes and chemical functionality have been used in prototypes suitable for targeting disease sites, controlled delivery of therapeutic/genetic or cosmoceutical materials, as well as a variety of imaging/diagnostic and personal care applications.
Dr. Tomalia, known as the "Father of Dendrimers", launched his academic / entrepreneurial ventures after a 25 year management and senior scientist career with The Dow Chemical Company. During that time, he was credited with numerous commercial developments which included Citrucel (now marketed by GlaxoSmithKline), cationic polymerization of 2-oxazolines and discovery of the fourth major class of macromolecular architecture; namely, "dendritic polymers." He is the inventor and originator of the term "dendrimers" and is listed on over 100 U.S. patents and more than 180 peer reviewed publications. Over 150 of these publications are focused on the dendrimer and dendritic polymer field, including a monograph entitled "Dendrimers and Other Dendritic Polymers". Dr. Tomalia serves as the President and Chief Technology Officer of Dendritic Nanotechnologies Inc., while he remains active in the academic community as Distinguished Visiting Professor (Columbia University), Distinguished Research Scientist/Professor (Central Michigan University), Co-Director of the National Center for Dendrimer Based Nanotechnology (Central Michigan University) and serves on the editorial advisory boards of Bioconjugate Chemistry and NanoLetters.
9:00-9:30 a.m.
DESIGN AND PRECLINICAL DEVELOPMENT OF DENDRIMER BASED TOPICAL MICROBICIDES FOR HIV AND STI PREVENTION
T. McCarthy, P. Karellas, S. Henderson, M. Giannis, D. O`Keefe, B. Matthews, B. Braggs, J. Paull, G. Heery, G. Krippner, G. Holan, Starpharma Limited, Melbourne, Australia
Dendrimers are a new class of macromolecule characterized by highly branched, three-dimensional architectures that are assembled in a precise, step-wise manner. This controlled synthesis allows the assembly of highly defined structures that radiate out in generations from a central initiator core. The result of this iterative growth process is a single macromolecular entity that contrasts with the polydisperse nature of alternative macromolecular structures such as traditional polymers. In developing dendrimers as pharmaceuticals, Starpharma has focused on the prevention of HIV and sexually transmitted infections (STIs) through the development of microbicide candidates. Early examples of Starpharma’s dendrimers had activity against HIV and herpes simplex virus-2. Lead optimization resulted in a series of optimized dendrimer based microbicides being identified from which SPL7013 emerged as a development candidate. Following a range of preclinical studies, Starpharma submitted an Investigational New Drug application (IND) for SPL7013 gel (VivaGel) to the United States Food and Drug Administration (FDA), the first such submission for a dendrimer based drug. This presentation will discuss the discovery of dendrimer based microbicides candidates, the lead optimization phase and the preclinical development path that led to the IND filing and the commencement of clinical trials of VivaGel.
www.bccresearch.com
Gruß, greenhorn
Gerade gefunden:
Nanotech and Biotech Convergence – 2004. The third annual BCC conference. Diagnostics, Drug delivery, and drug discovery.
Nanotechnology and biotechnology have been on a collision course for years and now, in the fourth year of the third millennium, BCC celebrates the inevitable convergence of these two technologies with the 3rd annual Nanotech and Biotech Convergence conference.
Where Does the Industry Stand Now? Where Is It Going?
Where the Technology Meets the Market: Directions, Opportunities
Blend of the Scientific and the Applied
Major Developments, Major Applications, Emerging Technologies
This conference has traditionally fielded a blend of academic and industry speakers, in the belief that cross-fertilization was the shortest path to a hybrid science of extraordinary vigor. This year will be no exception. However, we are now focusing on specific, high-value applications of nanobiotechnology: molecular diagnostics, biosensors, molecular imaging, MRI contrast agents, drug discovery, drug development and drug and vaccine delivery. Let it not be said that nanobiotech is the wave of the future. Nanotech-enabled drugs and drug delivery systems are in clinical trials NOW. Nanoscale devices, such as quantum dots, nanoparticles, single-molecule sensors and nanofluidic devices are being used in imaging and molecular diagnostics NOW.
This year there will be two workshops associated with the conference: Trends in Nanoscale Diagnostic Technologies, and Nanotech Patents and Licensing.
The following companies and institutions are among those represented at the conference by speakers, instructors, exhibitors or attendees:
Dendritic Nanotechnologies, C-Sixty, Starpharma Lmtd., MedActinium, Inc., Anosys, Inc., NanoSpectra Biosciences, BioTrove, Inc., Evident Technologies, Qiagen Sciences, NascaCell IP GmbH, Bionic Bros GmbH, Genencor, Nanosys, Harris & Harris, Min Hsieh and Hack, Kalow and Springut, Kereos, Business Communications Co., Phaelixe, Inc., Orion Recruiting Group, Biophan Technologies, Bawa Biotechnology Consulting, Nanodel Technologies GmbH, Foley and Lardner, Cooper Hill Partners, Mitsui Chemical America, Quantum Dot Corp., Eclipse Diagnostics, New York University, Central Michigan University, Penn State University, University of California at Los Angeles, University of California at San Diego, Massachusetts Institute of Technology, Massachusetts General Hospital, Harvard University, Rensselaer Polytechnic Institute, University of Magdeburg, Clarkson University, University of Florida, University of South Florida, Ohio State University, and Polytechnic University (Brooklyn, NY)...
March 29
Keynote Presentation 8:15-9:00 p.m.
THE ROLE OF DENDRIMERS IN NANOBIOLOGY: FROM BIOMIMICRY TO DRUG DELIVERY AND NANOMEDICAL APPLICATIONS
Donald A. Tomalia, Ph.D., President and CTO, Dendritic NanoTechnologies, Inc., Distinguished Research Scientist/Professor, Central Michigan University, Mt. Pleasant, MI
Dendrimers are the most significant and widely researched members of a new architectural class of macromolecules referred to as, dendritic polymers. Poly (amidoamine) (PAMAM) dendrimers are historically the first complete dendrimer family to be synthesized, characterized and commercialized. Based on this extensive activity, they are recognized as a unique new class of synthetic nanostructures that allows precise control of size, shape and placement of functional groups so desirable for many life science applications. Dendrimers have been referred to as "artificial proteins."
This lecture will overview the implications of dendrimers in nanobiology and discusses new nanoscale rules and relations that are evolving in this size regime. The role of "dendrimers" as fundamental synthetic building blocks for the creation of new nanodevices and nanopharmaceuticals will be introduced. As such, their precise nanoscale dimensions, shapes and chemical functionality have been used in prototypes suitable for targeting disease sites, controlled delivery of therapeutic/genetic or cosmoceutical materials, as well as a variety of imaging/diagnostic and personal care applications.
Dr. Tomalia, known as the "Father of Dendrimers", launched his academic / entrepreneurial ventures after a 25 year management and senior scientist career with The Dow Chemical Company. During that time, he was credited with numerous commercial developments which included Citrucel (now marketed by GlaxoSmithKline), cationic polymerization of 2-oxazolines and discovery of the fourth major class of macromolecular architecture; namely, "dendritic polymers." He is the inventor and originator of the term "dendrimers" and is listed on over 100 U.S. patents and more than 180 peer reviewed publications. Over 150 of these publications are focused on the dendrimer and dendritic polymer field, including a monograph entitled "Dendrimers and Other Dendritic Polymers". Dr. Tomalia serves as the President and Chief Technology Officer of Dendritic Nanotechnologies Inc., while he remains active in the academic community as Distinguished Visiting Professor (Columbia University), Distinguished Research Scientist/Professor (Central Michigan University), Co-Director of the National Center for Dendrimer Based Nanotechnology (Central Michigan University) and serves on the editorial advisory boards of Bioconjugate Chemistry and NanoLetters.
9:00-9:30 a.m.
DESIGN AND PRECLINICAL DEVELOPMENT OF DENDRIMER BASED TOPICAL MICROBICIDES FOR HIV AND STI PREVENTION
T. McCarthy, P. Karellas, S. Henderson, M. Giannis, D. O`Keefe, B. Matthews, B. Braggs, J. Paull, G. Heery, G. Krippner, G. Holan, Starpharma Limited, Melbourne, Australia
Dendrimers are a new class of macromolecule characterized by highly branched, three-dimensional architectures that are assembled in a precise, step-wise manner. This controlled synthesis allows the assembly of highly defined structures that radiate out in generations from a central initiator core. The result of this iterative growth process is a single macromolecular entity that contrasts with the polydisperse nature of alternative macromolecular structures such as traditional polymers. In developing dendrimers as pharmaceuticals, Starpharma has focused on the prevention of HIV and sexually transmitted infections (STIs) through the development of microbicide candidates. Early examples of Starpharma’s dendrimers had activity against HIV and herpes simplex virus-2. Lead optimization resulted in a series of optimized dendrimer based microbicides being identified from which SPL7013 emerged as a development candidate. Following a range of preclinical studies, Starpharma submitted an Investigational New Drug application (IND) for SPL7013 gel (VivaGel) to the United States Food and Drug Administration (FDA), the first such submission for a dendrimer based drug. This presentation will discuss the discovery of dendrimer based microbicides candidates, the lead optimization phase and the preclinical development path that led to the IND filing and the commencement of clinical trials of VivaGel.
www.bccresearch.com
Gruß, greenhorn
Buy 3.6T
91 Last
92
2 2.2%
10:31 am High
92 Open
92 Volume
2,667
92
Sell 23.3T Low
92 Prev. Close
90 Turnover
$2,453
9:42 am Half Yearly Report & Half Year Accounts
Trade No. Time Price Volume Value Conditions
1 2 10:09:08 am 92 667 $614
2 1 10:09:08 am 92 2,000 $1,840
SPL startet den Handel an der ASX heute mit einem Plus von 2,2 % bei 0,92 AUD, umgerechnet 0,57 €.
Umsatz von 2.267 Stück ist allerdings sehr schwach.
91 Last
92
2 2.2%
10:31 am High
92 Open
92 Volume
2,667
92
Sell 23.3T Low
92 Prev. Close
90 Turnover
$2,453
9:42 am Half Yearly Report & Half Year Accounts
Trade No. Time Price Volume Value Conditions
1 2 10:09:08 am 92 667 $614
2 1 10:09:08 am 92 2,000 $1,840
SPL startet den Handel an der ASX heute mit einem Plus von 2,2 % bei 0,92 AUD, umgerechnet 0,57 €.
Umsatz von 2.267 Stück ist allerdings sehr schwach.
Da gibts eine positive Nachricht heute ihr werdet sehen
Hallo Leute,
gibt es etwas neues bei Starpharma ?????? Wenn jemand Infos hat bitte damit nicht hinterm Berg halten, raus damit !!!!!
wurze
gibt es etwas neues bei Starpharma ?????? Wenn jemand Infos hat bitte damit nicht hinterm Berg halten, raus damit !!!!!
wurze
Hi!
Ich weiß nicht, ob es damit zusammenhängt:
http://www.ozestock.com.au/News.asp?Action=ShowAnnouncement&…
Ich denke eher - oder ich hoffe es zumindest - dass sich die Aktie aufgrund anstehender Nachrichten und vor allen Dingen aufgrund der Konferenz Ende März wieder nach oben orientiert. Die Konsolidierung war wichtig und gesund, vielleicht dauert sie noch ein paar Tage an. Aber es bald wieder nach gehen, meiner Meinung nach.
Gruß, greenhorn
Ich weiß nicht, ob es damit zusammenhängt:
http://www.ozestock.com.au/News.asp?Action=ShowAnnouncement&…
Ich denke eher - oder ich hoffe es zumindest - dass sich die Aktie aufgrund anstehender Nachrichten und vor allen Dingen aufgrund der Konferenz Ende März wieder nach oben orientiert. Die Konsolidierung war wichtig und gesund, vielleicht dauert sie noch ein paar Tage an. Aber es bald wieder nach gehen, meiner Meinung nach.
Gruß, greenhorn
greenhorn:
Das war wohl eine bereits veraltete Information von dir.Stammt aus dem Jahre 2003.
Das war wohl eine bereits veraltete Information von dir.Stammt aus dem Jahre 2003.
Uuups, tut mir sehr leid! Das kommt davon, wenn man nicht richtig hinsieht! Streichen wir #132 aus dem Protokoll
Aber schön, mal wieder was von dir zu hören, Neoe!
Bis zu den nächsten - wirklichen - Neuigkeiten!
Gruß, greenhorn
Aber schön, mal wieder was von dir zu hören, Neoe!
Bis zu den nächsten - wirklichen - Neuigkeiten!
Gruß, greenhorn
greenhorn:
Starpharma sorgt zur Zeit leider eher zwischen den Zeilen für Gesprächsstoff. Es scheint mir als würden einige Verhandlungen und sogar Projekte unter dem Deckmantel des Schweigens laufen. Confidential agreements, etc...man kennt es ja, wie es läuft, wenn größere Firmen ans Werk gehen, das Dendritic im Rüstungsbereich mit der amerikanischen Regierung zusammenarbeitet, macht die Kommunikation mit den Shareholdern auch nicht einfacher.
Die PhaseI-Studien mit VivaGel laufen, wie nochmals nebenbei im Halbjahrsbericht erwähnt wurde.
Mal was ganz anderes:
Absoluter Hammer wäre, wenn die Voraussage von Forbes zutreffen würde und Medikamente, die auf der Dendrimertechnologie basieren, generellen Fast-Track-Status von der FDA erhalten würden.....$$$$$$$$
Starpharma sorgt zur Zeit leider eher zwischen den Zeilen für Gesprächsstoff. Es scheint mir als würden einige Verhandlungen und sogar Projekte unter dem Deckmantel des Schweigens laufen. Confidential agreements, etc...man kennt es ja, wie es läuft, wenn größere Firmen ans Werk gehen, das Dendritic im Rüstungsbereich mit der amerikanischen Regierung zusammenarbeitet, macht die Kommunikation mit den Shareholdern auch nicht einfacher.
Die PhaseI-Studien mit VivaGel laufen, wie nochmals nebenbei im Halbjahrsbericht erwähnt wurde.
Mal was ganz anderes:
Absoluter Hammer wäre, wenn die Voraussage von Forbes zutreffen würde und Medikamente, die auf der Dendrimertechnologie basieren, generellen Fast-Track-Status von der FDA erhalten würden.....$$$$$$$$
Hallo Neoe!
Ich stehe gerade etwas auf dem Schlauch. Wo steht denn, dass Forbes vermutet, dass Medikamente, die auf der Dendrimer-Technologie basieren, generellen Fast-Track-Status erhelten könnten? Ich habe mir sowohl deinen Auszug (#117), als auch noch einmal den gesamten Artikel durchgelesen.
http://www.forbes.com/investmentnewsletters/2004/01/29/cz_jw…
"...With nanotech showing marked improvements in cancer treatments and the FDA showing interest in dendrimer technology, I wouldn`t be surprised if a major pharma company signs a partnership and licensing agreement with Starpharma in the next year ...
Meintest du diese Stelle? Da denkst du dann aber einen Schritt weiter, oder habe ich irgendetwas übersehen? Ich meine, du hast Recht: Das wäre natürlich der Hammer!
Gruß, greenhorn
Ich stehe gerade etwas auf dem Schlauch. Wo steht denn, dass Forbes vermutet, dass Medikamente, die auf der Dendrimer-Technologie basieren, generellen Fast-Track-Status erhelten könnten? Ich habe mir sowohl deinen Auszug (#117), als auch noch einmal den gesamten Artikel durchgelesen.
http://www.forbes.com/investmentnewsletters/2004/01/29/cz_jw…
"...With nanotech showing marked improvements in cancer treatments and the FDA showing interest in dendrimer technology, I wouldn`t be surprised if a major pharma company signs a partnership and licensing agreement with Starpharma in the next year ...
Meintest du diese Stelle? Da denkst du dann aber einen Schritt weiter, oder habe ich irgendetwas übersehen? Ich meine, du hast Recht: Das wäre natürlich der Hammer!
Gruß, greenhorn
Kommando zurück, ich stehe nicht mehr auf dem Schlauch! Entschuldigung, manchmal dauert es etwas länger bei mir
Man muss sich einfach mal eine halbe Stunde Zeit nehmen.
http://www.forbes.com/investmentnewsletters/2004/03/04/cz_jw…
Wie gesagt, das wäre der Hammer!!!
Gruß, greenhorn
Man muss sich einfach mal eine halbe Stunde Zeit nehmen.
http://www.forbes.com/investmentnewsletters/2004/03/04/cz_jw…
Wie gesagt, das wäre der Hammer!!!
Gruß, greenhorn
@Neoe
unter #1 hattest Du die DENDRIMERIE als "weiss-ich-was" genannt,
allerings stehen dort keinerlei Infos darüber, was dieses Gebiet eigentlich ist und kann
Bitte um Aufklärung
R.R.
unter #1 hattest Du die DENDRIMERIE als "weiss-ich-was" genannt,
allerings stehen dort keinerlei Infos darüber, was dieses Gebiet eigentlich ist und kann
Bitte um Aufklärung
R.R.
@MrRipley
Das kann man doch alles wunderprächtig auf der starpharma webseite http://www.starpharma.com nachlesen
Dendrimere sind globuläre starkverzweigte Makromoleküle. Man muss sich das wie einen Ball vorstellen, der nur aus Verzweigungen besteht. An den Enden dieser Zweige sitzen dann die funktionenllen Gruppen, die später die mit Zellen oder so agieren sollen
Das kann man doch alles wunderprächtig auf der starpharma webseite http://www.starpharma.com nachlesen
Dendrimere sind globuläre starkverzweigte Makromoleküle. Man muss sich das wie einen Ball vorstellen, der nur aus Verzweigungen besteht. An den Enden dieser Zweige sitzen dann die funktionenllen Gruppen, die später die mit Zellen oder so agieren sollen
Hallo zusammen!
Ich denke, wir haben einiges zu erwarten:
16 March 2004 STARPHARMA SUSPENDS TRADING PENDING CHANGE OF PDF STATUS Melbourne (Australia) 16 March 2004:
Starpharma Pooled Development Limited (ASX:SPL) has announced that it will be voluntarily handing back its pooled development fund licence. The company held a General Meeting of shareholders on 22nd January 2004 to seek shareholder approval for a proposal to give Directors the discretion to relinquish the company’s status as a PDF. Shareholders voted strongly in support of the proposal, which the Board had indicated would only proceed if circumstances arose where it was considered to be in the best interests of shareholders. The company now has an opportunity to make a follow-on investment in the US based entity Dendritic Nanotechnologies, Inc. (DNT). However as it is currently a PDF, Starpharma is prohibited from increasing its investment or participating in any US-based “spin-offs”. The Directors have therefore decided that it is now an appropriate time to seek revocation of the PDF registration. The Company has requested the ASX place its securities in pre-open, and has immediately applied to the Pooled Development Funds Registration Board to have the PDF registration declaration revoked. It is not known when the PDF Registration Board will make its decision. However the company will request the ASX to remove the trading halt as soon as the decision of the PDF Registration Board is received. When the PDF registration declaration is revoked, the name of the company will be changed to Starpharma Holdings Ltd. The company will write to all shareholders advising them of the application and the decision of the PDF registration board. Further details regarding any follow-on investment in DNT or spin-off entities will be announced as soon as possible. Starpharma Pooled Development Limited (SPL) is a registered pooled development fund with investments in wholly owned subsidiary biopharmaceutical companies focused on the development and application of dendrimer nanotechnologies as drugs against major diseases. SPL also has a 49.9% equity in a US based company – Dendritic Nanotechnologies, Inc. (DNT) – established with the US pioneer of dendrimer nanotechnology Dr Donald Tomalia. CONTACTS: Dr John Raff Mr Ben Rogers Chief Executive Officer Company Secretary +61 3 8532 2701 +61 3 8532 2702 www.starpharma.com
Wie muss man sich denn jetzt als Aktionär im fernen Deutschland verhalten? Ändert sich die WKN? Geht das alles bankentechnisch automatisch?
Gruß, greenhorn
Ich denke, wir haben einiges zu erwarten:
16 March 2004 STARPHARMA SUSPENDS TRADING PENDING CHANGE OF PDF STATUS Melbourne (Australia) 16 March 2004:
Starpharma Pooled Development Limited (ASX:SPL) has announced that it will be voluntarily handing back its pooled development fund licence. The company held a General Meeting of shareholders on 22nd January 2004 to seek shareholder approval for a proposal to give Directors the discretion to relinquish the company’s status as a PDF. Shareholders voted strongly in support of the proposal, which the Board had indicated would only proceed if circumstances arose where it was considered to be in the best interests of shareholders. The company now has an opportunity to make a follow-on investment in the US based entity Dendritic Nanotechnologies, Inc. (DNT). However as it is currently a PDF, Starpharma is prohibited from increasing its investment or participating in any US-based “spin-offs”. The Directors have therefore decided that it is now an appropriate time to seek revocation of the PDF registration. The Company has requested the ASX place its securities in pre-open, and has immediately applied to the Pooled Development Funds Registration Board to have the PDF registration declaration revoked. It is not known when the PDF Registration Board will make its decision. However the company will request the ASX to remove the trading halt as soon as the decision of the PDF Registration Board is received. When the PDF registration declaration is revoked, the name of the company will be changed to Starpharma Holdings Ltd. The company will write to all shareholders advising them of the application and the decision of the PDF registration board. Further details regarding any follow-on investment in DNT or spin-off entities will be announced as soon as possible. Starpharma Pooled Development Limited (SPL) is a registered pooled development fund with investments in wholly owned subsidiary biopharmaceutical companies focused on the development and application of dendrimer nanotechnologies as drugs against major diseases. SPL also has a 49.9% equity in a US based company – Dendritic Nanotechnologies, Inc. (DNT) – established with the US pioneer of dendrimer nanotechnology Dr Donald Tomalia. CONTACTS: Dr John Raff Mr Ben Rogers Chief Executive Officer Company Secretary +61 3 8532 2701 +61 3 8532 2702 www.starpharma.com
Wie muss man sich denn jetzt als Aktionär im fernen Deutschland verhalten? Ändert sich die WKN? Geht das alles bankentechnisch automatisch?
Gruß, greenhorn
Hier die letzten News:
http://www.asx.com.au/asxpdf/20040318/pdf/3l0k8448lsf10.pdf
BTC-Stellungnahme zur Transaktion:
http://www.asx.com.au/asxpdf/20040318/pdf/3l0k9jk516zwg.pdf
Was ändert sich durch die Aufhebung des PDF-Status:
http://www.asx.com.au/asxpdf/20040318/pdf/3l0v1kkfxrksv.pdf
http://www.asx.com.au/asxpdf/20040318/pdf/3l0k8448lsf10.pdf
BTC-Stellungnahme zur Transaktion:
http://www.asx.com.au/asxpdf/20040318/pdf/3l0k9jk516zwg.pdf
Was ändert sich durch die Aufhebung des PDF-Status:
http://www.asx.com.au/asxpdf/20040318/pdf/3l0v1kkfxrksv.pdf
Sieht so aus als würde es bei Dendritic endlich zu Veränderungen kommen. Ich erwarte im nächsten Quartal einen/einige Spin-off(s), vermutlich wird sich Starpharma direkt beteiligen.
Dendritic könnte ihre neuen Projekte mit mächtig großen Namen im Schlepptau beginnen.
Dendritic könnte ihre neuen Projekte mit mächtig großen Namen im Schlepptau beginnen.
So ein unfug 110 Euro Orderentgeld ich habe beim Kauf von Starpharma WKN 796461 beim S Broker 12,50 Euro Ordergeld bezahlt
mfg
Bully80
mfg
Bully80
bully80:
Zu der Zeit als ich in Starpharma eingestiegen bin, zahlte man 110 Euro Ordergebühren, da die Aktien damals nur in Australien handelbar waren. Der Kurs lag damals bei rund 0,2 Euro (umgerechnet).
Du zahlst 12,5 Euro Gebühren und gute 0,5 Euro pro Aktie.
Die Zeiten haben sich geändert, aber auf mein Eröffnungsposting habe ich natürlich keinen Einfluss mehr, dass wirst du verstehen.
Zu der Zeit als ich in Starpharma eingestiegen bin, zahlte man 110 Euro Ordergebühren, da die Aktien damals nur in Australien handelbar waren. Der Kurs lag damals bei rund 0,2 Euro (umgerechnet).
Du zahlst 12,5 Euro Gebühren und gute 0,5 Euro pro Aktie.
Die Zeiten haben sich geändert, aber auf mein Eröffnungsposting habe ich natürlich keinen Einfluss mehr, dass wirst du verstehen.
Hallo zusammen!
Article on Starpharma in theage.com.au
Starpharma places its future in good hands
By Eli Greenblat
March 19, 2004
Starpharma Holdings has attracted respected investment company Biotech Capital plus a crew of institutional investors to its $7.56 million share placement, as the Melbourne-based drug developer gears up to expand its promising US nanotechnology subsidiary.
The shares were placed with institutional clients of Michael Kroger`s JT Campbell & Company, which acted as lead manager and placement agent.
It is believed that the investors who took up the 9 million shares at 84ў each included Queensland Investment Company, AMP and ING. Biotech Capital also took up $2.5 million of Starpharma shares to become one of its biggest shareholders with a stake of 3.9 per cent.
Shares in Starpharma closed up 3ў at 93ў yesterday.
Starpharma chief executive John Raff said a majority of the newly raised funds would be directed towards corporate opportunities arising from its investee company, Dendritic Nanotechnologies. Starpharma is DNT`s biggest shareholder with a stake of 49.9 per cent. The subsidiary has gained worldwide attention as a leader in using dendrimer nanotechnology to create powerful new pharmaceutical applications.
Nanotechnology is the manipulation of matter, molecule by molecule, to create new materials with novel, tailored properties. Dendrimers can be designed to be similar in size to biological structures, such as proteins, and are suitable for the development of pharmaceuticals with unique activities, or for creating new and improved forms of existing drugs.
"We remain excited at the commercial opportunities . . . in both the short and longer term," Dr Raff said.
Einen schönen Abend wünscht ein sehr optimistischen greenhorn, das auch seit 0,34 AUD (damaliger Umrechnungskurs 0,20 EUR) dabei ist und ebenfalls über 100 Euro Gebühr zahlen musste. Und über das erste Posting dieser Diskussion freue ich mich noch immer, Neoe!
Article on Starpharma in theage.com.au
Starpharma places its future in good hands
By Eli Greenblat
March 19, 2004
Starpharma Holdings has attracted respected investment company Biotech Capital plus a crew of institutional investors to its $7.56 million share placement, as the Melbourne-based drug developer gears up to expand its promising US nanotechnology subsidiary.
The shares were placed with institutional clients of Michael Kroger`s JT Campbell & Company, which acted as lead manager and placement agent.
It is believed that the investors who took up the 9 million shares at 84ў each included Queensland Investment Company, AMP and ING. Biotech Capital also took up $2.5 million of Starpharma shares to become one of its biggest shareholders with a stake of 3.9 per cent.
Shares in Starpharma closed up 3ў at 93ў yesterday.
Starpharma chief executive John Raff said a majority of the newly raised funds would be directed towards corporate opportunities arising from its investee company, Dendritic Nanotechnologies. Starpharma is DNT`s biggest shareholder with a stake of 49.9 per cent. The subsidiary has gained worldwide attention as a leader in using dendrimer nanotechnology to create powerful new pharmaceutical applications.
Nanotechnology is the manipulation of matter, molecule by molecule, to create new materials with novel, tailored properties. Dendrimers can be designed to be similar in size to biological structures, such as proteins, and are suitable for the development of pharmaceuticals with unique activities, or for creating new and improved forms of existing drugs.
"We remain excited at the commercial opportunities . . . in both the short and longer term," Dr Raff said.
Einen schönen Abend wünscht ein sehr optimistischen greenhorn, das auch seit 0,34 AUD (damaliger Umrechnungskurs 0,20 EUR) dabei ist und ebenfalls über 100 Euro Gebühr zahlen musste. Und über das erste Posting dieser Diskussion freue ich mich noch immer, Neoe!
Ich noch mal.
Ich habe vor einigen Wochen eine Mail an Starpharma geschrieben, weil jüngst vermehrt Fragen bezüglich der Anwendung von VivaGel aufgekommen sind. Zumindest im ehemaligen "Aktie im Fokus-Forum". Habe mir erlaubt die Fragestellung zu erweitern und habe vor kurzem Antwort bekommen.
Dear xxxx,
the initial indication we are investigating for VivaGel is the protection of women from infection with HIV and sexually transmitted infections (e.g. genital herpes, Chlamydia) following vaginal sexual intercourse. The woman will place the gel in her vagina prior to sexual intercourse either with or without the knowledge of the male partner. As such this product concept will give women control over managing her risk of HIV and STI infection. While the product is intended to be used with a condom, in reality condom use is a male dominated decision. If the male chooses not to use a condom, the woman often either can’t or will not negotiate for condom use. Microbicides such as VivaGel are intended to be a female controlled HIV and STI prevention strategy irrespective of whether a condom is used.
Focus group studies conducted in the United States show a high degree of interest in this type of product concept. In addition, there are obviously many other medications that are applied intravaginally (e.g. antibacterials, antifungals, vaginal moisturizers etc) as well as the use of personal lubricants, so we don’t feel that the route of administration will be a barrier to acceptance. We are also investigating the use of VivaGel or a related formulation as a rectal microbicide to protect men as well as women who participate in anal intercourse.
Our presentation at the Nano/Bio Convergence 2004 conference will detail our dendrimer drug discovery program and focus on the processes and results that lead to the identification of SPL7013 and the commencement of clinical trials of VivaGel (SPL7013 Gel). It will also provide an illustrative example of how we are utilizing the development of our dendrimer platform technology in other disease states.
Thank you for your interest in Starpharma.
Regards,
Ben Rogers
Company Secretary
Starpharma Holdings Ltd
Gruß, greenhorn
Ich habe vor einigen Wochen eine Mail an Starpharma geschrieben, weil jüngst vermehrt Fragen bezüglich der Anwendung von VivaGel aufgekommen sind. Zumindest im ehemaligen "Aktie im Fokus-Forum". Habe mir erlaubt die Fragestellung zu erweitern und habe vor kurzem Antwort bekommen.
Dear xxxx,
the initial indication we are investigating for VivaGel is the protection of women from infection with HIV and sexually transmitted infections (e.g. genital herpes, Chlamydia) following vaginal sexual intercourse. The woman will place the gel in her vagina prior to sexual intercourse either with or without the knowledge of the male partner. As such this product concept will give women control over managing her risk of HIV and STI infection. While the product is intended to be used with a condom, in reality condom use is a male dominated decision. If the male chooses not to use a condom, the woman often either can’t or will not negotiate for condom use. Microbicides such as VivaGel are intended to be a female controlled HIV and STI prevention strategy irrespective of whether a condom is used.
Focus group studies conducted in the United States show a high degree of interest in this type of product concept. In addition, there are obviously many other medications that are applied intravaginally (e.g. antibacterials, antifungals, vaginal moisturizers etc) as well as the use of personal lubricants, so we don’t feel that the route of administration will be a barrier to acceptance. We are also investigating the use of VivaGel or a related formulation as a rectal microbicide to protect men as well as women who participate in anal intercourse.
Our presentation at the Nano/Bio Convergence 2004 conference will detail our dendrimer drug discovery program and focus on the processes and results that lead to the identification of SPL7013 and the commencement of clinical trials of VivaGel (SPL7013 Gel). It will also provide an illustrative example of how we are utilizing the development of our dendrimer platform technology in other disease states.
Thank you for your interest in Starpharma.
Regards,
Ben Rogers
Company Secretary
Starpharma Holdings Ltd
Gruß, greenhorn
Advectus(WKN:693000)=> STRONG BUY!!!
Absolute Einstiegspreise!
Charttechnisch die " Ruhe vor`m Sturm" !
Die Aktie u.a. im DAC - Fond!
-Advectus Life Sciences Inc. is an emerging life sciences company focused on the development and commercialization of processes using nanotechnology for the delivery of existing drugs across the blood-brain barrier to treat major and life-threatening diseases.
Absolute Einstiegspreise!
Charttechnisch die " Ruhe vor`m Sturm" !
Die Aktie u.a. im DAC - Fond!
-Advectus Life Sciences Inc. is an emerging life sciences company focused on the development and commercialization of processes using nanotechnology for the delivery of existing drugs across the blood-brain barrier to treat major and life-threatening diseases.
Hallo Leute!
Acorn Capital hat seinen Anteil an Starpharma noch einmal erhöht, wenn ich das richtig verstehe:
http://www.asx.com.au/
Der genaue Link funktioniert irgendwie nicht. Oder ich bin nicht in der Lage.
Müsst ihr vielleicht einmal "spl" bei "past company announcements" selber eingeben. Tut mir leid.
Einen schönen Sonntag noch!
Gruß, greenhorn
Acorn Capital hat seinen Anteil an Starpharma noch einmal erhöht, wenn ich das richtig verstehe:
http://www.asx.com.au/
Der genaue Link funktioniert irgendwie nicht. Oder ich bin nicht in der Lage.
Müsst ihr vielleicht einmal "spl" bei "past company announcements" selber eingeben. Tut mir leid.
Einen schönen Sonntag noch!
Gruß, greenhorn
Hi Neoe!
Ich wollte mal fragen, ob du irgendwas weißt bezüglich der BCC-Konferenz. Gibt es Neuigkeiten oder wann wird irgendetwas bekanntgegeben? Ist vielleicht schon was bekannt? Bin etwas verwirrt, dass ich nichts finden kann. Kann mir aber auch nicht vorstellen, dass es nichts zu finden gibt.
Naja. Vielleicht kannst du irgendwann kurz antworten.
Gruß, greenhorn
P.S.: Bin gerade eben über deine Prana-Diskussion im Biotech-Forum gestolpert. Sehr interessant.
Ich wollte mal fragen, ob du irgendwas weißt bezüglich der BCC-Konferenz. Gibt es Neuigkeiten oder wann wird irgendetwas bekanntgegeben? Ist vielleicht schon was bekannt? Bin etwas verwirrt, dass ich nichts finden kann. Kann mir aber auch nicht vorstellen, dass es nichts zu finden gibt.
Naja. Vielleicht kannst du irgendwann kurz antworten.
Gruß, greenhorn
P.S.: Bin gerade eben über deine Prana-Diskussion im Biotech-Forum gestolpert. Sehr interessant.
greenhorn:
Ich weiss nicht, ob du das schon gesehen hast:
http://www.bccresearch.com/nanobio2004/program.html
Wenn du dir das Programm des zweiten Tages genauer anschaust, siehst du das sowohl Dendritic (mit der Keynote von Svenson) und Starpharma an diesem Tag präsentierten.
Es hat mich verwundert das Dr.Thomalia nicht selbst anwesend war, wie ursprünglich erwartet wurde (wenn ich mich nicht täusche). So oder so wird man als Keynote-Speaker wohl weniger direkten bezug auf die eigene Company nehmen.
Starpharma hat, wenn sie streng nach Programm vorgingen, wohl auch nichts revolutionäres zu berichten gehabt. Bei VivaGel wird es ja auch erst wieder spannend, wenn die PhaseI abgeschlossen wird.
So erkläre ich mir jedenfalls die Ruhe (natürlich vor dem Sturm... )
Ich weiss nicht, ob du das schon gesehen hast:
http://www.bccresearch.com/nanobio2004/program.html
Wenn du dir das Programm des zweiten Tages genauer anschaust, siehst du das sowohl Dendritic (mit der Keynote von Svenson) und Starpharma an diesem Tag präsentierten.
Es hat mich verwundert das Dr.Thomalia nicht selbst anwesend war, wie ursprünglich erwartet wurde (wenn ich mich nicht täusche). So oder so wird man als Keynote-Speaker wohl weniger direkten bezug auf die eigene Company nehmen.
Starpharma hat, wenn sie streng nach Programm vorgingen, wohl auch nichts revolutionäres zu berichten gehabt. Bei VivaGel wird es ja auch erst wieder spannend, wenn die PhaseI abgeschlossen wird.
So erkläre ich mir jedenfalls die Ruhe (natürlich vor dem Sturm... )
Hi Neoe!
Danke für die prompte Antwort! Das Programm hatte ich gesehen (Posting 126), ich hatte auch Starpharma eine Mail geschickt und u.a. die Frage gestellt, was man von der Konferenz erwarten darf (Posting 147). Ich weiß auch nicht, was ich mir versprochen hatte. Auf keinen Fall in den Himmel schießende Kurse, mich wundert nur, dass man so gar nichts hört. Naja, warten wir es in Ruhe ab, da hast du recht. Ich freue mich auf den Sturm!
Bis zu den nächsten Neuigkeiten, oder vielleicht früher.
Gruß, greenhorn
Danke für die prompte Antwort! Das Programm hatte ich gesehen (Posting 126), ich hatte auch Starpharma eine Mail geschickt und u.a. die Frage gestellt, was man von der Konferenz erwarten darf (Posting 147). Ich weiß auch nicht, was ich mir versprochen hatte. Auf keinen Fall in den Himmel schießende Kurse, mich wundert nur, dass man so gar nichts hört. Naja, warten wir es in Ruhe ab, da hast du recht. Ich freue mich auf den Sturm!
Bis zu den nächsten Neuigkeiten, oder vielleicht früher.
Gruß, greenhorn
Hallo zusammen!
Ich denke, ich kann von mir behaupten, dass ich der englischen Sprache durchaus mächtig bin. Aber könnte mir vielleicht jemand kurz helfen? Ich habe im Nanalyze-Forum folgende Postings gefunden, mit denen ich nicht allzu viel anfangen kann. Ich bin halt auch kein Trader.
Da schrieb also jemand:
"I wrote this earlier for OBDCF it applies to Starpharma as well:
The reason the price goes up and down is because some people are making quick money on CHUMPS! I will explain, jus take a look @ nanovip.com and click the link for OBDCF on an "UP" day. You will find that it links you to CBS Marketwatch. What I noticed is that someone sometimes trades as little as 6 shares to push the PPS up and the next day you will see 12000 or so shares sell at a lower price. I think someone is illegally manipulating the price to take advantage of someone who does not do their DD. Anyway please go to these sites to confirm what I have been observing for the last couple of months especially with OBDCF and Starpharma. I`m really pretty sick by this and I think the SEC should be notified. Any feedback would be appreciated by all. Best wished!"
Und weiter:
"The following is proof that someone is trying to manipulate the stock! Who the hell sells 30 shares when the Broker commissions are much higher than the cost of the stock! This was copied from CBSMARKETWATCH.com today!!!! Look @ the volume!
Starpharma Pooled Dev Ltd (OTHER OTC) Profile News Chart Analyst Insider Financials Msgs SEC Options More
SPHRF Last: 0.55 Change: -0.05 -8.33% Volume: 30 5:21pm
4/14/2004 Choose your broker
Open: 0.55 Yield: n/a Shares Out: n/a
High: 0.55 P/E Ratio: n/a Market Cap: n/a
Low: 0.55 EPS: n/a 52wk High: 3/18/2004 0.73
Bid: n/a Ex Date: n/a 52wk Low: 4/8/2004 0.60
Ask: n/a Dividend: n/a Avg Volume: 10,800
Add to Alerts Add to My Portfolio Create SPHRF Alert at: $0.47 $0.63 ... Chart: 1dy 1mo 3mo 1yr
jeff silva"
Darauf zwei Antworten. Zum einen:
Brian79: That "volume: 30" is in thousands
Und:
Andreschilit: "Yup...I just checked my Scottrade trading platform and it listed today`s volume for SPHRF as 30,000."
Würde mich über kurze Antworten freuen.
Gruß, greenhorn
Ich denke, ich kann von mir behaupten, dass ich der englischen Sprache durchaus mächtig bin. Aber könnte mir vielleicht jemand kurz helfen? Ich habe im Nanalyze-Forum folgende Postings gefunden, mit denen ich nicht allzu viel anfangen kann. Ich bin halt auch kein Trader.
Da schrieb also jemand:
"I wrote this earlier for OBDCF it applies to Starpharma as well:
The reason the price goes up and down is because some people are making quick money on CHUMPS! I will explain, jus take a look @ nanovip.com and click the link for OBDCF on an "UP" day. You will find that it links you to CBS Marketwatch. What I noticed is that someone sometimes trades as little as 6 shares to push the PPS up and the next day you will see 12000 or so shares sell at a lower price. I think someone is illegally manipulating the price to take advantage of someone who does not do their DD. Anyway please go to these sites to confirm what I have been observing for the last couple of months especially with OBDCF and Starpharma. I`m really pretty sick by this and I think the SEC should be notified. Any feedback would be appreciated by all. Best wished!"
Und weiter:
"The following is proof that someone is trying to manipulate the stock! Who the hell sells 30 shares when the Broker commissions are much higher than the cost of the stock! This was copied from CBSMARKETWATCH.com today!!!! Look @ the volume!
Starpharma Pooled Dev Ltd (OTHER OTC) Profile News Chart Analyst Insider Financials Msgs SEC Options More
SPHRF Last: 0.55 Change: -0.05 -8.33% Volume: 30 5:21pm
4/14/2004 Choose your broker
Open: 0.55 Yield: n/a Shares Out: n/a
High: 0.55 P/E Ratio: n/a Market Cap: n/a
Low: 0.55 EPS: n/a 52wk High: 3/18/2004 0.73
Bid: n/a Ex Date: n/a 52wk Low: 4/8/2004 0.60
Ask: n/a Dividend: n/a Avg Volume: 10,800
Add to Alerts Add to My Portfolio Create SPHRF Alert at: $0.47 $0.63 ... Chart: 1dy 1mo 3mo 1yr
jeff silva"
Darauf zwei Antworten. Zum einen:
Brian79: That "volume: 30" is in thousands
Und:
Andreschilit: "Yup...I just checked my Scottrade trading platform and it listed today`s volume for SPHRF as 30,000."
Würde mich über kurze Antworten freuen.
Gruß, greenhorn
greenhorn:
Geht sowieso um die Pinksheets in Amiland, kann uns also egal sein.
Etwaige Kursmanipulationen sind natürlich möglich, aber an der OTC zwimal so schwer nachweisbar und da der Kurs in Australien gemacht wird, sowieso völlig unwichtig.
Geht sowieso um die Pinksheets in Amiland, kann uns also egal sein.
Etwaige Kursmanipulationen sind natürlich möglich, aber an der OTC zwimal so schwer nachweisbar und da der Kurs in Australien gemacht wird, sowieso völlig unwichtig.
die Aktie wird heute mit halten in Focusmoney erwähnt
Okay, okay! Ich gebe zu, dass ich das aus dem Nanalyze-Forum übernommen habe. Ich hoffe ihr seid nicht zu streng mit mir
Der User brian schrieb:
To those who don`t know Dendritic Nanotechnologies (DNT) , is 49.9% owned by Starpharma (SPL.AX), and they are planning to purchase more for a majority stake.
This is what Josh Wolfe has to say about DNT in the April 2004 edition of Forbes Nanotech Report:
"Dendritic Nanotechnologies is a new
company, founded by Donald Tomalia of
Central Michigan University (see Companies
to Watch, May 2004). Dendrimers are a type
of polymer that are synthesized from a central
point, like a nano-sized pom-pom with
branches. They can be created with specific
characteristics like charge, binding properties
or solubility. Dendritic is working with MIT
chemical engineering professor Paula Hammond
and the Army Research Laboratory at
Aberdeen, Maryland, to create dendrimer-
based creams to protect soldiers from biological
and chemical warfare agents."
I’ve got a feeling big news will be coming from them soon."
Naja, dann warten wir das doch mal ab, mit den "big news"
Gruß, greenhorn
Der User brian schrieb:
To those who don`t know Dendritic Nanotechnologies (DNT) , is 49.9% owned by Starpharma (SPL.AX), and they are planning to purchase more for a majority stake.
This is what Josh Wolfe has to say about DNT in the April 2004 edition of Forbes Nanotech Report:
"Dendritic Nanotechnologies is a new
company, founded by Donald Tomalia of
Central Michigan University (see Companies
to Watch, May 2004). Dendrimers are a type
of polymer that are synthesized from a central
point, like a nano-sized pom-pom with
branches. They can be created with specific
characteristics like charge, binding properties
or solubility. Dendritic is working with MIT
chemical engineering professor Paula Hammond
and the Army Research Laboratory at
Aberdeen, Maryland, to create dendrimer-
based creams to protect soldiers from biological
and chemical warfare agents."
I’ve got a feeling big news will be coming from them soon."
Naja, dann warten wir das doch mal ab, mit den "big news"
Gruß, greenhorn
orawan:
Starpharma ist minimum ein Kauf
Starpharma ist minimum ein Kauf
greenhorn:
Das wundert mich, was Wolfe da erzählt. Ich habe zwar gerade keine Zeit nachzustöbern, aber ich meine mich erinnern zu können, dass auf der Dendritic-Website eine PDF abzturufen war, in der Dendritic Nanotech seine Know-How im Bereich Sensorenentwicklung einbringen sollte.
Lohnt sich auf jeden Fall nochmal nachzuschauen.
P.S.: Wann machst du den Theratech-Thread auf ?
Das wundert mich, was Wolfe da erzählt. Ich habe zwar gerade keine Zeit nachzustöbern, aber ich meine mich erinnern zu können, dass auf der Dendritic-Website eine PDF abzturufen war, in der Dendritic Nanotech seine Know-How im Bereich Sensorenentwicklung einbringen sollte.
Lohnt sich auf jeden Fall nochmal nachzuschauen.
P.S.: Wann machst du den Theratech-Thread auf ?
greenhorn:
Hab nochmal nachgeschaut. In der folgenden PDF-Datei auf Seite 3 steht was zur Aufgabe von Dendritic Nanotech drin.
Obwohl keine klare Aussage gemacht wird, werden trotzdem lediglich Sensoren als Anwendungsgebiet der DNT-Technik benannt.
http://www.starpharma.com/PDFs/030526_DNT_MIT_NanoSoldier.pd…
Hab nochmal nachgeschaut. In der folgenden PDF-Datei auf Seite 3 steht was zur Aufgabe von Dendritic Nanotech drin.
Obwohl keine klare Aussage gemacht wird, werden trotzdem lediglich Sensoren als Anwendungsgebiet der DNT-Technik benannt.
http://www.starpharma.com/PDFs/030526_DNT_MIT_NanoSoldier.pd…
Hi Neoe!
"Dendritic Nanotechnologies Inc., a dendrimer company based in Michigan, will focus its partnership with ISN on polymers with highly branched structures that can be used to isolate specific biological or synthatic nanostructures. Such polymers may have applications as sensors for chemical and biological threats, for example."
Du hast natürlich Recht, wenn du sagst, dass lediglich Sensoren explizit benannt werden. Ich würde allerdings den Schwerpunkt deines Postings auf "keine klare Aussage" legen. Die PDF ist bezüglich DNT in der Kürze doch sehr schwammig formuliert und lässt meiner Meinung nach doch einigen Spielraum.
Naja, einen schönen Sonntag noch!
Gruß, greenhorn
"Dendritic Nanotechnologies Inc., a dendrimer company based in Michigan, will focus its partnership with ISN on polymers with highly branched structures that can be used to isolate specific biological or synthatic nanostructures. Such polymers may have applications as sensors for chemical and biological threats, for example."
Du hast natürlich Recht, wenn du sagst, dass lediglich Sensoren explizit benannt werden. Ich würde allerdings den Schwerpunkt deines Postings auf "keine klare Aussage" legen. Die PDF ist bezüglich DNT in der Kürze doch sehr schwammig formuliert und lässt meiner Meinung nach doch einigen Spielraum.
Naja, einen schönen Sonntag noch!
Gruß, greenhorn
greenhorn:
Je mehr sie machen, desto besser. Es ist nur von besonderem Interesse, da ja Starpharma schliesslich die Rechte an allen medizinischen Anwendungen und Neuentwicklungen hat. Hätte Wolfe recht, würde das von meiner Seite die Frage aufwerfen, inwiefern Starpharma indirekt an dem Projekt oder an den Lorbeeren beteiligt ist (mal abgesehen von der Beteiligung an Dendritic selbst)???
Wenn ich es nicht geträumt habe, hat man bei Starpharma mal irgendwas zur Zusammenarbeit mit US-Behörden gesagt, was mich damals etwas verwundert hat, da mir sonst bisher nichts davon bekannt war. Lohnt sich nochmal nachzuschauen.
Je mehr sie machen, desto besser. Es ist nur von besonderem Interesse, da ja Starpharma schliesslich die Rechte an allen medizinischen Anwendungen und Neuentwicklungen hat. Hätte Wolfe recht, würde das von meiner Seite die Frage aufwerfen, inwiefern Starpharma indirekt an dem Projekt oder an den Lorbeeren beteiligt ist (mal abgesehen von der Beteiligung an Dendritic selbst)???
Wenn ich es nicht geträumt habe, hat man bei Starpharma mal irgendwas zur Zusammenarbeit mit US-Behörden gesagt, was mich damals etwas verwundert hat, da mir sonst bisher nichts davon bekannt war. Lohnt sich nochmal nachzuschauen.
Hallo!
Endlich mal wieder was Neues!
Starpharma Drug for Prevention of HIV in Phase 1 Clinical Study – Advancing to Second Stage
Melbourne (Australia), 27 April 2004: Starpharma Holdings Limited (ASX:SPL) is pleased to announce that the current Phase 1 study for its investigational new drug for the prevention of HIV is advancing to the second stage in dose escalating studies underway in Adelaide, Australia. This study, involving the administration of different formulation strengths of the investigational drug SPL7013 gel, is the first assessment of the drug’s safety in humans and results will help determine the appropriate gel strengths for future clinical trials. A group of healthy women has to date been dosed with SPL7013 at 0.5% gel strength and the placebo gel. The study remains blinded and therefore it is not known which subjects received the active at this stage. Data relating to blood and urine chemistry, the impact of the gel on vaginal microflora, and the impact of the gel on the lining of the vagina and cervix was collected from all women in the first group. After reviewing this data, the clinical trial Drug Safety Monitoring Board (DSMB) concluded that the SPL7013 gel strength could be escalated to the next level. The DSMB consists of the Principal Investigator, the study medical monitor, CMAX representatives, Starpharma representatives and Starpharma’s US Agent for FDA purposes. Today, the second stage of the Phase 1 Study is commencing. This involves administration of SPL7013 at 1.0% gel strength and placebo gel to a second group of healthy women. The clinical trial, which is being performed under a US Food and Drug Administration (FDA) Investigational New Drug (IND) application, is being conducted at CMAX, a Division of IDT Australia Ltd, in Adelaide. Further progress updates will be made as the trial continues. Starpharma Holdings Limited (ASX:SPL) is focused on the development and application of dendrimer nanotechnologies as drugs against major diseases. Starpharma’s lead dendrimer product, VivaGel™ has received clearance from the US FDA for human clinical trials. VivaGel™ is a topical microbicide gel product that has been developed for women as a preventative against the sexual transmission of HIV. It is also active in animal studies for the prevention of other sexually transmitted diseases including Genital Herpes and Chlamydia. SPL also has an equity interest in a US based company – Dendritic Nanotechnologies Inc. (DNT) – established with the US pioneer of dendrimer nanotechnology Dr Donald Tomalia. CONTACTS: Dr John Raff Mr Ben Rogers Chief Executive Officer Company Secretary +61 3 8532 2701 +61 3 8532 2702 www.starpharma.com
Grüße cristrader
Endlich mal wieder was Neues!
Starpharma Drug for Prevention of HIV in Phase 1 Clinical Study – Advancing to Second Stage
Melbourne (Australia), 27 April 2004: Starpharma Holdings Limited (ASX:SPL) is pleased to announce that the current Phase 1 study for its investigational new drug for the prevention of HIV is advancing to the second stage in dose escalating studies underway in Adelaide, Australia. This study, involving the administration of different formulation strengths of the investigational drug SPL7013 gel, is the first assessment of the drug’s safety in humans and results will help determine the appropriate gel strengths for future clinical trials. A group of healthy women has to date been dosed with SPL7013 at 0.5% gel strength and the placebo gel. The study remains blinded and therefore it is not known which subjects received the active at this stage. Data relating to blood and urine chemistry, the impact of the gel on vaginal microflora, and the impact of the gel on the lining of the vagina and cervix was collected from all women in the first group. After reviewing this data, the clinical trial Drug Safety Monitoring Board (DSMB) concluded that the SPL7013 gel strength could be escalated to the next level. The DSMB consists of the Principal Investigator, the study medical monitor, CMAX representatives, Starpharma representatives and Starpharma’s US Agent for FDA purposes. Today, the second stage of the Phase 1 Study is commencing. This involves administration of SPL7013 at 1.0% gel strength and placebo gel to a second group of healthy women. The clinical trial, which is being performed under a US Food and Drug Administration (FDA) Investigational New Drug (IND) application, is being conducted at CMAX, a Division of IDT Australia Ltd, in Adelaide. Further progress updates will be made as the trial continues. Starpharma Holdings Limited (ASX:SPL) is focused on the development and application of dendrimer nanotechnologies as drugs against major diseases. Starpharma’s lead dendrimer product, VivaGel™ has received clearance from the US FDA for human clinical trials. VivaGel™ is a topical microbicide gel product that has been developed for women as a preventative against the sexual transmission of HIV. It is also active in animal studies for the prevention of other sexually transmitted diseases including Genital Herpes and Chlamydia. SPL also has an equity interest in a US based company – Dendritic Nanotechnologies Inc. (DNT) – established with the US pioneer of dendrimer nanotechnology Dr Donald Tomalia. CONTACTS: Dr John Raff Mr Ben Rogers Chief Executive Officer Company Secretary +61 3 8532 2701 +61 3 8532 2702 www.starpharma.com
Grüße cristrader
@Cristrader
Schön dich hier im Thread zu sehen
Freue mich auf deine Analysen in gewohnter Qualität.
Grüße derschweizer
Schön dich hier im Thread zu sehen
Freue mich auf deine Analysen in gewohnter Qualität.
Grüße derschweizer
Hört sich alles gut an, im Moment würde mich aber brennend interessieren, was Starpharma und Dendritic Nanotech (gemeinsam) ausbrüten. Ich hab mich vorsichtshalber vor ein paar Tagen nochmal ein bißechen eingedeckt
http://www.starpharma.com/PDFs/040428%20App%204C.pdf
QUARTERLY CASH FLOW REPORT - PERIOD ENDED 31 MARCH 2004
Attached is the Appendix 4C – Quarterly Cashflow Report for Starpharma Holdings
Ltd (ASX:SPL) for the quarter ended 31 March 2004.
The net cash balance increased by $5.7 million due to a capital raising during the
quarter. On 18 March 2004 the Company announced a share placement of 9 million
new shares to leading Australian and international investors at an issue price of
$0.84, raising $7.18 million after costs.
Expenditure for the period was in line with budget, with a net operating outflow of
$1.4 million for the quarter. The cash balance at the end of the quarter was $17.5
million.
Grüße cristrader
QUARTERLY CASH FLOW REPORT - PERIOD ENDED 31 MARCH 2004
Attached is the Appendix 4C – Quarterly Cashflow Report for Starpharma Holdings
Ltd (ASX:SPL) for the quarter ended 31 March 2004.
The net cash balance increased by $5.7 million due to a capital raising during the
quarter. On 18 March 2004 the Company announced a share placement of 9 million
new shares to leading Australian and international investors at an issue price of
$0.84, raising $7.18 million after costs.
Expenditure for the period was in line with budget, with a net operating outflow of
$1.4 million for the quarter. The cash balance at the end of the quarter was $17.5
million.
Grüße cristrader
tut sich nicht viel bei unserer Perle. Konsolidierung vor dem nächsten Anstieg?
Schon etwas Älter, kurz bevor Dendritic Nanotech ins Leben gerufen wurde, aber schöne Info über Tomalia:
DENDRIMER`S DAD THINKS HE`S TAMED THE MONEY-MUNCHING MOLECULE
By Jayne Fried
Small Times Correspondent
July 26, 2001 – Back in 1979, Donald Tomalia discovered how to make synthetic molecules branch out like trees. But until recently, he has not been able to get money to grow the same way.
Now, the former Dow Chemical Co. chemist says he
Donald Tomalia discovered a way to bring
order to the artificial. Dendrimers grew with
uniformity, each time doubling the number of
tips, just like branches on a tree. The result
was the ability to produce precise, pristine,
pure macromolecules, with seemingly endless
possibilities for biological science.
nearly has the venture capital lined up to get his new company, Ann Arbor, Mich.-based Dendritic Sciences Inc., up and running. It`s this company, Tomalia says, that will help him realize his two-decade-old dream of using his discovery -- what he dubbed dendrimers -- for everything from drug delivery to nanoscale machines.
But about nine years ago, he had similar hopes that never materialized. In 1992, as co-founder of Dendritech Inc., he had said he was going to make dendrimers by the ton – a goal that he did not have the means to attain.
Tomalia was touting the virtues of a unique branch of chemistry that had the potential to clean up all the messy problems for scientists trying to recreate nature. Dendrimers are synthetic products built on the nanoscale. What they have is precision. Tomalia and his Dow co-workers stumbled on a way to translate the branched structures of trees into chemical structures. That`s where the name "dendra," a Greek word meaning tree, sprang up.
"I was trying to imitate the branch of a tree with polymers," Tomalia said.
The significance is that until then, polymers, which are long, unruly molecules used to produce plastics, paints and coatings, had ruled the world of artificial products. Polymers were chaotic and the way they were made resulted in molecules in a range of sizes.
But Tomalia had found a way to bring order to the artificial. Dendrimers grew with uniformity, each time doubling the number of tips, just like branches on a tree. The mass doubled with every generation.
The result was the ability to produce precise, pristine, pure macromolecules. By 1990, Tomalia`s discovery was dazzling the scientific community. The largest dendrimers, which could be the size of proteins in living cells, intrigued Tomalia with biological possibilities. The potential seemed endless. Dendrimers could be used to build microscopic capsules for drug delivery or to build nanoscale machines.
There was only one problem. And in the world of the small, it was a big problem. Money. The cost to produce dendrimers has been prohibitive and has not resulted in major commercial applications for the products. Tomalia has yet to make dendrimers by the ton.
"An incredible amount of science has gone into developing many, many different (dendrimer) structures, but I would say hope springs eternal in terms of substantive commercialization," said Robert Nowak, president and chief executive officer of the nonprofit Michigan Molecular Institute (MMI) and former director of central research and development and chief scientist for Dow Chemical.
"Dendrimers are incredibly expensive to make," Nowak said. "They intrigue scientists and polymer chemists who have never seen these structures, but we`ve been having a terrible difficulty finding what they are good for."
Dendrimers are so expensive because they grow in generations. The bigger they get, the more time it takes to grow them. For instance, a 10th generation dendrimer would have to go through 22 different chemical reactions. "That could take three months," Nowak said. And time is money.
"If you start getting up to the levels for gene therapy or amino assays, you can`t afford it," he said. The cost, for instance, for generation four Polyamidoamine dendrimers, which is a trade name for one type of the product that has the potential to be used as a drug delivery system, would be about $15,000 a pound, Nowak estimated.
Dr. James Baker Jr., chief of allergy and immunology at the University of Michigan, agreed. Baker has been doing work on dendrimers related to drug delivery. "This is ongoing research," Baker said, adding that most of the work now is at a "nascent" level. "We don`t view this as an explosive area right now."
Tomalia remains determined to prove the concept is a good one.
When he is not earning accolades in academia, Tomalia tends his 50-acre tree farm. "It`s these branching patterns of trees that have always fascinated me," he said. "I`ve been growing trees since I was a teen-ager.
"I was trying to imitate the branch of a tree with polymers," Tomalia said.
He became fascinated with the artificially manufactured synthetic molecules. "We filed patents extensively at Dow," Tomalia said. However, according to Tomalia, Dow didn`t see how dendrimers fit its business at the time."
"I really believed in the technology, so I asked for a leave of absence" to continue research, Tomalia said. That decision led him to MMI, which offered him his first taste in business. In 1992, he co-founded Dendritech, a subsidiary of MMI that was licensed by Dow to manufacture and sell certain types of dendrimers.
But last year, Dendritech imploded. Dow ended up acquiring Dendritech`s assets, which included the original patent portfolio licensed in 1991 to MMI, and new technology developed after Dendritech was incorporated, Nowak said.
The only commercial application that Dendritech sells for now is very small additive for ink jets. "A couple of companies still use that material, it seems to enhance some of the attributes of writing with ink, particularly in very moist environments," Nowak said.
Tomalia is no longer with Dendritech. In a deal recently struck with Dow, Tomalia said the giant chemical company gave him licensing rights globally for his science applications in dendrimers. In return, Tomalia said, he waived future royalty rights that he had. "So I waived those (royalty) rights in return for these patent rights." That created the basis for Dendritic Sciences, he said.
"We expect to be the premier producer of dendrimers by the end of the year," Tomalia said last week at a nanobiotechnology conference in San Diego. As for start-up capital, he said, "we`re talking multimillions we feel we`re close to, or will be."
During the conference, Tomalia told a Ph.D.-laden audience about the biomedical applications of a certain type of dendrimers that have all the qualities of proteins. The technology is "quite remarkable," Tomalia said. "I`m very excited."
DENDRIMER`S DAD THINKS HE`S TAMED THE MONEY-MUNCHING MOLECULE
By Jayne Fried
Small Times Correspondent
July 26, 2001 – Back in 1979, Donald Tomalia discovered how to make synthetic molecules branch out like trees. But until recently, he has not been able to get money to grow the same way.
Now, the former Dow Chemical Co. chemist says he
Donald Tomalia discovered a way to bring
order to the artificial. Dendrimers grew with
uniformity, each time doubling the number of
tips, just like branches on a tree. The result
was the ability to produce precise, pristine,
pure macromolecules, with seemingly endless
possibilities for biological science.
nearly has the venture capital lined up to get his new company, Ann Arbor, Mich.-based Dendritic Sciences Inc., up and running. It`s this company, Tomalia says, that will help him realize his two-decade-old dream of using his discovery -- what he dubbed dendrimers -- for everything from drug delivery to nanoscale machines.
But about nine years ago, he had similar hopes that never materialized. In 1992, as co-founder of Dendritech Inc., he had said he was going to make dendrimers by the ton – a goal that he did not have the means to attain.
Tomalia was touting the virtues of a unique branch of chemistry that had the potential to clean up all the messy problems for scientists trying to recreate nature. Dendrimers are synthetic products built on the nanoscale. What they have is precision. Tomalia and his Dow co-workers stumbled on a way to translate the branched structures of trees into chemical structures. That`s where the name "dendra," a Greek word meaning tree, sprang up.
"I was trying to imitate the branch of a tree with polymers," Tomalia said.
The significance is that until then, polymers, which are long, unruly molecules used to produce plastics, paints and coatings, had ruled the world of artificial products. Polymers were chaotic and the way they were made resulted in molecules in a range of sizes.
But Tomalia had found a way to bring order to the artificial. Dendrimers grew with uniformity, each time doubling the number of tips, just like branches on a tree. The mass doubled with every generation.
The result was the ability to produce precise, pristine, pure macromolecules. By 1990, Tomalia`s discovery was dazzling the scientific community. The largest dendrimers, which could be the size of proteins in living cells, intrigued Tomalia with biological possibilities. The potential seemed endless. Dendrimers could be used to build microscopic capsules for drug delivery or to build nanoscale machines.
There was only one problem. And in the world of the small, it was a big problem. Money. The cost to produce dendrimers has been prohibitive and has not resulted in major commercial applications for the products. Tomalia has yet to make dendrimers by the ton.
"An incredible amount of science has gone into developing many, many different (dendrimer) structures, but I would say hope springs eternal in terms of substantive commercialization," said Robert Nowak, president and chief executive officer of the nonprofit Michigan Molecular Institute (MMI) and former director of central research and development and chief scientist for Dow Chemical.
"Dendrimers are incredibly expensive to make," Nowak said. "They intrigue scientists and polymer chemists who have never seen these structures, but we`ve been having a terrible difficulty finding what they are good for."
Dendrimers are so expensive because they grow in generations. The bigger they get, the more time it takes to grow them. For instance, a 10th generation dendrimer would have to go through 22 different chemical reactions. "That could take three months," Nowak said. And time is money.
"If you start getting up to the levels for gene therapy or amino assays, you can`t afford it," he said. The cost, for instance, for generation four Polyamidoamine dendrimers, which is a trade name for one type of the product that has the potential to be used as a drug delivery system, would be about $15,000 a pound, Nowak estimated.
Dr. James Baker Jr., chief of allergy and immunology at the University of Michigan, agreed. Baker has been doing work on dendrimers related to drug delivery. "This is ongoing research," Baker said, adding that most of the work now is at a "nascent" level. "We don`t view this as an explosive area right now."
Tomalia remains determined to prove the concept is a good one.
When he is not earning accolades in academia, Tomalia tends his 50-acre tree farm. "It`s these branching patterns of trees that have always fascinated me," he said. "I`ve been growing trees since I was a teen-ager.
"I was trying to imitate the branch of a tree with polymers," Tomalia said.
He became fascinated with the artificially manufactured synthetic molecules. "We filed patents extensively at Dow," Tomalia said. However, according to Tomalia, Dow didn`t see how dendrimers fit its business at the time."
"I really believed in the technology, so I asked for a leave of absence" to continue research, Tomalia said. That decision led him to MMI, which offered him his first taste in business. In 1992, he co-founded Dendritech, a subsidiary of MMI that was licensed by Dow to manufacture and sell certain types of dendrimers.
But last year, Dendritech imploded. Dow ended up acquiring Dendritech`s assets, which included the original patent portfolio licensed in 1991 to MMI, and new technology developed after Dendritech was incorporated, Nowak said.
The only commercial application that Dendritech sells for now is very small additive for ink jets. "A couple of companies still use that material, it seems to enhance some of the attributes of writing with ink, particularly in very moist environments," Nowak said.
Tomalia is no longer with Dendritech. In a deal recently struck with Dow, Tomalia said the giant chemical company gave him licensing rights globally for his science applications in dendrimers. In return, Tomalia said, he waived future royalty rights that he had. "So I waived those (royalty) rights in return for these patent rights." That created the basis for Dendritic Sciences, he said.
"We expect to be the premier producer of dendrimers by the end of the year," Tomalia said last week at a nanobiotechnology conference in San Diego. As for start-up capital, he said, "we`re talking multimillions we feel we`re close to, or will be."
During the conference, Tomalia told a Ph.D.-laden audience about the biomedical applications of a certain type of dendrimers that have all the qualities of proteins. The technology is "quite remarkable," Tomalia said. "I`m very excited."
Aüßerst interessanter Artikel. Schaut euch mal das Fettgedruckte an, besonders unter dem Aspekt, dass Dendritic NAnotech den Herstellungsvorgang von Dendrimeren bereits durch neue Verfahren erheblich verbilligt hat:
Mar 31, 2003
CMU-based dendrimer company joins government-industry coalition aiming to help soldiers survive
By Steve Pardo
Michigansmalltech.com Correspondent
Donald Tomalia
A Mt. Pleasant company operating out of Central Michigan University has been accepted into an elite Massachusetts Institute of Technology consortium working on improvements to military gear that some day may help heal injured soldiers and keep them safe from chemical and biological weapons.
Dendritic Nanotechnologies Ltd., headed by Dr. Donald Tomalia, will be part of a handful of companies working to integrate nanotechnologies for the next generation of military ground troops.
"You know the science fiction of the past -- night vision, global positioning systems?" Tomalia said. "We`re going to be taking it to the next level with nanotechnology."
In March 2002, the U.S. Army awarded the Cambridge university $50 million over a five-year period to spearhead the program called the Institute for Soldier Nanotechnology (ISN). Industry will contribute an additional $40 million in funds and equipment. The goals range from creating lightweight molecular materials to improvements to uniforms and equipment.
The university is partnering with several other companies ranging from founding partners such as E.I. du Pont de Nemours & Co. down to small companies.
Eve Downing, outreach director of the program for MIT, said the university is still in negotiations with several companies and can`t talk specifics until the negotiations are concluded.
"We are looking for industrial partners," Downing said. "The army is very interested in seeing real products emerging from this program."
The university will work with the companies to create prototypes over the next few years and expects to be able to provide prototypes to the army within that time frame.
"We are in the process of recruiting additional partners that will bring a core competency to the ISN," Downing said.
The partnership with MIT involves a substantial amount of research money for the company, Tomalia said. He declined to be specific. It also gives Dendritic exposure to cutting-edge challenges, he added.
"We feel really pleased that we have been invited into the consortium," Tomalia said.
"We`re the smallest and youngest company invited out of a competitive field of more than 135 companies."
Partnering companies also will saddle some of the expenses or provide expertise.
For Dendritic, that means Tomalia will lecture on dendrimeric properties. Tomalia, the pioneer of dendrimer technology, is a distinguished research scientist and professor at Central Michigan University as well as the president and chief technical officer of Dendritic Nanotechnologies.
The company was started about eight months ago when a company founded by Tomalia, Dendritic Sciences Inc., joined with the Australian biotechnology company Starpharma.
Tomalia is the creator of dendrimers -- synthetic polymers with branching parts designed to function, among other things, as nanoscale vehicles for drug delivery. Dendrimers are so small that thousands of them fit the width of one human hair.
And although the applications of dendrimers -- discovered by Tomalia in 1979 -- have long promised a slew of practical applications, widespread commercial applications have been few -- so far.
Current research is focusing on applications for medical diagnostics, drug delivery and using a form of dendrimers to battle viruses such as HIV.
The dendrimers have the potential to be as big as previous plastics innovations over the last century, he said. The minute, branching strands could have as big an impact as nylon, synthetic rubber and polyethlene did when they were created, he said.
And business is booming, Tomalia said. Research demands are exceeding the amount of dendrimers the company can make.
"Right now, as you can imagine with a new architecture, every research group in the world wants to be a part of it," Tomalia said. "What we`re doing is trying to keep up with the research market, which is really crazy."
He said the company is currently "slightly above the break-even point." But, he added, the company is only eight months old and startup costs typically are expensive.
There are about 14 people working for the company. And the company plans to add another five or six employees -- people skilled in synthetic chemistry and nanoinstrumentation.
A sticking point still is cost. Dendrimers cost about $200-$300 a gram.
"The very first nylon ever made was expensive," he pointed out. "Critics throughout the world said it would never be big because it was too expensive. Some clever group or person will find a way."
And for Tomalia, who already is the inventor of more than 100 patents, will soon receive an additional award. The Society of Polymer Science, Japan awarded Tomalia the SPSJ award for outstanding achievement in polymer science and technology. Tomalia and his family will fly to Japan at the end of May to accept the award.
Mar 31, 2003
CMU-based dendrimer company joins government-industry coalition aiming to help soldiers survive
By Steve Pardo
Michigansmalltech.com Correspondent
Donald Tomalia
A Mt. Pleasant company operating out of Central Michigan University has been accepted into an elite Massachusetts Institute of Technology consortium working on improvements to military gear that some day may help heal injured soldiers and keep them safe from chemical and biological weapons.
Dendritic Nanotechnologies Ltd., headed by Dr. Donald Tomalia, will be part of a handful of companies working to integrate nanotechnologies for the next generation of military ground troops.
"You know the science fiction of the past -- night vision, global positioning systems?" Tomalia said. "We`re going to be taking it to the next level with nanotechnology."
In March 2002, the U.S. Army awarded the Cambridge university $50 million over a five-year period to spearhead the program called the Institute for Soldier Nanotechnology (ISN). Industry will contribute an additional $40 million in funds and equipment. The goals range from creating lightweight molecular materials to improvements to uniforms and equipment.
The university is partnering with several other companies ranging from founding partners such as E.I. du Pont de Nemours & Co. down to small companies.
Eve Downing, outreach director of the program for MIT, said the university is still in negotiations with several companies and can`t talk specifics until the negotiations are concluded.
"We are looking for industrial partners," Downing said. "The army is very interested in seeing real products emerging from this program."
The university will work with the companies to create prototypes over the next few years and expects to be able to provide prototypes to the army within that time frame.
"We are in the process of recruiting additional partners that will bring a core competency to the ISN," Downing said.
The partnership with MIT involves a substantial amount of research money for the company, Tomalia said. He declined to be specific. It also gives Dendritic exposure to cutting-edge challenges, he added.
"We feel really pleased that we have been invited into the consortium," Tomalia said.
"We`re the smallest and youngest company invited out of a competitive field of more than 135 companies."
Partnering companies also will saddle some of the expenses or provide expertise.
For Dendritic, that means Tomalia will lecture on dendrimeric properties. Tomalia, the pioneer of dendrimer technology, is a distinguished research scientist and professor at Central Michigan University as well as the president and chief technical officer of Dendritic Nanotechnologies.
The company was started about eight months ago when a company founded by Tomalia, Dendritic Sciences Inc., joined with the Australian biotechnology company Starpharma.
Tomalia is the creator of dendrimers -- synthetic polymers with branching parts designed to function, among other things, as nanoscale vehicles for drug delivery. Dendrimers are so small that thousands of them fit the width of one human hair.
And although the applications of dendrimers -- discovered by Tomalia in 1979 -- have long promised a slew of practical applications, widespread commercial applications have been few -- so far.
Current research is focusing on applications for medical diagnostics, drug delivery and using a form of dendrimers to battle viruses such as HIV.
The dendrimers have the potential to be as big as previous plastics innovations over the last century, he said. The minute, branching strands could have as big an impact as nylon, synthetic rubber and polyethlene did when they were created, he said.
And business is booming, Tomalia said. Research demands are exceeding the amount of dendrimers the company can make.
"Right now, as you can imagine with a new architecture, every research group in the world wants to be a part of it," Tomalia said. "What we`re doing is trying to keep up with the research market, which is really crazy."
He said the company is currently "slightly above the break-even point." But, he added, the company is only eight months old and startup costs typically are expensive.
There are about 14 people working for the company. And the company plans to add another five or six employees -- people skilled in synthetic chemistry and nanoinstrumentation.
A sticking point still is cost. Dendrimers cost about $200-$300 a gram.
"The very first nylon ever made was expensive," he pointed out. "Critics throughout the world said it would never be big because it was too expensive. Some clever group or person will find a way."
And for Tomalia, who already is the inventor of more than 100 patents, will soon receive an additional award. The Society of Polymer Science, Japan awarded Tomalia the SPSJ award for outstanding achievement in polymer science and technology. Tomalia and his family will fly to Japan at the end of May to accept the award.
Und eine sehr aktuelle Vorstellung Tomalias und seiner Aktivitäten:
http://www.chem.monash.edu.au/19racioc/Docs/Tomalia_Profile.…
http://www.chem.monash.edu.au/19racioc/Docs/Tomalia_Profile.…
Meine Güte, bei Starpharma geht ja im Moment richtig die Post ab. 5 % runter in Australien - und das bei 13000 gehandelten Aktien.
Was ist da drüben los?
Gruß, ein sehr optimistisches greenhorn
Was ist da drüben los?
Gruß, ein sehr optimistisches greenhorn
Hallo Greenhorn:
Die Sache, die mich bei Starpharma immer wieder froh stimmt, ist die Tatsache, dass ich hier auch bei fallenden Kurse nie ins Zweifeln komme, ob ich hier richtig investiert bin, so wie das bei meiner Risiko-Zockbude so der Fall ist. Das liegt einfach daran, dass Starpharma, wenn auch im Moment Funkstille sein mag, in der Vergangenheit schon genug Infos auf den Tisch gebracht hat, die das tatsächliche Potential dieser Aktie erahnen lässt.
Prognose "unter uns": bis 2008 steht sie bei 1X,XX Euro
Die Sache, die mich bei Starpharma immer wieder froh stimmt, ist die Tatsache, dass ich hier auch bei fallenden Kurse nie ins Zweifeln komme, ob ich hier richtig investiert bin, so wie das bei meiner Risiko-Zockbude so der Fall ist. Das liegt einfach daran, dass Starpharma, wenn auch im Moment Funkstille sein mag, in der Vergangenheit schon genug Infos auf den Tisch gebracht hat, die das tatsächliche Potential dieser Aktie erahnen lässt.
Prognose "unter uns": bis 2008 steht sie bei 1X,XX Euro
Hi Neoe!
Die fallenden Kurse bringen mich auch so überhaupt nicht aus der Ruhe. Erst Recht nicht, wenn das mit so gigantischem Volumen passiert, wie derzeit.
Da aber gerade tatsächlich nicht so viel los ist, finde ich es doch ganz interessant mal zu diskutieren, wo Starpharma in fünf bis zehn Jahren stehen könnte. So mal ganz unter uns und vor allen Dingen unverbindlich.
Ich weiß, ist auch nicht ganz meine Lieblingsbeschäftigung, mit Kurszielen um sich zu werfen. Man wird immer sehr gerne in die ein oder andere Ecke gedrängt. Pushen usw., darum geht es mir gar nicht.
Es sind 100 Millionen Aktien (so grob) ausgegeben, richtig?
Du hast geschrieben: "2008 - 1x,xx Euro" - wären dann im höchstfall knapp 2 Milliarden Marktkapitalisierung. (Natürlich muss man damit rechnen, dass weitere Aktien auf den Markt kommen.)
Beruht diese Schätzung auf VivaGel - wenn alles gut geht? Oder was beziehst du da alles ein?
Okay, vielleicht ist diese Diskussion wirklich etwas blödsinnig, aber eigentlich finde ich es ganz interessant mal darüber zu reden, wie das Potenzial eines Unternehmens eingeschätzt wird. Wenn es sachlich passiert. Aber dass wir das können, haben wir ja schon bewiesen.
Eine sehr entscheidende Frage ist ja auch, wie kange man überhaupt eine Aktie hält, mit der man mit mehreren hundert Prozent im Plus ist. Irgendwann lockt die Versuchung, zu verkaufen. Ich habe es nicht wirklich recherchiert, aber ich glaube die wenigsten Leute, die in den Anfängen in Microsoft investiert waren und auch vom Potenzial überzeugt waren, sind wirklich reich geworden - weil viel zu früh verkauft.
Gruß, greenhorn, das sich überlegt, bei weiter nachgebenden Kursen vielleicht noch mal nachzulegen.
Die fallenden Kurse bringen mich auch so überhaupt nicht aus der Ruhe. Erst Recht nicht, wenn das mit so gigantischem Volumen passiert, wie derzeit.
Da aber gerade tatsächlich nicht so viel los ist, finde ich es doch ganz interessant mal zu diskutieren, wo Starpharma in fünf bis zehn Jahren stehen könnte. So mal ganz unter uns und vor allen Dingen unverbindlich.
Ich weiß, ist auch nicht ganz meine Lieblingsbeschäftigung, mit Kurszielen um sich zu werfen. Man wird immer sehr gerne in die ein oder andere Ecke gedrängt. Pushen usw., darum geht es mir gar nicht.
Es sind 100 Millionen Aktien (so grob) ausgegeben, richtig?
Du hast geschrieben: "2008 - 1x,xx Euro" - wären dann im höchstfall knapp 2 Milliarden Marktkapitalisierung. (Natürlich muss man damit rechnen, dass weitere Aktien auf den Markt kommen.)
Beruht diese Schätzung auf VivaGel - wenn alles gut geht? Oder was beziehst du da alles ein?
Okay, vielleicht ist diese Diskussion wirklich etwas blödsinnig, aber eigentlich finde ich es ganz interessant mal darüber zu reden, wie das Potenzial eines Unternehmens eingeschätzt wird. Wenn es sachlich passiert. Aber dass wir das können, haben wir ja schon bewiesen.
Eine sehr entscheidende Frage ist ja auch, wie kange man überhaupt eine Aktie hält, mit der man mit mehreren hundert Prozent im Plus ist. Irgendwann lockt die Versuchung, zu verkaufen. Ich habe es nicht wirklich recherchiert, aber ich glaube die wenigsten Leute, die in den Anfängen in Microsoft investiert waren und auch vom Potenzial überzeugt waren, sind wirklich reich geworden - weil viel zu früh verkauft.
Gruß, greenhorn, das sich überlegt, bei weiter nachgebenden Kursen vielleicht noch mal nachzulegen.
Hallo Greenhorn:
Da berechne ich folgendes ein:
1. VivaGel
2. Lizenzeinnahmen aus Kooperationen mit Pharmas (z.B.
im Bereich Krebs könnte schon dieses Jahr eine
anlaufen)
3. IPO von Dendritic, schätzungsweise 2006
4. Kommerzialisierung der Forschungsresultate aus der
Neuseeland-Kooperation
5. Wenn, dann auf jeden Fall schon mal hoch dausend:
Genereller Fast-Track-Status für dendrimerbasierte
Medikamente
Da berechne ich folgendes ein:
1. VivaGel
2. Lizenzeinnahmen aus Kooperationen mit Pharmas (z.B.
im Bereich Krebs könnte schon dieses Jahr eine
anlaufen)
3. IPO von Dendritic, schätzungsweise 2006
4. Kommerzialisierung der Forschungsresultate aus der
Neuseeland-Kooperation
5. Wenn, dann auf jeden Fall schon mal hoch dausend:
Genereller Fast-Track-Status für dendrimerbasierte
Medikamente
Hi Neoe!
Hier noch einmal der Auszug aus dem Forbes-Artikel, in dem es um die Möglichkeit geht, die FDA könnte allen Dendrimer-basierten Wirkstoffen Fast-Track-Status verleihen:
"(...)
Looking Ahead To 2004
As we predicted last year, nanobiotechnology has seen tremendous advancements during 2003. Not only have quantum dots been embraced by the biotech community, but the leading orthopedic and dental care companies have shown quantum leaps in their technology, cancer companies like Triton Biosystems (see "Nanotech Takes On Cancer") continue to advance new nano-enabled therapeutics and even the Food and Drug Administration began to embrace nanotech when it approved Starpharma`s (otc:SPHRF) use of a dendrimer-based anti-AIDS gel. What`s in store for 2004? Here are two predictions:
1. NanoImprint Lithography (NIL) will be embraced by the semiconductor industry. It`s not nanobio, but NIL is just too large to ignore. NIL needs just improvements to defect densities and better alignment for widespread industry adoption. Companies like Sweden-based Obducat (otc:OBDCF) and Molecular Imprints will benefit.
2. The FDA will fast-track nano-enabled cancer treatment. Whether it`s dendrimer, magnetic nanoparticle/antibody, soluble Taxol, biosilicon or gold nanoparticles, nanotech-enabled cancer treatments are flooding the therapeutic drug pipelines. The National Cancer Institute recently made nanomedicine one of its top five priorities and we wouldn`t be surprised to see the FDA follow suit."
Für wie wahrscheinlich hälst du dieses Szenario denn? In welchem Zusammenhang könnte das passieren? Es ist ja nun wahrscheinlich so, dass Forbes nicht einfach so ins Blaue schießt. Natürlich hat diese Technologie enormes Potenzial, das ist ja hier schon besprochen worden (Danke nochmal, Neoe!!!). Passieren kann viel, aber anscheinend gibt es vielleicht so etwas wie Anzeichen dafür, die die FDA zu diesem Schritt bewegen könnte. Wie gesagt, Forbes wird das ja nicht einfach so behaupten, dass es diese Möglichkeit geben könnte.
Naja, wünsche eine schönen Tag und bis nachher mal.
Gruß, greenhorn
Hier noch einmal der Auszug aus dem Forbes-Artikel, in dem es um die Möglichkeit geht, die FDA könnte allen Dendrimer-basierten Wirkstoffen Fast-Track-Status verleihen:
"(...)
Looking Ahead To 2004
As we predicted last year, nanobiotechnology has seen tremendous advancements during 2003. Not only have quantum dots been embraced by the biotech community, but the leading orthopedic and dental care companies have shown quantum leaps in their technology, cancer companies like Triton Biosystems (see "Nanotech Takes On Cancer") continue to advance new nano-enabled therapeutics and even the Food and Drug Administration began to embrace nanotech when it approved Starpharma`s (otc:SPHRF) use of a dendrimer-based anti-AIDS gel. What`s in store for 2004? Here are two predictions:
1. NanoImprint Lithography (NIL) will be embraced by the semiconductor industry. It`s not nanobio, but NIL is just too large to ignore. NIL needs just improvements to defect densities and better alignment for widespread industry adoption. Companies like Sweden-based Obducat (otc:OBDCF) and Molecular Imprints will benefit.
2. The FDA will fast-track nano-enabled cancer treatment. Whether it`s dendrimer, magnetic nanoparticle/antibody, soluble Taxol, biosilicon or gold nanoparticles, nanotech-enabled cancer treatments are flooding the therapeutic drug pipelines. The National Cancer Institute recently made nanomedicine one of its top five priorities and we wouldn`t be surprised to see the FDA follow suit."
Für wie wahrscheinlich hälst du dieses Szenario denn? In welchem Zusammenhang könnte das passieren? Es ist ja nun wahrscheinlich so, dass Forbes nicht einfach so ins Blaue schießt. Natürlich hat diese Technologie enormes Potenzial, das ist ja hier schon besprochen worden (Danke nochmal, Neoe!!!). Passieren kann viel, aber anscheinend gibt es vielleicht so etwas wie Anzeichen dafür, die die FDA zu diesem Schritt bewegen könnte. Wie gesagt, Forbes wird das ja nicht einfach so behaupten, dass es diese Möglichkeit geben könnte.
Naja, wünsche eine schönen Tag und bis nachher mal.
Gruß, greenhorn
Ich noch mal!
May 2004 Forbes Nanotech Report
From Styrofoam cups to acrylic paint to polyester shirts, polymers are everywhere. Since the discoveries of Plexiglas and Nylon in the 1930s, polymers have raked in billions for companies like Rohm & Haas [ROH] and DuPont [DD].Now a new type of polymer is making its presence known: dendrimers. Unlike traditional polymers, which tend to grow in a linear chain, dendrimers grow out from a central point, like the branches of a tree. Chemists can precisely synthesize dendrimers with specific properties,
from reactivity to conductivity to toxicity. They can also be created with empty space inside that can be used to carry cargo. So a dendrimer could hold a hard-to-dissolve drug, carry that drug to a specific tissue in the body and then emit light when it reaches its target to tell a
doctor how much drug is being delivered.
The first dendrimer patents were awarded to Dow Chemical
[DOW] in the early 1980s, based on the work of Donald Tomalia. Tomalia is now president and CTO of Dendritic NanoTechnologies. His company is working on several defense-related applications, including creams to protect soldiers form chemical and biological warfare agents. He retains non-exclusive licensing rights to those old Dow
patents and DNT recently filed new patent applications aimed at reducing the cost of dendrimer production—rather than adding on each branch layer by layer, with purification steps in between, they can now do it all in one shot. DNT also recently opened their Dendrimer Store,
with a product line of more than 200 dendrimers for sale. Customers can buy directly from DNT or through Sigma-Aldrich [SIAL]. The company did $300,000 in sales during the fourth quarter of 2003. DNT also shares a $3 million joint grant from the Army Research Laboratory with Central Michigan University to establish the first National Center of Excellence for dendrimer research and development.
Founding Dendritic NanoTechnologies investor Starpharma
[SPL.AX] (see Companies to Watch, December 2002) put up $2.3 million (it now has about a 43% stake), and DNT raised $1 million last year from private investors. Starpharma itself has developed VivaGel, currently in clinical trials, which is designed to prevent or reduce infection rates of STDs. VivaGel doesn’t use any DNT technology, but the two companies have initiated several joint projects.
DNT’s main competition is Dendritech Inc., founded in 1992 by Tomalia when Dow chose not to pursue dendrimers commercially. It is now a Dow-licensed dendrimer supplier, but focuses more on supplying dendrimers.
DNT’s main focus is on developing new products. It might take dendrimers a few years to really catch on. The biggest
problem now is the cost of adding on all those branches. If DNT’s new patents hold up, Tomalia and his company would be in a position to make dendrimers as prevalent as traditional polymers are today.
My team (ich nehme an Forbes)is hearing a lot of buzz about this company, and we expect to hear soon about some exciting new partnerships in the areas of pharmaceuticals and molecular batteries.
Das liest sich doch sehr gut!
Gruß, greenhorn
May 2004 Forbes Nanotech Report
From Styrofoam cups to acrylic paint to polyester shirts, polymers are everywhere. Since the discoveries of Plexiglas and Nylon in the 1930s, polymers have raked in billions for companies like Rohm & Haas [ROH] and DuPont [DD].Now a new type of polymer is making its presence known: dendrimers. Unlike traditional polymers, which tend to grow in a linear chain, dendrimers grow out from a central point, like the branches of a tree. Chemists can precisely synthesize dendrimers with specific properties,
from reactivity to conductivity to toxicity. They can also be created with empty space inside that can be used to carry cargo. So a dendrimer could hold a hard-to-dissolve drug, carry that drug to a specific tissue in the body and then emit light when it reaches its target to tell a
doctor how much drug is being delivered.
The first dendrimer patents were awarded to Dow Chemical
[DOW] in the early 1980s, based on the work of Donald Tomalia. Tomalia is now president and CTO of Dendritic NanoTechnologies. His company is working on several defense-related applications, including creams to protect soldiers form chemical and biological warfare agents. He retains non-exclusive licensing rights to those old Dow
patents and DNT recently filed new patent applications aimed at reducing the cost of dendrimer production—rather than adding on each branch layer by layer, with purification steps in between, they can now do it all in one shot. DNT also recently opened their Dendrimer Store,
with a product line of more than 200 dendrimers for sale. Customers can buy directly from DNT or through Sigma-Aldrich [SIAL]. The company did $300,000 in sales during the fourth quarter of 2003. DNT also shares a $3 million joint grant from the Army Research Laboratory with Central Michigan University to establish the first National Center of Excellence for dendrimer research and development.
Founding Dendritic NanoTechnologies investor Starpharma
[SPL.AX] (see Companies to Watch, December 2002) put up $2.3 million (it now has about a 43% stake), and DNT raised $1 million last year from private investors. Starpharma itself has developed VivaGel, currently in clinical trials, which is designed to prevent or reduce infection rates of STDs. VivaGel doesn’t use any DNT technology, but the two companies have initiated several joint projects.
DNT’s main competition is Dendritech Inc., founded in 1992 by Tomalia when Dow chose not to pursue dendrimers commercially. It is now a Dow-licensed dendrimer supplier, but focuses more on supplying dendrimers.
DNT’s main focus is on developing new products. It might take dendrimers a few years to really catch on. The biggest
problem now is the cost of adding on all those branches. If DNT’s new patents hold up, Tomalia and his company would be in a position to make dendrimers as prevalent as traditional polymers are today.
My team (ich nehme an Forbes)is hearing a lot of buzz about this company, and we expect to hear soon about some exciting new partnerships in the areas of pharmaceuticals and molecular batteries.
Das liest sich doch sehr gut!
Gruß, greenhorn
Hi Greenhorn, vielen Dank, sehr informativer Artikel. DNT als auch Starpharma machen ja kaum öffentliche Angaben zu Geschäften (von DNT).
Weitere Zukäufe institutioneller Investoren:
http://www.asx.com.au/asxpdf/20040517/pdf/3llpbzh6ft1ps.pdf
Auf jeden Fall positiv.
http://www.asx.com.au/asxpdf/20040517/pdf/3llpbzh6ft1ps.pdf
Auf jeden Fall positiv.
Handelsvolumen steigt ebenfalss wieder. Ich denke es wird etwas passieren in den nächsten Wochen.
Moin zusammen!
Der Kurs hat sich stabilisiert und schleicht sich langsam nach oben. Nur das Volumen war noch etwas dürftig in den letzten Tagen, aber das kommt, denke ich. Ebenso wie die Neuigkeiten
Ich habe zwar von Charttechnik keine Ahnung (bin auch nicht wirklich ein Freund dieser Betrachtungsweisen von Aktien), aber kann es sein, dass sich kurzfristig eine kleine und vor allen Dingen umgedrehte SKS gebildet hat? Das wäre ja sehr positiv, der Sprung auf 0,77 AUD gestern quasi eine Bestätigung der Trendumkehr, hin Richtung Norden.
Sollte das Quatsch sein - streichen wir das am besten aus dem Protokoll
Aber immerhin ist der Thread jetzt mal wieder oben
Gruß, greenhorn
Der Kurs hat sich stabilisiert und schleicht sich langsam nach oben. Nur das Volumen war noch etwas dürftig in den letzten Tagen, aber das kommt, denke ich. Ebenso wie die Neuigkeiten
Ich habe zwar von Charttechnik keine Ahnung (bin auch nicht wirklich ein Freund dieser Betrachtungsweisen von Aktien), aber kann es sein, dass sich kurzfristig eine kleine und vor allen Dingen umgedrehte SKS gebildet hat? Das wäre ja sehr positiv, der Sprung auf 0,77 AUD gestern quasi eine Bestätigung der Trendumkehr, hin Richtung Norden.
Sollte das Quatsch sein - streichen wir das am besten aus dem Protokoll
Aber immerhin ist der Thread jetzt mal wieder oben
Gruß, greenhorn
Hier noch ein bisschen was:
GI Joe Goes Nano
Josh Wolfe, Forbes/Wolfe Nanotech Report, 05.27.04, 11:07 AM ET
As the casualty count rises in Iraq, the safety of our soldiers is paramount in the minds of defense researchers. Nowhere is that more evident than at the Institute for Soldier Nanotechnologies, established at the Massachusetts Institute of Technology in 2002 with a five-year, $50 million grant from the U.S. Army.
Find out which stocks Forbes` gurus are buying and selling each week with Forbes` free Investment Guru weekly e-mail.
The ISN is a unique undertaking. It pulls together 44 MIT faculty and more than 100 students and postdoctoral researchers to interact with the Army and industrial partners. The ISN officially opened its doors last May, and I expect that this new incubator will bring important lifesaving improvements to military science. It`s all part of the Army`s Objective Force Warrior (OFW) program, which recognizes that despite developments in weapons, tanks and planes, a soldier`s uniform essentially hasn`t changed in the last 100 years.
The OFW`s goal is "to create a lightweight, overwhelmingly lethal, fully integrated individual combat system." What does that mean? Well, for starters, the average soldier today can carry up to 130 pounds on a march. Some call it the "Christmas tree" effect, where the Army keeps adding new things to the soldier`s load. Ideally, all of those items could be lightened, combined or integrated.
Focusing on the soldier, ISN already has a blue chip roster of supporters, including founders DuPont (nyse: DD - news - people ), Raytheon (nyse: RTN - news - people ) and Partners HealthCare, a health care network that includes Massachusetts General and Brigham and Women`s hospitals. Other companies have signed on in three tiers: major and small-business industrial members like Dow Corning (nyse: GLW - news - people ), Carbon Nanotechnologies, Dendritic Nanotechnologies, Nomadics and Triton Systems, all of which participate directly in collaborative research and may contribute cash, personnel or equipment.
ISN completed an open prospectus period on April 6 for companies interested in partnerships. The institute won`t just bring in anyone, ISN`s Ned Thomas says, but is looking for specific core competencies in areas such as processing equipment, fabrication and materials. It expects to add a handful of new companies this year, mostly in the small-business category.
DuPont is engaged at the ISN in areas like energy dissipation--how to absorb energy from bullets and shrapnel to reduce the impact on an individual. Part of that is an effort to design new molecules that respond differently to energy than traditional materials do. DuPont is already in the bulletproof vest business with its Kevlar, so it has a vested interested in using nanotechnology to improve its products and possibly increase its market share.
Another DuPont project involves controlling pore sizes in membranes to provide protection against chemical warfare agents. Normal fabric has holes of all different sizes and shapes; of particular importance is to be able to cover or block the largest holes. Alternatively, the membranes could be used in conjunction with coatings to degrade biological agents.
Dendritic Nanotechnologies is a new company, founded by Donald Tomalia of Central Michigan University. Dendrimers are polymers that are synthesized from a central point, like a nano-sized pom-pom with branches. They can be created with specific characteristics like charge, binding properties or solubility. Dendritic is working with MIT chemical engineering professor Paula Hammond and the Army Research Laboratory at Aberdeen, Md., to create dendrimer-based creams to protect soldiers from biological and chemical warfare agents. I`ve got a feeling big news will be coming from them soon.
But the ISN isn`t just capitalizing on its faculty and business partners. A meeting at Fort Polk, Louisiana, in January 2003 led to a soldier design competition involving 75 MIT undergraduates, graduate students, post-docs, staff and alumni. The event kicked off last September with six Army-identified challenges, with needs ranging from silent Velcro to new release mechanisms for parachutes. The winner was TacShot, a lightweight rocket, camera and software combination that allows soldiers to take aerial pictures on demand. Participants kept the intellectual property rights to their inventions and were encouraged to participate in MIT`s $50,000 Entrepreneurship Competition.
Beyond ISN
Defense-related nanotech research is not confined to the ISN, however; nor is it focused only on the soldier. Boeing (nyse: BA - news - people ) is developing nanophase metals (getting aluminum to act like titanium without the weight) and has teamed with Nanosphere to develop biosensors for homeland security. The company is also working to improve the precision and accuracy of satellite gyroscopes--the devices that keep satellites properly oriented for communication to the Earth and power from the sun.
Lockheed Martin (nyse: LMT - news - people ) takes a similar approach. It is looking to improve strength-to-weight ratios in materials and to embed sensors or computing capabilities into those materials to provide for increased range or intelligence in unmanned vehicles such as the LOCAAS--the low-cost autonomous attack system. It is a small guided missile that flies over an area and hovers there until its laser radar seeker recognizes a target such as a tank.
To increase LOCAAS` wingspan without increasing its weight, researchers designed 4-by-16-inch, 50 micrometers-thick "bucky papers" made out of carbon nanotubes and reinforced with epoxy resins to extend the wings of LOCAAS. Carbon nanotubes are 250 times stronger than steel and ten times lighter by volume. Lockheed still has improvements in mind and the wings haven`t been flight-tested yet, but the company is optimistic about the military and commercial opportunities of its bucky papers.
Opportunities For Investors
Many of the exciting nanotech advances in defense research are happening within major corporations, but there is also a stable of exciting startups. We have talked about some of these companies before. Nanosphere is developing biosensors with Boeing, and Carbon Nanotechnologies is providing the nanotubes for products like Lockheed`s bucky papers. Another startup, Buffalo, N.Y.-based NanoDynamics, is using nanomaterials like zirconium oxide to develop a solid oxide fuel-cell battery that weighs only 3.2 kilograms and generates 50 watts of power for more than 50 hours. A conventional lithium ion battery producing comparable power would weigh 22 kilograms.
Watch for all of these companies to do research breakthroughs that eventually make their way into the commercial sector. When DuPont took a hard look at its research areas, it found that military applications tended to take a lead because of the military`s stringent requirements. Then, according to DuPont research manager and ISN liaison Wayne Marsh, "invariably what we find as we develop the technology is that things lead back to the commercial world--first responders, firefighters, police, even into the medical community."
Will there be carbon nanotubes on the wings of your grandchild`s model plane? Stay tuned.
Gruß, greenhorn
GI Joe Goes Nano
Josh Wolfe, Forbes/Wolfe Nanotech Report, 05.27.04, 11:07 AM ET
As the casualty count rises in Iraq, the safety of our soldiers is paramount in the minds of defense researchers. Nowhere is that more evident than at the Institute for Soldier Nanotechnologies, established at the Massachusetts Institute of Technology in 2002 with a five-year, $50 million grant from the U.S. Army.
Find out which stocks Forbes` gurus are buying and selling each week with Forbes` free Investment Guru weekly e-mail.
The ISN is a unique undertaking. It pulls together 44 MIT faculty and more than 100 students and postdoctoral researchers to interact with the Army and industrial partners. The ISN officially opened its doors last May, and I expect that this new incubator will bring important lifesaving improvements to military science. It`s all part of the Army`s Objective Force Warrior (OFW) program, which recognizes that despite developments in weapons, tanks and planes, a soldier`s uniform essentially hasn`t changed in the last 100 years.
The OFW`s goal is "to create a lightweight, overwhelmingly lethal, fully integrated individual combat system." What does that mean? Well, for starters, the average soldier today can carry up to 130 pounds on a march. Some call it the "Christmas tree" effect, where the Army keeps adding new things to the soldier`s load. Ideally, all of those items could be lightened, combined or integrated.
Focusing on the soldier, ISN already has a blue chip roster of supporters, including founders DuPont (nyse: DD - news - people ), Raytheon (nyse: RTN - news - people ) and Partners HealthCare, a health care network that includes Massachusetts General and Brigham and Women`s hospitals. Other companies have signed on in three tiers: major and small-business industrial members like Dow Corning (nyse: GLW - news - people ), Carbon Nanotechnologies, Dendritic Nanotechnologies, Nomadics and Triton Systems, all of which participate directly in collaborative research and may contribute cash, personnel or equipment.
ISN completed an open prospectus period on April 6 for companies interested in partnerships. The institute won`t just bring in anyone, ISN`s Ned Thomas says, but is looking for specific core competencies in areas such as processing equipment, fabrication and materials. It expects to add a handful of new companies this year, mostly in the small-business category.
DuPont is engaged at the ISN in areas like energy dissipation--how to absorb energy from bullets and shrapnel to reduce the impact on an individual. Part of that is an effort to design new molecules that respond differently to energy than traditional materials do. DuPont is already in the bulletproof vest business with its Kevlar, so it has a vested interested in using nanotechnology to improve its products and possibly increase its market share.
Another DuPont project involves controlling pore sizes in membranes to provide protection against chemical warfare agents. Normal fabric has holes of all different sizes and shapes; of particular importance is to be able to cover or block the largest holes. Alternatively, the membranes could be used in conjunction with coatings to degrade biological agents.
Dendritic Nanotechnologies is a new company, founded by Donald Tomalia of Central Michigan University. Dendrimers are polymers that are synthesized from a central point, like a nano-sized pom-pom with branches. They can be created with specific characteristics like charge, binding properties or solubility. Dendritic is working with MIT chemical engineering professor Paula Hammond and the Army Research Laboratory at Aberdeen, Md., to create dendrimer-based creams to protect soldiers from biological and chemical warfare agents. I`ve got a feeling big news will be coming from them soon.
But the ISN isn`t just capitalizing on its faculty and business partners. A meeting at Fort Polk, Louisiana, in January 2003 led to a soldier design competition involving 75 MIT undergraduates, graduate students, post-docs, staff and alumni. The event kicked off last September with six Army-identified challenges, with needs ranging from silent Velcro to new release mechanisms for parachutes. The winner was TacShot, a lightweight rocket, camera and software combination that allows soldiers to take aerial pictures on demand. Participants kept the intellectual property rights to their inventions and were encouraged to participate in MIT`s $50,000 Entrepreneurship Competition.
Beyond ISN
Defense-related nanotech research is not confined to the ISN, however; nor is it focused only on the soldier. Boeing (nyse: BA - news - people ) is developing nanophase metals (getting aluminum to act like titanium without the weight) and has teamed with Nanosphere to develop biosensors for homeland security. The company is also working to improve the precision and accuracy of satellite gyroscopes--the devices that keep satellites properly oriented for communication to the Earth and power from the sun.
Lockheed Martin (nyse: LMT - news - people ) takes a similar approach. It is looking to improve strength-to-weight ratios in materials and to embed sensors or computing capabilities into those materials to provide for increased range or intelligence in unmanned vehicles such as the LOCAAS--the low-cost autonomous attack system. It is a small guided missile that flies over an area and hovers there until its laser radar seeker recognizes a target such as a tank.
To increase LOCAAS` wingspan without increasing its weight, researchers designed 4-by-16-inch, 50 micrometers-thick "bucky papers" made out of carbon nanotubes and reinforced with epoxy resins to extend the wings of LOCAAS. Carbon nanotubes are 250 times stronger than steel and ten times lighter by volume. Lockheed still has improvements in mind and the wings haven`t been flight-tested yet, but the company is optimistic about the military and commercial opportunities of its bucky papers.
Opportunities For Investors
Many of the exciting nanotech advances in defense research are happening within major corporations, but there is also a stable of exciting startups. We have talked about some of these companies before. Nanosphere is developing biosensors with Boeing, and Carbon Nanotechnologies is providing the nanotubes for products like Lockheed`s bucky papers. Another startup, Buffalo, N.Y.-based NanoDynamics, is using nanomaterials like zirconium oxide to develop a solid oxide fuel-cell battery that weighs only 3.2 kilograms and generates 50 watts of power for more than 50 hours. A conventional lithium ion battery producing comparable power would weigh 22 kilograms.
Watch for all of these companies to do research breakthroughs that eventually make their way into the commercial sector. When DuPont took a hard look at its research areas, it found that military applications tended to take a lead because of the military`s stringent requirements. Then, according to DuPont research manager and ISN liaison Wayne Marsh, "invariably what we find as we develop the technology is that things lead back to the commercial world--first responders, firefighters, police, even into the medical community."
Will there be carbon nanotubes on the wings of your grandchild`s model plane? Stay tuned.
Gruß, greenhorn
Ich bin ja dankbar für jedes Häppchen an neuer Info:
Patenterteilung in den USA:
http://www.asx.com.au/asxpdf/20040607/pdf/3lsqhmdkb4gp6.pdf
Patenterteilung in den USA:
http://www.asx.com.au/asxpdf/20040607/pdf/3lsqhmdkb4gp6.pdf
Interessante Mitteilung. Wieso lizensieren die sich Patente ein, wo die doch genug eigene haben???
Scheint ja wohl so zu sein, das die Mitteilung im Zusammenhang mit der letzten Kapitalerhöhung steht (wo ja angekündigt wurde, das man die Interessen erweitert) und das man jetzt konsequent das gesamte Dendrimer Gebiet abdeckt.
Scheint wohl auch so zu sein, das man "überschüssiges Geld" hat, d.h. die Luft für strategische Investitionen ist da.
Insofern sehe ich die Mitteilung sehr positiv.
Ich bin gespannt, wann Sie das Feld Biotech/Dendrimer verlassen und auf andere spannende Anwendungen gehen, beispielsweise Solarzellen, was die bestehenden Patente ja hergeben.
gruss,
cybercoach
Scheint ja wohl so zu sein, das die Mitteilung im Zusammenhang mit der letzten Kapitalerhöhung steht (wo ja angekündigt wurde, das man die Interessen erweitert) und das man jetzt konsequent das gesamte Dendrimer Gebiet abdeckt.
Scheint wohl auch so zu sein, das man "überschüssiges Geld" hat, d.h. die Luft für strategische Investitionen ist da.
Insofern sehe ich die Mitteilung sehr positiv.
Ich bin gespannt, wann Sie das Feld Biotech/Dendrimer verlassen und auf andere spannende Anwendungen gehen, beispielsweise Solarzellen, was die bestehenden Patente ja hergeben.
gruss,
cybercoach
Cybercoach:
Ich denke, dass das Patent nicht direkt von Starpharma genutzt wird, sondern an Dendritic lizenziert wird bzw. an eines der Joint Ventures die Dendritic in nächster Zeit eingehen wird.
Greenhorn:
Starpharma steigt wieder, immer noch alles unter recht geringen Umsätzen, aber ich gehe trotzdem davon aus, dass das was zu sagen hat. Immerhin harren wir jetzt schon ein halbes Jahr aus, um wieder mal was bahnbrechendes von Starpharma zu hören.
Ich denke, dass das Patent nicht direkt von Starpharma genutzt wird, sondern an Dendritic lizenziert wird bzw. an eines der Joint Ventures die Dendritic in nächster Zeit eingehen wird.
Greenhorn:
Starpharma steigt wieder, immer noch alles unter recht geringen Umsätzen, aber ich gehe trotzdem davon aus, dass das was zu sagen hat. Immerhin harren wir jetzt schon ein halbes Jahr aus, um wieder mal was bahnbrechendes von Starpharma zu hören.
wird einfach mal Zeit, das Forum nach oben zu hieven, sonst finde ich es gar nicht mehr.
Dafür, dass es zuletzt nicht viel zu melden gab, finde ich zumindest die Kursentwicklung bemerkenswert. Sehr stabil mit eher steigender Tendenz. Daran alleine wird eigentlich sichtbar, dass es sich hier um einen Wert mit Substanz handeln muss. Vor allem wenn ich mir die Schwankungsbreite manch hochgejubelten "Nanowerts" anschaue.
Bald gehts los, ich spürs
Ich auch
Scheint ansteckend zu sein. D:
Ich spür`s auch , ganz deutlich
Aber eigentlich schon seit März, mindestens
Naja, ich hab Zeit
Gruß, greenhorn
Aber eigentlich schon seit März, mindestens
Naja, ich hab Zeit
Gruß, greenhorn
Jetzt, da ihr es sagt: Ich spürs ebenfalls
Hallo zusammen!
Ein bisschen was zum lesen, wobei das, was sich hinter dem ersten Link verbirgt, vom Dezember 2003 ist. Aber macht ja nix.
http://aac.asm.org/cgi/content/full/47/12/3784?view=full&pmi…
Und noch eine zweite Sache:
http://www.wwj.com/listingsEntry.asp?ID=210227&PT=Technology
Dendrimer dreaming: New breed of nanotech R&D blooms in Michigan
Nanotechnology has been heralded as the Next Big Thing in technology. If you wonder why, just have a chat with someone like Nicholas Beeson.
Beeson is a senior research associate at the Center for Biologic Nanotechnology at the University of Michigan. The center was established in 1998 with start-up funding from the UM Medical School. Its mission -- bring together several disciplines, engineering, materials sciences, biological sciences, chemistry and physics -- to use nanotechnology to solve biological problems.
The center`s work concentrates on the dendrimer, a form of engineered molecule discovered at Dow Chemical Co. in Midland in the 1980s. Dendrimers are unusual because unlike other molecules, they`re constructed rather like trees -- a thicker "trunk" in the middle and increasingly smaller "branches" toward the outside of the molecule. This creates a molecule with a lot of empty space inside -- which can be used to store and carry other stuff -- and small branches on the outside that can be custom-fitted with different kinds of chemicals.
Beeson said the center "started out with the dendrimer nanoparticle as a platform, and we are attaching to it various functional units that perform tasks." Right now, Beeson said, the center is animal testing a dendrimer loaded with a currently available anti-cancer drug, and its outside branches fitted with chemicals that seek out cancer cells. Chemotheraphy drugs kill all cells -- and they kill fast-growing cells the fastest, which is why they kill cancer cells (as well as kill the fast-growing cells that produce hair, which is why your hair falls out during chemo, and the fast-growing cells in your stomach, which is why chemo makes you sick). With the chemo drugs loaded in the dendrimer, Beeson said, "We are seeing a vastly reduced, a 100-fold reduced, level of toxicity. The mice don`t lose weight and the mice don`t lose their hair."
The center is also testing dendrimers loaded with chemicals that improve the imagery of magnetic resonance imaging tests, and chemicals that detect the death of cancer cells. "The goal, of course, is to put the targeting, the cancer drug, the MRI contrast enhancing agent and the death-reporting dye on one device," Beeson said.
About 35 people work at the center, which gets major funding from the National Cancer Institute and NASA. More at this link.
The UM center is hardly the only place in Michigan where research into dendrimers is taking place. There`s also Dendritic Nanotechnologies Inc. in Mt. Pleasant, part of Central Michigan University`s aggressive push into high-tech spinoffs.
DNT was founded in 2002 by Donald Tomalia, an inventor of the dendrimer at Dow, who had earlier worked at the UM center and a couple of other Dow spinoffs in Midland. According to DNT CEO Charles R. Burke, the company selected Mt. Pleasant because it had plenty of available lab space and a strong sense of welcome from CMU.
The company has pulled more than $2 million in funding from an Australian drug company, Star Pharma, and a pair of $3 million research grants from the United States Army to build its research capabilities. DTI`s board now includes luminaries like former Dow Corning CEO Richard Hazelton, and University of California professor and dendrimer pioneer Jean Frechet.
Burke said DNT`s major activity so far is the "Dendrimer Store," more than 200 types of dendrimers for sale directly over the Internet.
"The purpose of this is threefold," Burke said. "The immediate purpose is, we sell dendrimers and make money. Second, because dendrimers are unlike other chemical structures, you buy dendrimers as a tool kit to do what you want to do. So we get to talk to literally hundreds of potential customers, and they talk about applications of dendrimers we would have never thought of. For example, making CDs copy proof. Another guy wants to use them for rocket fuel. They are potentially valuable for better flat panel displays. We want to use them for cancer treatment. Third, if we are the world`s experts on making dendrimers, we can couple with people who have very significant needs, between the combination of our IP and our know-how, we can set up a series of joint ventures or major license deals."
Burke said DNT has a major announcement on a new project coming soon, so stay tuned. More at www.dnanotech.com/.
Gruß, greenhorn
Ein bisschen was zum lesen, wobei das, was sich hinter dem ersten Link verbirgt, vom Dezember 2003 ist. Aber macht ja nix.
http://aac.asm.org/cgi/content/full/47/12/3784?view=full&pmi…
Und noch eine zweite Sache:
http://www.wwj.com/listingsEntry.asp?ID=210227&PT=Technology
Dendrimer dreaming: New breed of nanotech R&D blooms in Michigan
Nanotechnology has been heralded as the Next Big Thing in technology. If you wonder why, just have a chat with someone like Nicholas Beeson.
Beeson is a senior research associate at the Center for Biologic Nanotechnology at the University of Michigan. The center was established in 1998 with start-up funding from the UM Medical School. Its mission -- bring together several disciplines, engineering, materials sciences, biological sciences, chemistry and physics -- to use nanotechnology to solve biological problems.
The center`s work concentrates on the dendrimer, a form of engineered molecule discovered at Dow Chemical Co. in Midland in the 1980s. Dendrimers are unusual because unlike other molecules, they`re constructed rather like trees -- a thicker "trunk" in the middle and increasingly smaller "branches" toward the outside of the molecule. This creates a molecule with a lot of empty space inside -- which can be used to store and carry other stuff -- and small branches on the outside that can be custom-fitted with different kinds of chemicals.
Beeson said the center "started out with the dendrimer nanoparticle as a platform, and we are attaching to it various functional units that perform tasks." Right now, Beeson said, the center is animal testing a dendrimer loaded with a currently available anti-cancer drug, and its outside branches fitted with chemicals that seek out cancer cells. Chemotheraphy drugs kill all cells -- and they kill fast-growing cells the fastest, which is why they kill cancer cells (as well as kill the fast-growing cells that produce hair, which is why your hair falls out during chemo, and the fast-growing cells in your stomach, which is why chemo makes you sick). With the chemo drugs loaded in the dendrimer, Beeson said, "We are seeing a vastly reduced, a 100-fold reduced, level of toxicity. The mice don`t lose weight and the mice don`t lose their hair."
The center is also testing dendrimers loaded with chemicals that improve the imagery of magnetic resonance imaging tests, and chemicals that detect the death of cancer cells. "The goal, of course, is to put the targeting, the cancer drug, the MRI contrast enhancing agent and the death-reporting dye on one device," Beeson said.
About 35 people work at the center, which gets major funding from the National Cancer Institute and NASA. More at this link.
The UM center is hardly the only place in Michigan where research into dendrimers is taking place. There`s also Dendritic Nanotechnologies Inc. in Mt. Pleasant, part of Central Michigan University`s aggressive push into high-tech spinoffs.
DNT was founded in 2002 by Donald Tomalia, an inventor of the dendrimer at Dow, who had earlier worked at the UM center and a couple of other Dow spinoffs in Midland. According to DNT CEO Charles R. Burke, the company selected Mt. Pleasant because it had plenty of available lab space and a strong sense of welcome from CMU.
The company has pulled more than $2 million in funding from an Australian drug company, Star Pharma, and a pair of $3 million research grants from the United States Army to build its research capabilities. DTI`s board now includes luminaries like former Dow Corning CEO Richard Hazelton, and University of California professor and dendrimer pioneer Jean Frechet.
Burke said DNT`s major activity so far is the "Dendrimer Store," more than 200 types of dendrimers for sale directly over the Internet.
"The purpose of this is threefold," Burke said. "The immediate purpose is, we sell dendrimers and make money. Second, because dendrimers are unlike other chemical structures, you buy dendrimers as a tool kit to do what you want to do. So we get to talk to literally hundreds of potential customers, and they talk about applications of dendrimers we would have never thought of. For example, making CDs copy proof. Another guy wants to use them for rocket fuel. They are potentially valuable for better flat panel displays. We want to use them for cancer treatment. Third, if we are the world`s experts on making dendrimers, we can couple with people who have very significant needs, between the combination of our IP and our know-how, we can set up a series of joint ventures or major license deals."
Burke said DNT has a major announcement on a new project coming soon, so stay tuned. More at www.dnanotech.com/.
Gruß, greenhorn
Vielen Dank Greenhorn, sehr lesenswert.
Die Frage für uns bleibt, was bedeutet das "soon" im letzten Satz. Anspielungen werden ja schon seit Monaten gemacht, dass einige Dinge im Umfeld von DNT passieren.
Die Frage für uns bleibt, was bedeutet das "soon" im letzten Satz. Anspielungen werden ja schon seit Monaten gemacht, dass einige Dinge im Umfeld von DNT passieren.
Die Regierung fördert Starpharma mit Mitteln in Höhe von 440000 AUD. Die zwei Projekte hören sich vielversprechend an, leider sind sie nicht sehr detailliert beschrieben:
http://www.asx.com.au/asxpdf/20040706/pdf/3m2bhrlm1bw6x.pdf
http://www.asx.com.au/asxpdf/20040706/pdf/3m2bhrlm1bw6x.pdf
Hallo zusammen!
Vielleicht schätze ich die Situation ja auch falsch ein, aber ich bin schon positiv überrascht, dass die Aktie auch heute in Australien doch recht deutlich nach oben marschiert ist. Unter ordentlichen Umsätzen. Alles aufgrund der letzten News?
Mir soll`s recht sein.
Gruß, greenhorn
Vielleicht schätze ich die Situation ja auch falsch ein, aber ich bin schon positiv überrascht, dass die Aktie auch heute in Australien doch recht deutlich nach oben marschiert ist. Unter ordentlichen Umsätzen. Alles aufgrund der letzten News?
Mir soll`s recht sein.
Gruß, greenhorn
Hallo zusammen!
Wenn ich nicht irre, war an diesem Wochenende ja eine große Aids-Konferenz, bei der es nicht nur um Aufklärung und dergleichen gehen sollte, sondern auch um medizinische und therapeutische Ansätze. Kann man sich davon auch irgendwelche Impulse für Starpharma versprechen? Einfach mal so ins Blaue gefragt.
Gruß und noch einen schönen Restsonntag!
greenhorn
P.S.: Bin ja mal gespannt, wann sich mal die ganzen "soons" und "next months or weeks" der letzten hinsichtlich News bei DNT/Starpharma zu einem NOW mausern.
Wenn ich nicht irre, war an diesem Wochenende ja eine große Aids-Konferenz, bei der es nicht nur um Aufklärung und dergleichen gehen sollte, sondern auch um medizinische und therapeutische Ansätze. Kann man sich davon auch irgendwelche Impulse für Starpharma versprechen? Einfach mal so ins Blaue gefragt.
Gruß und noch einen schönen Restsonntag!
greenhorn
P.S.: Bin ja mal gespannt, wann sich mal die ganzen "soons" und "next months or weeks" der letzten hinsichtlich News bei DNT/Starpharma zu einem NOW mausern.
Warum sind wir eigentlich fast immer 10% unter Parität. 0,81 $ sind eigentlich 0,495 €.
Na ja...
Na ja...
Habe starpharma nicht auf der Teilnehmerliste der Aids Konferenz gefunden.
Schaut euch mal die Umsatzzahlen an. Das ist doch was im Busch.
Schaut euch mal die Umsatzzahlen an. Das ist doch was im Busch.
Ich finde die Umsatzzahlen nicht überwältigend, sie liegen sogar wieder unter dem Durchschnitt. Trotzdem wird die Liste zu erwartender Neuigkeiten mit jeder vergangenen Woche größer. Wenn alles eintreffen würde, was Starpharma Anfang des Jahres angekündigt hat, würden wir bis Ende des JAhres locker über 1 AUD stehen. Aber manches dürfte wohl nich dieses Jahr mehr realisiert werden, wenn doch wird es lustig.
Hallo zusammen!
Irgendwelche Meinungen hierzu?
http://www.asx.com.au//asxpdf/20040713/pdf/3m4gf29yh7cxw.pdf
Gruß, greenhorn
Irgendwelche Meinungen hierzu?
http://www.asx.com.au//asxpdf/20040713/pdf/3m4gf29yh7cxw.pdf
Gruß, greenhorn
Ehrlich gesagt nicht. Das Paket ist zu klein, um es mit einer Sonderbehandlung von grösseren Einzelinvestoren zu erklären.
Vielleicht ist das Paket aber schon zu groß, um es über die Börse zu schieben, ohne den Kurs nach unten zu drücken.
Man sollte hier ein Auge drauf haben, insbesondere darauf, ob die Fonds weiter drinbleiben oder ein weiteres Paket geschoben wird. Im letzteren Fall sieht es gar nicht so gut aus.
Vielleicht ist das Paket aber schon zu groß, um es über die Börse zu schieben, ohne den Kurs nach unten zu drücken.
Man sollte hier ein Auge drauf haben, insbesondere darauf, ob die Fonds weiter drinbleiben oder ein weiteres Paket geschoben wird. Im letzteren Fall sieht es gar nicht so gut aus.
Hi zusammen!
Danke dir, CyberCoach. Ich habe mal eine andere Meinung ausgegraben, ein finn1 aus dem Nanalyze-Board äußert sich wie folgt. Vor allen Dingen der zweite Teil seiner Aussage ist wirklich nicht uninteressant:
"The announcement actually says a company which the director is a shareholder of sold two parcels of shares equal to the holding allotment of two other shareholders within that company.
It quite clearly states the shares sold were not sold by the director.
Of more interest is the latest option issue as "payment for investment banking services". Very short option span and convertable at $1.00 an option pre October 2004 or $1.25 March 2005, after that they expire.
250,000 of these options issued and doesn`t say if they were payment in full for the service or part payment plus a cash consideration.
"savvy" bankers don`t take short options which are out of the money unless they have a lot of confidence or unless they were an attractive "add on" to fees already charged. Either way, it`s not a long time frame to wait.
Wonder what type of "investment banking services" were provided?"
Gruß, greenhorn
Danke dir, CyberCoach. Ich habe mal eine andere Meinung ausgegraben, ein finn1 aus dem Nanalyze-Board äußert sich wie folgt. Vor allen Dingen der zweite Teil seiner Aussage ist wirklich nicht uninteressant:
"The announcement actually says a company which the director is a shareholder of sold two parcels of shares equal to the holding allotment of two other shareholders within that company.
It quite clearly states the shares sold were not sold by the director.
Of more interest is the latest option issue as "payment for investment banking services". Very short option span and convertable at $1.00 an option pre October 2004 or $1.25 March 2005, after that they expire.
250,000 of these options issued and doesn`t say if they were payment in full for the service or part payment plus a cash consideration.
"savvy" bankers don`t take short options which are out of the money unless they have a lot of confidence or unless they were an attractive "add on" to fees already charged. Either way, it`s not a long time frame to wait.
Wonder what type of "investment banking services" were provided?"
Gruß, greenhorn
@all
Hallo Leute,
seit über 10 Tagen kein Posting mehr
Fast schon zu ruhig, oder?
Alle warten wohl auf News, mich wundert dabei, das der Kurs weiterhin so stabil vor sich hindümpelt.
Ein kleines Wunder, wenn man den Bio-Sektor anschaut.
grüße euch derschweizer
Hallo Leute,
seit über 10 Tagen kein Posting mehr
Fast schon zu ruhig, oder?
Alle warten wohl auf News, mich wundert dabei, das der Kurs weiterhin so stabil vor sich hindümpelt.
Ein kleines Wunder, wenn man den Bio-Sektor anschaut.
grüße euch derschweizer
Dafür heute ein toller Anstieg, 7% in Aussiland. Müsste umgerechnet bei 0,47 € stehen. Jetzt gehts los
Hallo zusammen!
Das stimmt schon. Finde ich auch sehr erfreulich, dass sich Starpharma so gut hält. Zwar ist das Volumen noch nicht sonderlich bemerkenswert, aber die Aktie ist stabil. Gestern ein schöner Satz nach oben in Australien, ohne News. Oder habe ich welche übersehen? Das ist doch eigentlich ein gutes Zeichen. Vielleicht werden die guten Neuigkeiten dann später nachgereicht.
Gruß von einem greenhorn, dass sich mit dem Investment in Starpharma sehr wohl fühlt, seinen Optimismus zügeln muss und das sich wundert, wie dehnbar doch die Begriffe "soon" und "near future" doch sind. Aber das erwähnte ich glaube ich schon einmal.
Wäre schön, wenn wir die 80 Cent heute Nacht überwinden könnten. Vom Gesamtmarkt heute wieder an der Nasdaq wohl schwierig, aber Starpharma koppelt sich ja schon seit Wochen vom Markt ab.
Das stimmt schon. Finde ich auch sehr erfreulich, dass sich Starpharma so gut hält. Zwar ist das Volumen noch nicht sonderlich bemerkenswert, aber die Aktie ist stabil. Gestern ein schöner Satz nach oben in Australien, ohne News. Oder habe ich welche übersehen? Das ist doch eigentlich ein gutes Zeichen. Vielleicht werden die guten Neuigkeiten dann später nachgereicht.
Gruß von einem greenhorn, dass sich mit dem Investment in Starpharma sehr wohl fühlt, seinen Optimismus zügeln muss und das sich wundert, wie dehnbar doch die Begriffe "soon" und "near future" doch sind. Aber das erwähnte ich glaube ich schon einmal.
Wäre schön, wenn wir die 80 Cent heute Nacht überwinden könnten. Vom Gesamtmarkt heute wieder an der Nasdaq wohl schwierig, aber Starpharma koppelt sich ja schon seit Wochen vom Markt ab.
Hallo zusammen!
84 Cents, das sieht doch wirklich gut aus.
http://www.starpharma.com/PDFs/040730 App4C.pdf
Gruß, greenhorn
84 Cents, das sieht doch wirklich gut aus.
http://www.starpharma.com/PDFs/040730 App4C.pdf
Gruß, greenhorn
Nur die Bilanz kann es nicht gewesen sein, sieht eher langweilig aus. Wie es halt bei einem Biotech/Nanotech-Unternehmen in der Researchphase aussieht.
Die kürzlich veröffentlichte Bilanz war es sicher nicht, da der Kurs seit 2 Monaten langsam aber stetig hochschleicht.
Sieht aus, als stünden gute Nachrichten an.
Der Artikel ist zwar alt, aber diese Kooperation trägt demnächst wohl in Euro messbare Früchte:
http://www.prnewswire.co.uk/cgi/news/release?id=71633
Und Starpharma ist mit 49% beteiligt an der Firma.
Sieht aus, als stünden gute Nachrichten an.
Der Artikel ist zwar alt, aber diese Kooperation trägt demnächst wohl in Euro messbare Früchte:
http://www.prnewswire.co.uk/cgi/news/release?id=71633
Und Starpharma ist mit 49% beteiligt an der Firma.
Die Ärztezeitung berichtete am 11. Mai unter anderem über Starpharma.
"Mehr als alter Wein in neuen Schläuchen":
http://www.aerztezeitung.de/docs/2004/05/11/087a1001.asp?cat…
Wüsste ich nicht, dass der Kurs in Australien gemacht wird... fällt aber tatsächlich mit dem Kursanstieg zusammen.
Googelt mal, da finden sich sehr interessante Sachen zu Starpharma.
"Mehr als alter Wein in neuen Schläuchen":
http://www.aerztezeitung.de/docs/2004/05/11/087a1001.asp?cat…
Wüsste ich nicht, dass der Kurs in Australien gemacht wird... fällt aber tatsächlich mit dem Kursanstieg zusammen.
Googelt mal, da finden sich sehr interessante Sachen zu Starpharma.
6,1% auf 0,87 in Aussiland
Und ein sehr guter Annual Report:
04
SX:SPL) today
the full year ending 30 June 2004. The Company had cash
reserves of $15.6 million at year end, and is well positioned to advance its development
Operating expenditure for the full year was similar to the previous year, after adjusting for the
es Ltd (DNT),
rations, and was
tal of A$3.9
and currently owns 44.5% of the company. This has been an important
strategic investment for Starpharma, and the company is optimistic about the potential of
mmercialisation
rights to DNT’s intellectual property in the area of polyvalent dendrimer based
p
T ncluding:
l
ss with Phase I clinical trials for VivaGel™, the microbicide
Starpharma is developing for the prevention of HIV. In February 2004, VivaGel™
reached a major development milestone with the initiation of a Phase I human clinical trial
plication.
linical trial for a
a number of new institutional shareholders over the past year
and over a third of the company’s share register is now represented by Australian
i tutions on the register provides an
excellent foundation for future growth of the company.
search and
urther expand its shareholder base
in the US over the coming year.
In January 2004 shareholders voted comprehensively to support a proposal to allow the
company to relinquish its PDF status, and this was put into effect in March 2004. This
change in status is part of the evolution of Starpharma and will allow the company to
better take advantage of international commercial opportunities.
For Australian shareholders there were capital gains tax implications in this change of
status. Generally, shareholders were deemed to have disposed of their shares and to
Commentary on results for year ended 30 June 20
Melbourne (Australia), 25 August 2004: Starpharma Holdings Limited (A
announced financial results for
programs over the next three years.
impact of operating expenses of the associated entity Dendritic Nanotechnologi
prior to that entity being deconsolidated at the end of March 2003.
DNT was established in August 2001 as an Australian company with US ope
incorporated as a US company in March 2003. Starpharma has invested a to
million in DNT,
DNT. In addition to the value of the equity investment, Starpharma has co
harmaceuticals.
he past year has seen a number of material developments for Starpharma, i
Clinical Trials – world first for dendrimer based pharmaceutica
There was significant progre
under a U.S. Food and Drug Administration “Investigational New Drug” ap
Starpharma thus became the first company in the world to initiate a c
dendrimer-based pharmaceutical.
Institutional shareholder base
Starpharma has attracted
nstitutional investors. The presence of these insti
Because of Starpharma’s presence in the US (through DNT and other re
commercial initiatives) the company will be looking to f
Change in Pooled Development Fund (PDF) status.
04, the date of
nd this became the
cost base for calculation of future capital gains tax on disposal of these shares.
lopment of its lead
ivaGel as part of a broader focus on women’s reproductive health. The key
diseases targeted in this market niche include HIV, genital herpes, genital warts and
a’s core
expertise and IP position in dendrimer nanotechnology and the company’s strategy is to
partner with other companies in the development of these opportunities. Starpharma is very
optimistic about the year ahead.
have immediately re-acquired the shares at market value on 17 March 20
PDF licence revocation. The share price at this time was A$0.90, a
Starpharma’s commercialisation strategy is to progress in-house the deve
product V
Chlamydia.
There are a number of other development opportunities arising from Starpharm
John W Raff
Chief Executive Officer
Starpharma Holdings Limited (ASX:SPL) is focused on the development and appl
dendrimer nanotechnologies as
ication of
drugs against major diseases. Starpharma’s lead dendrimer product,
VivaGel™ has received clearance from the US FDA for human clinical trials. VivaGel™ is a topical
gel product that has been developed for women as a preventative against the sexual
transmission of HIV. It is also active in animal studies for the prevention of other sexually transmitted
ia. SPL also has an equity interest in a US based
lished with the US pioneer of dendrimer
r Donald Tomalia.
+61 3 8532 2702
www.starpharma.com
microbicide
diseases including genital Herpes and Chlamyd
company – Dendriti logies Inc. (DN c Nanotechno T) – estab
nanotechnology, D
CONTACTS:
Dr John Raff Mr Ben Rogers
Chief Executive Officer Company Secretary
+61 3 8532 2701
Starpharma Holdings Limited (Starpharma) is admitted to the official list of the Australian Stock Exchange
Limited (ASX). At this time, Starpharma has not agreed to be listed, or to have its securities quoted, on any other
financial market. If investing in Starpharma through another financial market you should be aware that you may
not acquire direct ownership of securities issued by Starpharma nor be recognised by Starpharma as a holder of
its securities for the purposes of corporate actions, and that Starpharma does not usually make announcements
to the operators of such markets.
STARPHARMA HOLDINGS Limited
ABN 20 078 532 180
ASX Preliminary final report – 30 June
2004
Lodged with the ASX under Listing Rule 4.3A
Contents
Results for Announcement to the Market 2
Preliminary consolidated statement of financial performance 3
Preliminary consolidated statement of financial position 4
Preliminary consolidated statement of cash flows 5
Supplementary Appendix 4E Information 10
Page 1 of 11
STARPHARMA HOLDINGS Ltd
Year ended 30 June 2004
(Previous corresponding period:
Year ended 30 June 2003)
Results for Announcement to the Market
$
Revenue from ordinary activities up/down 8% to 1,390,603
Profit/(loss) from ordinary activities after tax
attributable to members up/down 29% to (5,497,850)
Net profit/(loss) for the period attributable to
members up/down 29% to (5,497,850)
Dividends/distributions Amount per security Franked amount per
security
Final dividend Nil Nil
Interim dividend Nil Nil
Record date for determining entitlements to the dividend Not Applicable
No dividends have been paid or declared by the entity since the beginning of the current reporting
period. No dividends were paid for the previous corresponding period.
Explanation of Revenue
Revenue consisted of grant income from a Commonwealth Government R&D START Grant of
$656,148 (2003: $839,251), Interest revenue of $640,247 (2003: $558,674), and other revenue of
$94,208 (2003: $112,495).
Explanation of Net Profit/(loss)
The consolidated loss of $5,497,850 is after fully expensing all research and development expenditure
and patenting costs. The reduction of 29% in the net loss is primarily the result of excluding the
revenues and expenses of the former controlled entity Dendritic Nanotechnologies Ltd from the
consolidated entity. This is further explained in the section “Material factors affecting the revenues
and expenses of the consolidated entity for the current period” on page 6.
Page 2 of 11
STARPHARMA HOLDINGS Ltd
Consolidated statement of financial performance
For the year ended 30 June 2004
Consolidated
2004 2003
$ $
Revenue from ordinary activities 1,390,603 1,510,420
Expenses from ordinary activities
Administration expense (2,211,604) (2,026,347)
Research and development expense (4,119,259) (5,713,405)
Occupancy expense (324,664) (439,175)
Depreciation (plant and equipment) (603,089) (604,642)
Borrowing (12,011) (15,529)
Other expense from ordinary activities - (25,513)
Share of results of associates accounted for using the equity method 382,174 (230,530)
PROFIT (LOSS) FROM OPERATING ACTIVITIES BEFORE
TAX (5,497,850) (7,544,721)
Income tax on ordinary activities - -
PROFIT (LOSS) FROM OPERATING ACTIVITIES AFTER TAX (5,497,850) (7,544,721)
(Profit) Loss attributable to outside equity interest - (175,062)
PROFIT (LOSS) FROM OPERATING ACTIVITIES AFTER TAX (5,497,850) (7,719,783)
Page 3 of 11
STARPHARMA HOLDINGS Ltd
Consolidated statement of financial position
As at 30 June 2004
Consolidated
30 June 2004 30 June 2003
ASSETS $ $
CURRENT ASSETS
Cash assets 15,658,300 7,891,543
Receivables 471,139 420,257
Other 113,044 147,540
TOTAL CURRENT ASSETS 16,242,483 8,459,340
NON CURRENT ASSETS
Property, plant and equipment 1,556,265 2,005,400
Investments accounted for using the equity method 692,194 250,700
TOTAL NON-CURRENT ASSETS 2,248,459 2,256,100
TOTAL ASSETS 18,490,942 10,715,440
LIABILITIES
CURRENT LIABILITIES
Payables 445,908 720,809
Provisions 249,015 205,729
Interest-bearing liabilities 60,007 60,007
Other - 282,243
TOTAL CURRENT LIABILITIES 754,930 1,268,788
NON-CURRENT LIABILITIES
Interest-bearing liabilities 143,516 203,522
TOTAL NON-CURRENT LIABILITIES 143,516 203,522
TOTAL LIABILITIES 898,446 1,472,310
NET ASSETS 17,592,496 9,243,130
EQUITY
Contributed equity 46,821,956 33,034,058
Foreign currency translation reserve 12,709 (46,609)
Retained profits (Accumulated losses) (29,242,169) (23,744,319)
TOTAL EQUITY 17,592,496 9,243,130
Page 4 of 11
STARPHARMA HOLDINGS Ltd
Consolidated statement of cash flows
For the year ended 30 June 2004
Consolidated
Full-year
2004 2003
$ $
CASH FLOWS FROM OPERATIONS
Receipts from trade and other debtors 36,197 125,086
Grant Income (Inclusive of GST) 560,529 948,285
Interest received 613,010 646,677
Interest expense (11,993) (15,529)
Payments to suppliers and employees (Inclusive of GST) (7,004,922) (8,687,731)
NET CASH INFLOWS (OUTFLOWS) FROM OPERATING
ACTIVITIES (5,807,179) (6,983,212)
CASH FLOWS FROM INVESTING ACTIVITIES
Cash eliminated on deconsolidation - (933,239)
Proceeds from sale of property, plant and equipment - 40,411
Payments for property, plant and equipment (153,955) (1,610,181)
NET CASH INFLOWS (OUTFLOWS) FROM INVESTING
ACTIVITIES (153,955) (2,503,009)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issue of shares 14,494,200 -
Share issue transaction costs (706,302) -
Lease repayments (60,007) (56,471)
NET CASH INFLOWS (OUTFLOWS) FROM FINANCING
ACTIVITIES 13,727,891 (56,471)
NET INCREASE (DECREASE) IN CASH HELD 7,766,757 (9,542,692)
CASH AT THE BEGINNING OF THE FINANCIAL YEAR 7,891,543 17,434,235
CASH AT THE END OF THE FINANCIAL YEAR 15,658,300 7,891,543
Page 5 of 11
STARPHARMA HOLDINGS Ltd
Notes to the full-year report
For the period ended 30 June 2004
Material factors affecting the revenues and expenses of the consolidated entity
for the current period
There was a reduction of 29% in the operating loss of the consolidated entity during the current period
compared with the previous year. This is attributable to the following factors:
Loss of Control of Dendritic Nanotechnologies Ltd
During the previous year the revenues and expenses of the consolidated entity were affected by the
change in the level of control of the former controlled entity Dendritic Nanotechnologies Ltd (“DNT
Ltd”). From 27th March 2003 Dendritic Nanotechnologies Ltd became a wholly owned subsidiary of
the US entity Dendritic Nanotechnologies, Inc. (“DNT Inc”) and Starpharma Holdings Ltd held
49.99% of the issued shares in DNT Inc. The revenues and expenses of DNT Ltd were included in
the consolidated results of the Company from 1 July 2002 to 27 March 2003, but as control in DNT
Ltd ceased on 27 March 2003 from that date the accounts of DNT Ltd and DNT Inc have been
excluded from the consolidated accounts.
Revenue
Revenue from ordinary activities decreased by $119,817. This was primarily due to the exclusion of
revenues of the former controlled entity DNT Ltd and a reduction in grant income associated with
completion of R&D START grants.
Operating costs
The 2003 costs included $1.83 million of operating expenses and $68,171 of depreciation attributable
to DNT Ltd prior to that entity being deconsolidated. Excluding the impact of DNT Ltd in the
calculation of the 2003 costs, operating expenditure and depreciation attributable to remaining group
members was $6.39 million and $536,470 respectively in 2003 compared with operating expenditure
of $6.66 million and depreciation of $603,089 in 2004.
Share of results of associates
The application of equity accounting methods in relation to the investment in DNT Inc. has resulted in
a gain of $382,174 on the Consolidated Statement of Financial Performance.
Material factors affecting the assets, liabilities and equity of the consolidated
entity for the current period
New Equity
There was an increase in contributed equity of $13,787,898 (from $33,034,058 to $46,821,956) as a
result of:
$
An issue of 13,335,000 fully paid ordinary shares @ $0.52 each
under a share placement on 10th September 2003 6,934,200
Less: Issue costs 328,418
6,605,782
An issue of 9,000,000 fully paid ordinary shares @ $0.84 each
under a share placement on 18th March 2004 7,560,000
Less: Issue costs 377,884
7,182,116
DNT Inc – Associated Entity
DNT Inc has been treated as an associated company with effect from 27 March 2003. The investment
in DNT Inc was initially valued at cost in the accounts of the consolidated entity. Subsequent to that
date, normal equity accounting principles have been applied in the determination of the carrying value
of the investment in the accounts of the consolidated entity.
There were no other material factors affecting the assets, liabilities and equity of the consolidated
Page 6 of 11
entity for the current period not otherwise disclosed in this report.
Material factors affecting the cash flows of the consolidated entity for the
current period
Capital investments
There was a significant reduction in payments for property, plant and equipment compared with the
previous year. During the previous year capital expenditure of $1,430,920 relating to the fit out of the
chemistry laboratory and corporate headquarters on Level 6 of the Baker Heart Research Building was
incurred.
Cash position
Cash at bank at the end of the current period included the proceeds of the two share placements
referred to in the section above headed “New Equity”.
Reconciliation of cash
Consolidated
2004
$
2003
$
Cash at bank and on hand 2,118,872 1,444,750
Deposits at call 13,539,428 6,446,793
15,658,300 7,891,543
Balance of cash as shown in the statement of cash flows 15,658,300 7,891,543
The deposits are bearing floating interest rates of 5.37% (2003: 4.75%).
Cash flow information
Reconciliation of net cash flows from operating
activities to operating profit/(loss) after income tax Consolidated
2004
$
2003
$
Operating profit/(loss) after income tax (5,497,850) (7,544,721)
Depreciation and amortisation 603,089 604,642
(Increase) decrease in receivables and other assets (16,386) 86,435
Increase (decrease) in trade creditors (274,901) (484,048)
Increase (decrease) in employee provisions 43,286 27,364
Increase (decrease) in deferred income (282,243) 111,484
Share of results of associates accounted for using the equity
method (382,174) 230,530
Gain on sale of property, plant and equipment - (14,898)
Net cash inflows/(outflows) from operating activities (5,807,179) (6,983,212)
Income tax
The consolidated entity has recorded a nil income tax expense for the period and has substantial future
income tax benefits not brought to account at balance date because the directors do not believe it
appropriate to regard the realisation of the future income tax benefit benefits as virtually certain.
Page 7 of 11
Changes in accounting policies
The accounting policies adopted are consistent with those of the previous year.
Segment note
Business Segments
The consolidated entity operates in the following business segments:
Virology – development and commercialisation of dendrimers for prevention and treatment
of virus diseases, particularly sexually transmitted diseases.
Angiogenesis – development and commercialisation of dendrimers that inhibit angiogenesis.
Other Pharmaceuticals – development of dendrimers with novel pharmaceutical activity.
Geographical Segments
The consolidated entity operates in the one geographical segment of Australia.
Equity Accounted Investment
The consolidated entity owns 44.54% of Dendritic Nanotechnologies, Inc., a research, development
and commercialisation company located in Michigan, USA which in the determination of the fullyear
result to and balance sheet as at 30 June 2004, is accounted for using the equity method. As at
and for the full-year ended 30 June 2003, the consolidated entity owned 49.99% of Dendritic
Nanotechnologies, Inc.
Prior Year Comparison
The consolidated entity owned 55% of Dendritic Nanotechnologies Ltd. for the previous year to date
ending 27 March 2003. Therefore, the subsidiary’s results enter into the determination of that fullyear
result and segment note.
Segment Information for Year Ending 30 June 2004
Primary Basis - Business Segments
REVENUE Virology Angiogenesis
Other
Pharmaceuticals Unallocated Consolidated Total
External Revenue - 656,148 47,012 687,443 1,390,603
Total Segment
Revenue - 656,148 47,012 687,443 1,390,603
SEGMENT RESULT
Profit/(Loss) from
Ordinary Activities
before Income Tax (2,347,094) (1,104,520) (1,760,994) (285,242) (5,497,850)
DEPRECIATION & AMORTISATION
Depreciation 241,235 241,235 60,310 60,309 603,089
LIABILITIES
Total Segment
Liabilities - - - 898,446 898,446
ASSETS
Total Segment Assets 3,920,059 1,260,938 3,513,964 9,795,981 18,490,942
SEGMENT ASSETS ACQUIRED DURING THE REPORTING PERIOD
Property, Plant &
Equipment 61,074 61,074 15,269 16,538 153,955
Investments in
Associates - - - 692,194 692,194
Page 8 of 11
Segment Information for Year Ending 30 June 2003
Primary Basis - Business Segments
REVENUE Virology Angiogenesis
Other
Pharmaceuticals
Dendritic
Nanotechnologies
Limited
Unallocated Consolidated Total
External
Revenue 134,700 704,551 - 77,627 568,029 1,484,907
Total Segment
Revenue 134,700 704,551 - 77,627 568,029 1,484,907
SEGMENT
RESULT
Profit/(Loss)
from Ordinary
Activities before
Income Tax (3,216,985) (966,975) (1,689,574) (2,118,634) 272,385 (7,719,783)
DEPRECIATION & AMORTISATION
Depreciation 214,588 214,588 53,647 68,171 53,648 604,642
LIABILITIES
Total Segment
Liabilities - 282,243 - - 1,190,067 1,472,310
ASSETS
Total Segment
Assets 4,437,793 4,437,793 1,109,448 - 730,406 10,715,440
SEGMENT ASSETS ACQUIRED DURING THE REPORTING
PERIOD
Property, Plant
& Equipment 804,072 804,072 161,018 - 161,019 1,930,181
Investments in
Associates - - - 250,700 - 250,700
Events occurring after balance date
There are no significant events occurring after balance date.
Page 9 of 11
STARPHARMA HOLDINGS Ltd
Supplementary Appendix 4E information
Additional dividend/distribution information
No dividends have been paid or declared by the entity since the beginning of the current reporting
period.
No dividends were paid during the previous corresponding period.
Accumulated Losses
30 June 2004
$
30 June 2003
$
Accumulated losses at the beginning of the financial period (23,744,319) (16,024,536)
Net profit (loss) attributable to members of STARPHARMA
HOLDINGS Ltd (5,497,850) (7,719,783)
Retained profits at the end of the financial period (29,242,169) (23,744,319)
NTA Backing
2004 2003
Net tangible asset backing per ordinary share $0.16 $0.10
Associates and Joint Venture entities
Name Ownership
interest
Aggregate share of
profits/(losses),
where material
Contribution to net
profit/(loss),
where material
2004
%
2003
%
2004
$
2003
$
2004
$
2003
$
Dendritic
Nanotechnologies, Inc. 44.5 49.9 (193,436) (3,570,739) (193,436) (3,570,739)
Share of Result of Associate
2004 2003
Gain on deconsolidation - 3,340,209
Share of loss (193,436) (3,570,739)
Gain on issue of new equity by associate 575,610 -
Share of result of associate per statement of financial
performance 382,174 (230,530)
Other significant information
Earnings per share
2004 2003
Cents Cents
Basic Earnings/(Loss) per share (5.38) (8.68)
Diluted Earnings/(Loss) per Share (5.38) (8.68)
Weighted average number of shares used as the denominator
2004 2003
Number Number
Weighted average number of shares used as the denominator
in calculating basic earnings per share 102,169,098 88,900,000
Page 10 of 11
Potential ordinary shares not considered dilutive:
As at 30th June 2004 the company had on issue:
240,000 options over unissued capital exercisable on or before the 31st December 2005 at the price of
93.75 cents per ordinary share
220,000 options over unissued capital exercisable on or before the 11th April 2007 at the price of 93.75
cents per ordinary share.
200,000 options over unissued capital exercisable on or before the 30th June 2007 at the price of 93.75
cents per ordinary share.
200,000 options over unissued capital exercisable on or before the 31st December 2008 at the price of
73.00 cents per ordinary share.
749,000 options over unissued capital exercisable on or before the 8th February 2009 at the price of
93.75 cents per ordinary share.
4,750,000 options expiring 31 March 2005 exercisable at $1.00 if exercised before 30 September 2004
and at $1.25 if exercised between 1 October 2004 and 31 March 2005.
Other Supplementary Information
On 23 January 2004 the Company announced the results of a General Meeting of shareholders
convened to consider a proposal to give Directors the discretion to relinquish the company’s status as a
pooled development fund (PDF). Shareholders voted in support of the proposal, giving the Company
the discretion to apply to the PDF Registration Board at any time prior to the Company’s next Annual
General Meeting (to be held in November 2004) to have its PDF registration declaration revoked. The
Company applied to the PDF Registration Board to have its PDF registration declaration revoked on
16 March 2004. On 17 March 2004, the PDF Registration Board revoked the Company’s PDF
registration application.
The Board’s decision to apply to have the Company’s PDF registration declaration revoked was taken
to ensure that the Company would be able to make strategic decisions such as follow-on investments in
the US based Dendritic Nanotechnologies, Inc. or other spin-out opportunities that may arise in the
future. As a PDF registered entity, the Company was precluded from making further investments in
overseas opportunities.
Appendix 4E items 4, 5, 6, 8 and 9 are not applicable.
Audit
This report is based on accounts which are in the process of being audited.
Compliance Statement
This preliminary final report was approved by a resolution of the Board of Directors of the Company
on 25 August 2004.
Ben Rogers
Company Secretary
25 August 2004
Page 11 of 11
04
SX:SPL) today
the full year ending 30 June 2004. The Company had cash
reserves of $15.6 million at year end, and is well positioned to advance its development
Operating expenditure for the full year was similar to the previous year, after adjusting for the
es Ltd (DNT),
rations, and was
tal of A$3.9
and currently owns 44.5% of the company. This has been an important
strategic investment for Starpharma, and the company is optimistic about the potential of
mmercialisation
rights to DNT’s intellectual property in the area of polyvalent dendrimer based
p
T ncluding:
l
ss with Phase I clinical trials for VivaGel™, the microbicide
Starpharma is developing for the prevention of HIV. In February 2004, VivaGel™
reached a major development milestone with the initiation of a Phase I human clinical trial
plication.
linical trial for a
a number of new institutional shareholders over the past year
and over a third of the company’s share register is now represented by Australian
i tutions on the register provides an
excellent foundation for future growth of the company.
search and
urther expand its shareholder base
in the US over the coming year.
In January 2004 shareholders voted comprehensively to support a proposal to allow the
company to relinquish its PDF status, and this was put into effect in March 2004. This
change in status is part of the evolution of Starpharma and will allow the company to
better take advantage of international commercial opportunities.
For Australian shareholders there were capital gains tax implications in this change of
status. Generally, shareholders were deemed to have disposed of their shares and to
Commentary on results for year ended 30 June 20
Melbourne (Australia), 25 August 2004: Starpharma Holdings Limited (A
announced financial results for
programs over the next three years.
impact of operating expenses of the associated entity Dendritic Nanotechnologi
prior to that entity being deconsolidated at the end of March 2003.
DNT was established in August 2001 as an Australian company with US ope
incorporated as a US company in March 2003. Starpharma has invested a to
million in DNT,
DNT. In addition to the value of the equity investment, Starpharma has co
harmaceuticals.
he past year has seen a number of material developments for Starpharma, i
Clinical Trials – world first for dendrimer based pharmaceutica
There was significant progre
under a U.S. Food and Drug Administration “Investigational New Drug” ap
Starpharma thus became the first company in the world to initiate a c
dendrimer-based pharmaceutical.
Institutional shareholder base
Starpharma has attracted
nstitutional investors. The presence of these insti
Because of Starpharma’s presence in the US (through DNT and other re
commercial initiatives) the company will be looking to f
Change in Pooled Development Fund (PDF) status.
04, the date of
nd this became the
cost base for calculation of future capital gains tax on disposal of these shares.
lopment of its lead
ivaGel as part of a broader focus on women’s reproductive health. The key
diseases targeted in this market niche include HIV, genital herpes, genital warts and
a’s core
expertise and IP position in dendrimer nanotechnology and the company’s strategy is to
partner with other companies in the development of these opportunities. Starpharma is very
optimistic about the year ahead.
have immediately re-acquired the shares at market value on 17 March 20
PDF licence revocation. The share price at this time was A$0.90, a
Starpharma’s commercialisation strategy is to progress in-house the deve
product V
Chlamydia.
There are a number of other development opportunities arising from Starpharm
John W Raff
Chief Executive Officer
Starpharma Holdings Limited (ASX:SPL) is focused on the development and appl
dendrimer nanotechnologies as
ication of
drugs against major diseases. Starpharma’s lead dendrimer product,
VivaGel™ has received clearance from the US FDA for human clinical trials. VivaGel™ is a topical
gel product that has been developed for women as a preventative against the sexual
transmission of HIV. It is also active in animal studies for the prevention of other sexually transmitted
ia. SPL also has an equity interest in a US based
lished with the US pioneer of dendrimer
r Donald Tomalia.
+61 3 8532 2702
www.starpharma.com
microbicide
diseases including genital Herpes and Chlamyd
company – Dendriti logies Inc. (DN c Nanotechno T) – estab
nanotechnology, D
CONTACTS:
Dr John Raff Mr Ben Rogers
Chief Executive Officer Company Secretary
+61 3 8532 2701
Starpharma Holdings Limited (Starpharma) is admitted to the official list of the Australian Stock Exchange
Limited (ASX). At this time, Starpharma has not agreed to be listed, or to have its securities quoted, on any other
financial market. If investing in Starpharma through another financial market you should be aware that you may
not acquire direct ownership of securities issued by Starpharma nor be recognised by Starpharma as a holder of
its securities for the purposes of corporate actions, and that Starpharma does not usually make announcements
to the operators of such markets.
STARPHARMA HOLDINGS Limited
ABN 20 078 532 180
ASX Preliminary final report – 30 June
2004
Lodged with the ASX under Listing Rule 4.3A
Contents
Results for Announcement to the Market 2
Preliminary consolidated statement of financial performance 3
Preliminary consolidated statement of financial position 4
Preliminary consolidated statement of cash flows 5
Supplementary Appendix 4E Information 10
Page 1 of 11
STARPHARMA HOLDINGS Ltd
Year ended 30 June 2004
(Previous corresponding period:
Year ended 30 June 2003)
Results for Announcement to the Market
$
Revenue from ordinary activities up/down 8% to 1,390,603
Profit/(loss) from ordinary activities after tax
attributable to members up/down 29% to (5,497,850)
Net profit/(loss) for the period attributable to
members up/down 29% to (5,497,850)
Dividends/distributions Amount per security Franked amount per
security
Final dividend Nil Nil
Interim dividend Nil Nil
Record date for determining entitlements to the dividend Not Applicable
No dividends have been paid or declared by the entity since the beginning of the current reporting
period. No dividends were paid for the previous corresponding period.
Explanation of Revenue
Revenue consisted of grant income from a Commonwealth Government R&D START Grant of
$656,148 (2003: $839,251), Interest revenue of $640,247 (2003: $558,674), and other revenue of
$94,208 (2003: $112,495).
Explanation of Net Profit/(loss)
The consolidated loss of $5,497,850 is after fully expensing all research and development expenditure
and patenting costs. The reduction of 29% in the net loss is primarily the result of excluding the
revenues and expenses of the former controlled entity Dendritic Nanotechnologies Ltd from the
consolidated entity. This is further explained in the section “Material factors affecting the revenues
and expenses of the consolidated entity for the current period” on page 6.
Page 2 of 11
STARPHARMA HOLDINGS Ltd
Consolidated statement of financial performance
For the year ended 30 June 2004
Consolidated
2004 2003
$ $
Revenue from ordinary activities 1,390,603 1,510,420
Expenses from ordinary activities
Administration expense (2,211,604) (2,026,347)
Research and development expense (4,119,259) (5,713,405)
Occupancy expense (324,664) (439,175)
Depreciation (plant and equipment) (603,089) (604,642)
Borrowing (12,011) (15,529)
Other expense from ordinary activities - (25,513)
Share of results of associates accounted for using the equity method 382,174 (230,530)
PROFIT (LOSS) FROM OPERATING ACTIVITIES BEFORE
TAX (5,497,850) (7,544,721)
Income tax on ordinary activities - -
PROFIT (LOSS) FROM OPERATING ACTIVITIES AFTER TAX (5,497,850) (7,544,721)
(Profit) Loss attributable to outside equity interest - (175,062)
PROFIT (LOSS) FROM OPERATING ACTIVITIES AFTER TAX (5,497,850) (7,719,783)
Page 3 of 11
STARPHARMA HOLDINGS Ltd
Consolidated statement of financial position
As at 30 June 2004
Consolidated
30 June 2004 30 June 2003
ASSETS $ $
CURRENT ASSETS
Cash assets 15,658,300 7,891,543
Receivables 471,139 420,257
Other 113,044 147,540
TOTAL CURRENT ASSETS 16,242,483 8,459,340
NON CURRENT ASSETS
Property, plant and equipment 1,556,265 2,005,400
Investments accounted for using the equity method 692,194 250,700
TOTAL NON-CURRENT ASSETS 2,248,459 2,256,100
TOTAL ASSETS 18,490,942 10,715,440
LIABILITIES
CURRENT LIABILITIES
Payables 445,908 720,809
Provisions 249,015 205,729
Interest-bearing liabilities 60,007 60,007
Other - 282,243
TOTAL CURRENT LIABILITIES 754,930 1,268,788
NON-CURRENT LIABILITIES
Interest-bearing liabilities 143,516 203,522
TOTAL NON-CURRENT LIABILITIES 143,516 203,522
TOTAL LIABILITIES 898,446 1,472,310
NET ASSETS 17,592,496 9,243,130
EQUITY
Contributed equity 46,821,956 33,034,058
Foreign currency translation reserve 12,709 (46,609)
Retained profits (Accumulated losses) (29,242,169) (23,744,319)
TOTAL EQUITY 17,592,496 9,243,130
Page 4 of 11
STARPHARMA HOLDINGS Ltd
Consolidated statement of cash flows
For the year ended 30 June 2004
Consolidated
Full-year
2004 2003
$ $
CASH FLOWS FROM OPERATIONS
Receipts from trade and other debtors 36,197 125,086
Grant Income (Inclusive of GST) 560,529 948,285
Interest received 613,010 646,677
Interest expense (11,993) (15,529)
Payments to suppliers and employees (Inclusive of GST) (7,004,922) (8,687,731)
NET CASH INFLOWS (OUTFLOWS) FROM OPERATING
ACTIVITIES (5,807,179) (6,983,212)
CASH FLOWS FROM INVESTING ACTIVITIES
Cash eliminated on deconsolidation - (933,239)
Proceeds from sale of property, plant and equipment - 40,411
Payments for property, plant and equipment (153,955) (1,610,181)
NET CASH INFLOWS (OUTFLOWS) FROM INVESTING
ACTIVITIES (153,955) (2,503,009)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issue of shares 14,494,200 -
Share issue transaction costs (706,302) -
Lease repayments (60,007) (56,471)
NET CASH INFLOWS (OUTFLOWS) FROM FINANCING
ACTIVITIES 13,727,891 (56,471)
NET INCREASE (DECREASE) IN CASH HELD 7,766,757 (9,542,692)
CASH AT THE BEGINNING OF THE FINANCIAL YEAR 7,891,543 17,434,235
CASH AT THE END OF THE FINANCIAL YEAR 15,658,300 7,891,543
Page 5 of 11
STARPHARMA HOLDINGS Ltd
Notes to the full-year report
For the period ended 30 June 2004
Material factors affecting the revenues and expenses of the consolidated entity
for the current period
There was a reduction of 29% in the operating loss of the consolidated entity during the current period
compared with the previous year. This is attributable to the following factors:
Loss of Control of Dendritic Nanotechnologies Ltd
During the previous year the revenues and expenses of the consolidated entity were affected by the
change in the level of control of the former controlled entity Dendritic Nanotechnologies Ltd (“DNT
Ltd”). From 27th March 2003 Dendritic Nanotechnologies Ltd became a wholly owned subsidiary of
the US entity Dendritic Nanotechnologies, Inc. (“DNT Inc”) and Starpharma Holdings Ltd held
49.99% of the issued shares in DNT Inc. The revenues and expenses of DNT Ltd were included in
the consolidated results of the Company from 1 July 2002 to 27 March 2003, but as control in DNT
Ltd ceased on 27 March 2003 from that date the accounts of DNT Ltd and DNT Inc have been
excluded from the consolidated accounts.
Revenue
Revenue from ordinary activities decreased by $119,817. This was primarily due to the exclusion of
revenues of the former controlled entity DNT Ltd and a reduction in grant income associated with
completion of R&D START grants.
Operating costs
The 2003 costs included $1.83 million of operating expenses and $68,171 of depreciation attributable
to DNT Ltd prior to that entity being deconsolidated. Excluding the impact of DNT Ltd in the
calculation of the 2003 costs, operating expenditure and depreciation attributable to remaining group
members was $6.39 million and $536,470 respectively in 2003 compared with operating expenditure
of $6.66 million and depreciation of $603,089 in 2004.
Share of results of associates
The application of equity accounting methods in relation to the investment in DNT Inc. has resulted in
a gain of $382,174 on the Consolidated Statement of Financial Performance.
Material factors affecting the assets, liabilities and equity of the consolidated
entity for the current period
New Equity
There was an increase in contributed equity of $13,787,898 (from $33,034,058 to $46,821,956) as a
result of:
$
An issue of 13,335,000 fully paid ordinary shares @ $0.52 each
under a share placement on 10th September 2003 6,934,200
Less: Issue costs 328,418
6,605,782
An issue of 9,000,000 fully paid ordinary shares @ $0.84 each
under a share placement on 18th March 2004 7,560,000
Less: Issue costs 377,884
7,182,116
DNT Inc – Associated Entity
DNT Inc has been treated as an associated company with effect from 27 March 2003. The investment
in DNT Inc was initially valued at cost in the accounts of the consolidated entity. Subsequent to that
date, normal equity accounting principles have been applied in the determination of the carrying value
of the investment in the accounts of the consolidated entity.
There were no other material factors affecting the assets, liabilities and equity of the consolidated
Page 6 of 11
entity for the current period not otherwise disclosed in this report.
Material factors affecting the cash flows of the consolidated entity for the
current period
Capital investments
There was a significant reduction in payments for property, plant and equipment compared with the
previous year. During the previous year capital expenditure of $1,430,920 relating to the fit out of the
chemistry laboratory and corporate headquarters on Level 6 of the Baker Heart Research Building was
incurred.
Cash position
Cash at bank at the end of the current period included the proceeds of the two share placements
referred to in the section above headed “New Equity”.
Reconciliation of cash
Consolidated
2004
$
2003
$
Cash at bank and on hand 2,118,872 1,444,750
Deposits at call 13,539,428 6,446,793
15,658,300 7,891,543
Balance of cash as shown in the statement of cash flows 15,658,300 7,891,543
The deposits are bearing floating interest rates of 5.37% (2003: 4.75%).
Cash flow information
Reconciliation of net cash flows from operating
activities to operating profit/(loss) after income tax Consolidated
2004
$
2003
$
Operating profit/(loss) after income tax (5,497,850) (7,544,721)
Depreciation and amortisation 603,089 604,642
(Increase) decrease in receivables and other assets (16,386) 86,435
Increase (decrease) in trade creditors (274,901) (484,048)
Increase (decrease) in employee provisions 43,286 27,364
Increase (decrease) in deferred income (282,243) 111,484
Share of results of associates accounted for using the equity
method (382,174) 230,530
Gain on sale of property, plant and equipment - (14,898)
Net cash inflows/(outflows) from operating activities (5,807,179) (6,983,212)
Income tax
The consolidated entity has recorded a nil income tax expense for the period and has substantial future
income tax benefits not brought to account at balance date because the directors do not believe it
appropriate to regard the realisation of the future income tax benefit benefits as virtually certain.
Page 7 of 11
Changes in accounting policies
The accounting policies adopted are consistent with those of the previous year.
Segment note
Business Segments
The consolidated entity operates in the following business segments:
Virology – development and commercialisation of dendrimers for prevention and treatment
of virus diseases, particularly sexually transmitted diseases.
Angiogenesis – development and commercialisation of dendrimers that inhibit angiogenesis.
Other Pharmaceuticals – development of dendrimers with novel pharmaceutical activity.
Geographical Segments
The consolidated entity operates in the one geographical segment of Australia.
Equity Accounted Investment
The consolidated entity owns 44.54% of Dendritic Nanotechnologies, Inc., a research, development
and commercialisation company located in Michigan, USA which in the determination of the fullyear
result to and balance sheet as at 30 June 2004, is accounted for using the equity method. As at
and for the full-year ended 30 June 2003, the consolidated entity owned 49.99% of Dendritic
Nanotechnologies, Inc.
Prior Year Comparison
The consolidated entity owned 55% of Dendritic Nanotechnologies Ltd. for the previous year to date
ending 27 March 2003. Therefore, the subsidiary’s results enter into the determination of that fullyear
result and segment note.
Segment Information for Year Ending 30 June 2004
Primary Basis - Business Segments
REVENUE Virology Angiogenesis
Other
Pharmaceuticals Unallocated Consolidated Total
External Revenue - 656,148 47,012 687,443 1,390,603
Total Segment
Revenue - 656,148 47,012 687,443 1,390,603
SEGMENT RESULT
Profit/(Loss) from
Ordinary Activities
before Income Tax (2,347,094) (1,104,520) (1,760,994) (285,242) (5,497,850)
DEPRECIATION & AMORTISATION
Depreciation 241,235 241,235 60,310 60,309 603,089
LIABILITIES
Total Segment
Liabilities - - - 898,446 898,446
ASSETS
Total Segment Assets 3,920,059 1,260,938 3,513,964 9,795,981 18,490,942
SEGMENT ASSETS ACQUIRED DURING THE REPORTING PERIOD
Property, Plant &
Equipment 61,074 61,074 15,269 16,538 153,955
Investments in
Associates - - - 692,194 692,194
Page 8 of 11
Segment Information for Year Ending 30 June 2003
Primary Basis - Business Segments
REVENUE Virology Angiogenesis
Other
Pharmaceuticals
Dendritic
Nanotechnologies
Limited
Unallocated Consolidated Total
External
Revenue 134,700 704,551 - 77,627 568,029 1,484,907
Total Segment
Revenue 134,700 704,551 - 77,627 568,029 1,484,907
SEGMENT
RESULT
Profit/(Loss)
from Ordinary
Activities before
Income Tax (3,216,985) (966,975) (1,689,574) (2,118,634) 272,385 (7,719,783)
DEPRECIATION & AMORTISATION
Depreciation 214,588 214,588 53,647 68,171 53,648 604,642
LIABILITIES
Total Segment
Liabilities - 282,243 - - 1,190,067 1,472,310
ASSETS
Total Segment
Assets 4,437,793 4,437,793 1,109,448 - 730,406 10,715,440
SEGMENT ASSETS ACQUIRED DURING THE REPORTING
PERIOD
Property, Plant
& Equipment 804,072 804,072 161,018 - 161,019 1,930,181
Investments in
Associates - - - 250,700 - 250,700
Events occurring after balance date
There are no significant events occurring after balance date.
Page 9 of 11
STARPHARMA HOLDINGS Ltd
Supplementary Appendix 4E information
Additional dividend/distribution information
No dividends have been paid or declared by the entity since the beginning of the current reporting
period.
No dividends were paid during the previous corresponding period.
Accumulated Losses
30 June 2004
$
30 June 2003
$
Accumulated losses at the beginning of the financial period (23,744,319) (16,024,536)
Net profit (loss) attributable to members of STARPHARMA
HOLDINGS Ltd (5,497,850) (7,719,783)
Retained profits at the end of the financial period (29,242,169) (23,744,319)
NTA Backing
2004 2003
Net tangible asset backing per ordinary share $0.16 $0.10
Associates and Joint Venture entities
Name Ownership
interest
Aggregate share of
profits/(losses),
where material
Contribution to net
profit/(loss),
where material
2004
%
2003
%
2004
$
2003
$
2004
$
2003
$
Dendritic
Nanotechnologies, Inc. 44.5 49.9 (193,436) (3,570,739) (193,436) (3,570,739)
Share of Result of Associate
2004 2003
Gain on deconsolidation - 3,340,209
Share of loss (193,436) (3,570,739)
Gain on issue of new equity by associate 575,610 -
Share of result of associate per statement of financial
performance 382,174 (230,530)
Other significant information
Earnings per share
2004 2003
Cents Cents
Basic Earnings/(Loss) per share (5.38) (8.68)
Diluted Earnings/(Loss) per Share (5.38) (8.68)
Weighted average number of shares used as the denominator
2004 2003
Number Number
Weighted average number of shares used as the denominator
in calculating basic earnings per share 102,169,098 88,900,000
Page 10 of 11
Potential ordinary shares not considered dilutive:
As at 30th June 2004 the company had on issue:
240,000 options over unissued capital exercisable on or before the 31st December 2005 at the price of
93.75 cents per ordinary share
220,000 options over unissued capital exercisable on or before the 11th April 2007 at the price of 93.75
cents per ordinary share.
200,000 options over unissued capital exercisable on or before the 30th June 2007 at the price of 93.75
cents per ordinary share.
200,000 options over unissued capital exercisable on or before the 31st December 2008 at the price of
73.00 cents per ordinary share.
749,000 options over unissued capital exercisable on or before the 8th February 2009 at the price of
93.75 cents per ordinary share.
4,750,000 options expiring 31 March 2005 exercisable at $1.00 if exercised before 30 September 2004
and at $1.25 if exercised between 1 October 2004 and 31 March 2005.
Other Supplementary Information
On 23 January 2004 the Company announced the results of a General Meeting of shareholders
convened to consider a proposal to give Directors the discretion to relinquish the company’s status as a
pooled development fund (PDF). Shareholders voted in support of the proposal, giving the Company
the discretion to apply to the PDF Registration Board at any time prior to the Company’s next Annual
General Meeting (to be held in November 2004) to have its PDF registration declaration revoked. The
Company applied to the PDF Registration Board to have its PDF registration declaration revoked on
16 March 2004. On 17 March 2004, the PDF Registration Board revoked the Company’s PDF
registration application.
The Board’s decision to apply to have the Company’s PDF registration declaration revoked was taken
to ensure that the Company would be able to make strategic decisions such as follow-on investments in
the US based Dendritic Nanotechnologies, Inc. or other spin-out opportunities that may arise in the
future. As a PDF registered entity, the Company was precluded from making further investments in
overseas opportunities.
Appendix 4E items 4, 5, 6, 8 and 9 are not applicable.
Audit
This report is based on accounts which are in the process of being audited.
Compliance Statement
This preliminary final report was approved by a resolution of the Board of Directors of the Company
on 25 August 2004.
Ben Rogers
Company Secretary
25 August 2004
Page 11 of 11
Wann brechen wir endlich aus...
Starpharma bleibt meiner Meinung nach der Top Nano/Biotech-Wert, problematisch ist aber die derzeitge Unterbewertung vieler Unternehmen im Biotech-Sektor.
Da muss ich sagen, daß bei Starpharma momentan nicht einmal eine Unterbewertung vorliegt. Kurzfristig sehe ich also kein fulminantes Potential, außer es kommt was bahnbrechendes im Stile der Theravance/Glaxo-Kooperation (also ein Mehrere-Hundert-Millionen-Dollar-Langzeitdeal).
Sonst werden wir wohl noch etwas warten müssen bis die 1 AUD-Grenze fällt.
10-15 Prozent sind natürlich auch jetzt noch drin bei anderen guten News, allerdings bin ich kurzfristig Short. Es gab kürzlich sogar einen Ami-Bio-/Nanotech mit einem Medikament direkt vor der Marktzulassung und 35 Millionen Dollar Marketcap, da hat Starpharma doch noch ein Stück weg zu gehen.
Mittel- bis langfristig natürlich nach wie vor Strong Buy. Ich hoffe ihr bleibt dem Thread erhalten, ich werde mich auch während meiner "Abwesenheit" aus der Aktie die Entwicklung weiter verfolgen und hoffe das dieses Forum weiterhin alle NAchrichten und sonstiges von Starpharma aufzeigen kann.
Bis dann und danke nochmals an alle, die dafür sorgen, daß die Diskussion hier immer sachlich und informativ abläuft.
Da muss ich sagen, daß bei Starpharma momentan nicht einmal eine Unterbewertung vorliegt. Kurzfristig sehe ich also kein fulminantes Potential, außer es kommt was bahnbrechendes im Stile der Theravance/Glaxo-Kooperation (also ein Mehrere-Hundert-Millionen-Dollar-Langzeitdeal).
Sonst werden wir wohl noch etwas warten müssen bis die 1 AUD-Grenze fällt.
10-15 Prozent sind natürlich auch jetzt noch drin bei anderen guten News, allerdings bin ich kurzfristig Short. Es gab kürzlich sogar einen Ami-Bio-/Nanotech mit einem Medikament direkt vor der Marktzulassung und 35 Millionen Dollar Marketcap, da hat Starpharma doch noch ein Stück weg zu gehen.
Mittel- bis langfristig natürlich nach wie vor Strong Buy. Ich hoffe ihr bleibt dem Thread erhalten, ich werde mich auch während meiner "Abwesenheit" aus der Aktie die Entwicklung weiter verfolgen und hoffe das dieses Forum weiterhin alle NAchrichten und sonstiges von Starpharma aufzeigen kann.
Bis dann und danke nochmals an alle, die dafür sorgen, daß die Diskussion hier immer sachlich und informativ abläuft.
Gude Neoe
Erst die leute heiss machen und dann nicht mal sagen um welchen Wert es sich handelt.
Welches Ami Bio/Nanotech wert ist es denn ?
Danke und Grüsse
B.M.
Erst die leute heiss machen und dann nicht mal sagen um welchen Wert es sich handelt.
Welches Ami Bio/Nanotech wert ist es denn ?
Danke und Grüsse
B.M.
brauch geld:
Heiss machen ist nicht mehr. Ich bin vor einigen Tagen so ziemlich am 52 week low in Access Pharmaceuticals eingestiegen, seither lief das Ding schon 60 Prozent, war mehr ein Glücksgriff (weil normalerweise: never catch a falling knife).
Übrigens das Produkt, dass vor der Markteinführung steht beinhaltet zwar revolutionäre Technik, ist aber kein Nanotech-Produkt.
Da es sich bei Produktzulassung aber langfristig um einen echten HAmmer handeln könnte, werde ich in den nächsten Tagen noch einen Thread eröffnen: Die Pipeline der Firma hat es wirklich in sich.
Heiss machen ist nicht mehr. Ich bin vor einigen Tagen so ziemlich am 52 week low in Access Pharmaceuticals eingestiegen, seither lief das Ding schon 60 Prozent, war mehr ein Glücksgriff (weil normalerweise: never catch a falling knife).
Übrigens das Produkt, dass vor der Markteinführung steht beinhaltet zwar revolutionäre Technik, ist aber kein Nanotech-Produkt.
Da es sich bei Produktzulassung aber langfristig um einen echten HAmmer handeln könnte, werde ich in den nächsten Tagen noch einen Thread eröffnen: Die Pipeline der Firma hat es wirklich in sich.
Hi Neoe!
Du findest mich etwas überascht, dass du dich so plötzlich hinsichtlich Starpharma zurückziehst. Naja, ich hoffe du bist bald wieder mit dabei. Vielen Dank für die Infos und die Arbeit, die du dir gemacht hast.
Gruß, greenhorn
Du findest mich etwas überascht, dass du dich so plötzlich hinsichtlich Starpharma zurückziehst. Naja, ich hoffe du bist bald wieder mit dabei. Vielen Dank für die Infos und die Arbeit, die du dir gemacht hast.
Gruß, greenhorn
Hi greenhorn:
Schön mal wieder von dir zu hören, ich schreib dir mal persönlich in den nächsten Tagen, würde mich interessieren, wo du gerade so engagiert bist.
Wie schon gesagt, mein temporärer Rückzug aus Starpharma hat sicher nichts damit zu tun, dass ich in irgendeiner Weise an der Zukunft dieses Unternehmens zweifle.
Ich fühl mich ja schon fast unwohl, jetzt da ich sie nicht im Depot habe....also lange wird es nicht dauern.
Schön mal wieder von dir zu hören, ich schreib dir mal persönlich in den nächsten Tagen, würde mich interessieren, wo du gerade so engagiert bist.
Wie schon gesagt, mein temporärer Rückzug aus Starpharma hat sicher nichts damit zu tun, dass ich in irgendeiner Weise an der Zukunft dieses Unternehmens zweifle.
Ich fühl mich ja schon fast unwohl, jetzt da ich sie nicht im Depot habe....also lange wird es nicht dauern.
Hi Neoe
Ich bin auch bei Access eingestiegen und bin schon damit leicht im plus .
Hab 2 fragen und zwar
1.Wann wird mit der zulassung etwa gerechnet ?
2.Wie hoch wird das Umsatzpotential für das Produkt geschätzt ?
Danke und Grüsse
B.M.
Ich bin auch bei Access eingestiegen und bin schon damit leicht im plus .
Hab 2 fragen und zwar
1.Wann wird mit der zulassung etwa gerechnet ?
2.Wie hoch wird das Umsatzpotential für das Produkt geschätzt ?
Danke und Grüsse
B.M.
Aktualisierung, wär schade wenn der Thread zuweit nach hinten rutscht. Wann bist du wieder an Bord, Neoe????
Anstieg unter hohem Volumen, vielleicht passiert bald was. Ich werde es (leider) von der Seitenlinie betrachten müssen.
Ist das nicht schön? Steigende Umsätze und der Kurs bricht mal wieder durch die 90 cent.
Guten Morgen!
Es ist wirklich sehr schön zu beobachten, dass sich Starpharma trotz fehlender News nahe an den Hochs befindet. Und das mit überdurchschnittlichem Volumen. Ich bin gespannt, wie das Volumen aussieht, sollten bald gute Nachrichten vorliegen. Wann das sein wird, vermag ich natürlich nicht zu sagen. Habe mir mittlerweile abgewöhnt zu denken, dass bald News kommen könnten, nur weil die Aktie unter etwas steigendem Volumen ein bisschen anzieht. Wir müssen weiter abwarten. Cool bleiben
Gruß, greenhorn
Es ist wirklich sehr schön zu beobachten, dass sich Starpharma trotz fehlender News nahe an den Hochs befindet. Und das mit überdurchschnittlichem Volumen. Ich bin gespannt, wie das Volumen aussieht, sollten bald gute Nachrichten vorliegen. Wann das sein wird, vermag ich natürlich nicht zu sagen. Habe mir mittlerweile abgewöhnt zu denken, dass bald News kommen könnten, nur weil die Aktie unter etwas steigendem Volumen ein bisschen anzieht. Wir müssen weiter abwarten. Cool bleiben
Gruß, greenhorn
Hi Neoe!
Steigende Kurse tun schon ein bisschen weh, wenn ich weiß, dass du derzeit nicht drin bist. Kann diese erfreuliche Entwicklung der letzten Tage gar nicht wirklich einschätzen. Kommen bald News? Das haben wir schon so oft gesagt. Das Volumen ist auf jeden Fall sehr erfreulich. Momentan steht wieder einmal nur die 1 AUD-Marke im Weg zwischen Himmel und Hölle.
Gruß, greenhorn
Steigende Kurse tun schon ein bisschen weh, wenn ich weiß, dass du derzeit nicht drin bist. Kann diese erfreuliche Entwicklung der letzten Tage gar nicht wirklich einschätzen. Kommen bald News? Das haben wir schon so oft gesagt. Das Volumen ist auf jeden Fall sehr erfreulich. Momentan steht wieder einmal nur die 1 AUD-Marke im Weg zwischen Himmel und Hölle.
Gruß, greenhorn
Hallo Greenhorn,
kein Problem, ich wünsche dir satte Gewinne in den nächsten Tagen und Wochen. Bis 1 AUD hat Starpharma Luft, alles andere ist nur durch eine wirklich bahnbrechende Neuigkeit zu erreichen. Wenn sowas passieren sollte, müsste ich aber wirklich die ein oder andere Träne verdrücken....
kein Problem, ich wünsche dir satte Gewinne in den nächsten Tagen und Wochen. Bis 1 AUD hat Starpharma Luft, alles andere ist nur durch eine wirklich bahnbrechende Neuigkeit zu erreichen. Wenn sowas passieren sollte, müsste ich aber wirklich die ein oder andere Träne verdrücken....
Hallo zusammen!
Es gibt News:
Starpharma to lead a US$5.4M NIH-funded project to develop a preventative treatment for HIV and other sexually transmitted diseases
Melbourne, Victoria Australia, September 30, 2004:
Melbourne-based nanotechnology company Starpharma (ASX:SPL) will lead a consortium to develop a second generation microbicide for the prevention of infection by HIV and other sexually transmitted diseases (STDs). This consortium is being funded by a US$5.4 million (A$7.5 million) grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National
Institutes of Health (NIH).
The consortium consists of Starpharma and ReProtect, Inc., together with research groups from the Johns Hopkins University, the University of Texas Medical Branch, the
University of Kentucky, the University of Washington and the Burnet Institute in Melbourne.
Microbicides are chemical agents that in the form of gels can be used before intercourse to inactivate STD pathogens. Microbicides are currently being viewed by health officials as one of the best potential opportunities for stemming the spread of HIV/AIDS.
“It is very significant for us that NIH and NIAID have recognized not only the tremendous potential of microbicides in the fight against AIDS, but through their Peer Review system, have awarded our research consortium a grant to exploit the particular strengths of the
complementary technologies owned by Starpharma and ReProtect," said John Raff, CEO of Starpharma.
According to Thomas Moench, President of ReProtect: “Attaining the goal of developing a
combination microbicide against HIV and other STDs can be likened to putting both seat belts and airbags into cars, rather than building hospital beds for traffic accident victims. Success in this undertaking with Starpharma would provide an exciting new product with the broadest and most reliable protection against pregnancy and disease."
Both Starpharma and ReProtect already have microbicides in clinical trials. VivaGel™, Starpharma’s product based on proprietary dendrimer technology, is in Phase I clinical
trials. ReProtect`s BufferGel is currently in an NIH sponsored Phase II/IIb safety and efficacy trial for the prevention of HIV transmission.
A strength of the companies` working together is the opportunity to develop a microbicide that combines several protective actions to prevent transmission of a broad spectrum of STDs including HIV, herpes, chlamydia and human papilloma virus.
In the US, STDs including genital herpes affect more than 70 million people annually. It was estimated in 1999 that the annual cost of all STDs was more than US$10 billion a
year.
About Starpharma: Starpharma Holdings Limited (ASX:SPL) is focused on the development and application of
dendrimer nanotechnologies as drugs against major diseases. Starpharma’s lead dendrimer product, VivaGel™ has received clearance from the US FDA for human clinical trials. VivaGel™ is a topical microbicide gel product that has been developed for women as a preventative against the
sexual transmission of HIV. It is also active in animal studies for the prevention of other sexually transmitted diseases including genital herpes and chlamydia. SPL also has an equity interest in a US based company – Dendritic Nanotechnologies, Inc. (DNT) – established with the US pioneer of dendrimer nanotechnology Dr Donald Tomalia.
About ReProtect, Inc.: ReProtect is a US company with a research and commercialisation focus in reproductive health. The company`s mission is to prevent unwanted pregnancies and STDs by providing the most
effective and innovative products to women and men throughout the world. Reprotect is the first company to offer a vaginal microbicide that works by reinforcing a natural protective action of the female reproductive tract, avoiding the use of hormones or potentially-toxic
detergents. ReProtect`s goal is to provide safe, reliable and effective form of female contraception which incorporates the ability to prevent the transmission of STDs.
Gruß, greenhorn
Es gibt News:
Starpharma to lead a US$5.4M NIH-funded project to develop a preventative treatment for HIV and other sexually transmitted diseases
Melbourne, Victoria Australia, September 30, 2004:
Melbourne-based nanotechnology company Starpharma (ASX:SPL) will lead a consortium to develop a second generation microbicide for the prevention of infection by HIV and other sexually transmitted diseases (STDs). This consortium is being funded by a US$5.4 million (A$7.5 million) grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National
Institutes of Health (NIH).
The consortium consists of Starpharma and ReProtect, Inc., together with research groups from the Johns Hopkins University, the University of Texas Medical Branch, the
University of Kentucky, the University of Washington and the Burnet Institute in Melbourne.
Microbicides are chemical agents that in the form of gels can be used before intercourse to inactivate STD pathogens. Microbicides are currently being viewed by health officials as one of the best potential opportunities for stemming the spread of HIV/AIDS.
“It is very significant for us that NIH and NIAID have recognized not only the tremendous potential of microbicides in the fight against AIDS, but through their Peer Review system, have awarded our research consortium a grant to exploit the particular strengths of the
complementary technologies owned by Starpharma and ReProtect," said John Raff, CEO of Starpharma.
According to Thomas Moench, President of ReProtect: “Attaining the goal of developing a
combination microbicide against HIV and other STDs can be likened to putting both seat belts and airbags into cars, rather than building hospital beds for traffic accident victims. Success in this undertaking with Starpharma would provide an exciting new product with the broadest and most reliable protection against pregnancy and disease."
Both Starpharma and ReProtect already have microbicides in clinical trials. VivaGel™, Starpharma’s product based on proprietary dendrimer technology, is in Phase I clinical
trials. ReProtect`s BufferGel is currently in an NIH sponsored Phase II/IIb safety and efficacy trial for the prevention of HIV transmission.
A strength of the companies` working together is the opportunity to develop a microbicide that combines several protective actions to prevent transmission of a broad spectrum of STDs including HIV, herpes, chlamydia and human papilloma virus.
In the US, STDs including genital herpes affect more than 70 million people annually. It was estimated in 1999 that the annual cost of all STDs was more than US$10 billion a
year.
About Starpharma: Starpharma Holdings Limited (ASX:SPL) is focused on the development and application of
dendrimer nanotechnologies as drugs against major diseases. Starpharma’s lead dendrimer product, VivaGel™ has received clearance from the US FDA for human clinical trials. VivaGel™ is a topical microbicide gel product that has been developed for women as a preventative against the
sexual transmission of HIV. It is also active in animal studies for the prevention of other sexually transmitted diseases including genital herpes and chlamydia. SPL also has an equity interest in a US based company – Dendritic Nanotechnologies, Inc. (DNT) – established with the US pioneer of dendrimer nanotechnology Dr Donald Tomalia.
About ReProtect, Inc.: ReProtect is a US company with a research and commercialisation focus in reproductive health. The company`s mission is to prevent unwanted pregnancies and STDs by providing the most
effective and innovative products to women and men throughout the world. Reprotect is the first company to offer a vaginal microbicide that works by reinforcing a natural protective action of the female reproductive tract, avoiding the use of hormones or potentially-toxic
detergents. ReProtect`s goal is to provide safe, reliable and effective form of female contraception which incorporates the ability to prevent the transmission of STDs.
Gruß, greenhorn
Nette Sache für Starpharma. Ende 2004/ Anfang 2005 sollten auch die Phase I Ergebnisse zu VivaGel vorliegen (laut Jahresbericht)
N`abend zusammen!
Annual General Meetin
...und zwar am 17. November 2004.
Gruß, greenhorn, der den Thread mal wieder nach oben holen wollte.
Annual General Meetin
...und zwar am 17. November 2004.
Gruß, greenhorn, der den Thread mal wieder nach oben holen wollte.
Der Thread ist zuschön um nach hinten zu versinken.
Die Zeit von Starpharma wird kommen, auch wenn es gerade ruhig ist.
Die Ruhe hat natürlich auch viel mit dem Aufgabengebiet von Dendritic Nanotech zu tun. Ich denke hier gäbe es genügend mitteilungswerte Infos. Da Dendritic aber hauptsächlich mit Militäraufträgen beschäftigt ist(und darüber hinaus bei vielen anderen Projekten noch in der Anfangsphase steckt), können wir kaum davon ausgehen, allzuviel zu erfahren.
Der Kursverlauf macht Starpharma sehr interessant, aber bis Jahresende erwarte ich keine größeren Bewegungen mehr, ausgenommen unerwartete News treffen ein.
Die Ruhe hat natürlich auch viel mit dem Aufgabengebiet von Dendritic Nanotech zu tun. Ich denke hier gäbe es genügend mitteilungswerte Infos. Da Dendritic aber hauptsächlich mit Militäraufträgen beschäftigt ist(und darüber hinaus bei vielen anderen Projekten noch in der Anfangsphase steckt), können wir kaum davon ausgehen, allzuviel zu erfahren.
Der Kursverlauf macht Starpharma sehr interessant, aber bis Jahresende erwarte ich keine größeren Bewegungen mehr, ausgenommen unerwartete News treffen ein.
Hallo zusammen!
Ich muss sagen, bei Starpharma gibt man sich wirklich Mühe!
Hatte in der letzten Woche eine E-Mail Richtung Australien geschickt, in der ich um eine Stellungnahme hinsichtlich der Konkurrenzsalbe von VivaGel gebeten hatte. Nachzulesen war das ganze u.a. im Science-Magazin. In einem Artikel wurde die Arbeit des Forscherteams um Michael Lederman (Case Western Reserve University/Cleveland, Ohio) vorgestellt.
Nun, die Mail hatte ich an Ben Rogers geschickt, geantwortet hat Alexander Szabo, Ph.D., MBA
Vice President, Business Development
Starpharma, Ltd.
Dear Mr. xxx,
Ben Rogers, our company secretary, asked me to respond to your email. We are aware of these experiments and were intrigued that this report gained so much media attention when the product contemplated is quite far in development behind Vivagel. I suspect that the reason for this high degree of interest is that the scientific article describes a novel potential mechanism for a microbicide. However, it should be noted that this is very much an experimental academic study of a potential microbicide active ingredient. But the group would have a long ways to go and many obstacles to overcome for it to reach market or even to reach the stage of development of Vivagel.
In addition to progressing VivaGel, Starpharma is also investigating many alternative methods that could provide additional or complementary benefits. However, our analysis of this method leaves us with a number of concerns about this approach and suggests it may fail in the future for one or more of the following reasons:
Susceptibility to resistance – The experiments were designed to prove that an agent that blocks the CCR5 receptor can prevent infection. But it turns out that there are other variants of HIV that infect via a different receptor, called CXCR4. It is not likely that RANTES would be effective at all against those strains. Our in studies give us confidence that VivaGel, because of its more general mechanism, will be effective against all major strains and variants.
Potential toxicity – RANTES is a natural human protein with an existing function. Thus, there is a potentially a high likelihood that it would cause undesired effects such as toxicity. We will be reporting soon on our own human studies of toxicity for Vivagel. But based upon animal studies, we believe that problems are unlikely.
Manufacturing cost – Manufacturing cost for a synthetic or recombinant protein may be prohibitive. In one account of the work I read, the leader of the study recognized that it would be cost prohibitive to produce product at the doses which were actually effective in the study.
Although molecules like RANTES can be expensive to produce, Dr. Lederman said the cost-effectiveness of the molecule could come down to a reasonable level depending on what scale-up could be achieved. "In principle, we should be able to scale it up to a level where it is affordable at doses where there is activity," he told Reuters Health. "The question then is what dose is that going to be-- I think that is the really hard thing."
The problem with lowering the dose to reduce cost is that in the study conducted, except for the highest dose, some of the animals became effective.
Stability – As a protein, it may be difficult to develop a formulation that would be stable in gel stored at room temperature. Most therapeutic proteins are provided by hospitals and are administered intravenously. This would not be practical at all for a product of this type.
This a small subset of many potential concerns about this approach. Hopefully, it gives you some appreciation of the rigor of analysis we have applied in developing VivaGel and our confidence that it will become a useful product.
With best regards,
Alexander Szabo, Ph.D., MBA
Vice President, Business Development
Starpharma, Ltd.
Baker Building
Commercial Road
Melbourne, VIC 3004
Australia
Office: +61 3 8532 2739
Mobile: +61 4 0736 4155
Email: alex.szabo@starpharma.com
Gruß, greenhorn
Ich muss sagen, bei Starpharma gibt man sich wirklich Mühe!
Hatte in der letzten Woche eine E-Mail Richtung Australien geschickt, in der ich um eine Stellungnahme hinsichtlich der Konkurrenzsalbe von VivaGel gebeten hatte. Nachzulesen war das ganze u.a. im Science-Magazin. In einem Artikel wurde die Arbeit des Forscherteams um Michael Lederman (Case Western Reserve University/Cleveland, Ohio) vorgestellt.
Nun, die Mail hatte ich an Ben Rogers geschickt, geantwortet hat Alexander Szabo, Ph.D., MBA
Vice President, Business Development
Starpharma, Ltd.
Dear Mr. xxx,
Ben Rogers, our company secretary, asked me to respond to your email. We are aware of these experiments and were intrigued that this report gained so much media attention when the product contemplated is quite far in development behind Vivagel. I suspect that the reason for this high degree of interest is that the scientific article describes a novel potential mechanism for a microbicide. However, it should be noted that this is very much an experimental academic study of a potential microbicide active ingredient. But the group would have a long ways to go and many obstacles to overcome for it to reach market or even to reach the stage of development of Vivagel.
In addition to progressing VivaGel, Starpharma is also investigating many alternative methods that could provide additional or complementary benefits. However, our analysis of this method leaves us with a number of concerns about this approach and suggests it may fail in the future for one or more of the following reasons:
Susceptibility to resistance – The experiments were designed to prove that an agent that blocks the CCR5 receptor can prevent infection. But it turns out that there are other variants of HIV that infect via a different receptor, called CXCR4. It is not likely that RANTES would be effective at all against those strains. Our in studies give us confidence that VivaGel, because of its more general mechanism, will be effective against all major strains and variants.
Potential toxicity – RANTES is a natural human protein with an existing function. Thus, there is a potentially a high likelihood that it would cause undesired effects such as toxicity. We will be reporting soon on our own human studies of toxicity for Vivagel. But based upon animal studies, we believe that problems are unlikely.
Manufacturing cost – Manufacturing cost for a synthetic or recombinant protein may be prohibitive. In one account of the work I read, the leader of the study recognized that it would be cost prohibitive to produce product at the doses which were actually effective in the study.
Although molecules like RANTES can be expensive to produce, Dr. Lederman said the cost-effectiveness of the molecule could come down to a reasonable level depending on what scale-up could be achieved. "In principle, we should be able to scale it up to a level where it is affordable at doses where there is activity," he told Reuters Health. "The question then is what dose is that going to be-- I think that is the really hard thing."
The problem with lowering the dose to reduce cost is that in the study conducted, except for the highest dose, some of the animals became effective.
Stability – As a protein, it may be difficult to develop a formulation that would be stable in gel stored at room temperature. Most therapeutic proteins are provided by hospitals and are administered intravenously. This would not be practical at all for a product of this type.
This a small subset of many potential concerns about this approach. Hopefully, it gives you some appreciation of the rigor of analysis we have applied in developing VivaGel and our confidence that it will become a useful product.
With best regards,
Alexander Szabo, Ph.D., MBA
Vice President, Business Development
Starpharma, Ltd.
Baker Building
Commercial Road
Melbourne, VIC 3004
Australia
Office: +61 3 8532 2739
Mobile: +61 4 0736 4155
Email: alex.szabo@starpharma.com
Gruß, greenhorn
News vom 17.11.04
Aktuelle Präsentation
http://www.starpharma.com/PDFs/041171%20AGM%20Chairmans%20Ad…
http://www.starpharma.com/PDFs/041117%20Starpharma%20to%20es…
17 November 2004 STARPHARMA TO ESTABLISH LEVEL I AMERICAN DEPOSITARY RECEIPTS PROGRAM Melbourne (Australia) 17 November 2004: Starpharma Holdings Limited (ASX:SPL) today announced that it has taken steps toward the establishment of a sponsored Level I American Depositary Receipts (ADR) program in the United States in the next couple of months. The establishment of the Level I ADR program will be subject to regulatory approval in the United States. The purpose of the Level I ADR Program is to encourage foreign investment in Starpharma shares through the United States over-the-counter (OTC) market, thereby expanding Starpharma`s shareholder base and name recognition in the United States. Starpharma expects to make a further announcement following the establishment of the Level I ADR program in the United States.
Grüße cristrader
Aktuelle Präsentation
http://www.starpharma.com/PDFs/041171%20AGM%20Chairmans%20Ad…
http://www.starpharma.com/PDFs/041117%20Starpharma%20to%20es…
17 November 2004 STARPHARMA TO ESTABLISH LEVEL I AMERICAN DEPOSITARY RECEIPTS PROGRAM Melbourne (Australia) 17 November 2004: Starpharma Holdings Limited (ASX:SPL) today announced that it has taken steps toward the establishment of a sponsored Level I American Depositary Receipts (ADR) program in the United States in the next couple of months. The establishment of the Level I ADR program will be subject to regulatory approval in the United States. The purpose of the Level I ADR Program is to encourage foreign investment in Starpharma shares through the United States over-the-counter (OTC) market, thereby expanding Starpharma`s shareholder base and name recognition in the United States. Starpharma expects to make a further announcement following the establishment of the Level I ADR program in the United States.
Grüße cristrader
Schade, ein Listing am NasdaqSC-Markt waere sehr schoen gewesen, damit waere Starpharma ein unmittelbarer Profiteur des naechsten Nano-Hypes geweorden.
Andererseits: Starpharma steht fuer Qualitaet, wer braucht da den Hype ???
Andererseits: Starpharma steht fuer Qualitaet, wer braucht da den Hype ???
Guten Morgen, wollte nur mal den Thread nach vorne holen. Alles Gute den Investierten. Neoe, bist du wieder investiert?????
CyberCoach:
Wie immer am Ende des Jahres gibt es einige sehr verlockende Investments, leider kann da Starpharma momentan nicht ganz so mithalten. Zu Dendritic fehlt leider zur Zeit jegliche Info. Ich hatte eigentlich das ein oder andere neue Joint-Venture erwartet. Ich muss sagen, dass dieses Jahr wenig passiert ist im Verhaeltnis zu den gemachten Versprechungen.
Deswegen: 2005 bin ich wieder dabei.
Wie immer am Ende des Jahres gibt es einige sehr verlockende Investments, leider kann da Starpharma momentan nicht ganz so mithalten. Zu Dendritic fehlt leider zur Zeit jegliche Info. Ich hatte eigentlich das ein oder andere neue Joint-Venture erwartet. Ich muss sagen, dass dieses Jahr wenig passiert ist im Verhaeltnis zu den gemachten Versprechungen.
Deswegen: 2005 bin ich wieder dabei.
Weiss einer von euch, wieso dieses Riesenpaket von 22280000 Stück im Ask liegt bei 75 cent????
Könnten das Leerverkäufe sein?
Könnten das Leerverkäufe sein?
Der Thread sollte erhalten bleiben, undzwar oben.
Wer kurzfristig an Starpharma interessiert ist, sollte sich jetzt auf jeden Fall positionieren. Demnaechst sollten die Phase-I-Ergebnisse fuer VivaGel gemeldet werden.
CyberCoach:
Ich danke dir fuer deine regelmaessigen Beitraege, grundsaetzlich liegt mir der Thread auch am Herzen und meine Rueckkehr ist fuer 2005 in Planung.
CyberCoach:
Ich danke dir fuer deine regelmaessigen Beitraege, grundsaetzlich liegt mir der Thread auch am Herzen und meine Rueckkehr ist fuer 2005 in Planung.
Hallo Neoe,
wegen des anstehenden Deals mit Dow Corning solltest du dir vielleicht überlegen, wieder erste Positionen aufzubauen.
Gruss,
cybercoach
wegen des anstehenden Deals mit Dow Corning solltest du dir vielleicht überlegen, wieder erste Positionen aufzubauen.
Gruss,
cybercoach
Alles rueckwaerts und ein dickes Sorry:
Wer sich fuer Starpharma interessiert hat es natuerlich gemerkt:
Die Phase-I-Daten sind natuerlich laengst draussen, deswegen muss ich zu meiner eigenen Schande zugeben, dass ich DERZEIT nicht mehr besonders gut informiert bin, was Starpharma betrifft.
Cyber Coach:
Bitte gib mir mal einen Wink. Dow Corning erwarte ich schon seit Monaten und nichts passiert. Daher auch meine Vermutung, dass vielleicht nicht alles oeffentlich gemacht wird, was im Falle von Dendritic einfacher ist, da nicht gelistet.
Wer sich fuer Starpharma interessiert hat es natuerlich gemerkt:
Die Phase-I-Daten sind natuerlich laengst draussen, deswegen muss ich zu meiner eigenen Schande zugeben, dass ich DERZEIT nicht mehr besonders gut informiert bin, was Starpharma betrifft.
Cyber Coach:
Bitte gib mir mal einen Wink. Dow Corning erwarte ich schon seit Monaten und nichts passiert. Daher auch meine Vermutung, dass vielleicht nicht alles oeffentlich gemacht wird, was im Falle von Dendritic einfacher ist, da nicht gelistet.
Starpharma hitches ride on Dow deal
By Rebecca Urban
January 20, 2005
Page Tools
Email to a friend Printer format
Melbourne pharmaceutical developer Starpharma Holdings is on the verge of signing a strategic deal with Dow Chemical Company that would shore up its intellectual property position and give it access to an estimated 200 patents in the competitive field of nanotechnology.
The deal, which could be finalised by the end of next week, is expected to involve the transfer of Dow`s extensive intellectual property portfolio into Starpharma`s subsidiary Dendritic Nanotechnologies (DNT). In return, Dow will receive a 31 per cent equity stake in DNT.
Sources have told The Age that the three companies have been in discussions for several months and that Starpharma chief executive John Raff will travel to the US early next week to close the deal.
The publicly listed company owns about 44 per cent of DNT and is expected to lighten its stake to accommodate its new partner. Other DNT shareholders include Central Michigan University and Donald Tomalia, the scientist who discovered dendrimers - a class of polymers - in the late 1970s.
Advertisement
AdvertisementThe deal is strategic to Starpharma because it will give the company access to a broader intellectual property position given that Dow, which has a market value of $US47 billion ($A62 billion), obtained many of the early dendrimer patents and earns substantial revenue from licensing activities.
Starpharma is also expected to secure automatic commercialisation rights in its specialty area of polyvalent pharmaceuticals, where its lead product is a dendrimer-based microbicide being developed to prevent the transmission of HIV and other sexually transmitted diseases.
This deal will also be the latest step in Starpharma`s plan to expand its US presence. Last year it ceased to be a pooled development fund to increase its investment in DNT. It has since completed the first level of an American depositary receipt program allowing US investors to trade in its securities.
Starpharma has made no secret of its plan to build a globally competitive biotechnology company.
Nanotechnology is an emerging area of science and almost two-thirds of the 30 companies listed on the Dow Jones Industrial Average funded research into nanotechnology last year. Experts predict increased corporate activity in the sector, led by mergers and acquisitions. Starpharma could not be contacted for comment last night. Starpharma shares yesterday closed 1¢ down at 81¢.
By Rebecca Urban
January 20, 2005
Page Tools
Email to a friend Printer format
Melbourne pharmaceutical developer Starpharma Holdings is on the verge of signing a strategic deal with Dow Chemical Company that would shore up its intellectual property position and give it access to an estimated 200 patents in the competitive field of nanotechnology.
The deal, which could be finalised by the end of next week, is expected to involve the transfer of Dow`s extensive intellectual property portfolio into Starpharma`s subsidiary Dendritic Nanotechnologies (DNT). In return, Dow will receive a 31 per cent equity stake in DNT.
Sources have told The Age that the three companies have been in discussions for several months and that Starpharma chief executive John Raff will travel to the US early next week to close the deal.
The publicly listed company owns about 44 per cent of DNT and is expected to lighten its stake to accommodate its new partner. Other DNT shareholders include Central Michigan University and Donald Tomalia, the scientist who discovered dendrimers - a class of polymers - in the late 1970s.
Advertisement
AdvertisementThe deal is strategic to Starpharma because it will give the company access to a broader intellectual property position given that Dow, which has a market value of $US47 billion ($A62 billion), obtained many of the early dendrimer patents and earns substantial revenue from licensing activities.
Starpharma is also expected to secure automatic commercialisation rights in its specialty area of polyvalent pharmaceuticals, where its lead product is a dendrimer-based microbicide being developed to prevent the transmission of HIV and other sexually transmitted diseases.
This deal will also be the latest step in Starpharma`s plan to expand its US presence. Last year it ceased to be a pooled development fund to increase its investment in DNT. It has since completed the first level of an American depositary receipt program allowing US investors to trade in its securities.
Starpharma has made no secret of its plan to build a globally competitive biotechnology company.
Nanotechnology is an emerging area of science and almost two-thirds of the 30 companies listed on the Dow Jones Industrial Average funded research into nanotechnology last year. Experts predict increased corporate activity in the sector, led by mergers and acquisitions. Starpharma could not be contacted for comment last night. Starpharma shares yesterday closed 1¢ down at 81¢.
Folgendes Update des CEO empfehle ich allen, die sich fuer Starpharma interessieren:
http://www.starpharma.com/PDFs/050201%20Investor%20Update%20…
http://www.starpharma.com/PDFs/050201%20Investor%20Update%20…
Hallo, bin nach langer Zeit wieder investiert.
Ich erwarte kurzfristig keine Hammernews, der Grund für den Einstieg war die meiner Meinung nach zu niedrige Bewertung:
Rund 36 Millionen Euro Marketcap scheint mir für Vivagel, die Dendritic-Beteiligung und das Cash das noch vorhanden ist zu wenig. Außerdem gibt es ja noch andere, kleinere Beteiligungen, Kooperationen und Projekte, die derzeit alle noch schwer zu bewerten sind.
Ich erwarte kurzfristig keine Hammernews, der Grund für den Einstieg war die meiner Meinung nach zu niedrige Bewertung:
Rund 36 Millionen Euro Marketcap scheint mir für Vivagel, die Dendritic-Beteiligung und das Cash das noch vorhanden ist zu wenig. Außerdem gibt es ja noch andere, kleinere Beteiligungen, Kooperationen und Projekte, die derzeit alle noch schwer zu bewerten sind.
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
229 | ||
75 | ||
67 | ||
54 | ||
52 | ||
44 | ||
43 | ||
42 | ||
33 | ||
29 |
Wertpapier | Beiträge | |
---|---|---|
28 | ||
26 | ||
23 | ||
21 | ||
19 | ||
19 | ||
19 | ||
18 | ||
17 | ||
15 |